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« Le chimiste, par le jeu de l’analyse et du raisonnement… » 
A. Wurtz 
Résumé 
L’industrie pharmaceutique doit répondre à une demande croissante  de mise sur le marché de 
substances enantiomériquement pures, rendant nécessaire le développement de voies de synthèse 
asymétrique alternatives, efficaces pour pouvoir produire en masse des médicaments ou des 
candidats-médicaments. 
C’est dans ce contexte que se situe ce travail de thèse, qui concerne trois types de substances 
médicamenteuses actives. Afin d’introduire la stéréochimie requise par les  molécules cibles, nous 
avons basé notre étude sur le développement de procédures faisant intervenir comme réactions 
clefs : des additions Michael par voie organocatalytique et des réactions Henry catalysée par des 
complexes de cuivre.  
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Au terme de ce travail, nous sommes en mesure de proposer de nouvelles stratégies pour la 
synthèse de l’Aliskiren, inhibiteur de la rénine. Parmi toutes les voies de synthèse que nous avons 
testées pour préparer des précurseurs de l’Aliskiren, l’une a été appliquée avec succès, après 
optimisation, pour une production au KiloLab. Cette nouvelle approche basée sur la préparation d’un 
dérivé-clef, de type nitré, enantiomériquement pur, a fait l’objet d’un brevet en 2011. Nous avons 
également défini trois autres voies de synthèse potentiellement utilisables, après optimisation, pour 
préparer l’Aliskiren. En outre, nous avons pu mettre en évidence la possibilité d’une séquence de 
type domino en « one-pot », impliquant l’enchaînement suivant de réactions: 
Knoevenagel/Michael/Henry/acétylation/ isomérisation. 
Notre étude a également porté sur la préparation d’un nouveau candidat-médicament à activité anti-
Parkinsonienne (AFQO56). Nous avons évalué la faisabilité d’une addition, de type aza-Michael par 
voie organocatalytique. Nous avons pu, dans  le meilleur des cas, isoler les précurseurs de l’AFQ056 
qu’avec une enantiosélectivité modérée.   
En outre, un certain nombre de travaux que nous avons menés ont eu pour but de développer une 
voie asymétrique d accès au candidat-médicament Novartis KAE 609 à potentialité anti-malaria. Bien 
que nous n’ayons pas réussi à isoler les précurseurs chiraux souhaités du KAE609, nous proposons, 
une voie d’accès générale et rapide à ses précurseurs du type indolylnitroalcènes. Un procédé de 
synthèse en une seule étape d’une série de précurseurs d’analogues du KAE 609, potentiellement 
bioactifs pourrait ainsi être appliqué. 
Mots cles 
Addition de Michael par voie catalytique - Réactions de Henry catalysée par des complexes de cuivre 
– Enamine – Ion iminium - Synthèse de molécules bio-actives  -  
Summary 
The increasing demand for the marketing of enantiomerically pure substances has forced the 
pharmaceutical companies to develop efficient enantioselective procedures for the large scale 
synthesis of their drug candidates or commercial drugs.  
In this work, we focused our attention on the preparation of three Novartis pharmaceutically active 
substances.  We planed to introduce the desired stereochemistry into the targeted molecules via 
asymmetric copper-ligand based and chiral amine promoted organocatalytic procedures and focused 
our attention on the two well known C-C bond-forming reactions that are the Henry reactions and 
the Michael additions.  
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We were able to propose novel alternative routes to the renin inhibitor Aliskiren (Rasilez). We 
focused our attention on the asymmetric preparation of β-and δ-hydroxyl nitro compounds, via 
different successful catalytic asymmetric strategies, involving as key steps, enamine and iminium 
promoted Michael additions and copper catalyzed syn-selective asymmetric Henry reactions. Among 
the synthetic routes we reported for the preparation of Aliskiren precursors, the first one was 
successfully applied after optimization to a Kilo-Lab campaign. A novel approach based on the 
preparation of a novel key nitro derivative, has been patented in 2011. After optimizations, the three 
last investigated routes should/could be applied to the potential preparation of Aliskiren.  During our 
investigations on the chemistry of the nitro group, we also prepared stable tetrahydropyranol 
derivatives, from in-situ generated nitroalkene derivatives and different aldehydes, by a one-pot-
domino sequence involving the asymmetric Knoevenagel/Michael/Henry/acetalization/ 
isomerisation reactions.  
We also studied the preparation of a novel anti-Parkinson drug candidate (AFQ056) and examined 
the organocatalyzed aza-Michael addition of a selection of N-nucleophiles to cyclohexenone. In the 
best case, we are able to isolate two desired aza-Michael products with moderate enantiomeric 
ratios and poor isolated yields. We also described a successful approach to the 1,5,6,7-
tetrahydroindol-4-one building block  of AFQ056, involving an intramolecular proline catalyzed 
alkylation step. Our chemistry can be used in a continuous manufacturing process.  
Few investigations have also been performed to evaluate the viability of an asymmetric preparation 
of the Novartis promising anti-malaria drug candidate KAE609 from Novartis. Although we failed to 
isolate the desired chiral indolylnitroalkane precursors of KAE609, we prepare the indolylnitroalkene 
analogues with high yields.  We proposed thus a general one-step procedure to synthesize a range of 
precursors for potential bioactive analogues of KAE609.  
 
Keywords 
Asymmetric drug synthesis-Organocatalyzed Michael addition - Enamine catalysis - Iminium catalysis 
- Copper catalyzed syn-asymmetric Henry reaction - One-pot-domino multi component sequence  
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CHAPTER 1: INTRODUCTION 
 
Recent trends in the pharmaceutical industry demonstrate that the number of APIs (Active 
Pharmaceutical Ingredients) launched on the market or presents in the global pipeline, as single 
enantiomers has increased (Figure 1, by Farina1 in 2006). Until 1992, (but really until 2001) racemic 
mixtures are indeed no longer registered1 by the drug authorities, who require a level of undesired 
isomer(s) no higher than fractions of percent. 
 
 
 
 
Figure 1
1,2
: Single enantiomers versus racemates 
 
Moreover, in the recent years the interest in the specific pharmacological and toxicological activities 
of enantiomers of drugs or drug candidates (establishment of the importance of three dimensional 
spatial relationships between a drug compound and its action site in a macromolecular target3) grew 
up and emphasized this new tendency. It resulted in the so called “chiral switch”, and so, as reported 
in Figure 24, many racemic medications have been remarketed as single enantiomers (chiral switch).  
The difference of biological properties between a distomer and its corresponding eutomer has been 
then evaluated and proved.  
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Figure 2
4
: From racemates to enantiomeric pure medications: some examples 
 
 This important new trend resulted in the huge interest and development of novel strategies (Figure 
3) to prepare the enantiopure APIs, avoiding an increase of the production costs. 
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Figure 3:  Available methodologies for the preparation of enantiopure chiral drugs 
 
 As shown in Table 1, one of the preferred approaches is based on the use of the so-called chiral pool 
(“chirality from nature”), resulting in the conversion of cheapest and commercially available 
enantiopure appropriate starting  materials to enantiopure drugs or candidates; its success resulting 
from the huge commercial availability of chiral key building block intermediates.  Other alternative 
successful methodologies to prepare at lower costs enantiopure medications are grounded on the 
 3 
 
classical chemical or enzymatic resolution approach, or on crystallization (in case of 
diastereoisomers) methods. The progress made in the field of preparative analytical chiral 
technologies yielded also the increasing use of chromatography separation methods.  
Nevertheless, all these techniques required a large amount of expensive starting materials, and long 
synthetic routes. For that reason, the development of enantioselective synthetic methods would be a 
major revolution in the field of drug production, but few have found an application until 2003 on 
large scale production of APIs (Table 1)1. 
 
Entry Type 1992 1994 1996 1998 2000 2002 2003 
1 use of chiral pool 3 6 6 4 7 4 4 
2 resolution approach 1  3  2 4 2 
3 enantioselective synthesis 1 1 2 5 2 2 4 
 
Table 1: Used methodologies to introduce chirality 
 
Intensive efforts have been made, and are still required for the development of efficient and robust 
enantioselective synthesis, based on the considerable advances made in the field of asymmetric 
synthesis, providing5 thus general methods of producing drugs from prochiral or chiral substrates in 
large scale6.  The field of asymmetric synthesis includes various successful approaches7a,b (Figure 3) 
based on the utilization of chiral auxiliaries, metal complexes (homogeneous and heterogeneous 
phase), bio-catalysts, and in the last years, also of organocatalysts (as proof the number of papers 
published in the last years (Figure 4)). In all these cases high selectivity can be achieved by using the 
proper catalyst, ligand substrate and reaction conditions.   
 
 
Figure 4: Number of publications edited from 2000 to 2010, on the topic organocatalysis (SciFinder Research) 
 
Among the large number of C–C bond forming reactions, which have been explored and resulted in 
successful applications in the field of metal catalyzed and organocatalytic asymmetric synthesis, the 
nitroaldol or Henry reaction21 and the Michael addition7 represent powerful methods for the 
preparation of valuable and easily transformable synthetic intermediates.  
 
The progress made in the field of asymmetric synthesis and the request of the pharmaceutical 
industry to produce enantiopure APIs in the quickest, cheapest and “green” manner, resulted in the 
development of a new way of thinking: “the atom economy”8 was introduced.  
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I. Atom economy strategies 
  
The objectives of the pharmaceutical companies have always been to find the best way in term of 
yields, selectivities and safety to quickly produce a drug. In 1991, Trost8 introduced a new vision of 
the “chemical thinking” and suggested novel guidelines to assess the efficiency of a given process by 
“looking at the number of atoms of the reagent(s) actually ending up in the desired product(s)”.  
 
The concept of atom economy9, and the idea of using it as first condition for the improvement of 
chemical syntheses relies to the field of green chemistry, that was first introduced by Anastas in the 
early 1990s10 and forced the chemical community to reevaluate the criteria of chemistry and to look 
at a chemical reaction in a more “global” manner, considering aspects such as the origin of the 
reactants, the amount of energy necessary to make it work and the outcome of the generated 
waste11. 
 
The atom economy benefits from and is based on the progresses made in the field of catalysis. 
Although the major drawback of catalysis is the necessary recovery of the catalyst, it remains the first 
big step made for atom economy and the progress made in this field continues to prove its power. 
More recently, the chemical community turned its attention to the development of alternative 
efficient solvent- free procedures, and pointed out the utilization of water, supercritical fluids, or 
ionic liquids as potential alternative media.  
 
Theses progresses made in the development of efficient alternative methods and techniques led also 
to the emergence of new ways of synthesis planning allowing the preparation of complexe molecules 
in an ecologically and economically favorable way, such as tandem, cascade or domino reaction12.  
Such reactions are defined as one-pot processes involving “two or more bond-forming reactions 
under identical conditions, in which the subsequent transformation takes place at the functionalities 
obtained in the former transformation”12f, or “coupled catalysis that occurs sequentially and via two 
(or more) mechanistically distinct processes”13. The advantages of making several transformations in 
one operation are considerable, not only in terms of waste (one solvent, absence of work-up and 
purification steps) but also in terms of time, labor and resource management. 
 
The progress made in the design of tandem/domino/cascade reaction remained a challenge until 
Robinson14 reported his one-pot synthesis of tropinone (Figure 5). 
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Figure 5: Robinson syntheses of tropinone 
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II. Asymmetric synthesis 
 
Asymmetric synthesis, and especially the metal-chiral ligand based catalysis and the organocatalysis, 
is one of the most important and popular strategy to prepare enantiopure compounds. The 
enormous interest and progresses attached to chiral catalysts in asymmetric synthesis led to the 
award of the Nobel Prize for chemistry in 2001 to Knowles and Noyori (for their work on chirally 
catalyzed hydrogenation reactions) and to Sharpless (for his work on chirally catalyzed oxidation 
reactions)15. The pioneering work of these three Nobel laureates paved the way for the further 
development of asymmetric catalysis16. 
 
While the use of metal catalysts or metal-ligand catalysts dominated up to the end of the last 
century, a change in perception in recent years led to a switch in favor of organocatalysts. The 
utilization of small chiral organic molecules as metal-free catalysts, especially in the synthesis of 
pharmaceuticals afforded the ‘green’ advantage of the non contamination of the final product with 
traces of heavy metals17a-d,16.    
 
II.1. Induction of asymmetry  
 
II.1.1. Ligand- metal complexes based catalysis  
 
In asymmetric synthesis, the effort made in the field of ligand- metal based catalytic asymmetry led 
to the preparation of a wide range of complexes from various chiral ligands and metal species 
(among  them copper and zinc were the most widely used) being able to chelate monodentate or 
bidentate species (Figure 6)18. 
X
Ln*M X
Ln*M
X
2
. .
monodentate substrates
(poor stereodiscrimination)
bidentate substrates
(high stereodiscrimination)  
Figure 6: Plausible coordination ways of monodentate or bidentate species with chiral ligand-metal based 
complexes 
 
II.1.2. Organocatalysis  
 
In organocatalyzed asymmetric reactions, two modes of activation of the substrates have been 
proposed7b: i)  the generating asymmetry can result from the formation of covalent adducts between 
the catalyst and the substrate(s) within the catalytic cycle, the so called ‘‘covalent catalysis’’ ii) 
second from non-covalent interactions such as hydrogen bonding or the formation of ion pairs can 
provide organocatalyzed asymmetric reaction, the so-called ‘‘non-covalent catalysis’’ (Figure 7).  
 
In ‘‘covalent catalysis’’,  the activation of the substrate can occur for example, by single step Lewis-
acid–Lewis-base interaction or by multi-step reactions such as the formation of enamines from 
aldehydes and secondary amines. In ‘‘non-covalent catalysis”, the activation process is based on the 
formation of hydrogen-bonded adducts19 between substrate and catalyst or on 
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protonation/deprotonation processes. An other activation process belonging to this category is the 
phase-transfer catalysis (PTC) by organic phase-transfer catalysts, even if the PTC promotes reactivity 
not only by altering the chemical properties of the reactants but also involves a transport 
phenomenon7b.  
 
O
R XR
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R2R1
R4
R3
R2R1
N
+
R5
O
R1 R2
H H
X X
Organocatalysis
Covalent catalysis Non-covalent catalysis
Nucleophilic
catalysis
EXAMPLES
Acyl-transfer reactions by 
Lewis Basic amines
and phosphanes
+
Acyl
ammonium/phosphonium
intermediate
Amine catalysis
aldol reactions, 
Michael additions
Enamine or iminium ion 
intermediates
EXAMPLES
Activation of 
carbonyl compounds by 
hydrogen bounding to
amidinium cations, ureas...
Phase-transfer 
catalysis, formation of
chiral ion pairs
 
Figure 7: Example of asymmetric synthesis 
 
Most of the organocatalysts can be categorized either as Lewis bases/acids or Brønsted bases/acids. 
Lewis base catalysts initiate the catalytic cycle via nucleophilic addition to the substrate, resulting in 
the formation of a complex, which undergoes the reaction and then releases the product and the 
catalyst. In Lewis acid catalyzed cycle, the nucleophilic substrate is activated in the same manner. In 
the case of Brønsted base and acid catalysts, the catalytic cycles are initiated via a (partial) 
deprotonation or protonation step20. 
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                S
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P:
A-P+H
S:
 
Figure 8
20
: The general catalytic cycles proposed for the Lewis base/Lewis acid organocatalysts and for the 
Brønsted base/Brønsted acid catalysts 
 
II.2. Henry reaction 
 
One example of a well documented asymmetric catalytic reaction is the Henry reaction21. Discovered 
in 1895, the Henry reaction22 consists essentially in the reaction of an in situ generated reactive 
nitronate species (resulting from the deprotonation of an alkylnitro compound bearing α- hydrogens) 
with a carbonyl group, yielding in the formation of a nitroalcohol product bearing two new 
stereocenters (Figure 9).  
N
+
R2 H
R1
OO
O R4
R3
OH
R4
N
+
R2
R1
OO
R3
+
 
Figure 9: Principle of the Henry reaction (Nitro aldol reaction) 
 
Such derivatives are very useful in organic synthesis, being easily transformed into a variety of 
nitrogen- or oxygen-containing derivatives23: nitroalkenes (dehydration), aminoalcohols or amino 
ketone compounds (reduction24), aldehydes or carboxylic acids (Nef reaction25), and into other 
derivatives (substitution by carbon and heteroatom nucleophile26) 
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Figure 10
21b
: Possible transformations of the nitro-alcohol obtained by a Henry reaction 
 
The Henry reaction may be conducted under many different conditions, using diverse catalytic 
systems providing moderate-to-good enantioselectivities. The control of the configuration at the 
new formed stereocenters is often crucial. The reversible nature of many nitroaldol reactions, 
and the racemization of the carbon group in α position to the nitro functionality makes the 
control of the configuration difficult.  
Since the first asymmetric version of the Henry reaction was reported by Shibasaki27 in 1992, the 
interest in this area has grew up considerably and many procedures and methodologies have 
been published in the literature based on the development of various metal and non metal 
based catalysts. The development of new catalytic processes for asymmetric Henry reactions has 
been always based on the two following approaches: a) activation of the nitroalkane reactant via 
the pre-formation of a silyl nitronate species b) direct reaction without any previous activation of 
the reactants. 
 
II.2.1. Activation through the formation of silyl nitronate species  
 
The development of strategies based on the pre-activation of the nitroalkane derivatives relied on 
the pioneering work of Seebach28, who reported the preparation of silyl nitronates from primary and 
secondary nitroalkanes and their reactions with some carbonyl compounds, catalyzed by fluoride-
ion. On this basis, different methodologies providing anti selective Henry reaction have been 
developed using chiral quaternary ammonium salt fluorides (Maruoka29) or combinations of an 
achiral fluoride source and a chiral metal complex (Jorgensen30). 
 
II.2.2. Direct asymmetric reaction 
 
All the methodologies developed on this area are based on a cooperative activation of the 
nitroalkane and carbonyl components during a catalytic cycle: i) the nitroalkane by base-promoter 
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transfer ii) the carbonyl species by coordination to an acidic center21c. These approaches including 
metal based or organocatalysis, resulted in the preparation of Henry products with good yields and 
enantioselectivities. 
It is also worth to mention, that few researches on biocatalytic Henry reactions have been 
conducted. A recent paper published by Griengl31 describes the use of lyase from Hevea brasiliensis 
as biocatalyst buffered media to prepare nitro aldol products with moderate to good yields and 
enantioselectivities. 
 
II.2.2.1. General catalysts 
 
Henry reactions can be catalyzed by many types of catalysts and conditions; the first promoters of 
choice were strong bases as alkoxides or hydroxides in alcoholic or aqueous solvents21a. Organic 
bases such as 1,1,3,3 tetramethylguanidine or cyclic analogues in ether or THF and triethylamine or 
Hünig Base in alcoholic solvent have also been employed to perform Henry reactions21a.  
 
II.2.2.2. Metal based chiral catalysis 
 
II.2.2.2.1. Rare earth-BINOL complex 
 
In the field of metal catalyzed syn-asymmetric Henry reactions, many types of metal catalysts have 
been employed. The first example of this category ((S)-Binaphtol in conjunction with Lathanum 
oxide) was published by Shibasaki27. His pioneering work is based on bifunctional multimetallic 
catalysis32 (Figure 11) using rare earth metals; the good yields and enantioslectivities result from the 
cooperative action of Lanthanum and phenoxi-Li as Lewis acid and Brønsted base centers.  
La
OOLi Li
O
O O
O
Li
 
Figure 11: Heterodimetallic ambifunctional catalysts for Henry reactions 
 
Fine-tuning of the substituents of the ligand on 6 and 6’ positions and addition of water and BuLi 
(resulting in the formation of more active catalyst) lead to the improvement of the conversion rates 
and the syn/anti selectivity33(Figure 12).  
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Figure 12
21c
: Explanation of the difference in the activities of the first and second generation of catalysts 
 
Following the works of Shibasaki other efficient catalysts have been designed. Saá 34, for example, 
reported the utilization of catalysts containing a central La atom coordinated to three BINOL ligands, 
modified by attachment of an aminoalkyl side chain. He also proved that the addition of DBU and 
proton sponge to the reaction mixture enhanced rates and selectivities.  
 
II.2.2.2.2. Dinuclear zinc catalysts 
 
Other types of metal based catalysts for asymmetric Henry reactions using a central zinc atom have 
been designed. The more efficient example was published by Trost35 revealing a new class of 
dinuclear zinc complex with a semi-azacrown ligand (Figure 13).  
N
H
N
OAryl
Aryl
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O
Zn
O
Aryl
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Et
 
Figure 13: Dinuclear zinc complex 
 
Additional trinuclear zinc complexes from trimeric thioaza macrocyclic ligand and diethylzinc have 
also been described by Martell36 to perform asymmetric Henry reactions.  
 
II.2.2.2.3. Copper-based catalysts 
 
II.2.2.2.3.1. Bis(oxazoline) ligand 
 
The first example of complexes (Figure 14) from copper (II) salts and bis(oxazoline) ligands for the 
asymmetric Henry reaction of nitromethane and α-ketoester, has been reported by Jorgensen37. This 
procedure includes the presence of base additives (triethylamine) at room temperature and the 
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formation of a transition state intermediate, where only the aldehyde component coordinates to the 
copper atom.  
N
H
O
N
H
O
Cu
tBu
tBu
OTfTfO  
Figure 14: Jorgensen copper (II)–BOX complex 
 
In this method, the ratio of complex and base additive (triethylamine seems to be the best one) plays 
an important role in the selectivitities observed (up to 94%), triethylamine being an active participant 
as promoter of the reactive nitronate species and deactivator of the Lewis acid catalyst (Figure 15).  
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Figure 15: Proposed role of triethylamine and complex for the copper(II)-BOX complex catalyzed Henry 
reactions 
 
Related, but less effective catalysts have also been described by Du38, who performed the same 
Henry reaction using complexes of Cu(OTf)2 salt and bisoxazoline and thiazoline ligands.  
A more efficient analogue has been designed first by Evans39 and later by Singh40, based on a 
copper(II)-BOX complex, which would form a transition state species with the reactants where both 
aldehyde and nitronate components coordinate to the copper atom, resulting in the observed 
preferential configuration of the Henry adducts (Figure 16). The design of such catalysts are also 
based on the postulate that weakly Lewis acidic metal complexes bearing moderate charged ligands 
facilitate the formation of the nitronate species, as first step of the catalytic process21d. 
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Figure 16: Evans’ catalyst and proposed transition state species 
 
Related tridentate-bis-(oxazoline) ligands have also been reported to catalyze asymmetric Henry 
reactions.  Du38 designed also C2- symmetric tridentate- bis-thiazazoline and  bis-oxazoline ligands (A, 
B, Figure 17) that perfom asymmetric Henry reactions via the formation of a “chiral pocket” around 
the metal center, bis(thiazazoline) ligands leading to better enantioselectivities (up to 70%) than 
bis(oxazoline) ligands (up to 66%). 
X
O
N N
O
RR
N
X
R
X
N
R
N
H
X=N,O
X=0,N
A
B
 
Figure 17: tridentate-ligands 
 
The most interesting aspect of the utilization of complex type B is the reversal of the 
enantioselectivity by variation of the Lewis acid used. Thus, using complex formed from B type 
ligands and Cu(OTf)2 salts, provided (S)-product with up to 86% ee, while the utilization of ZnEt2 
generated (R)-products with up to 85% ee. An explanation for these results is based on the fact that 
the central NH moiety cannot be deprotonated by triethylamine, and also acts as hydrogen bond 
donor, orienting the nitronate species, resulting in the attack of the nucleophile only from the Si-
face. At the opposite, ZnEt2 can deprotonate the amino moiety allowing the formation of a dinuclear 
complex, whose environment forces the approach of the nucleophile from the Re-face.   
 
II.2.2.2.3.2. Imine ligand 
 
Imine ligands have also been reported by Zhou41 and Pedro42 as being able to form complexes with 
copper II salts and so to react via the same process described by Evans asymmetric Henry reactions 
(Figure 18).  
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Figure 18: Zhou’s and Pedro’s copper (II)-imine ligand complexes 
 
II.2.2.2.3.3. Chiral diamine ligands 
 
Chiral diamine complexes of copper (II) salts have also been described as useful catalysts for 
asymmetric reactions. Copper (II) complexes of (-)-sparteine have been, for example, reported 43 to 
perform Henry reactions with different catalytic activities depending on the nature of the copper salt 
used. Indeed, Cu(OAc)2 complexes promote Henry reactions without addition of an external base, 
while complexes from CuCl2 salt require the presence of triethylamine (even if in small quantities) to 
perform smooth reactions. This difference of reactivity of the complexes was explained by the 
difference in bond and torsion angles around the copper (II) center.  
Copper complexes of C2 symmetrical diamine ligands (Figure 19) have also been designed and are 
described44,45 as efficient catalysts for nitroaldol reactions of nitromethane with various aldehydes 
with up to 99% yields and 90% ee.  
NHN
NHN
NN
NN
 
Figure 19: Chiral diamine ligand for copper catalyzed Henry reactions 
 
As copper (I) complexes are challenging to handle, copper (II) complexes from tertiary amine ligands 
presented above (Figure 19) have been designed, based on the postulates of D. Evans39 that their 
relative strong basicity and coordination ability would influence the catalytic activity.  
 
II.2.2.2.3.4. Chiral bifunctional diamine ligands 
 
In 2009, Mao46  published conditions and designed bifunctional Schiff base ligands for copper 
catalyzed asymmetric Henry reactions. He based his approach on the work of Gröger and Shibasaki47 
who developed bifunctional catalysts for various asymmetric transition metal processes, proving that 
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such catalysts are Lewis acid-Lewis base systems, which are able to assemble both reactants in an 
ordinate transition state, bringing the substrates and nucleophiles into a close environment (Figure 
20).  
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Figure 20
46
: Lewis acid-Lewis base system 
 
Indeed, the related catalysts designed by Mao were supposed to activate the aldehyde (electrophile 
substrate) via the Lewis acid center. The Lewis base center is supposed activate the nitroalkane 
partner (nucleophile substrate) resulting in a double activation process.  
R
R
M
O NH
O
R R
Lewis Base center,
activates the nucleophile
Lewis Acid center,
activates the electrophile
 
Figure 21
46
: Bifunctional copper based catalyst for asymmetric Henry reactions 
 
The results observed by Mao proved the possibility of the utilization of such bifunctional copper 
based complexes for asymmetric Henry reactions of nitromethane with various aldehydes, providing 
Henry product with (S) configuration. It is here notable to say that the utilization of cobalt salts 
instead of copper salts resulted in a reverse enantioselectivity, with poor ee. The (S) selectivity 
observed could be explained by the formation of the following transition state as postulated by  
Evans39, where the three aromatic rings shield one site of the complex, so that the attack of the 
nitronate occurs on the Si face of the carbonyl group (Figure 22). 
R H
O
N
+
O
O
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O NH
O
R
OH
N
+
O
O
 
Figure 22: Proposed transition state models for the enantioselective Henry reactions 
 
Reduced C2 and C1 symmetric Schiff base analogues were also described by Woggon in 2009, and 
2011 as efficient copper based complex ligands for the asymmetric Henry reaction of various 
aldehydes  with nitromethane  with high (S)-enantioselectivity, and with 4-nitrobutyrate (and various 
prochiral nitroalkane)48,49 with high enantioselectivity  and syn/anti ratios (Figure 23). After screening 
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a wide range of ligands (for more informations on the variation done on R1 and R2, see48,49) and 
metal salts, his group identified the following derivative of Figure 23 to be the best one in term of 
enantio-and diastereoselectivity, when used in combination with Cu(OAc)2 salt.  
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Figure 23: Examples of chiral ligands developed by Woggon and co-workers 
 
Woggon proposed a mechanism of action for his catalytic asymmetric Henry reaction, in which the 
acetate unit of the in-situ generated complex I is replaced by the two reactants (intermediate II) so 
that the nitronate attacks preferentially one of the face of the aldehyde.  After release of the product 
addition of aldehyde and CH3NO2 regenerates the intermediate I, closing the cycle (Figure 24).  
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Figure 24: Proposed mechanism of Henry reaction catalyzed by Woggon catalysts 
 
In the same way, he explains the excellent syn-selectivity by the fact, that both, aldehyde and nitro 
partners coordinating with one oxygen atom, are not anti-periplanar oriented (as demonstrated by 
Cossio50), and by the bulky pocket around the metal center. 
 
II.2.2.2.4. Other metal based catalysts  
 
Cobalt (II) ketoimine and cobalt (II)-SALEN complexes have also revealed good catalytic activity for 
Henry reaction in the presence of an external base (Hünig Base)51.  
 
 
II.2.2.3. Organocatalysis for the enantioselective Henry reaction 
 
In view of the importance of the stereocontrol of the formation of nitroaldol products, a limited 
number of organocatalytic methods have been reported in the literature21b.  
The following design principles21c for an organocatalyst being able to perform Henry reactions with 
high chemical and stereochemical efficiency are: 1) the presence of a basic moiety (or external base) 
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to deprotonate the nitroalkane to the active  nitronate species,  2) some unit capable of binding the 
nitro (or nitronate) group either through hydrogen bonding or purely electrostatic interactions, 3) 
some unit capable of forming a hydrogen bond with the acceptor carbonyl. So far, cinchona alkaloids, 
phase transfer catalysts, thioureas and guanidines52 have been employed to this purpose.  
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Figure 25
53
: Some reported organocatalysts for Henry reactions 
 
The first organocatalysts for asymmetric Henry reactions have been described by Najera53, who 
reported the preparation of different C1 and C2 symmetric guanidines and their modest (ee< 56%) in 
the Henry reactions of nitromethane with isovaleraldehyde and benzaldehyde at room temperature. 
Later, related guanidines have been described by Murphy54  and Ma55, while didn’t afford better 
enantioselectivities and syn-diastereoselectivties.  
In 2005, Nagawasa56 designed the bifunctional organocatalyst, bearing guanidine and thiourea 
moieties. This catalyst showed the best results in terms of enantioselectivity for the reaction of 
nitromethane with α-branched aldehydes (up to 88%) and in terms of enantioselectivity (up to 95%) 
and syn diastereoselectivity (up to 99%) for the reaction of various nitroalkanes and aldehydes. The 
same tendency was also observed for the reaction of nitroalkanes and α-ketoesters.  
 
The authors56c,d explained the good syn-selectivity by the fact, that the anti, anti conformational 
transition state (nitro group and R1 are in an anti relationship, carbonyl group and R2 are anti) of the 
three possible transition states, is the more favorable in term of reduced steric repulsion (Figure 26).  
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Figure 26
56d
: Possible transition state models of the organocatalyst E for Henry reactions 
 
Because of the high enantioselectivity of these catalysts, they could be a good choice for the 
preparation of the syn-intermediate of Aliskiren. 
 
Chiral guanidine bases performing anti- diastereoselective Henry reaction have also been designed 
recently by Terada57, who reported their activities in the Henry reactions of various nitroalkanes with 
aldehydes. 
 
Chiral N-spiro-ammonium organocatalysts, for example the C2 symmetric catalyst (Figure 25), have 
also been reported by Maruoka58 as efficient phase transfer catalyst for Henry reactions of silyl 
nitronates with aldehydes. Thiourea pattern has also been used for the design of organocatalysts. 
Shi59 reported for example the efficient axially chiral bis(arylthiourea)-based organocatalyst . 
 
The Cinchona alkaloids are not only organocatalysts but also metal-ligand based catalysts of choice, 
which has been explained by different factors16b. The most important one is their ability to 
coordinate to metal centers with the nucleophilic nitrogen of the quinuclidine ring  and to bind  the 
substrate on the quinolinic ring. The relative positions of both quinuclidine and quinolinic ring can 
also explain their efficacy as catalysts for the Henry reactions (Figure 27).  
N
N
R2
OH
H
H
R1
R
Nucleophile
activation
Electrohile
activation
quinuclidine 
tertiary amine ring
quinoline 
aromatic ring
9
8
6'
 
 
Figure 27
16b
: Cinchona alkaloids scaffold and mode of activation 
 
As reported by Herrera21b and Singh16b, some cinchona derived catalysts have also been tested in the 
Henry reactions.  Hiemstra60  and Deng61 designed also related derivatives (Figure 25). 
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II.2.2.4. Application to the preparation of active pharmaceutical ingredients 
or intermediates 
 
In order to illustrate the importance of the development of asymmetric methods for the Henry 
reaction, it is worth to mention some of its applications in the pharmaceutical industry, as 
summarized by Luzzio in 200121a.  
For example, Shibasaki62 applied La-(R)Binaphthol complexes for the preparation of (S)-propanolol 
(Figure 28). 
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Figure 28: Preparation of (S)-propanolol 
 
The same procedure was employed for the preparation of N-phthalimido-1-nitrobutane, a precursor 
of the HIV inhibitors KNI227 and KNI273 (Figure 29)63.  
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Figure 29: Preparation of the HIV inhibitors KNI227 and KNI-273 
 
Shibasaki64 reported the preparation of a precursor of (S)-Pindolol, a β-adrenergic antagonist, in the 
presence of a Lanthanum/Lithium (R)-(+)-Binol complexe (Figure 30). 
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Figure 30: Preparation of (S)-Pindolol 
 
E. J. Corey described65 also the utilization of cinchona alkaloid derivatives as catalysts for the 
preparation of a precursor of the HIV protease inhibitor, Amprenavir (Figure 31).  
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Figure 31: Preparation of Amprenavir 
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II.2.3. Michael addition: nucleophilic addition to electron defficient C=C 
double bonds 
 
As shown in Figure 327b, in a Michael addition66, a nucleophile Nu- (usually generated by 
deprotonation of the precursor NuH) is added to the β position of an α,β-unsaturated acceptor A. 
Addition of Nu- to a prochiral acceptor A generates a new chiral center at the β-position of the 
acceptor A.  The reaction of the generated intermediate enolate anion with an electrophile E+ can 
afford a second chirality center at the α-position of the acceptor. The process suggests that the 
enantioface differentiation in the addition to the β-carbon can be performed in 2 ways: 1) by 
deprotonation of the Nu-H nucleophile by a chiral base , that would result in the formation of a chiral 
ion pair I, which could add to the acceptor asymmetrically 2) by deprotonation of the Nu-H 
nucleophile in one phase by a non-chiral base, and the transfer of the anion Nu- into the organic 
phase by a chiral phase-transfer catalyst, resulting again in the formation of a chiral ion pair.  
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Figure 32: Principle of the Michael addition 
 
Asymmetric versions of Michael reactions can also be performed using metal-ligand based catalysis.  
In recent years, two efficient and practical approaches have been developed to provide a chiral 
environment for the attacking nucleophile, yielding to asymmetric Michael reactions.  It consists first 
on the activation of the acceptor via the reversible formation of an chiral iminium ion, the face-
selective reaction with the nucleopile affording an enamine intermediate, that can be either 
hydrolyzed, or can react with an electrophile, yielding after hydrolysis a new β-chiral carbonyl 
compound.  
The second approach is the enamine pathway. If the nucleophile is an enolate anion, it can be 
converted into a reversible chiral enamine by condensation of the original carbonyl compound and a 
chiral secondary amine. 
Having both the same origin, but being interdependent, enamine and iminium catalysis are 
nominated as the “ying and the yang”67 by List67. 
The combination of these approaches yielded in the development of many tandem sequences as 
described for example by List68 or Mac Millan69, and resulted in the development powerful multiple 
component domino cascades12h,70.  
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Figure 33: Catalysis by iminium ion and enamine formation 
 
 
II.2.3.1. Intermolecular Michael additions of C- nucleophiles 
 
II.2.3.1.1. Metal ligand based catalysts  
 
Few examples of ligand-metal based complexes have been developed to catalyze Michael 
additions71. Mentionable are for example manganese-bisoxazoline complexes developed by 
Jackson72, the dinuclear zinc73 or lanthanum74 complexes of linked BINOL, aluminium-SALEN 
complexes75 , aluminum-lithium76 or ytrium BINOLATE complexes77. Scandium (III) salts in 
combination with chiral  biquinolinedioxide  or bis(hydroxymethyl)bipyridine78 , chiral ruthenium-
amido complexes79, palladium enolates 80, and  copper (II) -bisoxazoline complexes81 have also been 
reported to perform asymmetric Michael additions. 
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Figure 34: Metal based Ligands for asymmetric Michael reaction 
 
II.2.3.1.2. Chiral base and phase-transfer catalysts  
 
Chiral bases and phase transfer catalysts have been proved to perform efficient asymmetric synthesis 
as reported by Berkessel and Gröger7b. The first example was reported in 1975 by Wynberg and 
Herman82a. More recently, Deng83  and Soos84 reported the exploitation of related cinchona alkaloids 
(Figure 35) and Jorgensen85  reported also the catalytic activity of a new class of 6’-hydroxy cinchona 
alkaloids, with  a non-biaryl atropisomeric functionalization in 5’ position of the quinolinic ring, and 
for example the aminated derivative. Ammonium catalysts derived from natural compounds (such as 
t lysi i i  ion formation Cat lysis by enamine formation 
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tartaric acid86) or synthetic molecules (such as 1,1’-2,2’-binaphtol87) have also be reported to perform 
asymmetric Michael additions. 
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Figure 35: Example of modified cinchona alkaloids for Michael additions  
 
II.2.3.1.3. Organocatalysts for asymmetric Michael addition of C- nucleophiles 
 
Organocatalytic Michael additions of C-nucleophiles to electron deficient C=C double bounds, 
involving enamine and iminium processes have been well described in the literature7a-b,d, ,88. The most 
common organocatalyst is proline (Figure 36).  
It can indeed react with carbonyl compounds to form reversible iminium ions or with Michael 
acceptor or enamine intermediates, yielding the corresponding Michael products with high yields 
and enantioselectivities, due to its capacity to form higly organized transition states with extensive 
hydrogen-bound networks7a,d. The utilization of proline in the catalytic system afforded successful 
results in Michael reactions involving highly reactive donors and acceptors; while the proline 
catalyzed addition of aldehydes to simple enones have been less studied.  
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Figure 36: Proline 
 
For example, one successful utilization of proline, has been described by Hanessian and Pham89. 
Proline in combination with trans-2,5-dimethylpiperazine affords additions of a variety of 
nitroalkanes to acyclic enones with excellent enantioselectivity up to 93%, via (according to the 
authors) a “complex multi component chiral catalytic system”. 
 
Such as proline, proline derived organocatalyts have also been reported to perform efficient 
organocatalytic Michael addition. 
In 2005, Gellman and Chi90 achieved Michael addition of simple aldehyde to relatively non activated 
enones with up to 95-99% ees, using diphenylprolinol ether (Figure 37) as catalyst (1-5%).  
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Figure 37: Diphenylprolinol ether 
 
The combination of pyrrolidine and catechol as co-catalyst has also been described by the same 
group90, the catechol additive being supposed to activate electrophilically the enone via hydrogen-
bond donation to the carbonyl group (Figure 38). 
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Figure 38: Diphenylprolinol ether and cathecol used by Gellman and Chi
90
 
 
Other derivatives have been reported in the literature, such as chiral imidazolidinones (Figure 39), 
first prepared by MacMillan91 from L-phenylalanine, methylamine, acetone or pivalaldehyde 
respectively. Using the MacMillan catalysts in combination with cathecol, Gellman92 developed an 
efficient aldehyde-enone Michael addition. The most interesting results obtained by Gellman, involve 
the isolation of an imidazolidinone-enamine intermediate, as proof for the enamine process, while 
prior to him the activation of α,β-unsaturated aldehydes was supposed to proceed via an iminium 
activation93. In conclusion, imidazolidinones are able to activate carbonyl compounds by nucleophilic 
activation, in addition to their well known electrophilic activator nature94.   
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Figure 39: Mac Millan’s chiral imidazolidinones 
 
In addition, as cited above, the most used mode of activation for various Michael additions of 
stabilized carbon nucleophiles involved either enamine or iminium processes. They had thus 
application for the reaction of activated nucleophilic malonates or nitroalkanes95 to simple enones or 
of unactivated ketones or aldehydes with activated Michael acceptor (nitroalkenes)96.  
It is also notable to mention that malonates have also been successfully used by Jorgensen97 for 
enantioselective additions to α,β-unsaturated ketones and, α,β-unsaturated aldehydes (via iminium 
ion activation). 
 (S)-2-[bis(3,5-bistrifluoromethylphenyl) trimethylsilanyloxymethyl]pyrrolidine (Figure 40), for 
example, can perform Michael additions of several malonates to α,β-unsaturated aldehydes in good 
yields and in good to excellent enantioselectivities97b. 
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Figure 40: (S)-2-[bis(3,5-bistrifluoromethylphenyl) trimethylsilanyloxymethyl]pyrrolidine  
 
The group of Ley98a reported also the use of pyrrolidine analogues (Figure 41) for the Michael 
additions of malonates to various cyclic and acyclic enones with excellent enantioselectivities in the 
presence of piperidine. 
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Figure 41: 5-pyrrolidin-2-yltetrazole  
 
The addition of nitroalkanes to various cyclic and acyclic enones has also been developed by the 
same group98b,c using stoichiometric amounts of trans-2,5-dimethylpiperazine and 5-pyrrolidine-2-
yltetrazole as organocatalyst, with up to 98% ees. The mechanism of the reaction has not really been 
confirmed. It is postulated that the catalyst forms an iminium complex with the enone derivative.  
In 2005, Jorgensen99 reported also the use of a mixed chiral imidazolidine-2-yl tetrazole for the 
reaction, via iminium activation, of nitroalkanes with cyclic or acyclic enones with up to 92% ee 
(Figure 42). The same group described also the preparation of phenylalanine derived catalysts (Figure 
42) and their application as imimium activator for the addition of  dialkylmalonates and nitroalkanes 
to a variety of enones with good enantioselectivities (up to 79%)95a,b.  
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Figure 42: Chiral imidazolidin-2-yl tetrazole and phenylalanine derived catalyst 
 
α,α-diarylprolinol salts (Figure 37) in the presence of  p-nitro-benzoic acid proved also100 to be 
efficient  iminium activators in term of regio-, chemo-, diastereo- and enantioselectivities observed; 
the higher ees having been obtained for the reaction of linear or branched alkyl/aryl/heteroaryl 
substituted  aldehydes with cyclic, aromatic α,α-dicyanoolefins, while the same reaction performed 
in the presence of free prolinol derivatives didn’t afford good results, probably due to the formation 
of an unreactive hemiaminal compound101.  
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Figure 43: Chiral imidazolidine-2-yl tetrazole 
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II.2.3.2. Intermolecular nitro-Michael additions of C- nucleophiles 
 
Nitro alkenes are highly reactive partners for the addition of nucleophilic species. Because of the 
strong electron withdrawing properties of the nitro group and the excellent conjugation with the 
double bond, the negative charges, generated during the nucleophilic additions, are highly stabilized, 
resulting in a species less reactive than the nucleophile itself102.   
 
II.2.3.2.1. Metal based complexes 
 
As examples for the nitro-Michael reactions, the C2-symmetric bis(oxazoline) Magnesium complexes 
of Barnes103 , the bis(N,N-dibenzyl-trans-cyclohexanediamine)–Ni(II) complex of Evans104 can be 
mentioned (Figure 44).  
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Figure 44: Ligand-metal based catalysts for the nitro-Michael reactions 
 
II.2.3.2.2. Organocatalysts for intermolecular nitro-Michael additions of C- 
nucleophiles 
 
Many research projects105 have been conducted in recent years on the asymmetric organocatalytic 
conjugate addition of carbonyl compounds to nitroolefins, resulting in the development of a wide 
range of organocatalysts. Proline derived organocatalyts have been, for example, also used for nitro 
Michael additions with high yields and good to excellent enantioselectivities, such as homoproline by 
Oriyama106, (S)-2-[bis(3,5-bistrifluoromethylphenyl)trimethylsilanyloxymethyl]pyrrolidine by 
Hayashi107 , the S-homo-Pyrrolidine-2-yltetrazole108 by  Ley, chiral pyrrolidin-pyridine by Yu109, 
octahydro-indole-2-carboxylic acid by Herrera110 and related (S)-2,3-dihydro-1H-indole-2-carboxylic 
acid and analogue by Loh111, pyrrolidinyl-sulfamides by Chen and Xiao112.   
 
N
H
O
Si
N
H
N
N
N
N
H
H
N
H
H
OH
O
N
H
H
N
N
H
OH
OH
N N
H
CO
2
R
O
O
H
NH
N
H
S
N
H
R
OO
N
H
OH
OH
CF3
CF3
CF3
CF3Hayashi
Oriyama
Ley
Yu
Loh
Loh
Chen, Xiao Herrera
 
Figure 45: Proline related organocatalysts 
 
Gong113 , Wang114  or Cordova115 reported also efficient related organocatalysts in the nitro-Michael 
addition of various ketones.   
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Chiral thiourea derivatives (Figure 46) were also tested with success in asymmetric nitro-Michael 
addition. Tsogoeva116 , Jacobsen117, Tang 118 and Zu119 reported some examples performing highly 
enantioselective additions.  
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Figure 46: Chiral thiourea derivatives 
 
More “exotic” examples have also been designed, such as chiral amines derived from (2R,3R)-(+)-
tartaric acid by Barros and Phillips120 , N-alkyl-3,3’-bimorpholine derivatives by Alexakis121a,b  and/or 
Kanger 121c, or chiral trisimidazoline by Fujioka122. 
 
III. Conclusion  
 
A lot of progresses have been made in order to develop efficient syntheses of bioactive compounds 
such as natural products and analogs, drugs, resulting from the successful development in academia 
of innovative methods in the field of asymmetric synthesis, including metal based catalysis and 
organocatalysis and from their direct application in industry processes.  
This work will report some applications of these novel methodologies for the preparation of 
marketed drugs or drug candidates, via new alternative asymmetric pathways and discuss about the 
design of new catalysts and substrates, as well as the fine tuning of the reaction conditions to 
perform selected pharmaceutically important reactions under conditions applicable to an industrial 
synthesis. The example chosen for our studies is the synthesis of enantiomerically pure precursors of 
Aliskiren via organocatalytic Michael reactions and organometallic Henry reactions.  
The cases of aza-Michael addition and Friedel-Crafts alkylation will be reported in the corresponding 
chapter 3 and 4. These studies are related to the enantioselective synthesis of two Novartis drug 
candidates AFQ056 and KAE609. 
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CHAPTER 2: ASYMMETRIC SYNTHESIS OF RENIN PROTEASE INHIBITOR 
ALISKIREN (TEKTURNA/RASILEZ)  
 
I. Pharmacological activity 
 
Aliskiren 1, marketed as Tekturna in the US and as Rasilez in the EU, is the first non peptide-like renin 
protease inhibitor, being approved by the US authorities in March 2007 (in August 2007 in Europe) 
for the treatment of hypertension123, 109 years after the discovery of renin by Tigerstedt and 
Bergman in 1898. 
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Figure 47: Aliskiren 1 
 
Hypertension is the major risk factor for the cardiovascular diseases and mortality and affects more 
than 13% of the population worldwide. It is caused by a disfunction (overactivation) of the renin-
angiotensin-aldosterone cascade, a short term regulatory system to preserve blood pressure and 
blood volume124 (Figure 48). When a decrease in blood pressure or in blood volume occurs, renin is 
released into the circulation from the juxtaglomerular cells in the kidney and angiotensinogen, the 
only known substrate for renin, is released from the liver into the circulation. Renin cleaves the 
angiotensinogen from its N-terminus into the inactive decapeptide angiotensin I (AngI), which is 
converted in the blood to the active peptide angiotensin II (AngII) by the angiotensin converting 
enzymes (ACE) located in the endothelium. AngII binds then to receptors located on the blood 
vessels in the kidney, the adrenal gland, and the pituitary gland and neurons, which results in the 
activation of various signaling pathways to reduce excretion of sodium, retain body fluid and increase 
blood pressure yielding in the suppression of renin secretion. Most of these effects are mediated via 
the AngII type 1 (AT1) receptors and emphasized by the production of the aldosterone and 
norepinephrine resulting from the secretion of Ang II in the body, resulting also in the vascular 
remodeling, sodium re-absorption and an increase of the blood pressure.   
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123
: The renin-angiotensin-aldosterone (RAA) cascade 
 
As Skeggs125 reported, a therapeutic benefit in the control of hypertension could be achieved by 
interfering with this RAA cascade at several points: by blocking the AT1 receptors for AngII (such as by 
treatment later with for example Valsartan from Novartis), by inhibiting angiotensin converting 
enzyme (ACE) (such as for example by treatment later with the ACE inhibitor Benazepril from 
Novartis), or by preventing the formation of AngI through direct inhibition of renin. The author 
realizes so early that “Since renin is the initial and rate limiting substance in the renin-hypertensin 
system, it would seem that this last approach would be the most likely to succeed.” Nevertheless, the 
first marketed medications relied only on the treatment of the patients with ACE or Ang II receptors 
blockers which successfully led to a decrease of blood pressure.  Nevertheless, the activation of a 
concomitant feedback loop during the RAA cascade blockade results in the increase in the amount of 
Ang II, enhancing thus the secretion of renin, making the blockers inefficient towards the progression 
of cardiovascular diseases126.  Thus, direct renin inhibition has been long considered as the most 
attractive and logical drug target in the RAA cascade since it catalyzes the first step of the system 
with the highest substrate specificity. 
 
In the early 1980, Ciba-Geigy launched a research project to find out potent renin inhibitors leading 
to the discovery of Aliskiren in 1993.  
 
Aliskiren interacts with several binding pockets in distinct regions around the active site of renin, 
particularly with the subpocket S3sp of renin126a. Binding to this sub-pocket is essential for strong 
renin inhibition by Aliskiren (Figure 49).  
A-II-Receptor 
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Figure 49
126a
: Graphic depiction of the binding of Aliskiren to the active site of renin 
 
II. Preparation of Aliskiren base 1 
 
The development of Aliskiren 1 has been extremely challenging due to the presence of the four 
adjacent syn-stereocenters of the all-carbon linear skeleton. The enantioselective synthesis of its 
unique chemical structure became the centre of many investigations (Figure 50).  
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Figure 50
127
: Previous strategies of the synthesis of Aliskiren 
 
The first reported synthesis128 afforded Aliskiren 1 with poor stereoefficiency in more than 25 steps 
and required multiple chromatography preparations, making it not convenient for a large scale 
production. 
 
The first multikilogram scale route129 to Aliskiren 1 focused on synthesis of the key intermediate 2 of 
Figure 51, bearing already the syn-configurated 1,2-amino alcohols and 2,7-diisopropyl groups, the 
stereoselectivity being introduced by the use of Evans’ methodology to prepare compound 3.  
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Figure 51: First multikilogram scale strategy for the synthesis of Aliskiren 
 
An alternative and elegant version of the first industrial process was reported130 a few years later, 
allowing the production of Aliskiren in a cost effective process. This new strategy involved innovative 
key steps, such as the nickel catalyzed trans-selective cross coupling alkenylation of the Grignard 
reagent of 4, the bromolactonisation of 5 performing with high regio- and stereoinduction, and the 
transformation of 6 to 7 proceeding under complete regio- and stereocontrol with double inversion 
of the absolute configuration (Figure 52).  
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Figure 52: First large scale strategy for the synthesis of Aliskiren 1 
 
Many innovative routes have been investigated later to access the unique chemical structure of 
Aliskiren on a production scale131.  
 
We will present two synthetic routes to access two key intermediates of Aliskiren (Figure 54 and 
Figure 55), the C8 lactam-lactone 15 and C8 lactone 9, by introducing the required stereo 
configuration of Aliskiren via metal catalyzed and organocatalytic asymmetric reactions, using the 
work reported in 2007 and 2008 by Sedelmeier131i,j. 
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III. Novel successful alternative synthesis  
 
III.1. Introduction  
 
This work will report two different asymmetric strategies based on metal catalytic Henry reaction 
and organocatalytic Michael addition (Figure 53). Other alternative strategies for the preparation of 
some potential intermediates will be also described later. 
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Figure 53: Key bond formation of both strategies for the synthesis of Aliskiren 
 
Both strategies are based on the preparation of the following common C4 intermediate, the so called 
“Nitroalcohol A” 8 and the C8 lactone intermediate 9 (Figure 54), via two different pathways. 
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Figure 54: Retrosynthetic study of Aliskiren 
 
The first synthesis involved the convergent approach published by Sedelmeier in 2008131j, where the 
key “nitro compound A” 8 is obtained (as shown in Figure 55) via trimethylsilyl diphenylprolinol ether 
catalyzed Michael addition of nitroethylene to isovaleraldehyde. It is converted after protection of 
the alcohol moiety into its aldehyde analogue 12 via an oxidative Nef reaction.  Both reagents react 
then together via a metal catalyzed asymmetric syn-selective Henry reaction to yield the 
corresponding γ-syn-nitroalcohol derivative 14, bearing already all the syn-configurated 
functionalities of Aliskiren.  The lactam-lactone intermediate 15 can be obtained as described in the 
Sedelmeiers131i,j process by TEMPO and bleach oxidation after deprotection of the hydroxyl group, 
reduction of the nitro group to amino unit and protection/activation of the amino group with a Boc 
unit.  The resulting lactam moiety can then be selectively opened by the corresponding aryl lithium 
derivative or Grignard reagent thanks the introduction of the Boc group as an activating group at the 
lactam nitrogen.  Saponification of the lactone moiety and reduction of the carbonyl group (or 
reverse process) and subsequent hydrogenolysis allow the formation of the appropriate carboxylic 
acid derivative, that can be converted to Aliskiren base 1 under classical peptide reaction conditions.  
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Figure 55: Retrosynthetic study of the preparation of 1 via the novel intermediates 12 and 14 
 
The second process is represented in Figure 56, involved also as key reaction step a ligand-metal 
based catalyzed asymmetric syn-selective Henry reaction to afford the Henry Product 18 from the 
novel nitro compound 17 and the already described aldehyde 12. The challenge in the preparation of 
59 from the corresponding alcohol 62, is to retain the stereochemistry of the isopropyl group of 62 
during the oxidation step. The major benefit of this synthesis is to afford Aliskiren base 1 in a short 
route, which can be developed into a process whose costs are acceptable.  
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Figure 56: Retrosynthetic study of an alternative process for the preparation of Aliskiren 
 
III.2. Preparation of the Aliskiren precursor 8 via enamine or iminium ion 
catalyzed enantioselective Michael addition 
 
III.2.1. Introduction: the actual process 
 
The first synthesis of the γ-nitro alcohol derivative 8 was reported in 2007 by Sedelmeier 131j. It is 
prepared inter alia by an efficient organocatalytic Michael addition of nitroethylene to 
isovaleraldehyde, via in situ formation of an enamine intermediate with a proline derived catalyst. 
The subsequent in situ reduction of the generated aldehyde derivative with sodium borohydride 
allows the isolation of the key intermediate “nitroalcohol A” in good yield and with an excellent 
enantiomeric excess of 96% (Figure 57).  
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Figure 57: Actual process for the preparation of 8 via enamine catalysis 
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In spite of the high efficiency of this process, one drawback is the necessity of preparation and 
handling of large amounts of nitroethylene. We report here two novel methodologies to prepare 8 
from isovaleraldehyde 10 avoiding the utilization of nitroethylene. 
 
III.2.2. Novel alternative procedures 
 
A wide range of procedures1 are available in the literature for the enantioselective preparation of γ 
nitro alcohol derivatives via Michael addition, involving efficient ligand-metal complexes based 
catalyzed and organocatalyzed methodologies. We limited however our approach to the utilization of 
organocatalytic methods, involving enamine and iminium ion activation of the substrates with O-
trimethylsilyl diphenyl prolinol ether I as catalyst, as represented on Figure 58.  
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 Figure 58: New processes to „Nitro alcohol A“ 8  via enamine and iminium ion intermediates 22 and 26 
 
Compound 8 will be thus prepared: 1) via the asymmetric Michael addition of an in situ generated α-
substituted 2-Nitro-acrylic derivative 19 to isovaleraldehyde, via the formation of an enamine 
intermediate 22, and 2) via the organocatalytic Michael addition of nitromethane or related 
derivatives to (in-situ generated) isopropylacroleine 25, via the formation of the iminium ion 
intermediate 26. 
 
 
 
 
 
 
 
                                                          
1
 see chapter 1 
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III.2.3. Enamine catalyzed Michael addition of isovaleraldehyde to nitroalkene 
derivatives 
 
III.2.3.1. Introduction 
 
In this first approach, a muticomponent OTMS-diphenyl prolinol ether I catalyzed Michael addition of 
isovaleraldehyde to the in situ generated nitroethylene derivative was envisaged (Figure 59), 
applying the conditions described by Sedelmeier and co-workers131j, who performed the Michael 
addition of isovaleradehyde to nitroethylene in toluene in the presence of small amounts of the 
catalyst (2% mol.) and 2 equivalents of acetic acid (Figure 59). The advantage of the new process is 
the in situ preparation and immediate consumption of an highly reactive α-ester substituted 
nitroethylene reagent  19 through the condensation of the commercially available and safe nitro 
ester derivative 21  to aqueous formaldehyde. This process prevents the handling and use of risky 
intermediates. 
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Figure 59: Enamine strategy 
 
III.2.3.2. Results and discussion 
 
III.2.3.2.1. Preparation of nitroethylene analogue 
 
In a first study, we proved the possibility of formation of the nitroethylene analogue 19 under the 
Michael addition conditions published by Sedelmeier, by Knoevenagel condensation of commercially 
available and safe nitroacetate (1 equivalent) to aqueous formaldehyde132  (1 equivalent) in the 
presence of acetic acid (3 to 5 equivalents)  in THF at 40°C. The use of acetic acid appears to serve 
two functions: facilitating dehydration of the intermediate nitroaldol133 and activation of the 
enamine process. 
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Figure 60: The „in situ“- synthesis of 2-nitro-acrylic acid methyl ester 19 
 
During the process, in the reaction mixture, only the existence of nitro acetate 21 was detected, the 
nitroethylene intermediate 19 being immediately consumed in the Michael addition.  According to 
the DSC measurement (Figure 61) of commercially available nitro acetate 21, which revealed a 
decomposition start point at 150-160°C, the process is a safe alternative procedure. 
 
  
 
Figure 61: Dynamic and thermic DSC measurements of commercially available compound 21 
 
 The in situ generated β-nitro acrylic ester should then react with isovaleraldehyde to form the 
desired aldehyde compound 20 (Figure 59). 
 
III.2.3.2.2. Enamine formation  
 
In order to prove the viability of the enamine process, we studied the in situ formation of 22, 
generated from the condensation of isovaleraldehyde and OTMS diphenyl prolinol I.  In a general 
procedure, an equimolar amount of aldehyde and catalyst (1.0 mmol scale) are dissolved in 0.75 mL 
d6-DMSO. 1H NMR spectra in d6-DMSO after 5 min revealed the presence of the characteristic 
signals134 of the enamine: a doublet at δ 6.17-6.21 ppm with a coupling constant of ca 13.8 Hz 
attributed to the vinylic proton α to the nitrogen and at δ 3.79-3.84 ppm (3J = 13.8 Hz) corresponding 
to β-vinylic proton.  Based on NMR analysis, the enamine 22 is formed after 5 minutes at room 
temperature with a conversion of 75 % with a ratio E- and Z-enamine > 99:1, the only detectable 
product being the E-enamine (Figure 63).  
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Figure 62: E-enamine formation. NMR study performed on a 1.0 mmol scale with 1 equivalent of catalyst and 1 
equiv. of isovaleraldehyde in 0.75 mL DMSO-d
6
- Analysis after 5 min, Cconversion= 75% 
 
In order to prove the formation of the enamine 22 under reaction conditions of the Michael addition, 
an equimolar amount of aldehyde and catalyst (1.0 mmol scale) was mixed in THF at 35°C. NMR 
analysis (1H, d6-DMSO) revealed the formation of the enamine 22 after 20 minutes at room 
temperature with a conversion of 56 % and in a ratio of E and Z-enamine > 99:1, the only detectable 
product being the stable E-enamine (Figure 63).  
 
 
Figure 63: E-enamine formation. reaction was performed on a 1.0 mmol scale with 1 equivalent of catalyst and 
1 equiv. of isovaleraldehyde in 1 mL THF at 35°C - DMSO-d
6 
NMR Analysis after 20 min, Cconversion=56% 
 
After two days in d6-DMSO, we observed the coherent
134 formation of the oxazolidine 23, resulting 
from the desilylation of 22. 23 was also prepared by mixing an equimolar amount of aldehyde and 
diphenylprolinol in d6-DMSO (Figure 64). 
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Figure 64: E-enamine formation. NMR study was performed on 1.0 mmol scale with 1 equivalent of catalyst 
and 1 equiv. of isovaleraldehyde in 0.75 mL dmso-d
6
. The oxazolidine 23 was prepared at 1.0 mmol scale by 
mixing 1 equivalent of diphenylprolinol and 1 equiv. of isovaleraldehyde in 0.75 mL DMSO-d
6
 
 
III.2.3.2.3 Synthesis of the (S)-Aliskiren precursor 8 via organocatalyzed 
enantioselective Michael addition 
 
We performed the OTMS diphenylprolinol ether I organocatalyzed Michael addition of 
isovaleraldehyde with the in situ generated nitroethylene  derivative 19, by adding simultaneously at 
35°C an equimolar ratio of an aqueous solution formaldehyde (ca 37%) and nitroacetate 21 to a 
mixture of isovaleraldehyde (1.0 equivalent) , organocatalyst I (15%) and acetic acid (3.6 equivalents) 
in THF (Figure 65). The in situ formed nitroethylene analogue 19 reacted very fast (within 30 min) 
with the enamine, generated in situ by condensation of the proline related catalysts and 
isovaleraldehyde 10 to form the corresponding aldehyde intermediate 20, with a diastereomeric 
ratio ((S,R) versus (S,S)) of 63:37 (1HNMR analysis). Subsequent reduction of the aldehyde 
intermediate 20 with sodium borohydride (1.1 equivalents) after neutralization to pH=7 by addition 
of an aqueous solution of sodium hydroxide (2M) provided the desired nitro compound 8  with 66% 
yield and an enantiomeric excess of 96% (measured by chiral HPLC with a CHIRALPAK AD-H column at 
205.5 nm). The reduction step can also be performed by addition of NaBH3OAc (15 equivalents) after 
neutralization to pH=7 with aqueous sodium hydroxide (2M) yielding 8 with an enantiomeric excess 
of 90%. The Michael addition and reduction steps were conducted in one-pot sequential mode to 
avoid racemization on the α-position of the aldehyde moiety of 20.  
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To explain the formation of 8, we postulated that, under the slightly basic reaction conditions of the 
borohydride reduction, the aldehyde intermediate 20 is saponified and the nitro carboxylic acid 
easily decarboxylated to afford the desired chiral nitroalcohol 8. 
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Figure 65: Synthesis of nitrocompound 8 via the formation of intermediate 20 
 
III.2.3.2.4. Screening of catalysts for the Michael addition of isovaleraldehyde 
to the α-substituted nitroethylene derivative 19 
 
A selection of proline related catalysts was tested at 35°C (Table 2) to evaluate its influence on the 
stereoselectivity of the reaction.  
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O O
NO
2
O O
NO
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THF, 35°C
+
(S) (S,R)
10 2019  
   
N
H
OH
O
II  
  
Entry 1 2 3 4 
Reaction conditions  a a a b 
(SS:SR) ratio 
measured by 
1
H NMR 
on aldehyde 
intermediate  
63:37 62:38 52:48 No conversion 
Table 2: Screening of diverse catalysts-reaction conditions: reactions performed a) with isovaleraldehyde (1 
eq.), nitroacetate (1 eq.), formaline (1 eq.), selected catalyst (15%), acetic acid (3.6 eq.) in THF at 35°C b) with 
isovaleraldehyde (1 eq.), nitroacetate (1 eq.), formaline (1 eq.), selected catalyst (15%), in THF, at 35°C 
 
The L-proline II catalyzes the reaction affording moderate diastereoselectivity in the same range as 
the (S)-diphenyl prolinol silyl ether I, while its triflate salt IV doesn’t perform any reactions (Table 2, 
N
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N N
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Entry 4). The tested catalyzed Michael addition performing under acidic conditions, the acid form of 
IV was tested without addition of any acidic additive (Table 2, Entry 4).This result seems to be in 
accordance with the data collected by Seebach et al, who tested a wide range of additives with pKa 
values (in water) from 0.7 to 10.2 in (S)-diphenylprolinol silyl ether I catalyzed Michael additions, and 
proved the direct correlation between the pKa value of the additive and the reaction efficiency, the 
most effective pKa value being around 7 105.   
 
The (R)-5-pyrrolidine-2-yltetrazole catalyst III affords 20 without any diastereoselectivity under the 
described reaction conditions. 
 
III.2.3.2.5. Some drawbacks and advantages of the reaction 
 
The utilization of (S)-diphenyl prolinol silyl ether I in THF at 35°C in combination with acetic acid are 
suitable conditions for the highly enantioselective Michael addition of isovaleraldehyde to 
nitroalkene 19, via the activation of the aldehyde partner 10 by the formation of the enamine 
intermediate 22. Nevertheless, under the same conditions, 22 can also perform aldolization reactions 
in the presence of formaldehyde 24 to afford the α,β-unsaturated aldehyde 25 (Figure 66). When an 
excess of formalin 24 was used to perform the Knoevenagel step, or when both, nitroacetate 21 and 
formalin 24 were not added concomitantly (resulting in an excess of 24 in the reaction mixture), we 
observed indeed the competitive formation of the 2-isopropylacroleine 25, resulting in the 
consumption of isovaleraldehyde. Under our experimental conditions, self aldolization of aldehyde 
10 was not detected, in accordance with the literature135.  
H
O
H
O
NH
O
SiR
3
Acetic Acid
THF, 35°C
aq. Formaldehyde
          24
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Figure 66: In situ formation of 2-isopropyl acroleine 25 
 
While the formation of 25 can be regarded as a major drawback of the process, yielding in the 
consumption of the starting material 10, it can also be considered as a starting point for the 
development of a new methodology based on a multicomponent domino aldolisation-Michael136a-c 
addition sequence for the enantioselective preparation of the Aliskiren precursor 8. Methodologies 
were indeed reported in the literature for the preparation of chiral γ-nitro aldehyde derivatives via 
enantioselective Michael addition of nitromethane or substituted nitroalkanes to α,β-unsaturated 
aldehydes2. 
 
 
                                                          
2
 About enantioselective Michael addition of nitro methane or substituted nitroalkanes to α,β-unsaturated 
aldehydes: see Chapter 1 and references cited 
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III.2.3.2.6. Conclusion 
 
We proved that the building block 8 could be rapidly prepared with good yield and enantioselectivity 
under safe and  controlled reaction conditions via the use of 2-nitro-acrylic acid esters (as 19). The 
advantage of this procedure is the possibility of its application on large scale and potentially as a 
continuous flow process. 
 
III.2.4. Michael addition of nitromethane to 2-isopropyl acroleine 25 catalyzed 
by diphenylprolinol silyl ether I 
 
III.2.4.1. Introduction 
 
Several groups136 have reported the utilization of diphenylprolinol silyl ether as catalyst for the 
reaction of nitromethane to α,β-unsaturated aldehydes,  affording the desired Michael adducts with 
excellent yields and enantioselectivities. In all cases, the presence of an acid (benzoic acid, 
Hayashi136b, Wang136c) or a base (LiOAc, Wang136a) as co-catalyst was required to perform the 
reaction. Benzoic acid is incorporated to assist the formation of the iminium ion intermediate, while 
the use of LiOAc promotes the formation of a more reactive nitronate nucleophile. Palomo et al137 
demonstrated the possiblity to perform the reaction in water. 
 
We hoped that addition of nitromethane or nitro-acetic acid methyl ester 21 to a mixture of 2-
isopropyl acroleine 25, diphenylprolinol silyl ether I in the presence of a selected additive (see Table 
3) and subsequent in situ reduction of generated Michael product, would afford the (S)-Aliskiren 
precursor 8 with good enantioselectivity (Figure 67). 
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Figure 67: Preparation of 8 by Michael addition of nitromethane or related derivatives to the enone 25, via the 
formation of an iminium ion 26 
 
III.2.4.2. Results and discussion 
 
III.2.4.2.1. Addition of nitromethane to the α-substituted enone 25 
 
A selection of acid and base additives was screened in an appropriate solvent (in most of the cases, 
an alcoholic solvent). The reactions were performed on a 0.5 mmol scale by adding 2 equiv. of 
nitromethane 27 at 0°C or 25°C to a solution containing one equivalent of 25,  10% catalysts I and the 
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selected additive. The enantiomeric ratios (Table 3) of 12 were determined by chiral HPLC using  
CHIRALPAK AD-H column and were, after the in situ subsequent reduction of 12 to 8, confirmed with 
the literature data131j. 
 
H
O
H
O
NO
2CH3-NO2
25 27 12
+ cat. I, additive
 
 
 Catalyst Additives Solvent Temperature 
% 12 
 (%area) 
ee 
(%) 
1 - DBU DCM rt 100 (2h) 0 
2 - NaOEt, 21%EtOH EtOH rt degradation - 
3 - Tetramethylguanidine THF rt 100 (2h) 0 
4 10% Benzoic Acid MeOH 0°C 19 (4d) 64 
5 2 eq. Benzoic Acid MeOH 0°C 24 (4d) 64 
6 10% LiOAc MeOH/DCM rt 17 (4d) 0 
7 
 
10% AcOH MeOH 
 
0°C 
rt 
1 (4d) 
10 (24h) 
80 
66 
Table 3: Screening of a selection of additives. Reactions were performed on a 0.5 mmol scale with the desired 
amount of catalyst I at 0°C or 25°C (rt) and 2 equiv. of nitromethane in appropriate solvent. Enantiomeric 
excesses (ee) were determined by HPLC using a CHIRALPAK AD-H column and compared with literature data. 
Conversion rate was determined by reverse phase HPLC. 
 
Contrary to the high enantioselectivity observed by Wang136a, the use of lithium acetate as co-
catalyst in a mixture of methanol/dichloromethane performs the Michael addition with low rate and 
no enantioselectivity was observed (Table 3, Entry 5). Activation of the Michael donor via the 
formation of a more reactive nitronate species was also tested by introduction of a selection of bases 
(Table 3, Entry 1-4,6) and afforded the nitroaldehyde 12 within a short reaction time, but as racemic 
mixture (Table 3, Entry 1-4). The utilization of benzoic acid and acetic acid as additives in methanol at 
0°C, affords the (S)-Michael product with satisfactory enantioselectivities (ee up to 80%) with low 
conversion. Subsequent in situ reduction of the aldehyde intermediate 12 provides the (S)-Aliskiren 
precursor 8 with an enantiomeric excesses of 32%  up to 70%.  
 
A selection of proline related catalysts was tested to evaluate the influence of the catalyst on the 
rate and selectivity of the reaction (Table 4). The reactions were performed on a 0.5 mmol scale in 
MeOH at 0°C and then at 25°C using 10% of the selected catalyst, in the presence of 2 equiv. of 
nitromethane and 10% of benzoic acid. 
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H
CH3-NO2
25 27 12
+ cat., additive
II
III
V  
 Catalyst  
%12 
(%area) 
(2.5d, 0°C) 
%12 
 (%area) 
(24h, 25°C) 
ee 
 (%) 
1 I - 0.5 - 
2 IV - 0.2 - 
3 V 1.3 1.3 42 
 
Table 4: Screening of a selection of catalysts. Reactions performed on a 0.5 mmol scale with 10% of the 
selected catalyst at 0°C and then at 25°C, in the presence of 2 equiv. of nitromethane, 10% of benzoic acid in 
MeOH. Enantiomeric excess (ee) was determined by HPLC using a CHIRALPAK AD-H column and compared with 
literature data. Conversion rate was determined by reverse phase HPLC. 
 
(S)-proline I, and (R)-5-pyrrolidin-2-ylcumyltetrazole IV were ineffective in performing the Michael 
addition of nitromethane to 2-isopropylacroleine 25 affording the aldehyde 12 with unsatisfactory 
conversion rate (Table 4, Entry 1-2). It should be noted that the (R)-5-pyrrolidine-2-yl tetrazole V 
afforded the nitro aldehyde 12 with a satisfactory enantioselective excess of 42% but with a low 
conversion rate (Table 4, Entry 3). 
 
III.2.4.2.2. Multicomponent domino aldolization-Michael sequence 
 
An alternative process for the enantioselective preparation of 8 was envisaged using the more 
reactive nitro-acetic acid methyl ester 21 in a multicomponent domino aldolization-Michael reaction 
(Figure 68). 
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Figure 68: Multicomponent domino aldolization-Michael synthesis of the Aliskiren precursor 8 
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1H NMR studies were conducted in CDCl3 in order to evaluate the potential of the sequence. An 
equimolar ratio of isovaleraldehyde and formaldehyde were mixed in THF at 35°C in the presence of 
15% of OTMS diphenyl prolinol ether and 4.9 equivalents of acetic acid (Figure 66).  
 
1H NMR measurement (after 2h45) revealed the presence of the characteristic signals of the 
isopropyl acroleine derivative 25: a singulet at δ 9.5 ppm attributed to the aldehyde proton and at 
6.2 and 5.9 ppm corresponding to vinylic protons.  The absence of the signal attributed to the proton 
of the aldehyde moiety of isovaleraldehyde 10 at 9.7 ppm proved the complete conversion after 2 
hours 45 min of 10 to 25 (Figure 69).  
 
 
Figure 69: 
1
H NMR (CDCl3) of the reaction mixture after stirring over 2h45. Reaction performed on a 23 mmol 
scale with 15% of catalysts, 1 eq. of formalin and 1 eq. of isovaleraldehyde at 35°C in THF in presence of 4.9 eq. 
of acetic acid. 
 
One equivalent of nitroacetate was then added at 35°C to the reaction mixture. 1H NMR (CDCl3) 
analysis of the reaction mixture after 2 hours, 18 hours and 48 hours revealed the presence of the 
characteristic signals of the aldehyde intermediate 20:  at 9.63-9.64 ppm attributed to the aldehyde 
proton and at 5.17-5.25 ppm for the proton in α-position to the nitro group (Figure 70). Integration 
of the signals characteristic of 20 and of the starting material 25 revealed the formation of 82% of 20 
after two days.  
 
25 
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a)  
b)   
c)  
Figure 70: 
1
H NMR (CDCl3) of the reaction mixture after addition of 1 eq. of nitroacetate. a) after stirring over 
2 hours b) after stirring over 18 hours c) after stirring over 48 hours  
 
It is also important to note that the complete conversion of 10 to isopropyl acroleine 25 under the 
selected reaction conditions (the same as in the case of the preparation of 8 from isovaleraldehyde 
via diphenylprolinol silyl ether I catalyzed Michael addition) required the reaction mixture to be 
stirred over 2 hours 45 min. for the first step. The subsequent Michael addition with nitro-acetic acid 
methyl ester 21 was a very slow reaction, while the Michael addition of isovaleradehyde to the α-
substituted nitroethylene analogue 19 was completed within 30-40 min. The aldolization-Michael 
pathway is thus not competitive to the enamine process during the 1.4 conjugate addition of 
25 20 
25 20 
25 20 
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isovaleraldehyde to the in situ generated nitroalkene 19. It only results in the consumption of the 
starting material. 
 
1H NMR (CDCl3) analysis of the reaction mixture revealed also the formation of 20 with a satisfactory 
(S:S) or (S:R) ratio of 63:37, comparable to the selectivity resulting from the enamine pathway.  
The subsequent borohydride reduction of 20 was not performed, but according to the results 
obtained for the enamine pathway3, the reaction should afford the (S)-Aliskiren intermediate 8 with 
moderate to good enantioselectivity. 
 
III.2.4.3. Conclusion 
 
The first reported results relative to diphenylprolinol silyl ether catalyzed 1.4 conjugate addition of 
nitromethane and of its α-substituted analogue to the α-substituted enal 25 allow us to envisage the 
possibility of an alternative enantioselective procedure for preparation of the (S)-Aliskiren precursor 
8, involving the activation of 25 via the formation of an iminium ion. A multi component domino 
approach, involving aldolization and Michael addition steps can also be regarded as a potential 
sequence leading to the desired precursor 8, although the optimization of the reaction conditions is 
still required for its application to large scale production.  We proved the possibility to produce the 
C4 nitro intermediate 8 via a new safe process.   
 
III.2.5. Alternative procedure for the preparation of nitroethylene  
 
In 1992 Ballini138 reported the utilization of acidic Alox (Brockmann Activity I) for the dehydration of 
β-hydroxyl nitro compound into nitro olefin. Using the same reaction conditions, we envisaged to 
prepare nitroethylene by dehydration of nitroethanol 35 (Figure 71) and studied the reaction with 
the help of 1H NMR analysis in CDCl3. 
OH
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11
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Figure 71: Synthesis of 11 from nitroethanol 35 
 
One equivalent of nitroethanol 35 (0.9 mmol scale) was added in a sealed tube to a suspension of 
acidic Alox (Brockmann Activity I) and anhydrous magnesium sulfate in CDCl3 and heated to 70°C. 
1H 
NMR (CDCl3) analysis of the reaction mixture after 35 min and 1 hour 30 min. (Figure 72) revealed the 
presence of the characteristic signals of nitroethylene, at 5.6-5.9 ppm attributed to the vinylic proton 
in α-position to the nitro group, at 6.5-6.6 ppm and 7.0-7.2 ppm corresponding to the vinylic protons 
in β position.     
                                                          
3
 see Chapter 2, III.2.3  
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Figure 72: NMR study (
1
H, CDCl3) of the preparation of nitroethylene from nitroethanol. Reaction performed on 
0.9 mmol scale; 1 equivalent of nitroethanol was added in a sealed tube to a suspension of 13 equivalents of 
acidic Alox and 11 equivalents of anhydrous magnesium sulfate in 4 mL CDCl3 and heated to 70°C 
 
A selection of dehydrating agents, solvents and temperature were screened to accelerate the 
formation of 11 (Table 5). 
OH
NO
2
NO
2
35 11  
  (mmol) 
Alox 
(eq.) 
MgSO4 
(eq.) 
SiO2 Cellfloc 
Solvent 
(4mL/mmol) 
Tempe
-rature 
Conversion
(NMR) 
Conversion 
(%area, LC) 
1 0.9 12 10 - - Cl(CH2)2Cl 40°C 
11% 
(45min) 
54% 
(4h30) 
2 1.1 9 8 - - Cl(CH2)2Cl 70°C 
22% 
(35min) 
85% 
(4h30) 
3 5 6 - - - Cl(CH2)2Cl 80°C - 
76% 
(4h00) 
4 0.9 13 11  - CDCl3 70°C 
40% 
(35min) 
88% (1h30) 
- 
5 1.1 9 - - - Cl(CH2)2Cl 70°C 
18% 
(35min) 
- 
11 
11 
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6 1.1 - 8 - - Cl(CH2)2Cl 70°C 
No 
conversion 
(35min) 
- 
7 1.1 - - 15 - Cl(CH2)2Cl 70°C 2% (1h30) - 
8 1.0 - - - 
1.0676 
g 
Cl(CH2)2Cl 70°C - 1%(1h30) 
Table 5: Dehydration of nitroethanol to nitroethylene. Reactions were performed in sealed tube under the 
conditions described in table. 
a
SM= starting material 
 
Cellfloc and magnesium sulfate were ineffective in performing the dehydration (Table 5, Entries 6,8). 
The utilization of silica gel and acidic Alox (Brockmann Activity I) afforded the desired product but the 
reaction proceeded 10 times faster in the case of Alox in comparison to silica gel (Table 5, Entries 
5,7).  The best results were obtained when acidic Alox (Brockmann Activity I) was used in 
combination with magnesium sulfate at 70 to 80°C, the increase of the temperature accelerating the 
dehydration (Table 5, Entries 1-4).  
 
Distillation under reduced pressure at 49°C (bath temperature) at 100 mbar of the 1,2-
dichloroethane solution containing a mixture of nitroethanol and nitroethylene resulting from the 
utilization of Alox as dehydrating agent at 80°C (Table 5, Entry 3) afforded at a boiling point of 30° C a 
pure solution nitroethylene in 1,2-dichloroethane . 1H NMR (CDCl3) analysis of the distillation fraction 
revealed the presence of the characteristic signals of nitroethylene (Figure 73). The signals 
corresponding to nitroethanol (4.05-4.15 ppm and 4.4-4.5 ppm) were not detected.  
 
 
Figure 73: 
1
H NMR (CDCl3) of the purest destillation fraction of nitroethylene in solution in 1,2-dichloroethane 
 
An heterogeneous phase process for preparation of nitroethylene can be envisaged using Alox 
(Brockmann Activity I) in 1,2-dichloroethane in the presence of magnesium sulfate. Destillation under 
reduced pressure affords the nitroalkene derivative as a diluted solution in 1,2-dichloroethane. By 
replacing 1,2-dichloroethane by toluene and after optimization of the reaction conditions, we could 
produce the adequate nitroethylene solution for the OTMS diphenylprolinol ether catalyzed 
enantioselective synthesis of the Aliskiren precursor 8, from isovaleraldehyde.   
11 
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Figure 74: Hypothetical representation of a process for the preparation of Aliskiren precursor 8, involving acidic 
Alox (Brockmann Activity I) 
 
In the future, according to the publications of Ballini in 1992138 and 2006139, a one-pot sequence, 
starting from formaldehyde and nitromethane under basic Alox conditions could also be envisaged 
for the synthesis of Aliskiren precursor 8. 
 
III.2.6. Conclusion 
 
The 3rd generation synthesis of Aliskiren 1 requires the preparation of the (S)-precursor 8 with 
excellent enantioselectivity and yield. We envisaged to introduce the chirality by performing 
enantioselective organocatalyzed Michael addition, involving respectively activation of the substrate 
by the reversible formation of an enamine or iminium ion.  
 
In the first approach, we performed the OTMS diphenyl prolinol ether I catalyzed Michael addition of 
an in situ generated α-substituted analogue of nitroethylene to isovaleraldehyde affording in the 
presence of acetic acid, (and after in situ reduction of the Michael adduct) compound 8 with 
satisfactory yield (58%) and enantioselectivity (ee up to 84%). The α-substituted analogue 19, formed 
in situ by Knoevenagel condensation of commercially available nitro-acetic acid methyl ester 21 and 
formaldehyde was never detected in the reaction mixture, reacting immediately with the in situ 
generated enamine 22. 
Under the similar reaction conditions 22 performed also an aldolization reaction with formaldehyde 
to provide the α-substituted α,β unsaturated aldehyde 25. Nitromethane or nitroalkane analogues 
reacted slowly with 25 under the conditions studied, to yield the Aliskiren precursor with the desired 
(S)-configuration with moderate conversations. Good enantioselectivity of the reaction was observed 
using the organocatalyst I in methanol in the presence of benzoic acid or acetic acid as co-catalyst. A 
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one-pot multi-component domino aldolization-Michael addition cascade was evaluated for the 
synthesis of 8, involving isovaleraldehyde, formaldehyde and nitro-acetic acid methyl ester 19. 
Starting from the same reactants (isovaleraldehyde, formaldehyde and nitro-acetic acid methyl ester 
19), we were able to prepare the Aliskiren precursor 8 with good to high enantioselectivity via two 
different pathways. 
 
III.3. From C4-nitro alcohol intermediate to C8-lactam-lactone intermediate 
15 
 
III.3.1. Introduction 
 
The chemical structure of Aliskiren 1 requires the introduction of four adjacent syn-stereocenters. A 
convergent strategy was envisaged, involving a syn-enantioselective Henry reaction to prepare the 
eight-carbons-chain precursor 9 bearing all the syn-configurated substituent of Aliskiren.  
The general synthetic route we employed for this strategy was based on the approach patented by  
Sedelmeier131j,  who reported the effective and elegant preparation of Aliskiren 1 via the preparation 
of the lactam-lacton intermediate 15 from the syn-Henry product of nitro compound 8 and its 
aldehyde analogue 28 (Figure 75). 
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Figure 75: Strategy for the enantioselective synthesis of Akiskiren 1 
 
The scale up of the process developed by Sedelmeier required the optimization of all the steps of the 
synthesis to prepare all of the intermediates with excellent yields, enantioselectivities and under 
“production safe” conditions, in particularly the key intermediates 15, 28 and 8.  
 
Sedelmeier131j proposed to synthesize the O-benzyl protected aldehyde 28 from 8: 1) by introducing 
the benzyl protective group with 2,2,2-trichloroacetamidate and trifluoromethane sulfonic acid in 
dichloromethane and by performing the subsequent Nef reaction under classical methods or with 
sodium percarbonate;  2) in two steps from the (S)-2-chloromethyl-3-methyl-butoxymethyl-benzene 
31 via substitution with cyanide, and subsequent reduction of generated nitrile group with DIBAH.  
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 Figure 76: Reported preparation
131j
 of the aldehyde 28  
 
The major drawbacks of the reported processes for their applications on large scale remain: 
 
- the toxicity of cyanide ( handling on multi-ton scale) 
 
- the removal of Pd/C and its cost 
 
- the cost of the benzyl-trichloroacetimidate reactant 
 
- the recovery of triflic acid. 
 
By replacing the protective group on the alcohol moiety of 29, we hoped to develop a practical and 
cost-efficient synthesis of Aliskiren base 1. 
 
 
III.3.2. From the (S)-Aliskiren precursor 8 to its aldehyde analogues 
 
A selection of protective groups was installed including ethers, esters and carbamate derivatives 
(Figure 77). 
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Figure 77: Selection of protective groups introduced to nitro compound 8 
 
III.3.2.1. Ether derivatives 
 
Ethers are among the most used and well documented protective groups in organic synthesis. They 
involve simple methyl ether to elaborated substituted trityl ether. They are prepared and removed 
under various conditions140.  We introduced the following THP, THF, MIP and benzhydryl groups 
(Figure 78).  
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72h, 79 %
8
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or
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NO2 NO2
NO2
NO2  
Figure 78: Preparation of a selection of ether derivatives from nitro compound 8 
 
One drawback of the installation of the THP and THF onto the Aliskiren precursor 8 is the 
introduction of an additional stereocenter due to the presence of a stereogenic center on the 
tetrahydrofuran and tetrahydropyran ring. Nevertheless it didn’t have any negative influence on the 
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rest of the synthesis. These protective groups did not complicate the interpretation of the 
spectroscopic data. 
 
In the practical route, we prepared 32 and 33 by refluxing the corresponding dihydrofuran and 
dihydropyran starting materials at respective 88°C and 70°C over 58 and 9 hours in the presence of 
polymer bound pyridinium p-toluene sulfonate. A simple filtration and evaporation of the excess of 
reactants allowed the isolation of the products with respectively 94% and 85% yield.   
 
In a same way, the derivative 36 was synthezised according to the procedure of Mori et al141 from the 
corresponding ethylene derivative in presence of catalytic amounts of p-toluene sulfonic acid in 
dichloromethane at room temperature (addition of the reactants occurred at 0°C). After 63 hours, an 
aqueous basic work up led to the isolation of the desired protected nitro compounds 36, with 91% 
yield. 
 
The benzhydryl (diphenylmethyl) group is a relatively inexpensive protective group, stable towards a 
variety of reagents. The benzhydryl ethers are usually prepared by treatment of an alcohol with 
diphenylmethanol under acid conditions142 , including acid ion exchange resins142 and silica gel-
supported acid. We selected a perfluorinated sulfonic acid resin (Nafion-H)142 as catalyst for the DPM 
etherification of nitro compound 8.  In a practical way, nitro compound 8 was warmed to 90°C in 
presence of diphenylmethanol and catalytic amounts of Nafion-H in acetonitrile.  After 72 hours, 
removing of Nafion-H by filtration and evaporation of the solvent yielded crude material that was 
purified by column chromatography to give 37 with 79% yield.  
 
III.3.2.2. Ester derivatives 
 
The ester protective groups can be introduced under basic or acid conditions, by transesterification 
or biotransformation140.  
 
In a general procedure, nitro compound 8 and the selected acyl chloride derivatives were warmed to 
90°C in toluene. Evaporation of the solvent and purification by column chromatography on silica gel, 
yielded 38-41 with 48-69% yields (Figure 79).  
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Figure 79: Preparation of the ester derivatives 38-41 
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III.3.2.3. Carbamate derivatives 
 
Carbamate derivatives can be prepared from their corresponding isocyanate derivatives in presence 
of an anhydrous organic base (pyridine) at room temperature143. The alkyl N-phenyl and N-benzyl 
carbamates 42 and 43 have been synthesized without treatment with a base, by addition of phenyl 
or benzyl isocyanate in dichloromethane at room temperature. After 18 hours or 72 hours, 
purification by chromatography on silica gel yielded the phenyl and benzyl carbamate derivatives 42 
and 43 with respectively 40% and 48% yields (Figure 80).  
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Figure 80: Preparation of the carbamate derivatives 42 and 43 
 
III.3.2.4. Carbonate derivative 
 
Carbonates, like esters, can be cleaved by hydrolysis under basic conditions. They are nevertheless 
more stable towards hydrolysis because of the resonance effect of the second oxygen140.  That is why 
we tried to introduce a carbonate protective group to the alcohol moiety of the key C4-nitro alcohol. 
Benzyl carbonates can be prepared by treatment with benzylchloroformate in presence of a base, 
such as TMEDA at low temperature144.  
 
In our study, nitro compound 8 was converted in 48% yield to its carbonate derivative by treatment 
with the Z-succinimidyl derivative 88 in THF at room temperature in presence of triethylamine.  
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Figure 81: Preparation of the carbonate derivative 44 
 
Eleven new derivatives have been prepared with moderate to good yields and some of them have 
been converted to their aldehyde analogues via a Nef reaction.  
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III.3.3. Preparation of the aldehyde intermediates via a Nef reaction 
 
One of the first transformations involving the nitro group is its conversion into carbonyl unit, 
discovered by Nef145 in 1894. Since Nef reported145 that primary and secondary nitro compounds can 
upon treatment with mineral acids be transformed into aldehydes and ketones, several variations of 
the reaction conditions have been published146,147. 
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Figure 82: Mechanism of the original Nef reaction
147 
 
A limited number of reductive methodologies have also been published. The most important 
procedure (McMurry method) uses TiCl3 to reduce nitronate salts into aldehydes or ketones   via the 
formation of an oxime or nitroso intermediate148. Aluminium powder in the presence of 
NiCl2·6H2O
149, zinc dust- trifluoroacetic acid150 or magnesium powder-CdCl2-water in THF
151, such as 
treatment of primary nitroalkanes with SnCl2·2H2O in the presence of thiophenol and triethylamine, 
(followed by addition SnCl2·2H2O and tartaric acid–NaHSO3) allow the formation of an imine 
intermediate, which is rapidly hydrolysed to the corresponding aldehyde unit151. Various metal 
nitronates of secondary nitroalkanes can also be converted into the corresponding oximes by 
treatment with hexamethyldisilane152. 
 
At the opposite, many procedures in the literature employ oxidative conditions to convert the salts 
of nitroalkanes, obtained by their treatment with bases. The most widely employed oxidant for this 
conversion is the Mn04
- ion which has been used under various conditions146,163,163. But other 
oxidizing reagents such as sodium chlorite153, MoOPH154, t-BuOOH155, m-iodoxybenzoic  acid156, 
singlet oxygen157, dimethyldioxirane158 (prepared by the reaction of oxone with acetone) or other 
peroxide-based systems, bis(trimethylsilyl)-peroxide159 or sodium percarbonate (Na2CO3·1.5H2O2)
160, 
tetrapropylammonium perruthenate (TPAP) with N-methylmorpholine-N-oxide161 can also be used. 
Copper salts in mixtures with acetic acid in methanol162 are also able to oxidize nitro aldol to α-keto 
acids.  
 
Among them the promising works of Kornblum et al 146b and Shechter and later of Steliou and 
Poupart163, (who reported an oxidative procedure using KMnO4) seem to be a general, efficient, 
practical simple way to prepare of carbonyl derivatives from their nitro precursors. After 
modification of the previous procedures, Steliou and Poupart163 published that treatment of nitro 
derivatives with methanolic potassium hydroxide, in methanol at 0°C produces the corresponding 
potassium salts, that are in-situ oxidized into the corresponding carbonyl units by addition of a 
concentrated aqueous solution of KMn04 and MgSO4. (The principal function of the magnesium 
sulfate is to maintain the neutrality of the oxidation mixture by precipitating hydroxide ion as 
magnesium hydroxide146). 
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We prepared the THP protected aldehyde 45 applying a selection of conditions adapted from the 
literature (Ballini and Petrini153, Pinnick et al 164 and Steliou and Poupart163). In a general procedure, 
the nitronate intermediate was generated at 0°C by addition of the selected base. After stirring a few 
minutes, the oxidizing agent was added dropwise to the reaction mixture.  
    
OO
NO
2
O O
O
32 45  
Entry Base 
Oxidizing 
agent 
Solvent Additives Temperature 
% area 
(GC)f 
1 NaOHa aq.  (3 eq.) 
NaClO2aq. 
(0.15 equiv.) 
DCM d 
 
nBuNHSO4 
(0.1 eq.) 
 
RT 
8% (30 
min) 
43% (27h) 
2 NaOHa aq.  (3 eq.) 
NaClO2aq. 
(0.15 equiv.) 
DCM d 
 
- RT 
No 
conversion 
3 
NaOHa aq.  (3 
equiv.) 
NaClO2aq. 
(0.15 equiv.) 
tBuOH d 
Mebutene 
(0.04 
equiv.) 
RT 
2% (30 
min) 
14% (25h) 
4 NEt3
b (1.0 equiv.) 
KMnO4 aq. 
(1.0 equiv.) 
DCMd 
nBuNHSO4 
(0.1 equiv.) 
0-5°C 
 
0.3%  (10 
min) 
0.8% (23h) 
5 
NaOH/MeOH 
(1.2 equiv.) 
KMnO4
 b
 aq.  
(0.35 equiv.) 
MeOH/H2O
e  
 
MgSO4 
(0.07 
equiv.) 
0-5°C 
 
88% (30 
min) 
97% (3h) 
97% (23h) 
6 
NaOH/MeOH 
(1.2 equiv.) 
KMnO4
 b
 aq.  
(0.45 equiv.) 
MeOH/H2O
e 
MgSO4 
(0.07 
equiv.) 
0-5°C 
 
95% (t0) 
7 
NaOH/MeOH 
(1.2 equiv.) 
KMnO4 
b
 aq.  
(0.6 equiv.) 
MeOH/H2O
e 
MgSO4 
(0.07 
equiv.) 
5-10°C 
 
100% (t0) 
8 
NaOH/MeOH 
(1.2 equiv.) 
KMnO4
 c
 aq.  
(0.5 equiv.) / 
NaIO4 aq. (0.2 
equiv.) 
MeOH/H2O
e 
MgSO4 
(0.07 
equiv.) 
5-10°C 
 
100% (t0) 
9 
NaOH/MeOH 
(1.2 equiv.) 
KMnO4
 c
 aq.  
(0.12 equiv.) 
/ NaIO4
 
aq.  
(2.5 equiv.) 
MeOH/H2O
e 
MgSO4 
(0.07 
equiv.) 
5-10°C 
 
98.6% (t0) 
99.6% (1h) 
10 
NaOH/MeOH 
(1.2 equiv.) 
NaIO4
 c
 aq.  
(2.5 equiv.) 
MeOH/H2O
e 
MgSO4 
(0.07 
equiv.) 
5-10°C 
 
2% (t0) 
2% (1h30) 
11 
KOH/MeOH (1.2 
equiv.) 
KMnO4 aq.  
(0.7 equiv.) 
MeOH/H2O
e 
MgSO4 
(0.07 
equiv.) 
0-5°C 
 
100% (t0) 
Table 6: screnning of a selection of conditions for the Nef reaction on 32. 
a
1mmol nitro compound scale, 
b
4 
mmol scale, 
c
6 mmol scale, 
d
3mL/ mmol, 
e
32 mL/mmol,
 f
ratio measured by Gas Chromatography  
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We found that the most promising oxidative agent was the ion MnO4
-  alone or in mixture with NaIO4 
(Table 6, Entries 5-9,11). The utilization of NaClO2aq as oxidative agent was ineffective to perform the 
studied Nef reaction (Table 6, Entries 1-3).    
 
When an organic base such as triethylamine was used to depronate 32 to its nitronate analogue, the 
Nef reaction performed very slowly (Table 6, Entry 4). Methanolic solutions of NaOH or KOH, as 
described by Steliou, were the most promising methods to generate the nitronate anions (Table 6, 
Entry 5-11). 
 
We found that 0.6 equiv. of KMnO4 are the minimal required amount. Using a combination of KMnO4 
and NaIO4
 might allow to reduce the quantity of MnO2 produced.  
 
Using the modified procedure of Steliou et al 162 we prepared the following ether protected 
aldehydes 34, 45-48, from their corresponding nitro derivatives (Figure 83). In a general procedure, 
treatment of the nitro derivatives with a methanolic solution of potassium hydroxide (1.2 equiv.) at 
0°C and the subsequent additions of MgSO4 (0.07 equiv.) and dropwise of a concentrated aqueous 
solution of KMn04 (0.7 equiv.) afforded after filtration of the generated MnO2, the desired aldehydes 
34, 45 to 48 with yield from 68% up to 79%. No trace of over oxidation of the nitro compounds was 
detected at the end of the reaction. Nevertheless in some case, an inefficient work up (traces of 
MnO4
-, and base) can promote the conversion of the aldehyde intermediates into its carboxylic acid 
analogue during storage.  
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        1. KOH/MeOH, 0°C
2. MgSO4, KMnO4/H2O, 0°C
78% 79% 78%
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34 48  
Figure 83: Oxidative Nef reaction under Steliou et al conditions
162 
 
Treatment of the nitro compounds 38 to 41 and 43 with a methanolic solution of KOH did not afford 
the desired aldehyde derivatives 49-53 but yielded the cyclic acetal 54 resulting from the removal of 
the protective group under the reaction conditions. Using a suspension of K2CO3 in methanol to 
generate the nitronates species and subsequent addition of MgSO4 (0.07 equiv.) and an aqueous 
solution of KMn04 (0.7 equiv.) at 0°C afforded the aldehydes 49-53 with yields of 55% to 84% (Figure 
84). 
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Figure 84: Modified Nef conditions to afford the aldehyde derivatives 49-53 
 
III.3.4. Henry reaction 
 
III.3.4.1 Introduction 
 
A range of interesting organometallic complexes and organocatalytic protocols have been 
successfully explored and applied to perform syn-enantioselective Henry reaction 4. Among them, the 
use of complexes genereated from copper (I) and copper (II) salts and chiral ligands have been 
reported by Woggon48a-b et al who demonstrated that asymmetric Henry reaction of 4-
nitrobenzaldehyde and nitromethane can be catalyzed by copper (II) complexes of various reduced 
Schiff Base (as for example the ligand A in Figure 85) of various aldehydes with nitromethane with 
high (S)-enantioselectivity. They also demonstrated that 4-nitrobutyrate can react with various 
prochiral nitroalkanes48b,49 under similar conditions with high syn-enantioselectivity. 
N
NH
N
H
OHA
 
Figure 85: Chiral ligand A designed by Woggon et al.
 48a-b 
 
Applying similar conditions as  Woggon48, we hoped to be able to convert our protected aldehyde 45 
to the corresponding Henry product 54 with high syn-diastereoselectivity, affording the (S,S,S,S) 
configured diastereoisomers as the major products; the anti-products (the (S,S,R,S,S) and the 
(S,S,S,R,S) for example) being theoretically epimerized to their syn-analogues (Figure 86). In an other 
case5, (using of O-benzyl instead of the THP protective group), it could be shown that the 
epimerization from the syn- to the anti-products (and vice-versa) occurred with different kinetics, in 
                                                          
4
 for an overview see chapter 1 
5
 These results were obtained in the laboratory by A. Litzler and G. Sedelmeier 
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the presence of catalytic amounts of DBU in THF. Retro-Henry reaction could also be observed after 
24h reaction time. For previous analogue Henry reactions with 8 and the benzyl protected aldehyde 
28 see patent application cited in Literature 131j. 
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Figure 86: Example of the Henry reaction with THP protected aldehyde 45 and the nitro compound 8 
 
 
III.3.4.2. Results and discussion 
 
III.3.4.2.1. Henry reaction catalyzed by formation of a chiral ligand- copper (II) 
complex  
 
We applied the encouraging results of Woggon et al48a and performed the reaction of the protected 
aldehydes 45, 46 and 49 and the nitro compound 8 using an in situ generated complex from Cu(OAc)2 
and the chiral ligand A. 
O
OH
R
OH
NO
2
54
55
56
R= THP
R=Bz
R=MIP
 
Figure 87: Scaffold of Henry products 54 to 56 
 
In a general procedure, we prepared the ligand-copper (II) complexes by mixing in a 1:1 ratio of the 
ligand and CuOAc2 in acetonitrile. After few minutes, the selected aldehyde and the nitro compound 
8 were added to the reaction mixture, and stirred at 35°C. Chiral HPLC on CHIRALPAK AD-H (Table 7) 
of the reaction mixtures revealed the presence of a major signal6 (from 58 to 64%), characteristic of 
                                                          
6
 As we could show later, the diastereoisomers with opposite absolute configuration at the chiral center of the 
THP protecting group are not separated under the conditions used for the HPLC chromatography. The proof of 
the relative and absolute configuration of the major diastereoisomer was obtained by chemical correlation 
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the (S,S,S,S) diastereoisomer (as demonstrated by X-Ray analysis by Sedelmeier131j, in the case of 
R=benzyl). In all cases, the Henry reaction performed slowly and the Henry products 54 to 56 were 
isolated with moderate diastereoselectivity; the THP protected nitro alcohol 54 being prepared with 
the best syn-diasteroselectivity.  
O
O
R
O
OH
R
OH
NO
2
NH
N
H
N
OH
OH
NO
2
CH3CN, Cu(OAc)2
35°C
+
(S,S,S,S)
+ other diastereoisomers8
54,55-56
54
55
56
R= THP
R=C(=O)Bz
R=MIP
R= THP
R=Bz
R=MIP
45,46-49
45
46
49
A
 
Entry  Product Time Conversion  d.r. 
1 54 7 days 70 6:14:13:67 
2 55 2.5 days 77 7:7:27:59 
3 56 4 days 65 (+ 25% lactol) 25:17:58 
Table 7: Henry reaction of various aldehydes with nitro compound 8. All reactions were performed with 10% 
of ligand, 10% of Cu(OAc)2 in acetonitrile at 35°C. Diasteroisomeric ratios (d.r.) were determined by HPLC using 
CHIRALPAK AD-H column. 
 
Column chromatography on silica gel with a mixture of heptane/ethyl acetate allowed us in all cases 
to isolate the desired (S,S,S,S) diastereoisomer with a diastereoisomeric ratio > 90%. In the case of 
the MIP protected aldehyde 49, deprotection of the corresponding Henry product occurred during 
the reaction (Table 7, Entry 3). 
 
54 was also prepared with an isomeric ratio of (4:10:11:75) from 8 and 45 on a 6 mmol scale, using 
the conditions of Table 7. The (S,S,S,S) diastereoisomer was isolated as single isomer with 26% yield.  
To explain the syn-selectivity observed, we propose, according to the contributions of Evans39, the 
hypothesis of Woggon and the calculations done by Cossio50, the formation of the potential 
transition state TS-I. The nitro component 8 and the selected aldehyde should coordinate to the 
metal centre, so that it should position the nucleophile perpendicular to the ligand plane, and the 
electrophile in equatorial position.  The nitronate should attack favorably the aldehyde from one of 
its face, yielding to the formation in preponderance of the Henry Product with the syn (S,S,S,S) 
stereochemistry (Figure 88). The influence of the two stereocenters in the starting materials is not 
clear at the moment.  
                                                                                                                                                                                     
with the Aliskiren precursor 9, during a kilo-lab campaign. The other three pics could be until now characterized 
in regard of their absolute configuration. 
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Figure 88: Postulated transition state for the Cu(II) complex catalyzed Henry reaction for the synthesis of the 
Aliskiren precursors 
 
III.3.4.2.2. New chiral ligands and Cu(I) and Cu(II) salts for the Henry reaction 
 
III.3.4.2.2.1. Introduction 
 
The application on large scale of this strategy for the preparation of Aliskiren required the synthesis 
of the intermediate 15 with excellent yields and syn-enantioselectity. Optimization of the Henry 
reaction step was required to access better selectivity. The novel7 ligand48b B (Figure 89) was 
exploited in the reaction of nitro compound 8 to the aldehyde 45.  
 
NH
N
H
N
OH
B
 
Figure 89: New C1 symmetrical Ligand B 
 
We envisaged the formation of complexes from both, copper (I) and copper (II) salts.  Woggon48b et 
al had indeed shown that copper (I) system can also be efficient for the Henry reactions using a 
copper (I) complex of some symmetric ligands. 
                                                          
7
 The ligand B was first synthesized by J. Sedelmeier and successful applied in copper catalyzed Henry reactions 
within CHAD-Novartis. 
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III.3.4.2.2.2. Results and discussion 
 
Applying the conditions described by Woggon et al, we performed the Henry reaction of 8 to the THP 
protected aldehyde 45 in the presence of copper (I) salt in THF, and of a base additive (Figure 90).  
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Figure 90: Syn-Henry reaction of THP protected aldehyde 45 with nitro compound 8 
 
We mixed copper (I) iodide (0.10 eq) at room temperature to 0.06 equivalent of the ligand in THF. 
The suspension was stirred at room temperature, and after a period of 20 min, 0.5 equivalent of 
Hünig base was added.  The mixture was then allowed to stir at 30°C for 30 min before 1 equivalent 
of aldehyde 45 and 1 equivalent of nitro component 8 were added. The reaction mixture was stirred 
over a period of 2.5 days. Chiral HPLC on CHIRALPAK AD-H of the reaction mixture revealed the 
presence of a mixture of diastereoisomers in the ratio of 13:11:19:57. The major diastereoisomer 
was eluted with a retention time characteristic for the predicted (R/S,S,S,S,S) diastereoisomer, based 
on the postulated transition state for the Henry reaction.  
 
The crude material was purified in the laboratory of Dr. E. Francotte by chromatography on 
CHIRALPAK AD-H (30*250 nm) with CO2/isopropanol (8:2) and a flow of 120 g/min to yield in the 
pure fractions 54 (yield 12%) as a yellow oil containing the (S,S,S,S) configured 54 (as 50:50 ratio of 
(R,S,S,S,S) and (S,S,S,S,S) isomers) with a purity of 98%. 
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Figure 91: Chiral HPLC analysis of the isolated (R/S,S,S,S) diastereoisomers 54 isolated after chromatography on 
preparative CHIRALPAK AD-H with CO2/isopropanol (8:2). HPLC measurements were conducted on CHIRALPAK 
AD-H with a mixture hexan/isopropanol/methanol/ethanol 973:9:9:9, 1 mL/min, at 40°C and λ=215 nm 
 
The syn-selectivity observed can be rationalized based on a similar transition state as the transition 
state (TS-I) proposed in Figure 88, since, as postulated by Woggon et al, aerial oxidation of copper (I) 
to copper (II) can occur within the reaction. The role of the external base is not clear so far: is the 
nitronate species formed before it enters the “active pocket”? or does the nitro component enter 
the active specie and is then deprotonated? 
 
Performing the same reaction with copper (II) salts and ligand B afforded (S,S,S,S) configurated 
isomere of 54 with up to 75% purity. 
 
III.3.4.2.2.3. Conclusion 
 
Using catalytic systems involving the C1 symmetric ligand A and copper (II) salts, we were able to 
convert the THP, MIP and benzoate protected aldehydes 45, 46 and 49 into their respective β- 
hydroxyl nitro analogues 54 to 56 with moderate to satisfactory yields (21% to 56%) and purities.  
 
Using catalytic system involving a novel DPEN (diphenylethylenediamine)-Salan ligand B and copper 
(I) or (II) salts, we were also able to form the required (S,S,S,S) configured nitro aldol product 54 as 
major stereoisomer. It could be isolated by column chromatography with a purity of  up to 90% .  
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The reported strategy could be applied successfully after optimization of the Henry reaction for a 
kilo-lab campaign of Aliskiren intermediate 15. 
 
III.3.5. Towards the synthesis of Aliskiren precursor 14 
 
The THP protected (S,S,S,S) nitroaldol 14 can be easily hydrolyzed under acidic conditions in presence 
of p-toluene-sulfonic acid in methanol at 0°C affording the desired new nitrodiol compound 14 with 
86% yield (Figure 92).  
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Figure 92: Towards the synthesis of Alikiren precursor 15 
 
The conditions described by Sedelmeier131j could then be applied to the novel β-hydroxynitro 
intermediate 14. The nitro group can be hydrogenated with Ni-Ra at normal pressure in ethanol in 
the presence of Boc2O. The key Aliskiren precursor 15 could be generated from 58 by oxidation with 
catalytic amount of tetrapropylammonium perruthenate TPAP and N-Methyl-morpholine N-Oxide or 
in the presence of TEMPO and bleach as oxidant. The preparation of 15 from 14 was not studied in 
the course of this Ph.D. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 93: 
1
HNMR (CDCl3, 400 MHz) of 14 
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III.3.6. Conclusion 
 
While many ways of preparation of the renin inhibitor Aliskiren 1 have been published in the 
literature, a short, safe, diastereoselective process remains a challenge. We described the possibility 
to improve the promising manufacturing procedure published in 2008 by Sedelmeier131j:   
 
1) by replacing the risky nitroethylene reagent by its more safe in situ generated α-ester analogue 19, 
which reacts with isovaleraldehyde via enamine catalysis to form the desired (S)-Aliskiren precursor 8   
 
2) via a new multi-component aldolization-Michael addition sequence, undergoing via the iminium 
catalytic Michael addition of nitromethane or related derivatives to (in situ generated) 
isopropylacroleine 25 
 
3) by modifying the protective group on the terminal hydroxyl group of 8 and by the subsequent 
preparation of the related aldehyde intermediates  
 
4) by performing copper salts and chiral ligand B complexes catalyzed Henry reactions,  the β 
hydroxynitro intermediate can be prepared with moderate to satisfactory yield, depending on the 
protective group used and the reaction conditions. 
 
We were also able to isolate, thanks to standard silicagel column chromatography, the desired 
(S,S,S,S) Henry product 54 and so the new related intermediate 14 with good yield (86%) and 
enantiomeric purity (ee > 96%). 
 
These modifications in the current process allowed the convergent, elegant, economic and safer 
preparation of the highly advanced precursor 8 of Aliskiren drug 1 with moderate to good yield and 
stereoselectivity via key asymmetric Michael and Henry reactions. 
 
In the future, because of the short reaction times of the multi component domino enamine catalytic 
Michael addition, a continous flow process could be possible. The following protection and oxidative 
Nef steps could also be adequate for a continous process165.   
 
III.4. A new atom-economy strategy for the preparation of Aliskiren 1 
 
III.4.1. Introduction 
 
The concerns of the pharmaceutical companies have always been to find the best way in term of 
yields, selectivities, safety and ecology to produce quickly a drug. To that extend, we turned our 
attention to the development of alternative efficient approaches for the synthesis of Aliskiren 1. 
Using metal catalyzed and organocatalytic procedures, we proposed to prepare the drug substance 
in a shorter 4+4 approach, involving novel key intermediate 59 (Figure 94).  
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Figure 94: Retrosynthetic study for an alternative preparation of Aliskiren base 1 
 
A shown on Figure 95, the API intermediate 9 could be prepared in 10 (or 11) steps from the 
commercially available alcohol 62 (first described in the literature131a in 2000 by Maibaum et al). 
Aliskiren base 1 would be available in 11 or 12 steps. 
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Figure 95: Retrosynthetic analysis of key intermediates in the synthesis of Aliskiren 1 
 
The challenges of this novel approach for the preparation of Aliskiren 1 are: developping an efficient 
synthesis of the novel nitro intermediate 59 in excellent yield and enantiomeric purity. Subsequent 
 67 
 
copper catalyzed syn-enantioselective Henry reaction of 59 with the THP protected aldehyde 45 
should allow the introduction of the required (S,S,S,S) configuration of Aliskiren 1 (Figure 95). 
 
III.4.2. Synthesis of the novel key (S)-nitro compound 59 
 
A wide range of strategies was available for the preparation of 59 (Figure 96). It was successfully 
synthesized from the aldehyde intermediate 61 in 3 steps via consecutive Henry 
reaction/dehydration step/reduction of the nitro olefin sequence. As depicted in Figure 96, 59 is also 
available from the chloride analogue 16 in 3 steps8 (conversion into the nitrile derivative 65, 
reduction, and oxidation steps). Both aldehyde 61 and chloride 16 derivatives can be prepared from 
the common commercially available intermediate 62. Alkylation of nitromethane or nitroacetate 
with the chloride derivative 16 was also envisaged.  All the proposed routes were tested in the 
laboratory with more or less success. 59 was also prepared as racemic mixture. 
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Figure 96: Selected ways for the preparation of 59 
 
 
 
 
 
 
 
 
                                                          
8
 This approach was successfully applied by D. Grimler in the laboratory. 
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rac- 
III.4.2.1. Preparation of the Aliskiren precursor 59 as a racemic mixture 
 
59 was obtained in reasonably good yield (47%) via a three steps procedure (Figure 97).  
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Figure 97: Preparation of 59 as a racemic mixture 
 
The oxidation of the alcohol derivative 62 preceeded smoothly using Dess-Martin oxidation 
conditions166 affording 61 with 98% yield. HPLC measurements on CHIRALCEL OD-H proved, that no 
racemization on the α-position of the aldehyde occurred during the reaction and revealed the 
presence of 98% of the (R)-enantiomer and ca 2% of the (S)-enantiomer.  
 
 
 
 
Figure 98:  Chiral HPLC of crude 61 and comparison with the racemic mixture. The racemic version of 61 was 
prepared by addition of a few drops of DBU to the analysis vials. HPLC measurements were conducted on 
CHIRALCEL OD-H, hexane/isopropanol 9:1, 20°C, 0.5 mL/min, λ=215 nm 
 
It was important for the synthesis of the nitro compound 59 to find out under which conditions, 
racemization of the aldehyde 61 occurred. That’s why racemization studies were carried out by 
addition of  a few drops of DBU and followed by chiral HPLC on CHIRALCEL OD-H, as depicted in 
Figure 98. It is worth to mention that the addition of sparteine and triethylamine (26 mg/0.09 mmol 
of 61) don’t affect the stereochemistry of 61.  
 
Using the procedure of Pedras and Okinyo168 we prepared the nitro olefine 64, as racemic mixture, by 
treatment of 61 with ammonium acetate in nitromethane at 70°C. The chiral HPLC analysis (Figure 
O
O
O
O
H61
O
O
O
O
H61
ee=96%, crude material ee=2%, 2 hours after  
addition of DBU 
 69 
 
rac- 
99) revealed the presence of the signals of the (S)-enantiomer at 10.5 min and of the (R)-enantiomer 
at 11.4 min.  
 
 
Figure 99: Chiral HLC rac-64, CHIRALCEL OD-H, hexane/isopropanol 97:3, 20°C,1 mL/min, λ=215 nm 
 
The subsequent reduction167 with sodium borohydride yielded 59 as a racemic mixture in 48% yield 
over 2 steps168.  
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Figure 100: Preparation of rac-59  
  
Figure 101: Chiral HPLC of rac-59  on CHIRALCEL OD-H, hexane/isopropanol 93:7, 20°C,1 mL/min, λ=205, 210, 
215 and 220 nm 
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III.4.2.2. Asymmetric synthesis of Aliskiren precursor 59 
 
The Aliskiren precursor 59 was obtained from 62 with high enantioselectivity (ee 96%) and moderate 
yield (44%) via a four steps procedure, involving Dess-Martin oxidation, Henry reaction, dehydration 
and subsequent reduction with sodium borohydride.  
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Figure 102: Asymmetric synthesis of nitro-compound 59 
 
Henry reaction of (R)-61 with nitromethane (6 equivalents) was performed at room temperature in 
presence of 0.3 equivalent of sparteine to give the desired β-hydroxy nitro compound 70 with 67% 
yield with a diastereoisomeric excess of 60%.  
A selection of catalysts has also been tested for the Henry reaction of 61 with nitromethane, yielding 
or not 70 as a mixture of diastereoisomers P1/P2/P3/P4. 
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Entry Ligand 
Ligand 
/mol% 
Metal 
salt 
Metal 
/mol% 
Solvent 
Tempe- 
rature 
(P1:P2):P3:P4 
(%)b 
ee (new stereocenter) 
 (%)b 
1 (R,R)-A 5 CuOAc2 5 EtOH 35°C (1):1:89 96 
2 (S,S)- A 5 CuOAc2 5 EtOH 35°C (7):77:6 66 
3 
(S,S)- A 
5 CuOAc2 5 DCM 35°C 
no 
conversion 
no conversion 
4a Sparteine 30% - - - 35°C (5:1):26:68 44 
5a Sparteine 30% - - - 30°C (3):19:78 60 
Table 8: Enantioselective Henry reactions of CH3NO2 with aldehyde 61 under various conditions. All reactions 
were performed on a 1 mmol scale with 1 equiv. of aldehyde 61 and 2 equiv. of nitromethane in the solvent. 
a
 
reaction performed with 6 equiv. of nitromethane 
b 
determined by chiral HPLC using a CHIRALCEL OD-H column  
hexane/isopropanol 97:3, 20°C, 1 mL/min, λ=215 nm 
 
 
 
 71 
 
 
 
 
 
 
 
 
 
          
          
  
Figure 103: Chiral HPLC chromatograms of 70, under the tested conditions of Table 8, CHIRALCEL OD-H,  
 
Performing the Henry reaction of 61 with nitromethane in the presence of sparteine afforded the β-
hydroxyl compound 70 with a moderate enantioselectivity (Table 8, Entry 4,5), the temperature of 
the reaction influencing the selectivity. Better selectivities (ee up to 96%), as represented on the 
chromatograms of Figure 103, were obtained in the presence of in situ generated complexes from 
the chiral ligands (R,R)-A and (S,S)-A  and copper (II) salts in ethanol (Table 8, Entry 1-2). No reaction 
occurred when the reaction was performed in dichloromethane (Table 8, Entry 3).  
 
It was not important to find out the absolute configuration of the alcohol moiety, since this group will 
be eliminated. What is important is that the (R) configuration of the isopropyl group is not affected 
during the reaction. 
 
The diastereoisomers P3 and P4 were separated on preparative chiral column AD (Hept/EtOH/MeOH 
90:5:5, 400 mL/min) to yield both diastereoisomers with up to 93% purity for the diastereoisomer P3 
and up to 98% purity for the diastereoisomer P4. 
 
1H NMR analysis (DMSO-d6) revealed also the presence of both new (S) and (R) configured 
stereocentres: doublet at 5.41 ppm corresponding to proton of the P3 alcohol moiety, and at 5.30 
ppm attributed to proton of the alcohol moiety of the P4 isomer. A shift in the signal attributed to 
the proton of the generated stereocenter is also observed between P3 and P4. Both 
diastereoisomers can also been differentiated, since a schift is observed in region δ= 15-2.6 ppm. 
 
Subsequent Alox (Brockmann Activity I)138 dehydration afforded at room temperature the nitro 
olefine 64 in 83% yield and with 96% ee (Figure 105). It was important here to know if racemization 
occurred during the reaction. 
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Figure 104: Preparation of 64  
 
 
 
 
 
  
Figure 105: Chiral HPLC of 64  and rac-64, CHIRALCEL OD-H, hexane/isopropanol 97:3, 20°C, 1 mL/min, λ=205, 
215, 230 nm 
 
A selection of dehydrating agents, solvents and temperature has been investigated for the 
preparation of 64. An attractive conversion rate was achieved using Alox (Brockmann Activity I) at 
60°C in 1,2 dichloroethane (Table 9, Entry 3).  
 
Entry 
Dehydrating 
agent 
Solvent Temperature 
Reaction time 
(hours) 
% 64 formed 
(%area)c 
1a Alox DCM 25°C 17h 77 
2a Alox 1,2-dichloroethan 40°C 18h 100 
3a Alox 1,2-dichloroethan 60°C 1h45min. 100 
4a 
KHSO4  
(3.7 equiv.) 
DCM 25°C 18h - 
5a 
KHSO4  
(7.5 equiv.) 
1,2-dichloroethan 25°C 18h 1 
6a SiO2 1,2-dichloroethan 25°C 18h 1 
7b Ac20 DMSO 25°C 16h 12 
Table 9: Selection of conditions tested for the preparation of 64. 
a 
The reactions were performed on a 0.3 
mmol scale in 1 mL of the  selected solvent, in the presence of 150 mg of the dehydrating agent. 
b 
The reaction 
was performed on a 0.4 mmol scale in 3.5mL DMSO in the presence of 5.5 equiv. of Ac20 
c
determined by 
reverse phase HPLC, column INERTSIL, 40°C, λ=220 nm   
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The subsequent reduction of 64 with sodium borohydride at 10°C in ethanol afforded the desired (S)-
intermediate 59 with 93% yield. HPLC analysis on CHIRALCEL OD-H revealed the presence of 98% of 
the (R)-enantiomer and 2% of the (S) enantiomer, no racemization occurring during the synthesis. 
 
 
Figure 106: Chiral HPLC of (S)-59, CHIRALCEL OD-H, hexane/isopropanol 93:7, 20°C,1 mL/min, λ=215, 205 and 
230 nm 
 
III.4.3. Synthesis of Aliskiren precursor 60: proof of concept 
 
The general synthetic approach for the preparation of the known169,131e,h and crystalline (S,S,S,S)-
Aliskiren precursor 60  from 59 involves a sequence of four chemical transformations, which can be 
performed within two or three synthetic operations, depending on the protective group introduced 
on the nitro compound 8.   The key step in the synthesis of 60 remains the chiral ligand-copper-based 
catalysed syn-Henry reaction of 59 with the (S)-aldehydes 45 or 28 (Figure 107).  
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Figure 107: The preparation of the (S,S,S,S)-precursor 60 via copper catalyzed asymmetric Henry reaction of 
nitro compound 59 and aldehyde 45 
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III.4.3.1. Copper catalyzed asymmetric Henry reaction 
 
The slow diastereoselective Henry reaction of the nitro compound 59 with the THP protected 
aldehyde 45 was carried out via the in situ pre-formation of a complex from copper salts and the 
chiral ligand B. 
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Figure 108: Henry reaction of the nitro compound 59 with the THP protected aldehyde 45  
 
First, the reaction was carried out using copper (I) salt and the chiral ligand B, in the presence of an 
external base. In a general procedure, the B-copper complex was pre-formed by mixing in THF 0.1 
equivalent of Cu(I)I salt with 0.04 equivalent of the C1 symmetric Ligand B (in a 1:2 ratio) at room 
temperature (Figure 89) and subsequent addition of Hünig base (0.8 equivalent). After 45 min, 1 
equivalent of the nitro compound 59 and 1.3 equivalent of the THP protected aldehyde 45 were 
added at 30°C. The desired derivative 71 was isolated in moderate yield (40% yield) as a mixture of 
diastereoisomers containing 66% of the major stereoisomer (chiral HPLC analysis on CHIRALCEL OD-
H).  
 
A selection of conditions (copper (II) salts, additives) has then been investigated for the preparation 
of (S,S,S,S) 71. In a general procedure, the B- copper (II) complex was generated at a 0.1 equivalent 
scale by mixing an equimolar ratio of the Cu(II) salt and the C1 symmetric Ligand B (in a 1:2 ratio) at 
room temperature (Figure 89). After stirring at room temperature for a few minutes, one equivalent 
of the nitro compound 59 and 1.5 equivalent of the aldehyde 45 were added. The reactions were 
followed by CHIRALCEL OD-H, with hexane/isopropanol 97:3, 20°C, 1 mL/min, and λ=215 nm. 
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Entry Ligand 
Ligand 
/mol% 
Metal 
salt 
Metal 
/mol% 
Additives Solvent 
Tempe- 
rature 
 P1/P2/P3 
ratioa 
1 (R,R)-B 10 Cu(OTf2) 10 Hünig Base Dioxan 25°C 72:12:15 
2 - 30% -  Sparteine EtOH 25°C 50:26:24 
3 (R,R)-B 5 CuOAc2 5 Hünig Base  THF 30°C 67:17:16 
Table 10: Henry reactions of 59 with aldehyde 45. All reactions were performed with 1.3 equiv. of aldehyde 45 
and 1 equiv. of 59 in the selected solvent. 
a
 determined by chiral HPLC using a CHIRALCEL OD-H column; P2 and 
P3 contained mixture of isomers. 
 75 
 
Performing the reaction in ethanol at 25°C in the presence of sparteine afforded the major 
stereoisomer with a percentage of 50% (Table 10, Entry 2). As illustrated in Figure 109 and Table 10 
(Entry 1), CuOTf2 can be employed in dioxane as copper source to perform the Henry reaction of 59 
with the aldehyde 45, since it allowed the formation of the major stereoisomer with the highest 
ratio.  A combination of CuOAc2 and Hünig base in THF allowed also the formation of 71 with a 
comparable isomeric ratio (Table 10, Entry 3). 
 
 
Figure 109: Chiral HPLC of the reaction mixture during the preparation of (S)-71, using the conditions described 
in Table 10, Entry 1,  CHIRALCEL OD-H, hexane/isopropanol 97:3, 20°C,1 mL/min, λ=215 nm 
 
The complexes formed by coordination of a chiral ligand type B with copper(II) salts are reported to 
mediate syn-selective Henry reactions9.  According to our previous investigations, the major 
stereoisomer obtained would/should be the one with the desired (S,S,S,S) configuration. As depicted 
in Figure 110, the formation of the transition states TS-I, where both reactants coordinate the metal 
centre, driving the reaction to the formation of the syn (S,S,S,S) product, could be postulated to 
explain the stereoselectivity of the reaction. 
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Figure 110: Speculative transition state for the formation of the (S,S,S,S) Henry product 71 in the presence of 
the ligand B and Cu(OAc)2 
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III.4.3.2. Preparation of the (S,S,S,S) Aliskiren precursor 60 
 
Two non optimized routes were tested for the preparation of the crystalline amino-Boc-diol 
derivative 60 from 71. The analytical data of 60 are presented in Figure 111.  
 
 
Figure 111: 
1
HNMR (DMSO-d6) and chiral HPLC (CHIRALCEL OD-H) of the (S,S,S,S) configured isomer of 60. It 
was prepared in the laboratory by B. Berod from the API- intermediate 9 by LiBH4-reduction 
 
In the first one-pot approach, the removal of the tetrahydropuranyl protective group of 71 
(containing 58% of the major isomer) was carried out by treatment with catalytic amounts of p-
toluene sulfonic acid in methanol at room temperature. The successive hydrogenation of the nitro 
moiety of 73 and protection of the generated amino group, in presence of Raney-Ni and Boc2O in 
ethanol under a hydrogen atmosphere afforded the desired derivative 60 containing the desired 
(S,S,S,S) diastereoisomer as major stereoisomer. 
 
Figure 112: Chiral HPLC of the 60-crude material,  CHIRALCEL OD-H, hexane/isopropanol 97:3, 20°C,1 mL/min, 
λ=215 nm 
 
Filtration on silicagel of the crude material afforded 60 with (S,S,S,S) isomer as major isomer with an 
overall yield of 17%, over 3 steps, and four chemical transformations. 1H NMR (DMSO-d6) analysis of 
60 revealed indeed the presence of the characteristic signals of compound 60: doublet at 6.07-6.14 
ppm attributed to the NH(-Boc) proton of the (S)-configured Boc amino group and at 6.43-6.47 
corresponding to the proton of the (R)-configured Boc amino group in a ratio of ca. 76:24 (Figure 
113). Chiral HPLC analysis (CHIRALCEL OD-H) revealed the presence of the signal corresponding to 
the (S,S,S,S) configured Aliskiren precursor 60 as major one (Figure 113). Since the Henry reaction 
was expected to afford syn-selectivity, and according to the reported analysis, we assume the major 
diastereoisomer obtained being the (S,S,S,S) configured one. 
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 Figure 113: a)
 
Chiral HPLC (CHIRALCEL OD-H) of 60 b) 
1
H NMR (DMSO-d6) of 60 
 
The hydrogenation of 71 containing the major stereoisomer as an isomeric mixture with a ratio of 
60:20:20, and the concomitant protection of the generated amino group under hydrogen 
atmosphere in presence of Raney-Ni and Boc2O in ethanol at room temperature afforded the amino 
Boc derivative 72. Subsequent removal of the THP protective group at room temperature with 
catalytic amounts of p-toluene sulfonic acid in methanol providing 60 as a mixture of stereoisomers 
and a moderate overall yield of 41%, over 2 steps, and three chemical transformations.  
 
 
Figure 114: Chiral HPLC of the 60-crude material,  CHIRALCEL OD-H, hexane/isopropanol 97:3, 20°C,1 mL/min, 
λ=215 nm 
 
Purification on silicagel of the crude material afforded 60 with (S,S,S,S) isomer as major isomer with 
an overall yield of 44%, over 2 steps, and three chemical transformations. 1H NMR (DMSO-d6) 
analysis of crude material 60 revealed the presence of the characteristic signals of compound 60: 
doublet at 6.07-6.14 ppm attributed to the NH(-Boc) proton of the (S)-configured Boc amino group 
and at 6.43-6.47 corresponding to the proton of the (R)-configured Boc amino group in a ratio of ca. 
75:25 (Figure 115). Chiral HPLC analysis (OD-H) revealed the presence of the signal corresponding to 
the (S,S,S,S) configured Aliskiren precursor 60 as major one (Figure 115). Since the Henry reaction 
was expected to afford syn-selectivity, and according to the reported analysis, we assume the major 
diastereoisomer obtained being (S,S,S,S) configured. 
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Figure 115:
 1
HNMR (DMSO-d6) and chiral HPLC (CHIRALCEL OD-H) of the 60.  
 
III.4.3.3. Conclusion 
 
We reported there a new short route for the total synthesis of (S,S,S,S)-Aliskiren precursor 60, 
involving the enantiopure preparation of the two novel precursors 59 and 45. This strategy includes 
the use of a chiral ligand-copper catalytic system for the key asymmetric Henry reaction step, which 
afforded the novel intermediate 71. The (S,S,S,S)-Aliskiren precursor 60 was isolated from 71, 
without any optimization of the reaction steps. We have shown that the described synthetic route 
could be a practical route for the synthesis of Aliskiren in large scale.  
Experiments to isolate the major diastereoisomer of 60 are currently performed in the laboratory.   
Until now, crystallization assays failed.  
 
IV. New less successful alternative synthesis  
 
IV.1. Introduction 
 
Since the preparation of Aliskiren remains a challenge, we tested some other alternatives to access 
the precursor 9 from the nitro alcohol derivative 8 (Figure 116). 
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Figure 116: Novel strategies for the total synthesis of Aliskiren 1 
 
IV.2. Towards the synthesis of Aliskiren via pathway A 
 
IV.2.1. Introduction 
 
We proposed to prepare Aliskiren base 1 via a ”4+4 approach” involving the synthesis of the new 
nitroketone building block 75, bearing three of the required (S,S,S) configured substituents of 
Aliskiren (Figure 117). 
 
or THP 
or THP 
or THP 
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Figure 117: New retrosynthetic study for the preparation of Aliskiren 1 via a 4+4 strategy, involving the novel 
C8 building block 75 
 
Nitro ketone intermediates are widely used for the synthesis of different classes of compounds, and 
many methods for their preparation are available in the literature: 1) nitration of enol acetates, 
potassium enolates, and enol silyl ethers, 2) oxidation of olefins, 3) Henry reaction followed by 
oxidation, 4) C-α-acylation of the nitro compounds170 (Figure 118).  
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Figure 118: Selected methods for the preparation of nitro ketone derivatives 
 
As illustrated in Figure 119, the preparation of the novel nitroketone derivative 75 was based on the 
intramolecular acylation of the ester intermediate 82. We expected that the reaction would be 
driven by the formation of preferred six carbons ring intermediate via a “favoured 6-endo-trig” ring 
closure171 and hoped that no O-acylation will occur172.  
 
The lactam-lactone intermediate 15 could be obtained by successive: 1) enantioselective reduction of 
the nitro ketone 75 to the corresponding β-hydroxyl amino intermediate 58, 2) protection of the 
amino moiety by a Boc protective group, and 3) oxidation to the lactam-lactone intermediate 15 
(Figure 119).  
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Figure 119: Pathway A for the preparation of C8-lactam lactone intermediate 15 
 
IV.2.2. Preparation of the novel (S,S) Aliskiren intermediate 82 and 
intramolecular acylation assays 
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Figure 120: Preparation of the novel (S,S) Aliskiren intermediate 82 
 
Oxidation of the aldehyde derivative 28 into 7610 was performed with 84% yield according Pinnick 
oxidation conditions by addition of an aqueous solution of NaClO2 and KH2PO4 to a mixture of 
aldehyde and 2-methyl butene in t-butanol. 76 was converted to its novel ester analogue 82 with 
moderate yield 48%, using Amberlist 15173 in methylene chloride; the same esterification step 
performed by treatment with DCC/DMAP in dichloromethane at room temperature afforded only 
24% of the desired ester 82 after 4.5 days.  
 
The reaction sequence could be applied to a selection of protected aldehyde derivatives. The THP 
protected derivative 86 for example was prepared with 69% yield from its related nitro compound 32 
by treatment of 32 with an aqueous solution of KOH (0.5M) and K2HPO4 (1.25M) in t-butanol and 
successive oxidation by an aqueous solution of KMnO4 (Figure 121).  
                                                          
10
 76 was first isolated in our group by D. Grimler 
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Figure 121: Oxidation of 32 to acid carboxylic acid intermediate 86 
 
Three different procedures have been tested to prepare the nitro ketone derivative 75 (Figure 122): 
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Figure 122: Unsuccessful preparation of the nitro ketone intermediate 75 
 
1) applying the procedures of Katritzky et al (related to the synthesis of nitro ketones using N-
Acylbenzotriaoles174) and Jaeger et al 174b, we tried to deprotonate the nitro compound 32 to its 
nitronate analogue by treatment with two equivalents of t-BuOK in dimethyl sulfoxide at 10°C   
 
2) by addition of KF in DMSO  
 
3) by addition of triethylamine in THF.  
 
In all cases, the HPLC and 1H NMR (d6-DMSO) analysis confirmed the presence of the starting material 
32. 
 
IV.2.3. Conclusion 
 
The reported strategy was based on the synthesis of the nitro ketone intermediate 76, via the 
intramolecular acylation of the novel ester derivative 82. As no systematic screening has been 
performed, the potential preparation of 75 via the formation of the nitronate analogue of 82, 
remains possible.  Applying for example, the procedures of Seebach175a et al, who reported the 
preparation of silyl nitronates from primary and secondary nitroalkanes and the increase of the C-
nitronate nucleophily via the formation α,α-doubly deprotonated nitroalkane using a combination of 
nBuLi and HMPT in THF175b. KF or chiral quaternary ammonium salt fluorides176, LDA, or KHMBS could 
also be promoters of choice.  
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IV.3. Towards the synthesis of Aliskiren via the pathway B 
 
We envisaged the preparation of Aliskiren via a 3+5 strategy, involving the diastereoselective 
synthesis of the novel (S,S) lactone intermediate 77 (Figure 123).  
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Figure 123: Retrosynthesis proposed for the preparation of Aliskiren base 1 and novel (S,S) lactone 
intermediate 77 
 
We exploited the results we obtained for the Michael addition of α-nitroacrylate 22 to 
isovaleraldehyde, via in situ formation of an enamine intermediate with a proline derived catalyst11. 
Performing the in situ reduction of the intermediate 20 under acidic conditions provided the lactone 
intermediate 77 (Figure 124).  
The strategy for the multi-step synthesis of 9 or 15 from 77 would involve the preparation of 78 
(Figure 124).  
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Figure 124: 3+5 strategy for the preparation of Aliskiren base 1 
 
The Michael addition of the in situ generated α-nitro acrylate 22 to isovaleraldehyde was performed 
as reported in Chapter 2, III.2.3.2.3. The expected Michael product was obtained with a 
diastereoisomeric excess of ca. 50%. Subsequent in situ reduction under acidic conditions using an 
excess of NaBH3CN (7.7 equiv.) provided the desired lactone 77 in mixture with its alcohol precursor 
79 with a diastereoisomeric excess of 42% and 72% yield. Purification by columm chromatography on 
                                                          
11
 see chapter 2, III.2.3 
de = 42% 
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silicagel with heptane/ethyl acetate (3:1) afforded in the pure fractions the desired lactone 77 as an 
oil and the alcohol precursor 79. Addition of trifluoracetic acid to a mixture of the derivatives 79 and 
77 drives to the formation of pure lactone 77. 
 
Determination of the diastereoisomeric ratio by 1H NMR (CDCl3, 400 MHz) revealed the presence of 
71% of the diastereoisomer A and 29% of the diastereoisomer B (syn/anti stereoisomers) of the 
alcohol intermediate 79.  1H NMR (DMSO-d6, 400 MHz) analysis showed the presence of the 
characteristic signals of cis and trans configured intermediate 77 with 1:1 ratio: dd  at 5.98 ppm 
attributed to the cis-proton in α-position of the nitro group and a triplet at 6.04 ppm (J1=9 Hz) 
corresponding  to the trans-proton in α-position. 
 
The preparation of 77 as a 50:50 mixture of the cis and trans isomers is not satisfactory for the 
application of the strategy to the synthesis of Aliskiren in large scale. We didn’t perform the 
subsequent reaction steps.  
 
IV.4. Towards the synthesis of Aliskiren via the pathway C 
 
We envisaged preparing Aliskiren 1 via a 3+5 strategy, involving the novel C5 (S,S)-β hydroxyl nitro 
intermediate 81 (Figure 125). 
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Figure 125: Retrosynthetic study for the preparation of Aliskiren base 1, involving the novel intermediate 81 
 
We envisaged to prepare the (S,S) configured derivative 81 via a chiral ligand-copper based catalyzed 
asymmetric Henry reaction. Subsequent alkylation of 81 with the chloride derivative 63 should afford 
the Aliskiren precursor 80, bearing the 4 substituents in the C-8 chain of Aliskiren in an all syn-
configuration (Figure 126). 
Pg=protective group 
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Figure 126: New 5+3 strategy for the preparation of (S,S,S,S) Aliskiren precursor 60 
 
IV.4.1. Copper catalyzed asymmetric Henry reaction of 28 
 
A selection of conditions were investigated to prepare the (S,S) derivative 87, involving the formation 
of complexes from the chiral ligands (R,R)-B,  (R,R)-A and (S,S)-A  and copper (I) and (II) salts  or in the 
presence of sparteine (Table 11). The reactions were performed on a 1 mmol scale with 1 equiv. of 
aldehyde and 1.4 equiv. of nitromethane in the selected solvent. The enantiomeric ratios were 
determined by chiral HPLC using a CHIRALCEL OD-H column. 
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Entry Ligand Ligand/mol% 
Metal 
salt 
Metal/mol% Solvent Time/h er (%)a ee (%)a 
 
1 (R,R)-A 5 CuOAc2 5 MeCN 14h30 2:98 96  
2 (S,S)-A 5 CuOAc2 5 MeCN 14h30 98:2 96  
3b  (R,R)-A 10 CuI 10 THF 14h30 2:98 96  
4b (R,R)-B 10 CuI 10 THF 2.5 days 1:99 98  
5 sparteine 30 - - - 15h 40:60 20  
Table 11: Enantioselective Henry reactions of CH3NO2 with benzyl protected aldehyde in the presence of 
various ligands. All reactions were performed on a 1 mmol scale with 1 equiv. of aldehyde and 1.4 equiv. of 
nitromethane in the solvent. 
a
 determined by HPLC using a CHIRALCEL OD-H column 
b
 5 mol% iPr2EtN was 
added 
 
Performing the Henry reaction of 28 with nitromethane in the presence of sparteine afforded the β-
hydroxyl compound 87 with a moderate enantioselectivity (ee=20%, Table 11, Entry 5). Excellent 
enantioselectivities (ee up to 98%) were obtained in the presence of  in situ generated complexes 
from the chiral ligands (R,R)-A and (S,S)-A  and copper (II) salt  (Table 11, Entries 1-2) and in the 
nitromethane 
nitromethane 
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presence of  in-situ generated complexes from the chiral ligands (R,R)-A and (R,R)-B  and copper (I) 
salt  and of an external base (Table 11, Entry 3-4). It is interesting to note that the (R,R)-B  and copper 
(I) salt  system don’t perform the reaction as fast as the other tested systems.  
 
The (R,R)-A and (R,R)-B ligands afforded the diastereoisomer 87-A as the major isomer, while the 
(S,S)-A ligand provided the diastereoisomer 87-B as the major one. According to the literature 
speculations and our own results, we suppose the diastereoisomer 87-A to be the (S,S) configured 
isomer, and 87-B the (S,R) configured isomer. We propose to explain, for example, the formation of 
87-A, the formation of the transition state presented in Figure 127; the coordination of the nitro 
component and of the aldehyde to the catalytic system driving the stereochemistry of the formed 
product. 
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Figure 127: Proposed transition states for the formation of the 87-A 
 
The Henry reaction of 28 with nitromethane in the presence of (R,R)-A was performed on a 54 mmol 
scale, using (R,R)-A and Cu(OAc)2 in ethanol.  After 24 hours, the β-hydroxyl compound 87 was 
isolated with an excellent enantiomeric excess of 96%.  
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IV.4.2. Preparation of the C5 β-hydroxyl nitro intermediate 81 and α-
alkylation 
 
The alkylation step required the protection of the β-hydroxyl group of 87. We selected the MIP 
protective group. The protective group was introduced with 78% yield (after chromatography) under 
standard conditions by stirring 87 in a large excess of 2-methoxy propene at 36°C in the presence of 
catalytic amount of polymer bound pyridinium toluene-4-sulfonate. 
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Figure 128: MIP protection of the β-hydroxyl nitro intermediate 87 
 
The α-alkylation of 81 was performed 1) by applying the conditions described by Seebach et al177 
(additon of 6 equivalents of HMPA and 2 equivalents of nBuLi in THF to a solution of nitro derivative 
81 at low temperature) 2) by generating the nitronate analogue of 81 by addition of organic base, 
such as triethylamine. None of the selected conditions yielded the desired Aliskiren precursor 80 
(Figure 116).  
An alternative procedure might be tested, consisting in the α-alkylation of the nitro ketone 84 using 
for example the procedures of Stach et al, Ono et al or Ballini et al 178 (Figure 129).  
 
X
O
O
O
O
O
O
O
O NO
2
O
O
NO
2
84 85
88
 Figure 129: α-alkylation of the β-nitro ketone intermediate 84 
 
V. Conclusion 
 
Our interest in the development of new asymmetric alternative routes to the renin inhibitor Aliskiren 
base 1 led us to develop five different approaches for the synthesis of different advanced precursors 
of Aliskiren 1. 
 
During our investigations using the chemistry of the nitro group, we focused our attention on the 
asymmetric preparation of β-and δ-hydroxyl nitro compounds, via different catalytic asymmetric 
strategies: 
 
- via a multi-component Knoevenagel-Michael sequence, involving the Michael addition of 
commercially available aldehyde 10 and the  in-situ generated α-substituted nitroethylene  
19 derivative via the formation of enamine intermediate with proline related 
organocatalysts, 
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- via a multi-component aldolization-Michael sequence, involving the Michael addition of the 
in situ generated acrolein derivative 25 and nitroalkanes via the formation of iminium 
intermediates with proline related organocatalysts, 
 
- via copper catalyzed syn-Henry reactions, involving the in situ formation of complexes of 
chiral Salan ligands and copper (I) and (II) salts. 
 
Among the synthetic routes we have tested, the first one (the so-called III generation) was 
successfully applied after optimization to a kilo-lab campaign.  
 
The novel approach based on the preparation of the novel nitro derivative 59, has been patented in 
2011. At this stage the other alternative routes would need a major optimization effort to be applied 
for the preparation of Aliskiren.  
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CHAPTER 3: ASYMMETRIC SYNTHESIS OF A POTENTIAL 
DRUG FOR THE TREATMENT OF PARKINSON: AFQ056 
 
I. Pharmacological properties 
 
In the second part of this Ph.D. we worked on the preparation of another Novartis drug candidate: 
AFQ056 90, the (3aR, 4S, 7aR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-I-carboxylic acid methyl 
ester represented in  Figure 130. 
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Figure 130: Novartis drug candidate AFQ056 90 
 
It belongs to the therapeutic class of glutamate (mGluR5 - metabotropic receptor subtype 5) 
antagonists. These compounds, selective for mGlu receptors, particularly mGlu2/3 and/or mGlu5, have 
proven their efficacy in the treatment of disorders associated to irregularities of glutamatergic signal 
transmission and of central nervous disorders mediated by mGluR5 causing many diseases.  
 
Glutamate is the major neurotransmitter in mammalian central nervous system. It is released by 
nerve cells in the brain (about 70 % of all excitatory synapses in the central nervous system are 
stimulated by glutamate) and is responsible for sending signals between neurons, and so plays an 
important role in learning and memory. Glutamate mediates and regulates neurotransmission by its 
interactions with families of receptors and transporters, such as metabotropic G-protein-coupled 
glutamate (mGlu) receptors. Dysfunction of glutamatergic neurotransmission (overconcentration of 
glutamate or over sensibility of nerve cells to glutamate) can generate nerve cell damage or death, 
causing many diseases such as pain, anxiety179, psychiatric diseases, dementia, epilepsy, ischemic 
diseases, Parkinson's disease and disorders associated, Alzheimer, Huntington Chorea, and multiple 
sclerosis184. 
 
As specific mGluR5 antagonist, AFQ056 has the potential to become the first treatment of 
Parkinson’s disease levodopa12-induced dyskinesia13,180. The Parkinson’s disease is caused by a 
progressive loss of neurons in the nigratum stratum, the part of the brain that produces dopamine 
                                                          
12 Levodopa: L-3.4 dihydroxyphenylalanine was discovered by Hoffmann La Roche in 1973, and is 
marketed under the name of Modopar. It was the first antagonist shown to be selective of the mGlu5 
and mGlu1 receptor and it is used for the treatment of Parkinson’s disease.  
13 Levodopa-induced dyskinesia is the major problem in the treatment of Parkinson’s disease. It 
results from the chronic Levodopa treatment, yielding in the occurrence of abnormal involuntary 
movements. 
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and controls the movement; resulting in the decrease of production of dopamine and in abnormal 
and involuntary movements.  AFQ056 proved positive results in vitro, in vivo 180 and in clinical 
study181 and will be enrolled in a Phase IIb trial.  
AFQ056 showed also promising results in the treatment of other diseases, such as of behavioral 
symptoms linked to brain disorder, or autism. A recent study182 showed promising effects in the 
treatment of patients suffering from Fragile X syndrome (FXS). This syndrome is an X-linked damage 
that affects one per 5000 boys and one per 9000 girls and causes intellectual disability and behavior 
problems including anxiety, aggression, hyperactivity, impulsivity, shyness, attention deficit disorder, 
and autism. AFQ056 as specific glutamate mGluR5 antagonist blocks the expression of the FMR1 
gene (responsible of the over activation of mGluR5 pathways and of Fragile X Syndrome), and is a 
potential treatment of FragileX Syndrome.  
 
II. Preparation 
 
The preparation of the AFQ056 90 structure was first published in 2003 by Gasparini et al 183. In 2010, 
Kuesters et al 184 (and co-workers) patented an alternative process for the preparation of the 1,5,6,7-
tetrahydroindol-4-one building block (91, Figure 131) in four steps from the commercially available 
cyclohexenone 93. 
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Figure 131: Reported strategy for the preparation of AFQ056 90 
 
The first step of the synthesis involves, such as described by Dolfini and Dolfini in their paper185, the 
Michael addition of aziridine to cyclohexenone 93 affording the substituted cyclohexanone 94.  The 
resulting tertiary aziridine ring of 94 is then cleaved by addition of methyl chloroformate providing 
the halogenated intermediate named 92.   
 
Dolfini and Dolfini have indeed proved that alkyl chloroformate can convert the aziridine derivatives. 
The opening of the aziridine ring is due to release of the ring strain of the aziridinium salt (Figure 
132). 
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Figure 132: Aziridine ring opening 
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The cyclisation step is performed via the in situ formation of an enamine intermediate from a 
secondary amino base and 95, and affords as major compounds the both syn (R,R) and (S,S) 
stereoisomers 96, being separable on preparative chiral column chromatography.  
Addition 1-ethynyl-3-methyl-benzene in THF in the presence of nBuLi to 97 provides the desired drug 
product 90 with high enantioselectivity. 
  
O O
N
O
N
O O
Cl
N
O
O
O
N
O
O
O
H
H N
O
O
H
H
OH
aziridine ClCO2Me
pyrrolidine
HCl / water
chiral separation
94 95
97 9096
93
98
 
Figure 133: Patented process for the preparation of AFQ056 90
184 
 
One drawback of this process is clearly the preparation of compound 96 as racemic mixture, resulting 
in the loss of at least 50 % of the product. Therefore the development of an alternative asymmetric 
process is of great importance.  
 
III. New asymmetric strategy 
 
III.1. Introduction 
 
The challenge in the preparation of AFQ056 90 remains the introduction of the chirality on the early 
stage of the synthesis. 
 
To that purpose, we focus our attention on an organocatalytic asymmetric version of the current aza-
Michael addition, involving aziridine or more reactive nucleophiles (bearing or not the required two-
carbons side chain) and proceeding via iminium activation (Figure 134). 
 
Very few  organocatalytic asymmetric aza-Michael addition of amino nucleophiles to cyclohexenone 
are available in the literature (Jorgensen et al 186), whereas many publications report efficient racemic 
versions, using for example Lewis acid187, ionic liquid188 or copper complexes immobilized in ionic 
liquid189, copper salts190, FeCl3/Me3SiCl systems
191, phase transfer catalysts192. 
 
We based also our approach on the fact that the cyclisation step could be achieved via enamine 99 
activation (Figure 134), according to work published by List et al 193 relative to the catalytic 
asymmetric intramolecular α-alkylation of aldehydes using proline related catalysts. 
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Figure 134: Proposed new asymmetric approach for the preparation of AFQ056 intermediates 
 
This strategy offers the possibility to prepare of the enantiopure or enriched 1,5,6,7-tetrahydroindol-
4-one building block of AFQ056 (90) in a one pot sequence of a domino process, based on an 
iminium-enamine activation (101, 99) cascade (using the same organocatalyst for both steps). 
Moreover the amino ketone derivatives type 92 could be prepared via two different pathways 
(Figure 135): 
 
 1) In one step: using an activated aza-nucleophile bearing the required side chain and leaving group  
 
2) In two steps: via Michael addition of an activated secondary amino nucleophile to cyclohexenone 
93, and subsequent alkylation of the resulting amino derivative. 
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Figure 135: Asymmetric strategies for the preparation of intermediate 92 
 
III.1.1. Design of the nucleophiles 
 
The major concern relative to the design of an efficient aza-nucleophile is that, it has to be 
nucleophilic enough to undergo the Michael addition, but should not react with the α,β unsaturated 
enone to form an iminium ion.   
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To that extend, we based our design on the work of MacMillan et al 194 , Codorva et al 195 and Ricci et 
al 196 , who reported the addition of N-silylcarbamates to crotonaldehyde (MacMillan et al), catalytic 
asymmetric aziridination of α,β-unsaturated aldehydes (Cordova et al), and  O-benzyl hydroxyl amine 
to chalcones (Ricci et al). We tried to increase the nucleophilicity of the amino center via α-effect197 
generated by the introduction of a N-O functionality.  
The type of the substituents at the nitrogen atom of the nucleophile plays a role in the selectivity of 
the reaction. Indeed, as reported in 2011195b by Cordova et al, completely different chemoselectivity 
can be obtained depending on the substituents on the N-atom of the nucleophiles, affecting its pKa.  
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Figure 136
195b
: Influence of the N-substituents on the type of product formed by Michael additions 
 
For example, secondary hydroxylamines containing an electron-withdrawing substituent (carbamate 
or acyl group) at the N atom leads to a tandem aza-Michael/hemiacetal sequence to furnish 5-
hydroxyoxazolidines (Eq. 1, Figure 136). In contrast, having a protective group on the oxygen atom 
(trimethylsilyl (TMS), tert-butyldimethylsilyl (TBS), Me, or Bn) of a carbamate-protected 
hydroxylamine affords the desired aza-conjugate adduct if the enal is aliphatic (Eq. 2, Figure 136). 
However, reacting an O-protected N-aryl- or -alkyl-substituted hydroxylamine with an enal drives the 
reaction to the formation of an iminium ion195b.  
According to the considerations above, we selected the following O-benzylhyroxylamines as potential 
adequate nucleophiles (Figure 137).  
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Figure 137: Selected nucleophiles for aza-Michael additions 
 
In addition, we imagined the use of hydrazone derivatives, which are described by Jorgensen et al 186 
to be effective nucleophiles in aza-Michael addition to cyclic enones using cinchona alkaloids as 
catalysts (Figure 138).  
N
H
N
OH
110  
Figure 138: Selected hydrazone nucleophile 110 
 94 
 
 
III.1.2. Selection of the organocatalysts for the investigated aza-Michael 
additions to cyclohexenone 
 
The right catalysts194 should be able to form an iminium intermediate with the α-β unsaturated 
enone, but should not perform any 1,4 conjugate additions to the cyclohexenone 93, resulting in 
catalyst consumption. 
We selected proline related catalysts198a-b,195c, that are known to participate in asymmetric Michael 
addition via the formation of iminium species with acyclic or cyclic α-β unsaturated enones98b. 
 
III.2. Results and discussion  
 
III.2.1. Synthesis of the N-benzylhydoxylamine derivatives 107 and 109 
 
The N-benzylhydroxyl amines 107 and 109 were prepared according to the literature procedures. 
Many methods are available for the CBz- protection of amino groups140. The Z- protected N-
hyroxylbenzyl amine 109 was prepared (Figure 139) in 89% yield from the commercially available 
benzyl hydroxylamine hydrochloride 111 by addition of a solution of Z-succinimidyl 88 (1.0 
equivalent) and DMAP (0.1 equivalent) in tetrahydrofuran at room temperature.  
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Figure 139: Synthesis of Z- protected N-hyroxylbenzyl amine 109 
 
The nucleophile 107 was prepared from the commercially available Boc protected benzyl 
hydroxylamine 108 in 2 steps (Figure 140) according to the procedure of Slusky and Demers199. In the 
first step, the alkylation of 1.0 equivalent of 108 with 1.0 equivalent of 2-bromo-1-tert-
butvldimethylsilyloxy-ethane in the presence of 1.1 equivalent of NaH in DMF at 60°C afforded the 
novel tertiary amine 113 with 83% yield. Concomitant hydrolysis of the TBDMS and Boc protective 
groups was performed in dry dichloromethane at 0°C to room temperature in presence of 
trifluoroacetic acid. The base was generated in ethyl acetate by addition of potassium carbonate, 
yielding the nucleophile 107 in 96% yield. 
 95 
 
N
OO
O O
RNH
O
O O
O
R Br
N
H
OOH
1. NaH, DMF, RT
2.                 
          
          
R= TBS
1. TFA, CH2Cl2 0°C to RT
2. aq. K2CO3, AcOEt
83%
96%
R=TBS
108
107
113
112
, 60°C
 
Figure 140: Preparation of 107 
 
The commercially available bromo ethanol 114 was protected according to the procedure of 
Vader200, by addition of 1.0 equivalent of TBDMS triflate and 1.3 equivalent of imidazole at 0°C to a 
solution of 1.0 equivalent of bromoethanol in DMF at 0°C (Figure 141). 
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Figure 141: Tert-butyldimethylsilyloxy protection of bromoethanol 114 
 
III.2.2. Iminium catalysis 
 
We turned our attention to the racemic preparation of the following β-amino hexanone 
intermediates 115 and 116 (Figure 142). 
O
N
O
O O
O
N
O
O O
116115
New  
Figure 142: β-amino cyclohexanone intermediates 115 and 116 
 
The Michael adducts 115 and 116 (Figure 142) were prepared using the procedures of Park and 
Jeong192, related to the aza-Michael addition of tert-butyl benzyloxycarbamates to a wide range of 
electron deficient olefins using potassium hydroxide (50%w/w, 1.2 equivalent) in the presence of 10 
mol% of tetrabutylammonium bromide (TBAB) as phase-transfer catalyst in toluene phase. Mixing 
2.0 equivalents of the Boc-protected benzylhydroxyl amine derivative 106 and 0.1 equivalent of TBAB 
in toluene a room temperature and consecutive addition of an aqueous solution of potassium 
hydroxide and of 1.0 equivalent of cyclohexenone 93, afforded after 50 min at room temperature 
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and aqueous work-up, the desired Michael adduct 115 as racemic mixture with 30% isolated yield. 
With this material in hand, we were able to develop a analytical methods for the separation of the 
enantiomers. 
 
Using the same procedure for the Michael addition of benzyl  benzyloxycarbamate 109, afforded 
after 6 days the novel Michael adduct 116 in 77%. 
O
N
R
O
O
NH
R
O
R=Boc, 115
     Cbz, 116
R=Boc, 108
     Cbz, 109
TBAB, KOH, 
Toluene, rt
93
 
Figure 143: Racemic aza-Michael addition of tert-butyl- and benzyl- benzyloxycarbamates 108 and 109 to 
cyclohexenone 93 using TBAB as phase transfert catalysts 
 
III.2.2.1. First studies on the tert-butyl benzyloxycarbamate nucleophile 108 
 
With the analytical characterizations of the racemic mixture of the Michael adduct 115 in hand, we 
performed the screening of a selection of catalysts, solvents, additives, temperatures, to prepare 
them in an enantiomeric pure or enriched way. In the first studies we used the commercially 
available Boc protected hydroxyl amine 108 as nucleophile and screened the following catalysts I-VI 
(Figure 144). 
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Figure 144: Proline and related organocatalysts screened in the Michael addition of 108 to cyclohexenone 93 
 
The following tables compile some results, which were obtained during our investigations. 
-Table 12, influence of the catalyst 
-Table 15, influence of the base 
- Table 14, influence of the temperature 
 
First, we applied the promising conditions reported by Ley et al201 in 2008 for the organocatalytic 
enantioselective synthesis of nitrocyclopropanes from bromonitromethane and cyclic and acyclic 
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enones, using organocatalyst VI in the presence of morpholine in chloroform. We therefore screened 
the organocatalysts presented in Figure 144. 
 
It is first noteworthy to report that no reaction occured during the tested reaction time when no 
base additive was used. Only the R-tetrazole derivative VI and α-L-methyl proline II afforded the 
desired product with poor yields and enantioselectivity (Table 12, Entries 2 and 5). In the case of the 
OTBMS diphenyl prolinol ethers II and III without addition of a base, no conversion occurred (Table 
12, Entries 3 and 4). The L- and D- proline catalysts I and V did not provide any enantioselectivity 
(Table 12, Entries 1 and 6), but we observed better conversion rate.  
 
Entry Catalyst Temperature Base Solvent  
Reaction 
time  
% 115 
(%area) 
ee (%) 
1 I 
Room 
temperature 
Morpholine CHCl3 2 days 32 11 
2 II 
Room 
temperature 
Morpholine CHCl3 2 days 28 28 
3 III 
Room 
temperature 
- CHCl3 2 days - - 
4 IV 
Room 
temperature 
- CHCl3 16 hours  - - 
5 VI 
Room 
temperature 
Morpholine CHCl3 2 days 28 28 
6 V 
Room 
temperature 
Morpholine CHCl3 2 days 70 4 
7 VI 
Room 
temperature 
- CHCl3 2 days - - 
Table 12: Iminium catalysis, screening of catalysts Reactions were performed on 1 mmol scale at a 
concentration of 4 mL/mmol with 15% of catalyst in the presence of  1 equivalent of base, 1 equivalent of 
cyclohexenone and 1.5 equivalent of nucleophile. Conversion rate and enantiomeric excess were determined 
by chiral phase HPLC (CHIRALPAK AD-H). 
 
With the moderate effective organocatalyst VI in hand, optimization of the reaction conditions was 
undertaken by screening different solvents (acetonitrile, chloroform, dichloromethane, 
dimethylformamide, toluene, dimethylsulfoxide, diethyl ether), the best one being chloroform in 
term of both yields and enantioselectivities. Performing the reaction under solvent-free conditions 
resulted in the increase of the reaction rate, but yielded in the decrease of the enantioselectivity 
(Table 13). The same trend was obtained using L-proline I and triethylamine as base. 
 
Entry Catalyst Temperature Base Solvent  
Reaction 
time  
Conversion 
(%area) 
ee (%) 
1 VI O°C Morpholine - 3 days 36% 36 
2 VI 
room 
temperature 
Morpholine - 3 days 76% 24 
Table 13: Iminium catalysis,  Reactions were performed on 1 mmol scale with 15% of catalyst in the presence 
of  1 equivalent of base, 3 equivalents of cyclohexenone and 1.0  equivalent of nucleophile. Conversion rate 
and enantiomeric excess were determined by chiral phase HPLC (CHIRALPAK AD-H). 
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A similar trend was obtained (faster reaction, but lower enantioselectivity) by increasing the 
temperature (Table 14, Entries 1-3 and 4-6). The use of 15% of organocatalyst VI at 0°C or 10°C was 
found to be the best conditions, yielding the desired product with an enantiomeric excess of 54% 
(Table 14, Entries 2-3). 
 
Entry Catalyst  Temperature  
Reaction 
time  
Conversion 
(%area) 
ee (%) 
1 VI Room temperature 20h 16% 28 
2 VI 10°C 15h 7.5% 54 
3 VI 0°C 48h 8% 54 
4 I Room temperature 48h 32% 11 
5 I 10°C 15h 11% 28 
6 I 0°C 48h 13% 28 
Table 14: Iminium catalysis, impact of temperature Reactions were performed on 1 mmol scale at a 
concentration of 4 mL/mmol in chloroform with 15% of catalyst in the presence of 1 equivalent of morpholine. 
Conversion rate and enantiomeric excess were determined by chiral phase HPLC (CHIRALPAK AD-H). 
 
We then examined the impact of the base additives on the rate and enantioselectivity of the 
reaction. Increasing the pKa of the base additive drives the reaction to the racemic process, affording 
inferior enantioselectivity  (Table 15, Entries 1-4). Addition of 1 equivalent of piperazine  as additive 
in the presence of VI in chloroform at room temperature could be an appropriate combination 
according to Ley et al 98b. It accelerated indeed significantly the reaction (Table 15, Entry 7) until 
almost complete conversion, but we also observed lower enantiomeric excesses.  
 
Entry Catalyst temperature Base 
Reaction 
time 
(hours) 
Conversion 
(%area) 
ee 
(%) 
1 VI 0°C triethylamine 24h 18% 28 
2 VI 0°C morpholine 48h 2% 54 
3 VI 0°C N-methyl morpholine 48h - - 
4 VI 0°C Hünig Base 24h 15 10 
5 VI 0°C Immobilized morpholine  48h - - 
6 VI 0°C 
Immobilized Diisopropyl-(4-methyl-
benzyl)-amine 
48h - - 
7 VI 19°C trans-2,5- dimethylpiperazine 17h 89% 20 
8 I 0°C morpholine 48h 13% 28 
9 I 0°C Immobilized morpholine  48h - - 
10 I 0°C Immobilized Diisopropyl-(4-methyl-
benzyl)-amine 
48h - - 
Table 15: Iminium catalysis, impact of additives. Reactions were performed on 1 mmol scale at a 
concentration of 4 mL/mmol in chloroform with 15% of catalyst, in the presence of 1 equivalent of base. 
Conversion rate and enantiomeric excess were determined by chiral phase HPLC (CHIRALPAK AD-H). 
 
We then screened again some bases using dichloromethane as solvent.  
Without any catalyst but in the presence of a base, no reaction and also no side reaction occurred 
when triethylamine and Hünig base were used as additives (Table 16, Entries 1-2). This proves the 
mechanism of reaction, which is working via the formation of an iminium intermediate.  
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Nevertheless increasing the pKa of the base afforded the Michael adduct (Table 16, Entry 4) via a 
racemic pathway. Utilizing one equivalent of DBU yielded, for example, the formation of 47% 
conversion of the racemic desired product within 18 hours (Table 16, Entry 4).  
 
Adding the organocatalyst I or VI resulted in the formation of the desired product with all of the 
bases we tested with improved conversion rate but no enantioselectivity was observed. Nevertheless 
only the utilization of trans-2,5- dimethylpiperazine allows the formation of the Michael adduct with 
moderate enantioselectivity.  
 
Entry Catalyst Temperature 
 
Base 
Base 
equivalents  
Reaction 
time 
(hours) 
Conversion 
(%area) 
ee 
(%) 
1 - 19°C triethylamine  6 17h - - 
2 - 19°C Hünig Base  1 18h - - 
3 - 19°C sparteine  1 18h 3 - 
4 - 19°C DBU  1 18h 47 - 
5 VI 19°C DBU  1 17h 57 18 
6 VI 19°C 
trans-2,5- 
dimethylpiperazine 
1 17h 89 20 
7 VI 0°C DBU 1 17h 51 18 
8 VI 0°C Hünig Base 1 24h 15 10 
9 I 19°C triethylamine  1.1 8h 11 6 
10 I 19°C triethylamine  2 8h 16 4 
11 I 19°C triethylamine  6 8h 24 4 
12 I 19°C Hünig Base  0.4 18h 13 4 
13 I 19°C sparteine  0.4 18h 28 2 
14 I 19°C DBU  1 17h 56 2 
15 I 19°C DBU  0.4 17h 59 6 
16 I 0°C DBU  0.4 17h 52 6 
Table 16: Iminium catalysis, impact of additives. Reactions were performed on 1 mmol scale at a 
concentration of 4 mL/mmol in dichloromethane with 15% of catalyst or without catalyst. Conversion rate and 
enantiomeric excess were determined by chiral phase HPLC (CHIRALPAK AD-H). 
 
All the conditions we tried, didn’t allow us to isolate the Michael adduct with significant 
enantioselectivity and good conversion rate. The best conditions we obtained were the use of the 
organocatalyst VI and addition of one equivalent of morpholine at 0°C in chloroform or under 
solvent-free conditions (Table 13, Entry 1; Table 14, Entry 3; Table 15, Entry 3). 
 
The Michael addition of 108 to cyclohexenone 93 was performed on a representative 1.0 mmol  
scale, by adding at room temperature to a solution of 1.0  equivalent of cyclohexenone in 
chloroforme, 0.16 equivalent of 5-pyrrolidin-2-yltetrazole VI, 1.5 equivalents of nucleophile 108 and 
one equivalent of morpholine. The desired Michael product 115 was isolated after two days with 
19% yield and an enantiomeric excess of 32%.  
 
Having the “best” conditions in hand, we extended our studies to the Michael addition of the Z- 
protected N-hydroxylbenzyl amine 109, the N-hydroxylbenzyl amine 107 bearing the required 
ethanol side chain, and aziridine 102 to cyclohexenone 93. 
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III.2.2.2. First studies on the O-benzyl- benzyloxycarbamate nucleophile 109 
 
Applying the same conditions as for the derivative 115, we prepared the Z-protected analogue 116 
with moderate yield and enantioselectivity (Figure 145).  
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Figure 145: Michael addition of the Benzyl benzyloxy carbamate 109 to cyclohexenone 93 
 
Utilizing the tetrazole organocatalyst VI in presence of one equivalent of morpholine or trans-2, 5-
dimethylpiperazine in chloroform at room temperature or at 0°C yielded the best conversion rate 
(Table 17, Entries 4,6). Nevertheless only in the case of organocatalyst VI, in presence of morpholine 
in chloroform at 0°C, we observed significant enantiomeric excesses (Table 17, Entry 3).  Conducting 
the same reaction at room temperature or under solvent free conditions resulted in the decrease of 
e.e. (Table 17, Entry 2). When the reaction was performed under solvent-free conditions, we 
observed a complete conversion (Table 17, Entries 4, 5). Utilizing L-proline I as catalysts did not 
improve the reaction in terms of conversion and enantioselectivity (Table 17, Entry 1). 
 
Entry Catalyst temperature Base solvent  
Reaction 
time 
(hours) 
Conversion 
(%area) 
ee 
(%) 
1a I 19°C morpholine chloroform 72h 41 4 
2a VI 19°C morpholine chloroform 72h 40 8 
3b VI 0°C morpholine  chloroform 72h 15 44 
4c VI 0°C morpholine  - 72h 100 20 
5c VI 19°C morpholine  - 6h 12 26 
6b VI 19°C 
trans-2,5-
dimethylpiperazine  
chloroform 18h 98 8 
Table 17: Iminium catalysis. 
a
Reactions were performed on 1 mmol scale at a concentration of 4 mL/mmol in 
chloroform with 15% of catalyst, 1 equivalent of cyclohexenone, 1.5 equivalents of the amine, 1 equivalent of 
base
 b 
Reactions were performed on 1 mmol scale at a concentration of 4 mL/mmol in chloroform with 15% of 
catalyst, 3 equivalents of cyclohexenone, 1 equivalent of the amine, 1 equivalent of base
 c
Reactions were 
performed on 1 mmol scale with 15% of catalyst, 3 equivalents of cyclohexenone, 1 equivalent of the amine, 1 
equivalent of base. Conversion rate and enantiomeric excess were determined by chiral phase HPLC 
(CHIRALPAK AD-H). 
 
In the course of our investigations, we also observed degradation and retro-michael addition of the 
formed product at higher temperature. 
 
The Michael product 116 was also prepared on a 1 mmol scale, by adding to a solution of three 
equivalent of cyclohexenone, 0.16 equivalent of 5-pyrrolidin-2-yltetrazole VI, 1.5 equivalents of 
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nucleophile 109 and one equivalent of morpholine at room temperature. The desired Michael 
product 116 was isolated with 12% yield and an enantiomeric excess of 27%.  
 
III.2.2.3. Towards the asymmetric Michael addition of aziridine 102 to 
cyclohexenone 93 
 
An asymmetric version of the reported184 aza-Michael addition of commercially available aziridine 
102 to cyclohexenone 93 has also been investigated.  
 
O O
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Figure 146: Michael addition of aziridine 102 to cyclohexenone 93 
 
The conditions we tested, allow only the formation of the Michael adduct 117 as a racemic mixture. 
Performing the reaction in the ionic liquid BmimOH188c (Table 18, entry 2) enhanced, as described by 
Xhia et al188c, the reaction, but addition of L-proline I to the reaction mixture did not provide any 
enantioselectivity (Table 18, entry 3).  
 
Entry Catalyst 
Tempera-
ture 
Base Solvent 
Reaction 
time 
Conversion 
(%area) 
ee (%) 
1 - rt - water 35 min 2 - 
2 - rt - BmimOH 24 hours 16 - 
3 I rt - BmimOH 18 hours 80 8 
4 I rt triethylamine CHCl3 3 days 13 2 
5 I rt triethylamine CHCl3 18 hours 1 2 
6 I 0°C triethylamine CHCl3 18 hours 1 6 
7 I -50°C triethylamine CHCl3 4 days - - 
8 V rt triethylamine CHCl3 2 days 2 10 
9 VI rt triethylamine CHCl3 18 hours 1 10 
10 VI rt 
trans-2,5-
dimethylpiperazine 
CHCl3 18 hours 1 10 
11 VIII rt triethylamine CHCl3 18 hours - - 
Table 18: Iminium catalysis, aziridine as nucleophile Reactions were performed on 2 mmol scale at a 
concentration of 4 mL/mmol with 15% of catalyst in the presence of  1 equivalent of base, 3 equivalent of 
cyclohexenone and 1 equivalent of nucleophile. Conversion rate and enantiomeric excess were determined by 
chiral phase HPLC (CHIRALPAK AD-H). 
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III.2.2.4. Towards the asymmetric aza-Michael addition of 107 to 
cyclohexenone 93 
 
Conducting the Michael addition of the nucleophile 107 on cyclohexenone 93, in the presence of L-
proline I, morpholine at room temperature, provided after 7 days the desired product in a mixture of 
unknown side products. No enantioselectivity was observed. No more experiments have been done 
with this nucleophile. 
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Figure 147: Aza-Michael addition of 107 to cyclohexenone 93 
 
III.2.2.5. Aza-Michael addition of the hydrazone derivative 110 
 
One last study was undertaken based on the work of Jorgensen et al 186 concerning the first 
organocatalysed asymmetric aza-Michael addition of hydrazones to cyclic enones, mediated by 
cinchona alkaloids. He reported the possibility to prepare the Michael adducts with good 
enantioselectivities via the formation of a chiral intermediates resulting from the interaction of all 
reactants. 
 
Using the reaction conditions described by Jorgensen et al, we hoped to be able to prepare the 
following Michael adducts with good enantioselectivities (Figure 148). Further steps could allow us to 
prepare the chloride, bromide or mesylate derivatives, which could afford the desired AFQ056 
intermediate 121 via intermolecular alkylation via enamine catalysis. 
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Figure 148: Hydrazone strategy for the enantioselective preparation of AFQ056 90 
 
Applying the procedures of Jorgensen, by mixing three equivalents of cyclohexenone 93 with one 
equivalent of the hydrazone derivative 110 in the presence of 20% of hydro quinidine in toluene at 
room temperature afforded complex mixture. The major component was the desired Michael adduct 
120 (Figure 23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 149: LCMS chromatogram of the reaction residue 
 
Purification on preparative TLC using a mixture of heptan fraction/ethyl acetate yielded in the purest 
fraction the desired compound in mixture with the starting material and unknown compounds 
(Figure 150). Further investigations will be conducted in the next future to find out all of the side 
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products presents in the reaction mixture, LCMS analysis revealing that one of them could be the 
iminium specie 122 generated from cyclohexenone 93 and the nucleophile 110. 
 
 
Figure 150: LCMS chromatogram of the purest fraction 
 
III.2.3. Towards the preparation of the chloride derivative 92 and iminium ion 
formation 
 
The next step of the synthesis of AFQ056 90 involved the removal of the protective group of the 
Michael adduct 115. We performed the reaction using trifluoroacetic acid in dichloromethane (Figure 
151).  
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Figure 151: Deprotection of 115 
 
Under these conditions, the cleavage of the C-N bond occurred (retro-Michael addition), affording 
the nitrogen species 124. It subsequently condensed with the generated cyclohexenone yielding 
stable iminium species 126202 as trifluoroacetic salt with 55% yield and an isomeric ratio of 44:56 (E 
and Z isomers). The formation of 126 resulted from the condensation of the in situ generated amine 
124 and cyclohexenone 93. 124 and 93 were formed through the retro-Michael addition on the 
deprotected analogue of 115. 
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Figure 152: Formation of the iminium species 126 
 
III.2.4. Cyclisation step via enamine catalysis  
 
The next step in the synthesis of AFQ056 involves a ring closure step to yield 91. 
As reported in 2004 by List et al193, chiral cyclopentane, propane and pyrrolidine derivatives can be 
prepared in high yields and ee’s, via a highly enantioselective intramolecular direct aldehyde α-
alkylation, through the formation of enamine intermediates with L-proline I and α-methyl proline II. 
According to his procedures we prepared the bicyclic species 96, from a racemic mixture of 95 
(Figure 153). 95 was prepared in the laboratory by M. Blatter according to the literature reported by 
Küsters et al 184. 
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Figure 153: Cyclisation step via the formation of an enamine intermediate 127 
 
III.2.4.1. Batch results 
 
A selection of solvents has been screened using L-proline I (known to be able to form enamine 
intermediates) as catalyst in the presence of an organic base and 10% of potassium iodide. The 
investigations presented on Table 19 demonstrated the influence of the temperature and the solvent 
used and afford us the best solvent, base and temperature conditions for the intramolecular α-
alkylation (Table 19, Entry 6): triethylamine in DMSO at 150°C (Table 19). Conducting the reaction on 
an isomeric mixture of the starting material yielded only two diastereoisomers (R,R) and (S,S), in an 
equimolar ratio. 
 
 
 106 
 
Entry Solvent Base Temperature (°C) Time(hours) 
Conversion 
(%area) 
1 dichloromethane triethylamine 40 3h20 30 
2 chloroform triethylamine 60 3h20 88 
3 dichloroethane triethylamine 80 3h00 90 
4 chlorobenzene triethylamine 130 2h20 94 
5 trifluorotoluene triethylamine 140 2h30 33 
6 DMSO triethylamine 150 25 min 100 
7 xylene Hünig base 140 50 min 60 
Table 19: Enamine catalysis. Reactions were performed on 1 mmol scale at a concentration of 4 mL/mmol with 
10% of L-proline I in the presence of 10% of KI and 1 equivalent of base. Conversion rate was determined by 
chiral phase HPLC. 
 
A selection of additives has also been tested. Using TBAI as additive did not improve the reaction, in 
comparison to KI. But using 1% of TBAI still provides complete conversion within 15 min at 150°C 
(Table 20, Entry 5). Moreover, conducting the reaction in NMP or DMA at higher temperature didn’t 
enhance the conversion rate (Table 20, Entries 6-7). 
In conclusion, utilizing KI in DMSO at 150°C seemed to be the most appropriate conditions. 
 
Entry Solvent Base Additives 
Temperature 
(°C) 
Time(min) 
Conversion 
(%area) 
1 DMSO triethylamine 5% KI 150 7 min 100 
2 DMSO Hünig base 5% KI 130 >25 min 100 
3 DMSO Hünig base 5% KI 150 15 min 100 
4 DMSO Hünig base 5% TBAI 150 15 min 100 
5 DMSO Hünig base 1% TBAI 150 15 min 100 
6 DMSO Hünig base - 150 25 min 100 
7 NMP Hünig base 10% KI 180 15 min  100 
8 DMA  Hünig base 10% KI 166 15 min 100 
Table 20: Enamine catalysis Reactions were performed on 1 mmol scale at a concentration of 4 mL/mmol with 
10% of L-proline I in the presence of the additive and 1 equivalent of base. Conversion rate was determined by 
chiral phase HPLC. 
 
A selection of proline related catalysts has been tested. And as presented in Table 21, the nature of 
the substituent on the proline related catalyst doesn’t a have a huge influence on the kinetic of the 
reaction. Even if the organocatalyst VI seems to be more efficient (Table 21, Entry 2), L-proline I 
being a cheap commercially available compound, it will be used as organocatalyst in the next studies. 
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Entry Rcatalysts Base Additives 
Temperature 
(°C) 
Time(min) 
1  I Hünig base 10% KI 180 15 min  
2 VI Hünig base 10% KI 180 7 min  
3 VIII Hünig base 10% KI 180 15 min  
Table 21: Enamine catalysis. Reactions were performed on 1 mmol scale at a concentration of 4 mL/mmol with 
10% of catalyst in the presence of 10% of KI and 1 equivalent of Hünig base in NMP. Conversion rate was 
determined by chiral phase HPLC. 
 
Having good conditions for the rapid formation of the 1,5,6,7-tetrahydroindol-4-one derivative  96, 
we investigated the possibility of developing a continuous flow process. 
 
III.2.4.2. Continuous flow results  
 
The rapidity of the reaction and the low concentration of inorganic salts required let us to study an 
alternative continuous flow process. It was performed by injecting at a flow rate of 1 mL/min a pre-
mixed DMSO solution containing all the reactants into a heated tube. The collected fractions were 
analyzed by chiral HPLC using CHIRALPAK AD-H.  
 
 
 
 
 
Figure 154: Representation of the continuous flow apparatus 
 
We tested for practical and economic reasons the cyclisation step under the following conditions: 1 
equivalent of Hünig base in presence of 10% of L-proline I and 5% of TBAI at various temperatures. 
Entry Solvent 
Temperature 
(°C) 
Contact time(min) Conversion (%area) 
1 DMSO 160 2 min 84 
2 DMSO 160 5 min 94 
3 DMSO 160 8 min 100 
4 DMSO 160 15 min 100 
5 DMSO 150 5 min 96 
6 DMSO 150 10 min 100 
7 DMSO 150 15 min 100 
8 DMSO 140 5 min 99 
9 DMSO  140 10 min 100 
Table 22: Enamine catalysis Reactions were performed on 1 mmol scale at a concentration of 4 mL/mmol with 
10% of catalyst I in the presence of 10% of TBAI and 1 equivalent of Hünig base. Conversion rate was 
determined by chiral phase HPLC. 
 
This rapid screening proved the feasibility of a continuous flow process. With contact times less than 
10 min, we were able to convert 100% of the starting material (Table 22, Entries 3,5,9).  
 
 
95
 
in DMSO  (1 eq.) 
1 eq. of Hünig base , 
10% of L-Proline I, 
5% of TBAI  Chiral HPLC analysis 
CHIRALPAK AD-H 
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IV. Conclusion 
 
The aza-Michael addition of N-nucleophiles to cyclohexenone 93 still remains a challenge. Some 
interesting procedures were nevertheless reported in the literature for the Michael addition of 
nitroalkane (Ley et al) or hydrazine derivatives (Jorgensen et al) to cyclohexenone. Using similar 
procedures, we reported here a new strategy for the enantioselective preparation of AFQ056 
precursors, involving in the first step, the organocatalyzed aza-Michael addition of a selection of N-
nucleophiles to cyclohexenone. In the best case, we were able to isolate the two aza-Michael 
products 115 and 116 with moderate enantiomeric excess up to 30% and poor isolated yields (12% 
and 19%).  
Furthermore, we described a successful approach for the intramolecular alkylation step yielding the 
the 1,5,6,7-tetrahydroindol-4-one building block 96 of AFQ056 90 within short reaction time and high 
conversion rate. That proved the possibility of a continuous manufacturing of AFQ056. The next 
study should include the preparation of the the 1,5,6,7-tetrahydroindol-4-one building block pattern 
from an enantiomeric pure starting material. 
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CHAPTER 4: TOWARDS THE ASYMMETRIC PREPARATION 
OF THE ANTI-MALARIA DRUG CANDIDATE KAE609 
 
I.  Pharmacological activity 
 
KAE609 129 (NITD609) (Figure 155) is a phase I candidate belonging to a new class of potent anti-
malaria compounds: the tetrahydrospiroindole-β-carbolines203 and, which was awarded in 2009 
MMW204 Project of the Year 2009.  
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Figure 155:  New anti-malaria drug candidates  
 
Its identification is linked to the effort to discover new anti-malarial chemotypes with novel mode of 
actions to fight current drug resistances. Malaria is recognized as one of the major health problems 
especially in developping countries.  
 
Malaria is transmitted by an infected mosquito that transfers a parasite (Plasmodium) in the human 
blood (Figure 156). The parasites enter the human liver, where they multiply. They invade then the 
blood cells, where they multiply again, causing the rupture of the membrane of erythrocytes, 
producing the symptoms of the disease (generally fever, headaches). 
 
Figure 156: Transmission of malaria and Plasmodium development 
 
There are four species of parasites (vivax, ovale, malariae, falciparum) but only P. falciparum is 
known to cause the patient’s death. 
 
In vitro and ex vivo data studies205 of the inhibitory activity of spiroindoles proved the new 
mechanism of action of these compounds. In contrast to the current medicines (mefloquine, 
NITD609 
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artemisinine), the spiroindoles suppress the protein synthesis at the erythrocytic stage of 
development of the parasites P. falciparum and P. vivax and so retain activity against drug-resistant 
strains. 
 
II. Preparation 
 
The KAE609 analogues are synthesized1 in eight chemical transformations from the corresponding 
indoles203. The strategy of the synthesis is based on the preparation of a racemic mixture of the 
amines 133, which afford the active compounds 128 and 134 via a Pictet-Spengler206 cyclisation with 
5-chloroisatin, with a 9:1 diastereoisomeric excess of the favored (1R, 3S) and (1S, 3R) 
enantiomers203. The (1R, 3S) and (1S, 3R) enantiomers are in the end of the synthesis resolved by 
chiral chromatography.  
 
The racemic aminopropenylindoles intermediates 133 were prepared by Vilsmeyer-Haack 
formylation of the indoles, followed by Knoevenagel condensation with nitroethane in presence of 
ammonium acetate and reduction of the resulting nitro alkene derivatives in presence of LAH (Figure 
157). 
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Figure 157: Racemic synthesis of KAE609 spiroindoles
203 
128 and 134 
 
Nevertheless in vitro (P. falciparum) and in vivo (P. berghei) studies have proved the influence of the 
chirality on the parasitic activity of some tested compounds. As shown in Table 23 (entry 1-4), only 
the (1R,3S) stereoisomer presents a satisfactory IC50 (<10 nM)  similar to the one of artesunate
205,14. 
 
 
                                                          
14
 For a review about the bio-activity of artesunate see Q. Li , P. Weina, Pharmaceuticals 2010, 3, 2322-2332; 
For the structure of artesunate, see J. N. Lisgarten, B. Potter, R. A. Palmer, B. Chimanuka, J. Aymami, Journal of 
Chemical Crystallography 2002, 32(1-2),  43-48. 
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Entry Structure 
NF54 IC50  
(nM) 
KI IC50  
(nM) 
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Table 23: In vitro activity against two cell strains of P. falciparum: NF54 and Chloroquine resistant K1 strains
203
 
 
The promising anti-malaria activities of the enantiopure spirolindole derivatives 129 and 143 (Table 
23, Entries 8 and 10) resulted in an effort to provide alternative routes for their large scale 
preparation.  
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III. New alternative route 
 
III.1. Introduction 
 
III.1.1 Asymmetric route 
 
We based our strategy on the preparation of chiral α-substituted nitro indole derivatives 148a-d 
(Figure 158), from the corresponding indoles, via enantioselective Friedel-Crafts addition of the 
adequate α-substituted nitro alkenes (Figure 158).  
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Figure 158: New asymmetric strategy for the preparation of indole intermediates 148a-d and149a-d of 
NIDT609 
 
Although the Friedel-Crafts alkylation (first reported by Friedel and Crafts in 1887207) type addition of 
electron rich heterocyclic compounds with nitroalkenes has been described for a long time208, the 
development of enantioselective catalytic processes had to wait until 2005. Many type of metal 
based Lewis acids and organocatalysts have been described in the literature209,102a-b for the Friedel-
Crafts addition of indoles to substituted nitro alkenes: salen(Al)catalysts210, thioureas211, phosphoric 
acids212, bissulfonamides213, zinc214 and copper215 catalysts, cinchona alkaloids216, yielding to the 
formation of various β- substituted indoyl nitroalkanes (Figure 159). 
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Figure 159: β-substituted amino indoles pattern and chiral organocatalysts 
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However the catalytic enantioselective preparation of chiral α- substituted indolyl nitroalkanes via 
Friedel-Crafts alkylation still remains a challenge. Only some examples217 are available in the 
literature for their racemic preparation, by condensation of (substituted or non-substituted) indole 
derivatives with nitroolefins;  the former procedure being published by Ranganathan218 in the course 
of his study on the use of nitroethylene in organic chemistry.  
Nevertheless, using the available procedures for the conjugate addition of indoles to nitroalkenes 
and catalysts cited (Figure 159), we tried to develop a methodology to prepare the key α- substituted 
indolyl nitroalkane intermediates 148a-d in an asymmetric manner.  
 
 
III.1.2. New racemic route 
 
A shorter version of the current two-step Vilsmeier–Henry procedure203 process is possible in one 
step via the preparation of the α- substituted indoyl nitroalkenes intermediates using an adapted 
version of the procedure of Mak and Büchi219  (Figure 160) relative to nitro olefination of indoles with 
commercially available dimethylamino-2-nitroethylene 151. According to the literature203, 
subsequent reduction of the nitroalkene derivatives in presence of LAH or NaBH4 should deliver the 
desired tryptamine derivatives 149a-d.  
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Figure 160: “Mak and Büchi strategy” for the preparation of substituted nitro alkenes 
 
It is worth to mention that such procedures have been often employed for the preparation of natural 
products or pharmaceutical active compounds220, such as melatonin derivatives or Haplophytine 
during the last years.  
 
Thus, the α-methyl tryptamine intermediates 149a-d could be obtained by reaction of the 
corresponding indoles 147a-d with 4-((E)-2-nitro-propenyl)-morpholine 155 (that are known to 
undergo stereoselective nitroolefination of active methane of various carbonyl compounds221) in 
presence of TFA, followed by in situ reduction of the generated indolyl nitro alkene intermediates 
156a-d with LAH or NaBH4.  
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Figure 161: One-step procedure for the preparation of the indolylnitroalkene 156a-d 
Mak and Büchi process 
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The advantage of this procedure is its potential application to the synthesis of various α-substituted 
indolyl nitro alkane derivatives by variation on the α-substituent of the morpholino nitro alkene 
reactant.  
 
Using an asymmetric reduction procedure (Baker yeast222, Josiphos Ligand223, chiral TarB-NO2-BH4 
complex224) of the nitro alkene derivatives 156a-d, it could be possible to access enantiopure or 
enriched nitro alkane compounds 149a-d.  
 
III.2. Results and discussion 
 
III.2.1 Asymmetric Friedel-Crafts alkylation 
 
In an effort to develop a methodology to access the enantiopure α- substituted indolyl nitroalkane 
precursor of KAE609 (156a-d), a selection of catalysts has been tested in the Michael addition of a 
range of substituted indoles to nitropropene. The racemic version of the Friedel-Crafts alkylation was 
also investigated.  
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Figure 162: Selection of catalysts investigated in the NIDT609 Friedel- Crafts alkylation 
 
We selected the test thiourea catalyst I designed by Takemoto. Chiral ureas and thioureas have been 
successfully be used225 for diverse catalytic asymmetric reactions. The possibility of a double 
Hydrogen-bond interaction between the two basic oxygen atoms of the nitroalkene partner and the 
acidic protons of the urea moiety (Figure 163) led to the exploitation of these molecules for the 
asymmetric Friedel-Crafts alkylation of nitroalkenes.  
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Figure 163: Hydrogen-bond interaction between ureas and nitroarenes observed in solid state 
 
We selected also two commercially available chiral Binol-phosphoric acids II and III. Such catalysts 
have been reported to perform Friedel-Crafts alkylation of indoles with nitroalkenes (Akiyama226), 
with excellent enantioselectivies and yields. The excellent enantioselectivities observed can be 
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explained by concomitant activation of the nitro group and of the indole partner via hydrogen bond 
formation with the phosphoryl oxygen as represented on Figure 164227. 
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Figure 164: 3-3’-bistriphenylsilyl BINOL derived phosphoric acid and activation mode 
 
The required nitropropene solution was prepared either from nitroethanol using acidic Alox 
(Brockman Activity I) as dehydrating agent or using phthalic anhydride at 150°C228 (reaction 
performed in the laboratory by D. Grimler). 
 
III.2.1.1. Preparation of 148a-d as racemic mixtures 
 
As model reaction, we investigated first the Michael addition of indole 147a to nitropropene (Figure 
165). The racemic mixture of rac-148a was prepared in a procedure inspired by the publication of 
Nichols229 by mixing one equivalent of 147a in one equivalent of a diluted solution of nitropropene in 
toluene (C= 1.1 mmol/15 mL) at 40°C. We observed by HPLC analysis, that the reaction proceeded 
slowly. Only a very low conversion of the indole into its product rac-148a could be observed (6 area% 
product presents after 20 hours at 40°C). LCMS analysis of the reaction mixture confirmed the 
presence of the Michael product at a retention time of 6.4 min.  
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Figure 165: Michael addition of indole 147a to nitropropene 150 
 
The racemic Friedel-Crafts alkylations of indoles 147b and 147c were also tested, but resulted in the 
low formation of complex mixtures. It seems that electron poor indoles with withdrawing 
substituents are no suitable partners in Friedel-Crafts reactions with nitroalkenes.  
 
III.2.1.2. Towards the asymmetric preparation of the indolyl nitro alkanes 
148a-d  
 
Having developed an LC method for the detection of indolylnitroalkane 148a in hand, we 
investigated its asymmetric preparation screening the selection of catalysts of Figure 162. For the 
screening, we used 1.5 equivalents of a diluted solution of nitropropene in toluene (1.1 mmol/15 mL) 
were added to 1 equivalent of indole, and 0.1 equivalent of the selected catalyst (I, II and III) at room 
temperature. HPLC analysis of the reaction mixture on Inertsil ODS 3 C18 (using acetonitrile and 
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demineralized water buffered with 0.01% of NH4H2PO4 and a gradient of 55% to 97% acetonitrile in 
15 min at 40°C) revealed the presence of the desired product in mixture with side-products. The 
results were confirmed by LCMS analysis. It is noteworthy that, using 147a and 150 in solution, 
complete conversion could not be obtained; yielding only complex mixtures. Performing the reaction 
using pure nitropropene accelerated the conversion. Nevertheless for safety considerations, the use 
and handling of nitropropene as a solution in toluene is prefered.  
 
Optimization of the reaction conditions is still required to perform the asymmetric synthesis of the 
KAE609 precursor 148a. Also further investigations to identify the generated side products are 
necessary.  
 
III.2.2. New one-pot approach for the preparation of the nitropropenyl 
indoles 156b-d 
 
According to a modified version of the procedures of  Mak and Büchi219,  the reaction of the indoles 
147b-d with 4-((E)-2-nitro-propenyl)-morpholine 15515 in dichloromethane in the presence of 
trifluoroacetic acid afforded the α-substituted indoyl nitro alkanes 156b-d  with very good yields (up 
to 86%).  
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Figure 166: Novel one-pot approach for the preparation of 156b-d. 
 
The X-Ray analysis (Figure 167) of 156b revealed, that in the crystal state, the molecules of 156b form 
planar layers with an approximate spacing of 3.28 Å. Hydrogen bonding between two independent 
molecules in the crystal structure explain the infinite chains parallel formed to the crystallographic 1 
0 1 direction.  
 
                                                          
15 155 was prepared in the laboratory, on a multigram-scale, by D. Grimler  with 78% yield according 
to a procedure221 of  Fuji  et al by refluxing 5 equivalents of nitroethane, 2 equivalents of triethyl 
orthoformate and one equivalent of morpholine in the presence of p- toluenesulfonic acid.  
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Figure 167: Packing of 156b in the crystal and Hydrogen bonding in the crystal structure 
 
As despicted in Figure 168, we observed also the distortion of the side chain out of the plane of the 
indole moiety. The angle between the best plane through C2, C3, C4, C5, C6, N7, C8, C9, C10 and the 
best plane through C12, C13, C14, N15, O16, O17 is indeed 6.6(1)°, when in the molecule 2 the 
corresponding dihedral angle is 7.2(1)°. Moreover the distance of C14 (methyl group) to the indole 
plane is 0.455(4) Å, but C34 is 0.298(4) Å away from the indole plane. We can thus note a slight 
vertical displacement of the nitropropenyl moiety in molecule 1.  
 
Figure 168: Intramolecular twist in (E)-156b 
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The X-Ray analysis of 156d (Figure 169) reveals the herringbone type pattern formed by the 
molecules of 156d, with an angle of 92.4(2)° between the bones, the distance between parallel 
planes being 3.19(2) Å. Hydrogen bonding in the crystal structure of 156d explains the formation of 
infinite chains. In contrast to the in-plane arrangement in 156b, the chains are parallel to the 
crystallographic 3 0 1 direction. However, the neighboring molecules in 156d are almost 
perpendicular to each other.   
 
  
Figure 169: Packing of 156d in the crystal and Hydrogen bonding in the crystal structure  
 
An intramolecular twist in 156d is also observed (Figure 170). The angle between the best plane 
through C1, N2, C3, C4, C5, C6, C7, C8, C9 and the best plane through C10, C11, C12, N13, O14, O15 is 
11.4(1)°. The distance of C12 (methyl group) to the indole plane is 0.445(2) Å. 
 
Figure 170: Intramolecular twist in (E)-156d 
 
IV. Conclusion 
 
Preliminary experiments have been executed evaluating the viability of an asymmetric preparation of 
the Novartis promising drug candidate KAE609 from Novartis using an organocatalytic approach. We 
were able to prepare the indolylnitroalkene analogues 156b-c with high yields.  Based on these 
results we proposed a general one-step procedure to synthesize a range of precursors for potential 
bioactive analogues of KAE609. So far our trials to prepare the desired chiral indolylnitroalkane 148a-
d in enantiomerically enriched form failed. We had to separate the synthesized racemic precursors 
by chiral chromatography. 
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Applying asymmetric reduction procedures (Figure 171) (Baker yeast230, Josiphos ligand223, chiral 
TarB-NO2-NaBH4 complex
231) of the nitro alkene derivatives or chiral protonation processes have to 
be investigated allowing the preparation of the drugs KAE609 in large scale.  
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Figure 171: Strategies available for the asymmetric preparation of 149b-d reducing the prochiral precursors 
156b-d 
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CHAPTER 5: MULTI COMPONENT DOMINO REACTIONS 
 
I. Introduction 
 
In the recent years, the new trends in the chemical community to produce drugs or natural products 
in a cheaper, safer, more efficient manner, led to the emergence of a new powerful tool in organic 
chemistry:  domino multi component reactions received considerable attention (as proof: the 
increasing number of publications on the topic, see Figure 172).  
51
86 82 100
105
135 152
183
224
277
314
0
100
200
300
400
 
Figure 172: Number of publications edited from 2000 to 2010, on the topic “domino reactions”(SciFinder 
search) 
 In a domino multicomponent reaction several C-C bonds and stereocenters are formed from simple 
precursors. They therefore allow the rapid construction of structurally complex molecules232,12h,12e. 
In 2011, Hayashi et al 233 reported his asymmetric one-pot-four-component coupling reaction 
affording substituted tetrahydropyran derivatives via catalyzed Michael-Henry reactions. We 
discovered in 2009 in the course of our studies on alternative asymmetric preparation of the (S)-
Aliskiren precursor 8 (Figure 173) (see also chapter 2) from isovaleraldehyde, the formation of chiral 
substituted tetrahydropyran derivatives under our reaction conditions.  
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Figure 173: Preparation of nitroalkohol 8 via organocatalyzed Michael addition of isovaleraldehyde to 
nitroethylene ester 19 
basic conditions 
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As depicted in Figure 173, the multi component preparation of 8 was performed via the in situ 
Knoevenagel condensation of the commercially available nitro acetate 21 and formalin to the α-
nitroacrylic ester 19. Using an excess of formalin 24 led to the formation of the chiral tetra 
substituted tetrahydropyran derivatives 157 as represented in Figure 174.  
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Figure 174: Asymmetric Knoevenagel/Michael/Henry/acetalization reaction sequence for the preparation of 
157a 
 
Assuming that the chiral center carrying the isopropyl group has the (S)-configuration, four 
diastereoisomers of the constitution 157 can be formed. Applying an oxidation, saponification, 
decarboxylation, epimerization sequence the single isomer 89 (precursor of Aliskliren base 1) could 
be prepared from 157a-d. The formation of 89 should be favored due to the equatorial conformation 
of the nitro and isopropyl substituents. 
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Figure 175: Substituted tetrahydropyran derivatives 157 and formation of the Aliskiren precursor 89 
 
We rationalized our results by the sequence of reactions shown in Figure 174. According to our 
postulated mechanism the excess of formaldehyde reacts with the in situ generated β-substituted γ-
nitroaldehyde via a Henry reaction, producing the corresponding nitroaldol product.  A subsequent 
intramolecular cyclisation of the hydroxyl group formed by the NaBH4 reduction leads to the 
formation of the observed acetal product of Figure 176.  
 
Based on our mechanistic proposal, we proposed a novel four-component organocatalyzed 
Knoevenagel/Michael/Henry/acetalization reaction sequence, varying the Michael partners and two 
different aldehydes to deliver pentasubstitued tetrahydropyran derivatives 172 (Figure 176). 
    
89 
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Figure 176: Postulated four-component domino synthesis of substituted tetrahydropyran derivatives 172 
 
The same year, similar reaction sequences were reported234 in the literature for an asymmetric three-
component reaction, in which the conjugate addition of an aldehyde to a Michael acceptor was 
catalyzed by diphenylprolinol silyl ether, with a subsequent base-catalyzed addition/cyclization step.  
We report here the results of the experiments performed to validate the feasibility of our postulated 
process and the four-component domino synthesis of tetrahydropyran derivatives, in where all of the 
positions of the pyranol ring could be substituted with different groups. 
 
II. Results and Discussion 
 
II. 1. Experimental results  
 
We first reinvestigated the preparation of the compound 8 of Figure 173.  Using our established 
method for the Michael addition of isovaleraldehyde 10 to the in situ generated β-substituted 
nitroalkene derivative16, we prepared the γ-nitroaldehyde derivative. Subsequent treatment of the 
intermediate 20 with 3 equivalents of an aqueous solution of formaldehyde and 5 equivalents of 
sodium hydroxide produced the desired tetrahydrofuran products 157 as a mixture of four 
diastereoisomers with a ratio of 61:26:13, 157a being the major one (Figure 177).  
                                                          
16
 See chapter 2, III.2.3 
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Figure 177: Asymmetric Knoevenagel/Michael/Henry/acetalization reaction sequence for the preparation of 
157a 
 
The asymmetric Michael addition and the concomitant Knoevenagel reaction proceeded over 30 min 
in THF at 35°C in the presence of 10% of (S)-diphenylprolinol silyl ether and acetic acid (4.5 
equivalents). As reported, the Michael product could be isolated. The determination of the 
diastereoisomeric ratio of 20 by 1H NMR (CDCl3, 400 MHz) showed the presence of two 
diastereoisomers in a ratio of 71:29.  
 
Three equivalents of formaldehyde were added dropwise to the reaction mixture at 35°C. The Henry 
reaction proceeded over 7 hours, and 5 equivalents of an aqueous solution of sodium hydroxide (2M) 
were added to the reaction mixture, affording the desired lactols as a mixture of diastereoisomers 
with moderate yield (41% isolated yield). The crude mixture of four diastereoisomers was purified by 
column chromatography on silicagel.  The (2S, 5R, 7R) lactol 157a  could be obtained as white crystals 
(Figure 177).  
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X-Ray analysis revealed the chair conformation of 157a. The anomeric hydroxyl group and the nitro 
groups are in axial position. The isopropyl group and the ester group are in the preferred equatorial 
position ensuring the thermodynamically favorable conformation of these bulky substituents (Figure 
178)235.  
 
 
Figure 178: X-Ray structure of 157a 
 
The other stereoisomers could not be separated by column chromatography on silicagel.  
 
We investigated also the four-component Knoevenagel/Michael/Henry/acetalization reaction 
sequence, by modification of the nature of the aldehyde partners (Figure 179).  
N
+
O
OH
O
OO
O
O
OH
N
+
O
O
O
O
160159  
Figure 179: Chiral lactol derivatives 159 and 160 resulting from the variation of the nature of aldehyde partners 
 
For these studies, we condensed the in situ generated aldehyde 20 with isovaleraldehyde by 
performing the reaction in an excess of isovaleraldehyde (five equivalents) in acetic acid / THF media. 
After eight days an aqueous work-up and the purification of the crude material (isomeric mixture of 
five diastereoisomers with a ratio of 29:9:42:10:10) by column chromatography on silicagel afforded 
the desired lactol as isomeric mixture of four diastereoisomers with a ratio of 17:26:45:12 (38% 
yields). A white material could be obtained adding an 8:1 solution (v/v) of hexan-ethyl acetate and 
then by triturating in a 1:1 solution (v/v) of hexan-diethyl ether. Crystallization experiments and a 
second purification of the crude material by column chromatography on silicagel provided in the best 
case 159 as an isomeric mixture of two diastereoisomers with a ratio of 88:12. Unfortunately we 
could not get crystals of 159, which were suitable for X-Ray measurements. 
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Figure 180: Asymmetric Knoevenagel/Michael/Henry/acetalization reaction sequence for the preparation of 
159 
 
We prepared also, under the same conditions the γ-nitroaldehyde 163 by the concomitant addition 
at 35°C over 20 min of one equivalent of formalin (37%) in water and nitro acetate to a solution in 
THF of one equivalent of hydrocinnamaldehyde 162, 10% of diphenylprolinol silyl ether and acetic 
acid (4.5 equivalents) . After subsequent addition of two equivalents of formaldehyde, the reaction 
mixture was allowed to stir at 35°C over 24h. A basic work up afforded the desired lactol derivative 
160a (30% isolated yield) as an isomeric mixture of three diastereoisomers (diastereoisomeric ratio 
62:38).  
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Figure 181:  Asymmetric Knoevenagel/Michael/Henry/acetalization reaction sequence for the preparation of 
160a 
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Purification of the crude material by column chromatography on silicagel with hexane/ ethyl acetate 
(5:1) provided the (2S, 5R, 7R) lactol 160a in pure form (Figure 182).  The other diastereoisomers 
could not be obtained in pure form. X-Ray analysis revealed the chair conformation in the crystalline 
state of 160a. The anomeric hydroxyl group and the nitro groups are in axial position. The isopropyl 
group and the ester group are in the preferred equatorial position ensuring the thermodynamically 
favorable conformation of these bulky substituents (Figure 182).  
 
 
Figure 182: X-Ray structure of 160a 
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II.2. Preliminary remarks on the reaction sequence 
 
Hayashi et al  recently published233 a paper for a similar organocatalytic sequence.  
The following comments are based on our experimental observations.  
While Hayashi et al 233 performed the condensation step in the presence of a base (DBU), the Henry 
reaction between 174 and the aldehyde 170 could be performed under base-free conditions, 
resulting from the higher reactivity of our α-ester substituted nitro intermediate 174. Additionally, in 
contrast to the Hayashi sequence, in our system the nitro olefinic intermediate 168 is generated in 
situ from 166 and 167 (Figure 183).  
The formation of 172 can be explained by an intermolecular Henry reaction236 where the zwitterionic 
intermediate 174 (Figure 183) would react with the aldehyde 170 to deliver the intermediate 175. 
After hydrolysis, 175 will afford the δ-hydroxy aldehyde 171, which is spontaneously cyclized to the 
final pentasubstituted intermediate 172. 
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Figure 183: Postulated mechanism for the Michael/Henry sequence 
 
III. Conclusion 
 
We reported here the preparation of stable tetrasubstituted tetrahydropyranol derivatives, from in 
situ generated nitroalkene derivatives and two different aldehydes, by a one-pot-four-component-
domino sequence involving the asymmetric Knoevenagel/Michael/Henry/acetalization reactions.  
 
Thanks to possibilities of variation of the nature of the reactants that offers the presented reaction 
sequence, we could rapidly access a wide range of derivatives presented in Figure 183. Optimization 
of the reaction conditions is still needed. Investigations of the scope and limitation of this interesting 
field will continue in the future in Novartis. 
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CHAPTER 6: EXPERIMENTAL PART  
 
All chemicals were purchased either from commercial suppliers or internal sources. They were used 
without further purification unless otherwise stated. All the products were satisfactorily 
characterized by IR, 1H and 13C-NMR, MS, HR-MS. When possible, comparison of their analytical data 
was made with available literature data. 
 
 
Flash Chromatography 
 
Compounds were purified on  Merck silica gel 60, particle size 0.040-0.063 mm, at room temperature 
and eluted with the solvent system indicated. Thin-layer chromatographys were performed on Merck 
pre-coated glass silica gel plates of type 60 F254.  
 
 
High Performance Liquid Chromatography 
 
HPLC analysis were performed with an Agilent Series 1100. Column: inertsil ODS3 C18 4.6 mu 22 cm , 
The mobile phase was AcN / H2O + 0.01% NH4H2PO4  
Gradient: from 55% to 97% AcN,  40°C, λ=220nm,  
 
High Performance Chiral Liquid Chromatography 
 
HPLC analysis were performed with an Agilent Series 1100.  
Column: CHIRALPAK AD-h or CHIRALCEL OD-H. 
 
 
Nuclear magnetic resonance spectrometry (NMR) 
 
NMR spectra were done on a Bruker dpX400 (operating at 400.13 MHz for 1H and 100 Mz for 13C) or a 
Bruker dpX600 (operating at 600.00 MHz for 1H and 150 Mz for 13C) in the solvents indicated at 300 K 
and chemical shifts (in ppm) were referenced to residual solvent peaks (CDCl3: 7.27 ppm for 
1H, 77.2 
ppm for 13C ; d6-DMSO: 2.50 ppm for 
1H, 39.5 ppm for 13C).  
 
Mass spectral data (MS)   
 
Mass spectral data were recorded on a Water ZQ2000 Quadruple, electrospray mass spectrometer  
operating  in  positive  or  negative  ion  mode as  indicated,  or with a    
Varian 1200L Triple Quadrupole mass spectrometer. 
 
High resolution (HR-MS) mass spectra 
 
 High resolution and high accuracy mass spectra were acquired on a 9.4 Tesla Bruker APEXIII Fourier 
Transform Ion Cyclotron Resonance Mass Spectrometer (FT / ICR -MS) equipped with an electrospray 
ion source operated in both positive and negative ion mode; 32 spectra were accumulated and 
internally calibrated using the signals from the Agilent ES tune mix solution.  
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X-Ray analyses 
 
Diffraction data for all compounds were collected at 100 K with a Bruker AXS SMART 6000 CCD 
detector on a three-circle platform goniometer with Cu(K ) radiation from a fine-focus sealed tube 
generator equipped with a graphite monochromator or a microfocus rotating anode equipped with 
multilayer optics.  
 
I. EXPERIMENTAL PART OF CHAPTER 2  
 
I.1. Enamine catalysis 
 
(S)-3-methyl-2-(2-nitro-ethyl)-butan-1-ol 8  
CAS Number: 1067910-79-5 
G. Sedelmeier, WO-2008-119804 
Method 1 
O
O
NO
2
 
OH
NO
2
O O
OH
NO
2
 
O
H
O
O
NO
2
N
H O
Si
aque. 
H2C=O
1.NaOH
2.NaBHOAc3
THF, AcOH,
 35°C
(S)-810
21
MW: 161.20
MW: 86.13
MW: 119.08
I
20
 
 
63.4 mg of (S)-diphenyl-prolinol-O-TMS-ether I (0.18 mmol, 0.11 eq.) are dissolved in 4 mL THF. 282 
L of acetic acid (4.8 mmol, 4.0 eq.) and 165 L of isovaleraldehyde 10 (1.8 mmol, 1.0 eq.) are added 
to the mixture at room temperature. The mixture is then warmed to 35°C.  A solution of 148.1 mg of 
methyl nitroacetate 21 (1.8 mmol, 1.0 eq.) in 2 mL of  THF and a solution of 194 L of  aqueous  
formaldehyde (~37%) (1.8 mmol, 1.0 eq.) in 2 mL of THF are added simultaneously at 35°C over 30 
min (flow: 0.06 mL/min). This solution is then stirred at 35°C during 40 minutes. The mixture is 
cooled to 0°C and 280 mg of a solution of aqueous NaOH (50%) is added dropwise until pH 7. A 
solution of 600 mg of NaBH3OAc (2.8 mmol, 15 eq.) and 2 mL of ethanol (95%) is added portionwise. 
The reaction mixture is then allowed to warm to room temperature and is stirred over night (over 17 
hours). HLPC and NMR controls show the presence of the desired nitroalcohol 8 as major compound.  
The reaction mixture is quenched with 5 mL of water, and extracted with 10 mL of ethyl acetate. The 
organic phase was dried over MgSO4, and concentrated in vacuum to yield 202 mg of crude product 
8. 
 
The crude is purified by column chromatography on silicagel (0.040-0.063 nm) (40 g) with 
heptane:ethyl acetate (4:1) to give in the pure fractions 163 mg of the title nitro compound 8 as 
colorless oil (56%). 
 
(S)-8 
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Determination of the enantiomeric ratio by HPLC with a CHIRALPAK AD-H columm at λ = 205 nm 
(Hex/MeOH/EtOH/ iPrOH = 973:9:9:9, 2mL/min, 40°C) reveals the presence of 95% of the (S)-
enantiomer of 8 at 14.1min and 5% of the (R)-enantiomer of 8 at 14.8min. 
 
 
Spectroscopic data of nitroalcohol 8 are confirmed by the literature data. 
 
1H-NMR (400 MHz, CDCl3) δH (ppm)  
0.92 (d, 6H, CH3iPr). 1.43 (ddd, J1=8 Hz, J2=7.09 Hz, J3=4 Hz, 1H, CHiPr), 1.71 - 1.81 (m, 1H, CHiPr,) 1.96 - 
2.06 (m, 1H, CH2CH2NO2), 2.08 - 2.22 (m, 1H, CH2CH2NO2), 3.58 (dd, J1=11 Hz, J2=7 Hz, 1H, CH2OH), 
3.72 (dd, J1=11 Hz, J2=4 Hz, 1H, CH2OH), 4.42 - 4.65 (m, 2H, CH2NO2 ) 
 
IR: (FTIR-microscopy in transmission)  
3387 (OH), 2961, 2887 (C-Haliphatic), 1552 (NO2 as), 1389 (NO2 s), 1031 (C-O) 
 
MS: [M+NH4]
+ = 179 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm. tr=2.7 min 
 
(S)-3-methyl-2-(2-nitro-ethyl)-butan-1-ol 8 
CAS Number: 1067910-79-5 
G. Sedelmeier, WO-2008-119804 
Method 2 
O
O
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O
NO
2
N
H O
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1.NaOH
2.NaBH4
THF, AcOH,
 35°C
(S)-810
21
MW: 161.20
MW: 86.13
MW: 119.08
20
I
 
 
624.0 mg of (S)-diphenyl-prolinol-O-TMS-ether I (1.9 mmol, 0.15 eq.) are dissolved in 40 mL THF. 2.5 
mL of acetic acid (43 mmol, 3.6 eq.) and 1.3 mL of isovaleraldehyde 10 (12 mmol, 1.0 eq.) are added 
to the mixture at room temperature. The mixture is then warmed to 35°C.  A solution of 1.424 g of 
methyl nitroacetate 21 (12 mmol, 1.0 eq.) in 21 mL of THF and a solution of 1.071 g of aqueous  
formaldehyde (~37%) (13 mmol, 1.0 eq.) in 21 mL of THF are added simultaneously over 30 min 
(flow: 0.6 mL/min). This solution is then stirred at 35°C over an additional period of 15 min (although 
nitroacetate 21 is already consumed at the end of the addition (HPLC control)). The mixture is cooled 
to room temperature and an aqueous solution NaOH (2M) is added dropwise over 15 min until pH 
7.6. The reaction mixture is diluted at 0°C in 15 mL of ethanol (95%) . 500.3 mg of solid NaBH4 (13.2 
mmol, 1.1 eq.) are added portionwise at 0°C over 10 minutes. At the end of the addition all the in situ 
generated aldehyde is consumed (HPLC control), the reaction mixture is quenched with 200 mL of 
water, and extracted two times with 100 mL of dichloromethane, and once with 100 mL of tert-butyl 
(S)-8 
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methyl ether. The organic phase is dried over MgSO4, and concentrated in vacuum to yield 1.13 g of 
crude product 8. 
Determination of the enantiomeric ratio of this crude material by HPLC with a CHIRALPAK AD-H 
column at λ=205.5 nm (Hex:MeOH:EtOH: iPrOH = 973:9:9:9, 2mL/min, 40°C) showed 93% of the 
enantiomer S and 7% of the enantiomer R. 
The aqueous phase is extracted again four times with 100 mL of ethyl acetate. The ethyl acetate 
phase is dried over MgSO4, and concentrated in vacuum to yield 170 mg of crude product 8.  
Yield: 67% 
Determination of the enantiomeric ratio by HPLC with a CHIRALPAK AD-H column at λ=205.5 nm 
(Hex:MeOH:EtOH: iPrOH = 973:9:9:9, 2mL/min, 40°C) shows the formation of 92% of (S)-8 and 8% of 
the enantiomer (R)-8. 
 
Spectroscopic data of nitroalcohol 8 are confirmed by the literature data. 
 
1H-NMR: (400 MHz, CDCl3) δH (ppm)  
4.64-4.41 (m, 2H, CH2NO2),  3.72 (dd, 1H, J=10.8 Hz, 7.0 Hz, CH2OH), 3.58 (dd, 1H, J=10. 8 Hz, 7.0 Hz, 
CH2OH),  2.18-2.17 (m, 1H, CH2),  2.06-1.97 (m, 1H, CH2), 1.81-1.72 (m, 1H, CH(CH3)2),  1.47-1.39 (m, 
1H, CH), 0.92 (dd, 6H, J=7.0 Hz, -CH3) 
 
 
I.2. Iminium catalysis 
 
(S, R) and (S, S)-4-hydroxymethyl-5-methyl-2-nitro-hexanoic acid methyl ester 20 
 
O
H
O
H H
O
O
O
H
NO
2
O
O
NO
2
O
H
 
+
AcOH, THF,40°C
L-Ph2Prolinol-OTMS
MW: 86.13
MW: 217.22
10 24
25
21
20
(S,R) or (S:S)
or vice-versa
MW: 98.15
 
1.235 g of the catalyst (3.4 mmol, 0.15 eq.) is dissolved in 70 mL of THF. 7 mL of acetic acid (115 
mmol, 4.9 eq.) and 1.60 mL of isovaleraldehyde 10 (23mmol, 1.0 eq.) is added to the reaction 
mixture at room temperature. The mixture is then warmed to 35°C and a solution of 1.855 g of 
formaldehyde 24 (~37% in water) (23 mmol, 1.0 eq.) in 10 mL of THF is added. The reaction mixture is 
stirred at 35°C over a period of 2 hours 45 min. 1H NMR (400 MHz, CDCl3) control shows the 
formation of the 2-isopropyl acrolein 25, and complete conversion of the reactants.  
To 40 mL of the reaction mixture, is added dropwise at 35°C a solution of 686.1 mg of methyl 
nitroacetate 21 (5.7 mmol, 0.5 eq.) in 6 mL THF. The reaction mixture is stirred over 48 hours. NMR-
controls (1H, 400 MHz, CDCl3) show the formation of the desired α-methyl ester aldehyde 20, with a 
conversion ratio of 25% after 2 hours, 74% over night and 82% over two nights and a 
diastereoisomeric ratio of 70:30. 
No further purification is done. 
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1H NMR (400 MHz, CDCl3-d) δH (ppm) mixture of two diastereoisomers, d.r. 70% diastereoisomer 1 
and 30% of diastereoisomer 2 
0.94 - 1.07 (m, 6H, CH3iPr), 2.19 - 2.34 (m, 3H, CH2CHNO2, CHiPr, CHiPr) 2.40 - 2.62 (m, 1H, CH2CHNO2), 
[3.84 (s, CH3ester dia1), 3.86 (s, CH3ester dia2), 3H ], [5.22 (dd, J1=9Hz, J2=5Hz, CHNO2 dia1), 5.25 - 5.32 (m, , 
CHNO2 dia2), 1H ], 9.70 (d, J=6Hz, 1H, HC=O) 
 
 (S)-3-methyl-2-(2-nitro-ethyl)-butan-1-ol 8 
CAS Number: 1067910-79-5 
 
O
H
NO
2
 
O
H
NO
2 OH
NO
2
NaBH4
Ph2-OTMS-Prolinol, MeOH
Benzoic acid, 0°C
MW: 98.15
MW: 161.20
25 12 (S)-8
(S)
 
 
98.8 mg of 2-isopropyl acrolein 25 (1.0 mmol, 1.0 eq.) are dissolved at room temperature in 2 mL of 
methanol. The solution is then cooled down to 0°C and 36.7 mg of (S)-diphenyl-prolinol-O-TMS-ether 
(0.10 mmol, 0.1 eq.) and 12.3  mg of benzoic acid (0.1 mmol, 0.1 eq.) and 209.2 mg of nitromethane 
(3.4 mmol, 3.4 eq.) are added to the reaction mixture. The reaction mixture is stirred at 0°C over 5 
days. HPLC controls (reverse and chiral AD-H phase) reveal the low formation of the desired aldehyde 
12, with an enantiomeric ratio of 24 % (R-enantiomer) and 76% (S-enantiomer). 
80.7 mg of NaBH4 (2.1 mmol, 2.1 eq.) are added to the reaction mixture at 0°C in three portions, 
followed by addition 0.5 mL of acetic acid to maintain the pH=4. The reaction mixture is quenched by 
addition of 0.5 mL of water and is diluted in 1 mL of toluene. The organic phase is dried over MgSO4, 
and concentrated in vacuum. 
 
The enantiomeric ratio measured on CHIRALPAK AD-H (Hex:MeOH:EtOH:iPrOH = 973:9:9:9, 2mL/min, 
40°C) is 82 % of S-8  and 18% of R-8. 
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(S)-3-methyl-2-(2-nitro-ethyl)-butan-1-ol 8, as a racemic mixture 
CAS Number: 1067910-79-5 
 
O
H
NO
2
 
O
H
NO
2
OH
NO
2
NaBH4
25 12 rac-8
MW: 98.15
MW: 161.20
 
47.5 mg of 2-isopropylacrolein 25 (0.48 mmol, 1.0 eq.) are dissolved at room temperature in 2 mL of 
dichloromethane. 19.9 mg of DBU (0.12 mmol, 0.25 eq.) and 223.4 mg of nitromethane (3.6 mmol, 
7.6 eq.) are added at room temperature. The reaction mixture is stirred at room temperature over 2 
hours. HPLC controls (reverse and chiral AD-H phase) reveal the complete formation after two hours 
of the desired aldehyde 12, with an enantiomeric ratio of 50 % (R-enantiomer) and 50% (S-
enantiomer). 
Th reaction mixture is cooled down to 0°C and 40.2 mg of NaBH4 (1.1 mmol, 2.2 eq.) are added to the 
reaction mixture. The reaction mixture is quenched by addition of 0.5 mL of water and is diluted in 1 
mL of toluene. The organic phase is dried over MgSO4, and concentrated in vacuum. 
The enantiomeric ratio measured on CHIRALPAK AD-H (Hex:MeOH:EtOH:iPrOH = 973:9:9:9, 2mL/min, 
40°C) is 50 % of the S-enantiomer at 14.0 min and 50% of the R-enantiomer  at 14.9 min. 
        
 
 
 
(S)-3-methyl-2-(2-nitro-ethyl)-butan-1-ol 8 (representative scale) 
CAS Number: 1067910-79-5 
 
O
H
NO
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H
NO
2
OH
NO
2
NaBH4
Ph2-OTMSProlinol, MeOH
Benzoic acid, 0°C
25 12 (S)-8
MW: 161.20MW: 98.15
(S)
 
 
338.2 mg of (S)-diphenyl-prolinol-O-TMS-ether (1.0 mmol, 0.09 eq.) are dissolved at 0°C in 10 mL of 
methanol. 1.071 g of 2-isopropylacrolein 25 (10.9 mmol, 1.00 eq.) and 234.2 mg of benzoic acid (1.92 
mmol, 0.17 eq.) are added to the reaction mixture at 0°C. After 5 min, 2 mL of nitromethane (36.9 
mmol, 3.4 eq.) are added dropwise at 0°C. The reaction mixture is stirred at 0°C over 6 days. HPLC 
controls (reverse and chiral AD-H phase) show the low formation of the desired aldehyde 12, with an 
enantiomeric ratio of 27 % (R-enantiomer) and 73% (S-enantiomer). NMR control (1H NMR, 400 MHz, 
CDCl3-d) reveals a conversion rate of 20%. 
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764.9 mg of NaBH4 (20.9 mmol, 1.8 eq.) are added to the reaction mixture at 0°C in five portions. The 
reaction mixture is allowed to stir at 0°C over 1 hour until complete reduction of  the aldehyde 
intermediate 12 to the desired compound 8 (HPLC control). 
The reaction mixture is quenched by addition of 20 mL of water and is diluted in 20 mL of ethyl 
acetate. The phases are separated (pHaqueous phase = 10) and the organic phase is washed three times 
with 20 mL of water (pHaqueous phase = 8 to 6) until complete removal of nitromethane from the organic 
layer. The ethyl acetate phase is dried over MgSO4, and concentrated in vacuum to yield 1.03 g of the 
desired nitroalcohol 8 as a crude product. 
 
The enantiomeric ratio of the crude material measured on CHIRALPAK AD-H (Hex:MeOH:EtOH:iPrOH 
= 973:9:9:9) 2mL/min, 40°C, ג = 205 nm and 215 nm) is 66 % of the S-enantiomer  and 34% of the R-
enantiomer . 
 
The crude material is purified by column chromatography on silicagel (0.040-0.063 nm) (50 g) with 
heptane:ethyl acetate (4:1) to give in the pure fractions 311.5 mg of desired nitro compound 8 as a 
colorless oil. 
 
The enantiomeric ratio measured on CHIRALPAK AD-H (Hex:MeOH:EtOH:iPrOH = 973:9:9:9, 2mL/min, 
40°C, ג = 205 nm, 215 nm and 280 nm) is 68 % of the S-enantiomer  and 32% of the R-enantiomer . 
 
Spectroscopic data of nitro-aldehyde 12: 
O
H
NO
2
MW: 159.19
er: 68:32
(S)-12
 
1H NMR (400 MHz, CDCl3-d) δH (ppm)  
0.95 - 1.12 (m, 6H, CH3iPr), 2.07 - 2.43 (m, 4H, CHCHiPr, CHiPr, CH2CH2NO2), 4.35 (ddd, J1= 13 Hz, J2= 8 Hz, 
J3= 6 Hz, 1H, CH2OH), 4.42 - 4.59 (m, 1H, CH2OH), 9.73 (s, 1H, HC=O) 
 
Spectroscopic data of nitro-alcohol 8: 
Spectroscopic data  of  nitroalcohol are confirmed by the literature data. 
OH
NO
2
(S)-8
MW: 161.20  
 
1H NMR (400 MHz, CDCl3-d) δH (ppm)  
0.94 (d, 6H, CH3iPr ), 1.40 - 1.52 (m, 1H, CHCHiPr), 1.70 - 1.85 (m, 1H, CHiPr), 1.98 - 2.11 (m, 1H, , 
CH2CH2NO2), 2.12 - 2.26 (m, 1H, CH2CH2NO2), 3.61 (dd, J1=11 Hz, J2=7 Hz, 1 H, CH2OH), 3.74 (dd, J1=11, 
J2= 5 Hz, 1H, CH2OH) 4.34 - 4.68 (m, 2H, CH2NO2) 
 
13C NMR (101 MHz, CDCl3) δC (ppm)  
19.36 (-CH3iPr), 19.67 (-CH3iPr), 27.24 (CH2CH2NO2), 28.74 (CHiPr), 43.77 (CHCHiPr), 63.95 (CH2OH) 74.85 
(CH2NO2) 
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I.3. From nitro compound 8 to its aldehyde analogues 
 
I.3.1. (S)-3-methyl-2-(2-nitro-ethyl)-butoxy derivatives 
 
2-[(S)-3-methyl-2-(2-nitro-ethyl)-butoxy]-tetrahydro-pyran 32 
OH
NO
2 O
O O
NO
286°C, 58h, 94%
Pyridinium
toluene-4-sulfonate
polymer bound,
MW: 161.20
MW: 245.32
(S)-8
(S)-32
 
 
To a mechanically stirred solution of 20.0 g of nitroalcohol 8 (124 mmol, 1.0 eq.) in 3,4-dihydro-2H-
pyran (180 mL) are added at room temperature 7.14 g of polymer bound pyridinium toluene-4-
sulfonate (3.5 mmol/ g, 25 mmol, 0.2 eq.). The yellow suspension is warmed up to 86°C and stirred 
over 58 hours in refluxing 3,4-dihydro-2H-pyran. The suspension is then cooled down to room 
temperature. The polymer is filtered off and washed with dichloromethane. The yellow organic 
phase is concentrated in vacuum to yield 42.4 g  of a brown liquid.  
The crude product is purified by column cromatography on silica gel with heptane:ethyl acetate 
(10:1) to give in the pure fractions 28.77 g of 2-((S)-3-methyl-2-(2-nitroethyl)butoxy)-tetrahydro-2H-
pyran 32 as a slight yellow liquid (94%).  
 
1H NMR (400 MHz, CDCl3) δH (ppm) (mixture of diastereoisomers 1:1) 
0.94 (dd, J =7Hz, 6H CH3iPr) , 1.61-1.51 (m, 5H, CH2-CH2-NO2, CH-CHiPr, 2*HCHTHP), 1.82-1.67 (m, 3H, 
CHiPr, 2*HCHTHP), 2.06-1.93 (m, 1H, HCHTHP), 2.33-2.13 (m, 1H, HCHTHP), [3.86-3.80 (m, 1.5H, ), 3.72-
3.67 (m, 0.5H), 3.49-3.56 (m, 1H), 3.40 (dd, J=9Hz, 0.5H), 3.25 (dd, J 9Hz, 0.5H) (CH2THP-O, CH2-O)], 
4.62-4.46 (m, 3H, CH2NO2, CHTHP) 
 
13C NMR (150 MHz, CDCl3) δC (ppm) 
19.15-19.23 (CH3iPr) ,  24.91 (CH2THP), 27.34 (CH2THP), 28.85 (CHiPr), 30.09 (CH2THP), 41.07 (CH-CHiPr), 
61.74 (CH2THP-O), 68.59 (CH2-O), 74.08 (CH2NO2), 98.62-98.75 (CHTHP) 
 
IR: (FTIR-microscopy in transmission)  
2957 (C-H), 1554 & 1358 (NO2), 1123 (C-O-C), 1033 (C-O) 
 
MS: MH+ = 246 
 
HRMS (C12H24O4N, 0.3 ppm/MH+): [M+H] 
+= 246.16989, cal. 246.16999, C11H22O4N 
 
Rf (heptane/ethyl acetate, 8:1) = 0.39 
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2-[(S)-3-methyl-2-(2-nitro-ethyl)-butoxy]-tetrahydro-furan 33  
 
OO
NO
2
O
OH
N
+
O
O
70°C, 9h, 85%
Pyridinium
toluene-4-sulfonate
polymer bound,
MW: 231.2943
MW: 161.20
(S)-8 (S)-33
 
 
To a mechanically stirred solution of 20.08 g nitroalcohol 8 (124.0 mmol, 1 eq.) in 2,3-dihydrofuran 
(180 mL, 2.37 mol, 19 eq.) are added at room temperature 720 mg of polymer bound pyridinium 
toluene-4-sulfonate (3.5 mmol/ g, 2.5 mmol, 0.02 eq.). The yellow suspension is warmed up to 70°C 
and stirred over 6 hours in refluxing 2,3-dihydrofuran until complete conversion (GC measurement) 
of the starting material 8. The suspension is cooled down to room temperature. The polymer is 
filtered off and washed with dichlomethane. The collected yellow organic phases are concentrated in 
vacuum to yield 32.10 g of protected alcohol.  
The crude product is  purified by column cromatography on silica gel with heptane:ethyl acetate (8:1) 
to give in the pure fractions 24.38 g of 2-((S)-3-methyl-2-(2-nitroethyl)butoxy)-tetrahydrofuran 33 as 
a yellow liquid (85 %).  
 
1H-NMR: (400 MHz, CDCl3) δH (ppm) (mixture of diastereoisomers 1:1) 
0.91 (m, 6H, CH3iPr), 1.49-1.53 (m, 1H, CH-CHiPr), 1.68-2.20 (m, 7H, CHiPr, CH2-CH2-NO2, 2*CH2THF), [3.72 
(dd, J= 9Hz, 0.5H), 3.68 (dd, J=9Hz, 0.5H), 3.39 (dd, J=9Hz, 0.5H), 3.26 (dd, J= 9Hz, 0.5H), CH2-O], 3.85-
3.90 (m, 2H, CH2 THF -O), 4.40-4.55 (m, 2H, CH2NO2), 5.04-4.06 (m, 1H, CHTHF) 
 
13C-NMR (150 MHz, DMSO-d6) δC (ppm)  
18.9 (CH3iPr), 19.3 (CH3iPr), 23.0 (CH2THF), 25.8 (CH2-CH2-NO2), 28.3(CHiPr),  31.7 (CH2THF), 40.6 (CH-CHiPr), 
66.1 (CH2 THF -O), 67.2 (CH2-O), 74.3 (CH2NO2), 103.1 (CHTHF) 
 
IR: (FTIR-microscopy in transmission)  
2961 (C-H), 1554 & 1358 (NO2), 1038 (C-O) 
 
MS: MH+ = 232 
 
HRMS (C11H21O4N, 0.5 ppm/MH+): [M+H] 
+= 232.15422, cal. 232.15434, C11H22O4N 
 
Rf (heptane/ethyl acetate, 8:1) = 0.31 
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 (S)-3-(1-methoxy-1-methyl-ethoxymethyl)-4-methyl-1-nitro-pentane 36 
O
O
O
NO
2
OH
N
+
O
O
O°C -> 21°C
 toluene-4-sulfonate
acid
MW: 233.31
91%
MW: 161.20
(S)-8 (S)-36
 
 
20 mL of 2-methoxypropene (212.4 mmol, 3.3 eq.) are added dropwise at 0°C to a mechanically 
stirred solution of 10.15 g nitroalcohol 8 (62.9 mmol, 1 eq.) and 35.2 mg p-toluene-sulfonate acid 
(0.19 mmol, 0.003 eq.). The yellow solution is allowed to warm up to room temperature and stirred 
over 63 hours until completion (GC mesurement) of the reaction. After evaporation of the excess of 
methoxypropene, the residue is diluted in 50 mL dichloromethane and washed with 50 mL of 
aqueous NaHCO3 (20%). The collected yellow solution is dried over MgSO4 and concentrated in 
vacuum to yield 13.38 g of compound 36 (91%).  
 
1H NMR (400 MHz, DMSO-d6) δH (ppm) 
0.85 (d, J=6 Hz, 6H, CH3iPr), 1.24 (s, 6H, CH2MIP), 1.34 - 1.45 (m, 1H, CHiPr), 1.67 - 1.88 (m, 2H, HCH-CH2-
NO2, CH-CHiPr), 1.92 - 2.05 (m, 1H, HCH-CH2-NO2), 3.07 (m, 3H, OCH3MIP), 3.16 - 3.25 (m, 1H, HCH-
O),3.28 - 3.34 (m, 1H, HCH-O), 4.47 - 4.70 (m, 2H, CH2NO2) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm) 
18.88 (CH3iPr), 19.34 (CH3iPr), 24.09 (CH3MIP), 26.58 (CH2CH2NO2), 28.10 (CHiPr), 40.10 (CH CHiPr), 47.83 
(OCH3MIP), 61.02 (CH2-O), 74.57 (CH2NO2), 99.36 (CMIP) 
 
IR: (FTIR-microscopy in transmission)  
2961 (C-Haliphatic), 2830 (C-O). 1555 (NO2νas), 1435 (C-Hδ), 1381 (C-H3δ), 1371(NO2νs), 1213-1077-1043 
(C-O) 
 
MS: [M+H]+ = no response 
 
HRMS: no response 
 
GC: column Optima-1MN, 25mx0.32mmx0.35μm, Hydrogen flow: 30.0 mL/min, Air flow: 400.0 
mL/min, Helium flow: 20.0 mL/min, 75 to 200°C in 10 min, 3min at 200°C, 200 to 300°C in 10 min, 
2min50 at 300°C, tR = 13.18  min 
 
4-methoxy-4-[(S)-3-methyl-2-(2-nitro-ethyl)-butoxy]-trityl 37 
 
OH
O
NO
2
OH
NO
2
MW: 327.43
Nafion-H, AcN, 60°C
MW: 161.20
(S)-8
(S)-37
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4.04 g of nitroalcohol 8 (25.0 mmol, 1.00 eq.) are diluted in 35 mL of acetonitrile at room 
temperature. 5.63 g of diphenylcarbinol (30.5 mmol, 1.2 eq.) and 1.57 g of Nafion-H NR50 are added 
to the yellow solution. The reaction mixture is then warmed to 60°C and allows to stir at 60°C over 
3.5 days. The reaction mixture is then cooled down to room temperature and diluted in 15 mL of 
dichloromethane. Nafion H is filtered off and washed with 20 mL of dichloromethane. The organic 
phase is concentrated in vacuum to yield 9.99 g of crude material.  
The crude product is purified by column chromatography on silicagel (250g) with heptane/ethyl 
acetate (8:1) to give in the purest fractions 6.49 g of the desired nitro compound 37 (yield 79%) as a 
colorless oil. 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.76 - 0.87 (m, 6H, CH3iPr), 1.50 (ddd, J1=9 Hz, J2=5 Hz, J3=5 Hz, 1H, CH-CHiPr), 1.77 (dq, J1=12 Hz, J2=7 
Hz, 1H, CHiPr),1.82 - 1.96 (m, 1H, HCHCH2NO2), 1.96 - 2.12 (m, 1H, HCHCH2NO2), 3.17 - 3.50 (m, 2H, 
CH2-0), 4.41 - 4.82 (m, 2H, CH2NO2) 5.41 (s, 1H, CHBenzhydryl), 7.00 - 7.51 (m, 10H, CHarom) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
19.10 (CH3iPr) 19.42 (CH3iPr), 26.35 (CH2CH2NO2), 28.25 (CHiPr), 40.98 (CH CHiPr), 69.02 (CH2-O), 74.38 
(CH2NO2), 82.73 (CHBenzhydryl), 126.36 (CHarom), 126.55 (CHarom), 127.21 (CHarom) 128.30 (CHarom), 128.43 
(CHarom), 142.56 (Carom) 
 
IR: (FTIR-microscopy in transmission)  
3087-3029 (CHaromatic), 2960-2874 (C-Haliph), 1600 (Phenyl), 1551 (NO2νas),  1493 (Phenyl), 1384 (NO2νs), 
1091-1072 (C-O), 1029 (C-Hδaromatic), 743 (C-Hδaromatic), 702 (Phenylδ) 
 
MS: [M+NH4]
+ = 345.4 
        [MH]-= 326.2 
 
HRMS (0.5 ppm/MNH4+):  [M+NH4] 
+= =345.21710, cal. 345.21727, C20H29O3N2 
 
benzyl-carbamic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 43 
 
N O O
O
N
H
NO
2
OH
NO
2
Base
MED
25°C
MW: 294.35
MW: 161.20
(S)-8 (S)-43
 
 
162.4 mg of 8 (1.01 mmol, 1.00 eq.) are diluted in 1 mL of dry dichloromethane at room temperature 
(21°C). 123.5 µL of benzylisocyanate (1.00 mmol, 1.0 eq.) and 21.3 mg of DABCO (0.19 mmol, 0.19 
eq.) are added at room temperature. The reaction mixture is then warmed to 25°C and stirred at 
25°C over 2.5 hours, until complete conversion of benzylisocyanate. After 10 min, the precipitation of 
N,N-dibenzylurea 43b is observed. 43b is filtered off and washed with 10 mL of heptane resulting in 
the precipitation of 43b in the organic phase. The solid is removed of the suspension and the 
combined white solids are washed with 10 mL of heptane (No precipitation occurs). The organic 
phase is concentrated in vacuum and the crude material is diluted into 0.5 mL of dry 
dichloromethane. 123.5 µL of benzylisocyanate (1.0 mmol, 1.0 eq.) and 6 mg of DABCO (0.04 mmol, 
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0.04 eq.) are added to the reaction mixture, which is stirred at 25°C over 20 min. 10 mL of heptane 
are added in the reaction mixture, resulting in the precipitation of 43b. 43b is filtered off and washed 
with 10 mL of heptane. The organic phase is concentrated in vacuum to yield 265.4 mg of crude 
material. 
The crude product is purified by column chromatography on silicagel (10 g) with heptane/ethyl 
acetate (5:1) to give in the purest fractions 140.7 mg of the desired nitro compound 43 (yield 48%) as 
a colorless oil. 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  rotamers 
0.87 (d, J=6 Hz, 6H, CH3iPr), 1.47 - 1.57 (m, 1H, CH-CHiPr), 1.65 - 1.79 (m, 1H, CHiPr), 1.78 - 1.90 (m, 1H, 
HCHCH2NO2), 1.97-2.05 (m, 1H, HCHCH2NO2), 3.86 - 3.95 (m, 1H, HCH-O), 3.97 - 4.08 (m, 1H, HCH-O), 
4.18 (d, J=6 Hz, 2H, CH2-N), 4.45 - 4.71 (m, 2H, CH2NO2), 7.24 (d, J=7 Hz, 2H, CHarom) 7.30 (d, J=7 Hz, 
2H, CHarom), 7.65 (s, 1H, NH) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
18.97 (CH3iPr), 19.20 (CH3iPr), 25.91 (CH2CH2NO2), 28.01 (CHiPr), 40.34 (CH CHiPr), 43.73 (CH2Benz), 64.45 
(CH2OH), 74.20 (CH2NO2), 126.74 (CHarom), 126.96 (CHarom), 128.23 (CHarom), 139.79 (Carom ), 156.43 
(C=O) 
 
IR: (FTIR-microscopy in transmission)  
3334-3416 (NH), 3032 (CHaromatic), 2962 (C-Haliph), 1704 (C=Ocarbamate), 1605-1455 (Phenyl), 1552 
(NO2νas),  1525 (Amide II), 1384 (NO2νs), 1244 (C-O), 739-699 (C-Hδaromatic monosubst.) 
 
MS: MH+ =295 
 
HRMS C15H21O5N (0.3 ppm/MH+):  [MH] 
+= 296.15902, cal. 296.15925, C15H22O5N 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 6.9 min  
 
Rf (heptane/ethyl acetate, 1:1) = 0.63 
 
Spectroscopic data of N,N-dibenzylurea 43b: 
CAS Number: 1466-67-7 
 
NH
O
N
H
MW: 240.31
43b
 
 
1H NMR (600 MHz, DMSO-d6) H (ppm)  
4.25 (s, 4H, CH2benz), 6.46 (t, 2H, NH), 7.15-7.38 (m, 10H, CHarom), 
 
IR: (FTIR-microscopy in transmission)  
3325 (NH), 3031 (CHaromatic), 1628 (C=Ourea), 1573 (Amide II, Phenyl), 1494-1454 (Phenyl), 751-697 (C-
Hδaromatic monosubst.) 
 
MS: MH+ =241.1  
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phenyl-carbamic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 42 
 
O
O
N
H
NO
2
N O
OH
NO
2
MW: 280.33
MED, 25°C
MW: 161.20
(S)-8 (S)-42
 
 
329.1 mg of 8 (2.04 mmol, 1.00 eq.) are diluted in 0.8 mL of dry dichloromethane at room 
temperature (21°C) and 245.2 mg of phenylisocyanate (2.06 mmol, 1.0 eq.) are added. The reaction 
mixture is then warmed to 25°C and stirred at 25°C over 18 hours. Precipitation of N,N-diphenyl urea 
42b is observed. The reaction mixture is then cooled down to room temperature, the precipitate 
filtered off and washed with 3 mL of dichloromethane. The organic phase is concentrated in vacuum 
to yield 379 mg of crude material.  
The crude product is purified by column chromatography on silicagel (20 g) with heptane/ethyl 
acetate (5:1) to give in the purest fractions 227.3 mg of the desired nitro compound 42 (yield 40%) as 
a yellow oil. 
 
1H NMR (400 MHz, CDCl3) δH (ppm) 
0.91 (dd, J1= 7 Hz, J2= 2Hz, 6H, CH3iPr), 1.52 - 1.67 (m, 1H, CH-CHiPr), 1.75 - 1.96 (m, 2H, CHiPr, 
HCHCH2NO2), 1.99 - 2.16 (m, 1H, HCHCH2NO2), 3.98 - 4.06 (m, 1H, HCH-O), 4.08 - 4.21 (m, 1H, HCH-
O), 4.57 - 4.75 (m, 2H, CH2NO2), 6.95 - 7.02 (m, 1H, CHarom), 7.27 (t, J=8 Hz, 2H, CHarom), 7.46 (d, J=8 
Hz, 2H, CHarom), 9.56 (s, 1H, NH) 
 
IR: (FTIR-microscopy in transmission)  
3326 (NH), 3138(CHaromatic), 2963 (C-Haliph), 1714 (C=Ocarbamate), 1601-1445 (Phenyl),  1555 (Amide & 
NO2νas),  1384 (NO2νs), 1221 (C-O), 755-693(C-Hδaromatic), 
 
MS: MH+ = 281, M+Na+ = 303 
        MH- = 279 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.4 min  
 
Rf (heptane/ethyl acetate, 5:1) = 0.14 
 
Spectroscopic data of N,N-diphenylurea 42b: 
CAS Number: 102-07-8 
NH
O
N
H
MW: 212.25
42b
 
 
1H NMR (600 MHz, DMSO-d6) H ppm  
7.98 (t, J=8 Hz, 2H, CHarom), 7.27 (t, J=8 Hz, 4H, CHarom), 7.45 (t, J=8 Hz, 4H, CHarom), 8.68 (s,2H, NH) 
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IR: (FTIR-microscopy in transmission)  
3327-3291 (NH), 3036 (CHaromatic), 1650 (C=Ourea), 1556 (Amide II), 1498-1448 (Phenyl), 753-696 (C-
Hδaromatic monosubst.) 
 
MS: MH+ =213.1 
 
carbonic acid benzyl ester (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 44 
O
O
O
NO
2
OH
NO
2
N
O O
O
Cbz
MW: 295.34MW: 161.20
(S)-8 (S)-44
NEt3, THF, 22°C
88
 
 
170.1 mg of nitroalcohol 8 (1.06 mmol, 1.00 eq.) are diluted in 1 mL of dry tetrahydrofuran at room 
temperature (22°C). 1.24 g of benzyl N-succinimidyl carbonate (4.95 mmol, 4.9 eq.) and 1.0237 g of 
triethylamine (10.10 mmol, 10.0 eq.) are added dropwise at room temperature. The reaction mixture 
is then warmed to 25°C and allows stirring at 25°C over 2.5 days. The reaction mixture is then cooled 
down to room temperature and diluted with 10 mL of tert-butyl methyl ether yielding to the 
precipitation of a white solid (side products), which is then filtered off and washed with 10 mL of 
tert-butyl methyl ether.  The organic phase is extracted three times with 15 mL of citric acid (until a 
pH of 7) and with 15 mL of demineralized water. The organic phase is dried over MgSO4 and 
concentrated in vacuum to yield 414.6 mg of crude material. 
 
The crude product is purified by column chromatography on silicagel (20 g) with heptane/ethyl 
acetate (9:1) to give in the pure fraction 149.5 mg of the desired nitro compound 44 (yield 48%) as a 
colorless oil. 
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.95 (dd, J1= 8 Hz, J2= 5Hz, 6H, CH3iPr), 1.57 - 1.73 (m, 1H, CH-CHiPr), 1.73 - 1.91 (m, 1H, CHiPr), 1.93 - 
2.06 (m, 1H, HCHCH2NO2), 2.11 - 2.34 (m, 1H, HCHCH2NO2), 4.07 (dd, J1= 11 Hz, J2=7 Hz, 1H, HCH-O), 
4.24 (dd, J1= 11 Hz, J2=5 Hz , 1H, HCH-O), 4.37 - 4.58 (m, 2H, CH2NO2), 5.17 (s, 2H, CH2Benz), 7.29 - 7.51 
(m, 5H, CHarom) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
18.96 (CH3iPr), 19.05 (CH3iPr), 25.45 (CH2CH2NO2), 27.86 (CHiPr), 68.08 (CH2-O), 68.90 (CH2-O-C=O), 
73.91 (CH2NO2), 128.15 (CHarom), 128.35 (CHarom), 128.41 (CHarom), 128.50 (CHarom), 135.51 (Carom), 
154.38 (C=O) 
  
IR: (FTIR-microscopy in transmission)  
3035-3091 (CHaromatic), 2963-2877 (C-Haliph), 1746 (Phenyl), 1746 (C=Ocarbonate), 1554 (NO2νas),  1498 
(Phenyl), 1386 (NO2νs), 1264 (C-Ocarbonate), 1029 (C-Hδaromatic), 754-741 (C-Hδaromatic), 689 (Phenylδ) 
 
MS: (EI+) MH+ = 296.3 
 
HRMS (C15H22O5N, 0.7 ppm/MH+): [M+H] += 296.14902, cal. 296.14925, C15H22O5N 
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HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.9 min  
 
Rf (Hexan/Ethyl acetate 9:1) = 0.47 
 
benzoic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 38 
OO
NO
2O
Cl
OH
NO
2
MW: 265.31
Toluol, 90°C
MW: 161.20
(S)-8 (S)-38
 
 
 
9.2 g of benzoyl chloride (65.5 mmol, 1.05 eq.) are diluted in 35 mL of toluene at room temperature 
under Ar atmosphere. A solution of 10.01 g of 8 (62.1 mmol, 1.00 eq.) in 3 mL of toluene is added 
dropwise to the mixture at room temperature. The red solution is then warmed to 92°C and stirred 
at 92°C over 2 hours turning into a black solution. The formed HClgaz is quenched in an external trap 
with a solution of aqueous sodium hydroxide (1M). 0.8 mL of benzoyl chloride (6.9 mmol, 0.11 eq.) 
are then added to the mixture. The reaction mixture is stirred over night at 92°C (14 hours 30 min.) 
and then cooled down to room temperature. 45 mL of brine are added to the toluene phase and 
both phases are separated. The organic phase is again extracted with 20 mL of brine. The organic 
phase is dried over MgSO4 and concentrated in vacuum to yield 13.42 g of crude material (95%).  
 
The crude product is purified by column chromatography on silicagel (200 g) with heptane/ethyl 
acetate (5:1) to give in the pure fractions 7.92 g of the desired nitro compound 38 (yield 48%) as a 
colorless oil. 
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.89 - 1.01 (m, 6H, CH3iPr),1.60 - 1.69 (m, 1H, CH3iPr), 1.72 - 1.88 (m, J1= 7Hz, J2= 5Hz, 1H, CH-CHiPr), 
1.92 - 2.07 (m, 1H, HCHCH2NO2 ),  2.19 (m, 1H, HCHCH2NO2), 4.07 (dd, J1= 11 Hz, J2= 7Hz, 1H, HCH-O), 
4.24 (dd, J1= 11Hz, J2=  5Hz, 1H, HCH-O), 4.37 - 4.58 (m, 2H, CH2NO2), 7.31 - 7.46 (m, 5H, CHarom) 
 
13C NMR (101 MHz, CDCl3) δC (ppm) 
19.11-19.26 (CH3iPr), 25.86 (CH2CH2NO2), 28.30 (CHiPr), 64.97 (CH2-O), 74.00 (CH2NO2), 129.06-129.21 
(CHarom), 129.63 (Carom), 165.61 (CHarom), 165.61 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3065 (CHaromatic), 2963-2877 (C-Haliph), 1717 (C=Oester), 1602 (Phenyl), 1553 (NO2νas),  1383 (NO2νs), 1273 
(C-Oester),1113 (C-O), 712-688 (C-Hδaromatic monosubst.), 
 
MS: (EI+) MH+ = 266.3, M+NH4
+ = 283 
 
HRMS (C14H19O4N, 0.7 ppm/MH+): [M+H] 
+= 266.13848, cal. 266.13869, C14H20O4N 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.0 min  
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 4-bromo-benzoic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 39 
OO
Br
NO
2
O
Cl
Br
OH
NO
2
Toluol, 90°C
MW: 344.20
MW: 161.20
(S)-8
(S)-39
 
 
 
5.00 g of  8 (31.0 mmol, 1.00 eq.) are diluted in 20 mL of toluene at room temperature (22°C) and 
8.81 g of bromo benzoyl chloride (40.3 mmol, 1.3 eq) are added to the mixture. The yellow 
suspension is then warmed to 92°C and allows stirring at 92°C over night (22 hours 35 min.), turning 
into a yellow solution. The formed HClgaz is quenched in an external trap with a solution of aqueous 
sodium hydroxide (1M). The reaction mixture is then cooled down to room temperature. 40 mL of 
brine are added to the toluene phase and both phases are separated (pHaqueous phase=2). The organic 
phase is again extracted with 60 mL (pHaqueous Phase=4), 50 mL (pHaqueous phase=6) and 40 mL of brine 
(pHaqueous phase=7). The organic phase is dried over MgSO4 and concentrated in vacuum to yield 10.17 g 
of crude material (95%).  
 
The crude product is purified by column chromatography on silicagel (300 g) with heptane/ethyl 
acetate (5:1) to give in the pure fractions 4.65 g of the desired nitro compound 39 (yield 69%) as a 
yellow oil. 
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.93 (m, 6H, CH3iPr), 1.57 - 1.76 (m, 1H, CH-CHiPr), 1.77 - 1.88 (m, 1H, CHiPr), 1.89 - 2.02 (m, 1 H, 
HCHCH2NO2), 2.02 - 2.16 (m, 1H, HCHCH2NO2), 4.17 - 4.27 (m, 1H, HCH-O), 4.27 - 4.35 (m, 1H, HCH-
O), 4.64 - 4.70 (m, 2H, CH2NO2), 7.73 - 7.80 (m, 2H, CHarom), 7.86 - 7.93 (m, 2H, CHarom) 
 
13C NMR (101 MHz, CDCl3) δC (ppm) 
19.14 (CH3iPr), 19.39 (CH3iPr), 25.85 (CH2CH2NO2), 28.30 (CHiPr), 40.04 (CHCHiPr), 65.29 (CH2-O), 74.01 
(CH2NO2), 127.43 (Br-Carom), 128.88 (Carom), 131.09 (CHarom), 131.95 (CHarom), 165.01 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3094 (CHaromatic), 2962-2876 (C-Haliph), 1720 (C=Oester), 1581 (Phenyl), 1553 (NO2νas),  1398-1384 (NO2νs; 
(CH3)2d), 1272 (C-Oester),1103 (C-O), 1012 (CHarom), 848 (C-Hδaromatic.) 
 
MS: MH+ = 345 
 
HRMS (C14H18O4NBr, 0.5 ppm/MNH4+):  [M+NH4] 
+= 361.07558, cal. 361.07575, C14H22O4N2Br 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 8.9 min  
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 2-methoxy-benzoic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 41 
 
OO
O
NO
2
O Cl
O
OH
NO
2
Toluol, 90°C
MW: 161.20
(S)-8
MW: 295.34
(S)-41
 
 
2.51 g of 8 (15.6 mmol, 1.00 eq.) are diluted in 15 mL of toluene at room temperature and 2.68 g of 
o-methoxy benzoyl chloride (15.7 mmol, 1.3 eq) are added to the mixture. The yellow solution is then 
warmed to 92°C and stirred at 92°C over 2.5 days turning into a black solution. The formed HClgaz is 
quenched with/within a solution of aqueous sodium hydroxide (1M). The reaction mixture is then 
cooled down to room temperature. 30 mL of demineralized water are added to the toluene phase 
and both phases are separated (pHaqueous phase=3). The organic phase is again extracted with 20 mL 
(pHaqueous phase=4), and two times with 30 mL of demineralized water (pHaqueous phase=6). The organic 
phase is dried over MgSO4 and concentrated in vacuum to yield 4.06 g of crude material (88%).  
 
The crude product is purified by column chromatography on silicagel (150 g) with heptane/ethyl 
acetate (4:1) to give in the pure fractions 2.85 g of the desired nitro compound 41 (yield 62%) as a 
yellow oil  
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
1.01 (dd, J1= 6 Hz, J2= 5Hz, 6H, CH3iPr), 1.67 - 1.80 (m, 1H, CHiPr), 1.80 - 1.93 (m, 1H, CH-CHiPr), 2.01 - 
2.17 (m, 1H, HCHCH2NO2), 2.17 - 2.48 (m, 1H, HCHCH2NO2), 3.91 (s, 3H, OCH3), 4.20 (dd, J1=11 Hz, J2= 
7 Hz, 1H, HCH-O), 4.42 (dd, J1=11 Hz, J2= 4 Hz, 1H, HCH-O) ,4.48 - 4.70 (m, 2H, CH2NO2), 6.94 - 7.10 
(m, 2H, CHarom), 7.38 - 7.54 (m, 1H, CHarom), 7.79 (dd, J1=7 Hz, J2= 2 Hz, 1H, CHarom) 
 
13C NMR (101 MHz, CDCl3) δC (ppm) 
19.15-19.18 (CH3iPr),  25.93 (CH2CH2NO2), 28.19 (CHiPr), 56.63 (OCH3), 64.89 (CH2-O), 73.97 (CH2NO2), 
112.50 (CHarom), 120.07 (Carom), 130.72 (CHarom), 133.59 (CHarom), 158.16 (Carom- OCH3), 165.84 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3079 (CHaromatic), 2963 (C-Haliph), 2841 (OCH3), 1704 (C=O), 1602(Phenyl), 1555 (NO2νas),  1384 (NO2νs), 
1031-1253 (Ph-O, C-O), 757 (C-Hδaromatic) 
 
MS: (EI+) MH+ = 296, M+Na+ = 318 
        (EI-)M+HCOO- = 340 
 
HRMS (C15H21O5N, 0.2 ppm/MH+): [M+H] 
+= 296.14942, cal. 296.14925, C15H22O5N 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.4 min  
 
Rf (heptan/ethyl acetate 4:1)=0.21 
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4-methoxy-benzoic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 40 
 
OO
O
NO
2
O Cl
O
OH
NO
2
Toluol, 90°C
MW: 295.34
MW: 161.20
(S)-8
(S)-40
 
 
5.03 g of 8 (31.2 mmol, 1.00 eq.) are diluted in 50 mL of toluene at room temperature and 5.33 g of 
p-methoxy benzoyl chloride (30.2 mmol, 0.9 eq) are added to the mixture. The orange solution is 
then warmed to 92°C and stirred at 92°C over 24 hours turning into a black solution. The formed 
HClgaz is quenched in an external trap with a solution of aqueous sodium hydroxide (1M). The 
reaction mixture is then cooled down to room temperature. 50 mL of demineralized water are added 
to the toluene phase and both phases are separated (pHaqueous phase=4). The organic phase is again 
extracted twice with 60 mL of demineralized water (pHaqueous phase=6). The organic phase is dried over 
MgSO4 and concentrated in vacuum to yield 8.11 g of crude material (89%).  
 
The crude product is purified by column chromatography on silicagel (150 g) with heptane/ethyl 
acetate (4:1) to give in the pure fractions 5.15 g of the desired nitro compound 40 (yield 56%) as a 
yellow oil. 
 
1H NMR (400 MHz, DMSO) δH (ppm)  
0.92 (t, J=6 Hz, 6H, CH3iPr), 1.67 (ddd, J1= 8 Hz, J2=5 Hz, J3=5 Hz, 1H, CHiPr), 1.82 (td, J1= 7Hz, J2= 5 Hz, 
1H, CH-CHiPr), 1.90-1.99 (m, 1H, HCHCH2NO2), 2.08 (ddd, J1= 14 Hz, J2= 7 Hz, J3= 5 Hz, 1H, 
HCHCH2NO2), 3.83 (s, 3H, OCH3), 4.15-4.21 (m, 1H, HCH-O), 4.25-4.29 (m, 1H, HCH-O), 4.63-4.70 (m, 
2H, CH2NO2), 7.04-7.06 (m, 2H, CHarom), 7. 89-7.93 (m, 2H, CHarom) 
 
13C NMR (150 MHz, CDCl3) δC (ppm) 
19.10-19.26 (CH3iPr),  25.91 (CH2CH2NO2), 28.32 (CHiPr), 55.48 (OCH3), 64.82 (CH2-O), 74.02 (CH2NO2), 
114.03 (CHarom), 121.84 (Carom), 131.17 (CHarom), 163.14 (Carom- OCH3), 165.28 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3080 (CHaromatic), 2963 (C-Haliph), 2842 (OCH3), 1712 (C=O), 1607 (Phenyl), 1554 (NO2νas), 1029 (Phenyl),  
1383 (NO2νs), 1275-1285, 1029 (Ph-O, C-O), 849 (C-Hδaromatic), 
 
MS: MH+ = 296.3 
 
HRMS (C15H21O5N, 0.7 ppm/MH+): [M+H] 
+= 296.14948, cal. 296.14925, C15H22O5N 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.4 min  
 
Rf (heptan/ethyl acetate 4:1)=0.22 
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I.3.2. (S)-aldehyde derivatives 
 
(S)-4-methyl-3-(tetrahydro-pyran-2-yloxymethyl)-pentanal 45 
 
O O
NO
2
O O
O
0-2°C, 78%
MW: 245.32
1. KOH/MeOH
2. MgSO4, KMnO4/H2O
MW: 214.31
(S)-32
(S)-45
 
 
To a mechanically stirred solution of 4.85 g of 32 (19.9 mmol, 1 eq.) in methanol (140 mL) is added 
dropwise, at 0 °C under an atmosphere of argon, over a period of 2h a freshly prepared methanolic 
(200 mL) solution of KOH (pallets) (1.35 g, 24.9 mmol, 1.2 eq.). After stirring for an additional 23 min, 
178 mg MgSO4, (1.5 mmol, 0.07 eq.) are added. A freshly prepared solution of KMnO4 (2.15 g, 13.6 
mmol, 0.7 eq.) and water (300 mL) is added dropwise, with vigorous stirring, over 2h (at a rate that 
maintained the reaction temperature at 0-2°C). Upon complete addition, the reaction mixture is 
stirred for an additional 2h at 0°C and then filtered over a layer of celite. The collected material is 
washed with toluene (3 x 50 mL), triturated with an additional 200 mL of toluene, and refiltered over 
a new layer of celite. The filtrates and washings are combined and washed with 200 mL brine. The 
aqueous layer is extracted four times with 200 mL of toluene. The organic phases are combined, 
dried over MgSO4, and concentrated in vacuum (bath temperature not permitted to exceed 35 °C). 
The yellow liquid is then dried again in vacuum to yield 3.36 g (78%) of 45. 
 
1H-NMR: (400 MHz, CDCl3) δH (ppm)  
0.94 (m, 6H, CH3iPr), 1.48-1.82 (m, 9H, 3*CH2THP, CHiPr), 2.18-2.24 (m, 1H, CHCHiPr), 2.31-2.43 (m, 2H, 
CH2C=O), [3.84-3.89 (m), 3.73-3.84 (m), 3.61-3.65 (m), 3.49-3.54 (t), 3.42 (dd, J=9Hz), 3.18 (dd, 
J=9Hz)] (CH2-0, CH2-OTHP), 4.59 (t, J=3Hz, 0.5H, CH-OTHP), 4.52 (t, 0.5H, CH-OTHP), 9.74-9.77 (dd, J 3Hz, 
1H, HC=O) 
 
13C-NMR (101 MHz, DMSO-d6) δC (ppm) 
19.15-19.23 (CH3iPr) , 24.91 (CH2THP), 27.34 (CH2THP), 28.85 (CHiPr), 30.09 (CH2THP), 41.07 (CH-CHiPr), 
61.43-61.74 (CH2THP-O), 68.32-68.44 (CH2-O), 98.15 (CHTHP), 203.07 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
2956 (C-H), 1726 (C=O aldehyde), 1122 (C-O-C), 1033 (C-O) 
 
MS: [M+H]+ = 215 
HR-MS: no response by EI/CI-MS  
 
GC: column Optima-1MN, 25mx0.32mmx0.35μm, Hydrogen flow: 30.0 mL/min, Air flow: 400.0 
mL/min, Helium flow: 20.0 mL/min, 75 to 200°C in 10 min, 3min at 200°C, 200 to 300°C in 10 min, 
2min50 at 300°C, tR = 13.41  min 
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(S)-4-methyl-3-(tetrahydro-furan-2-yloxymethyl)-pentanal 46 
 
 
O
O
OOO
NO
2
0-2°C, 79%
1. KOH/MeOH
2. MgSO4, KMnO4/H2O
MW: 200.28MW: 231.29
(S)-33 (S)-46
 
 
To a mechanically stirred solution of 2.32 g of 33 (10.0 mmol, 1 eq.) in methanol (70 mL) is added 
dropwise, at 0 °C under an atmosphere of argon, a freshly prepared methanolic (100 mL) solution of 
KOH (pallets) (0.75 g, 13.4 mmol, 1.3 eq.) over a period of 1h. After stirring for an additional 15 min, 
89.5 mg MgSO4, (7.3 mmol, 0.07 eq.) are added. Then a freshly prepared solution of KMnO4 (1.24 g, 
7.8 mmol, 0.7 eq.) in water (150 mL) is added dropwise, with vigorous stirring, over 1 hour 40 min (at 
a rate that maintained the reaction temperature at 0-2°C). Upon complete addition, the reaction 
mixture is stirred over 2 hours 35 min at 0°C and then filtered over a layer of celite. The collected 
material is washed with toluene (3 X 25 mL), triturated with an additional 100 mL of toluene, and 
refiltered over a new layer of celite. The filtrates and washings are combined and washed with 100 
mL of brine. The aqueous layer is extracted four times with 100 mL of toluene. The organic phases 
are combined, dried over MgSO4, and concentrated in vacuum (bath temperature not permitted to 
exceed 35 °C). The yellow liquid was then dried in vacuum to yield 1.58 g (78%) of 46.  
 
1H-NMR: (400 MHz, CDCl3) δH (ppm)  
0.92 (m, 1H), 1.76-1.95 (m, 5H, CH2THF, CHiPr), 2.12-2.20 (m, 1H, CHCHiPr), 2.33-2.37 (m, 2H, CH2C=O), 
3.42 (dd, J=9 Hz), 3.18-3.22 (m)](CH2O, CH2OTHF), 3.55 (t, J= 9Hz),  5.02-5.06 (m, 1H, CHTHF), [3.81-3.88 
(m), 3.76 (dd, J=9Hz), 9.71 (dt, J 4Hz, 1H, HC=O) 
 
13C-NMR (150 MHz, CDCl3) δC (ppm)  
18.31-19.22 (CH3iPr), 24.68 (CH2THF), 28.45 (CHiPr),  30.09 (CH2THF), 42.61 (CH2-HC=O, CHCHiPr), 61.29 
(CH2THP-O), 68.63 (CH2-O), 98.00 (CHTHF), 202.53 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
2960 (C-H), 2723 (CH aldehyde), 1725 (C=O aldehyde), 1102 (C-O-C), 1039 (C-O) 
 
MS: [M+H]+ = 201 
 
HR-MS: no response by EI/CI-MS  
 
(S)-3-(1-methoxy-1-methyl-ethoxymethyl)-4-methyl-pentanal 47  
 
 
O
O
NO
2
O
O
O
O°C -2°C
MW: 233.31
1.KOH/MeOH
2.KMnO4/H20
MW: 202.30
79%
(S)-36 (S)-47
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To a mechanically stirred solution of 4.93 g of 36 (21.1 mmol, 1.00 eq.) in methanol (180 mL) is added 
dropwise at 0 °C under an atmosphere of argon over a period of 1h a freshly prepared methanolic 
(215 mL) solution of KOH (pallets) (1.44 g, 24.3 mmol, 1.15 eq.). After stirring for an additional 20 
min, 194.0 mg MgSO4, (1.6 mmol, 0.07 eq) are added. Then a freshly prepared solution of KMnO4 
(2.33 g, 14.7 mmol, 0.7 eq.) and water (320 mL) is added dropwise, with vigorous stirring, over 1 hour 
20 min (at a rate that maintained the reaction temperature at 0-2°C). Upon complete addition, the 
reaction mixture is stirred for an additional 40 min at 0°C and then filtered over a layer of celite. The 
collected material is washed four times with 100 mL of toluene. The filtrates and washings are 
combined, and washed with 200 mL of brine (200 mL). The aqueous layer is extracted three times 
with 200 mL of toluene. The organic phases are combined, dried over MgSO4, and concentrated in 
vacuum (bath temperature not permitted to exceed 35 °C) to yield 3.32 g (79%) of 47. 
 
1H-NMR: (400 MHz, CDCl3) δH (ppm)  
0.85 (dd, J1=13Hz, J2=7Hz, 6H, CH3iPr), 1.21 (d, J=3Hz, 6H, CH3), 1.66 - 1.80 (m, 1H, CHiPr), 1.99 - 2.09 
(m, 1H, CHCHiPr), 2.16 - 2.27 (m, 1H, HCHC=O), 2.34 - 2.42 (m, 1H, HCHC=O), 3.05 (s, 3H, O CH3), 3.12 - 
3.19 (m, 1H, HCHC-O), 3.29 - 3.34 (m, 1H, HCHC-O), 9.63 (s, 1H, HC=O) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm) 
18.94 (CH3iPr), 19.91 (CH3iPr), 24.06 (CH3MIP), 24.13 (CH3MIP), 28.14 (CHiPr), 43.33 (CH2C=O), 47.89 
(OCH3MIP), 61.55 (CH2-O), 99.45 (CMIP), 203.03 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
       2960 (C-Haliph.), 2877 (CH3νs), 2829 (O-CH3), 2723 (aldehyde), 1726 (C=Oaldehyde), 1467 (CHδ), 1370 
((CH3)2δ), 1214-1048(C-O) 
 
MS: LC/MS (ESI) no response 
        GC/MS (EI) no response 
HR-MS: no response by EI/CI-MS  
 
GC: column Optima-1MN, 25mx0.32mmx0.35μm, Hydrogen flow: 30.0 mL/min, Air flow: 400.0 
mL/min, Helium flow: 20.0 mL/min, 75 to 200°C in 10 min, 3min at 200°C, 200 to 300°C in 10 min, 
2min50 at 300°C, tR = 10.4  min 
 
 benzyl-carbamic acid (S)-3-methyl-2-(2-oxo-ethyl)-butyl ester 52    
 
 
O
O
N
H
NO
2
O
O
N
H
O
1. K2CO3/MeOH
2. MgSO4,KMnO4/H2O
MW: 294.35 MW: 263.34
(S)-43 (S)-52
 
 
66.0 mg of nitro compound 43 (0.22 mmol, 1.0 eq.) are diluted in 1 mL of methanol at room 
temperature under Ar. The light yellow solution is cooled down to 0°C and 172.1 mg of K2CO3 (1.2 
mmol, 5.7 eq.) are added, followed by 5.1 mg of MgSO4 (0.04 mmol, 0.2 eq.). A solution of 26.6 mg of 
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KMnO4 (0.17 mmol, 0.7 eq.) in 5 mL of demineralized water is then added dropwise over 4 min 
resulting in the precipitation of MnO2. The reaction mixture is allowed to stir at 0°C over a period of 
24 min. 
5 mL of toluene are added to the reaction mixture over stirring and the resulting suspension is 
filtered over a layer of celite. The collected material is washed twice with 10 mL of toluene. The 
filtrates and washings are combined and extracted twice with 15 mL of brine. The organic layer is 
dried over MgSO4 and concentrated in vacuum to yield 32.0 mg of colourless oil (55%) 52.  
 
1H NMR (400 MHz, DMSO-d6) δH ppm  
0.81 - 0.91 (m, 6H, CH3iPr), 1.67 - 1.83 (m, 1H, CHiPr), 2.07 - 2.20 (m, , 1 H, CHCHiPr), 2.25 - 2.46 (m, 2H, 
CH2CHO), 3.76 - 3.91 (m, 1H, HCH-O), 3.94 - 4.04 (m, 1H, HCH-O), 4.16 (d, J=6 Hz, CH2Benz), 7.19 - 7.40 
(m, 5H, CHarom), 9.62 - 9.84 (m, 1H, HC=O) 
 
IR: (FTIR-microscopy in transmission)  
3339 (NH), 3032 (CHaromatic), 2961 (C-Haliph), 2727 (Aldehyde), 1717 (C=Oaldehyde, carbamate), 1585-1455 
(Phenyl), 1526 (Amide sec.), 1246-1137-1042 (C-O), 739-699 (C-Hδaromatic monosubst) 
 
MS: MH+ = 264, M+Na+ = 286 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.1 min  
 
4-methoxy-benzoic acid (S)-3-methyl-2-(2-oxo-ethyl)-butyl ester 51 
 
 
O
O
O
NO
2
O
O
O
O
1. K2CO3/MeOH
2. MgSO4,KMnO4/H2O
MW: 295.33
MW: 264.32
(S)-40 (S)-51
 
 
 
294.8 mg of 40  (0.99 mmol, 1.0 eq.) are diluted in 10 mL of methanol under Ar atmosphere at room 
temperature (22°C). The yellow solution is cooled down to 0°C and 809.6 mg of K2CO3 (5.85 mmol, 
5.9 eq.) are added. 23.8 mg of MgSO4 (0.19 mmol, 0.2 eq.) are added to the suspension. A freshly 
prepared solution of 116.7 mg of KMnO4 (0.74 mmol, 0.7 eq.) in 22 mL of demineralized water is then 
added dropwise over a period of 11 min resulting in the precipitation of MnO2. The reaction mixture 
is allowed to stir at 0°C over a period of 14 min. 
40 mL of toluene are added to the reaction mixture over stirring and the resulting suspension is 
filtered over a layer of celite to remove MnO2. The collected material is washed with 60 mL of 
toluene. The filtrates and washings are combined and extracted four times with 50 mL of brine (pH of 
the aqueous layer decreases from 10 to 7). The organic layer is dried over MgSO4 and concentrated in 
vacuum to yield 213.0 mg of colourless liquid 51 (80%).  
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.91 (t, J1=7 Hz, 6H, CH3iPr), 1.81 (td, J1=7 Hz, J2=5 Hz, 1H, CHiPr), 2.23 - 2.62 (m, 1H, CHCHiPr), 3.14 - 
3.38 (m, 2H, CH2CO), 3.83 (m, 3H, OCH3), 4.12 (dd, J1=11 Hz, J2=7 Hz, 1H, HCH-O), 4.27 (dd, J1=11 Hz, 
J2=5 Hz, 1H, HCH-O), 6.62 - 7.26 (m, 2H, CHarom), 7.65 - 8.00 (m, 2H, CHarom), 9.72 (s, 1H, HC=O) 
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13C NMR (101 MHz, DMSO-d6) δC (ppm)  
19.10 (CH3iPr), 19.64 (CH3iPr), 28.38 (CHiPr), 37.59 (CHCHiPr), 42.86 (CH2CO), 55.50 (OCH3), 65.53 (CH2O), 
114.04 (CHarom), 121.80 (CHarom), 131.21 (CHarom) 163.16 (O-Carom), 165.27 (C=O), 203.01 (HC=O) 
 
IR: (FTIR-microscopy in transmission)  
3081 (CHaromatic), 2962 (C-Haliph), 2841 (OCH3), 1713 (C=O), 1607-1512 (Phenyl), 1275 (Carom-O, C-O), 
1257 (C-O), 849 (C-Hδaromatic) 
 
MS: MH+ = 265, M+Na+ = 287 
 
HRMS (C15H20O4, 0.2 ppm/MH+): [M+H] 
+= 265.14336, cal. 265.14344, C15H21O4 
 
2-Methoxy-benzoic acid (S)-3-methyl-2-(2-oxo-ethyl)-butyl ester 53 
 
 
O
OO
NO
2
O
O
OO
1. K2CO3/MeOH
2. MgSO4,KMnO4/H2O
MW: 295.33 MW: 264.32
(S)-41 (S)-53
 
 
 
295.3 mg of 41 (1.00 mmol, 1.0 eq.) are diluted in 10 mL of methanol under Ar atmosphere at room 
temperature (22°C). The yellow solution is cooled down to 0°C and 803.5 mg of K2CO3 (5.81 mmol, 
5.8 eq.) and 23.6 mg of MgSO4 (0.19 mmol, 0.2 eq.) are added to the suspension. A fresh prepared 
solution of 123.4 mg of KMnO4 (0.78 mmol, 0.8 eq.) in 22 mL of demineralized water is then added 
dropwise over a period of 17 min, resulting in the precipitation of MnO2. The reaction mixture is 
allowed to stir at 0°C over a period of 3 min. 
30 mL of toluene are added to the reaction mixture over stirring and the resulting suspension is 
filtered over a layer of celite to remove MnO2. The collected material is washed with 50 mL of 
toluene. The filtrates and washings are combined and extracted three times with 50 mL of brine (pH 
of the aqueous layer decreases to 6-7) and once with 20 mL of demineralized water. The organic 
layer is dried over MgSO4 and concentrated in vacuum to yield 217 mg of 53 as a colourless liquid  
(82%).  
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.85 - 0.98 (m, 6H, CH3iPr), 1.80 (td, J1=7 Hz, J2=5 Hz, 1H, CHiPr), 2.25 (td, J1=7 Hz, J2=5 Hz, 1 H, CHCHiPr), 
2.39 - 2.61 (m, 2H, CH2CO), 3.80 (s, 3H, OCH3), 4.10 (dd, J1=11 Hz, J2=7 Hz, 1H, HCH-O), 4.23 (dd, J1=11 
Hz, J2=5 Hz, 1H, HCH-O), 7.00 (td, J1=7 Hz, J2=1Hz, 1H, CHarom), 7.13 (d, J=8 Hz, 1H, CHarom), 7.53 (ddd, 
J1= 9Hz, J2=7 Hz, J3=2 Hz, 1H, CHarom), 7.61 (dd, J1=7 Hz, J2=2 Hz, 1H, CHarom), 9.70 (s, 1H, HC=O) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
18.74 (CH3iPr), 19.24 (CH3iPr), 28.50 (CHiPr), 38.12 (CHCHiPr), 41.50 (CH2CO), 53.08 (OCH3) 64.40 (CH2O), 
112.54 (CHarom), 119.61 (Carom), 130.68 (CHarom), 133.61 (CHarom) 158.23 (O-Carom), 165.69 (C=O), 203.08 
(HC=O) 
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IR: (FTIR-microscopy in transmission)  
3079 (CHaromatic), 2962 (C-Haliph), 2840 (OCH3), 1725 (C=O), 1601-1466 (Phenyl), 1253 (Carom-O, C-O), 
1080 (C-O), 757 (C-Hδaromatic) 
 
MS: [M+H]+ = 265, M+Na+ = 287 
 
HRMS (C15H20O4, 0.7 ppm/MH+): [M+H] 
+= 265.14324, cal. 265.14344, C15H21O4 
 
 
 benzoic acid (S)-3-methyl-2-(2-oxo-ethyl)-butyl ester 49 
 
 
OO
NO
2
OO
O
MW: 265.31 MW: 234.29
(S)-38 (S)-49
 
 
 
500.2 mg of 38 (1.88 mmol, 1.0 eq.) are diluted in 14 mL of methanol under Ar atmosphere at room 
temperature (22°C). The yellow solution is cooled down to 0°C and 1.5072 g of K2CO3 (5.7 mmol, 5.7 
eq.) and 31.7 mg of MgSO4 (0.26 mmol, 0.14 eq.) are added to the suspension. A freshly prepared 
solution of 252.3 mg of KMnO4 (1.6 mmol, 0.8 eq.) in 35 mL of demineralized water is then added 
dropwise over a period of 19 min resulting in the precipitation of MnO2. The reaction mixture is 
allowed to stir at 0°C over a period of 5 min. 
The reaction mixture is filtered over a layer of celite and the collected material is washed with 50 mL 
of toluene. The filtrates and washings are combined and extracted once with 10 mL and three times 
with 20 mL of brine. The organic layer is dried over MgSO4 and concentrated on vacuum to yield 370 
mg of a liquid 49 (84%).  
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.87 - 0.98 (m, 6H, CH3iPr), 1.79-1.87 (m, 1H, CH-CHiPr), 2.31-2.36 (m, 1H, CHCHiPr), 2.40 - 2.66 (m, 2H, 
CH2CO), 4.17 (dd, J1=11 Hz, J2=7Hz, 1H, HCH-O), 4.32 (dd, J1=11 Hz, J2=5Hz, 1H, HCH-O), 7.53 (t, J=7Hz, 
2H, CHarom), 7.60 - 7.75 (m, 1H, CHarom), 7.87 - 8.04 (m, 2H, CHarom H), 9.65 - 9.87 (m, HC=O) 
 
 
13C NMR (150 MHz, DMSO-d6) δC (ppm)  
18.83 (CH3iPr), 19.30 (CH3iPr), 28.39 (CHiPr), 37.85 (CHCHiPr), 43.31 (CH2CO), 65.69 (CH2O), 127.97 
(CHarom), 129.17 (Carom), 132.78 (CHarom) 158.23 (O-Carom), 166.04 (Carom-C=O), 241.03 (HC=O) 
 
IR: (FTIR-microscopy in transmission)  
3065-3035 (CHaromatic), 2962-2877 (C-Haliph), 2725 (Aldehyde), 1721 (C=O), 1584 (Phenyl), 1390-1312 
(CHδtertiary), 1274 (C-O), 1080 (C-O), 712 (C-Hδaromatic, monosubs.) 
 
MS: (EI+) [M+Na]+ = 257, M+NH4
+ = 283 
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 (S)-3-(4-Methoxy-benzyloxymethyl)-4-methyl-pentanal 34 
 
O
O
NO
2
O
O
O
O°C -2°C
1.KOH/MeOH
2.KMnO4/H20
MW: 281.35 MW: 250.34
(S)-34(S)-34-a
 
 
 
1.497 g of nitro compound 34-a (5.3 mmol, 1.0 eq.) is diluted in 45 mL of methanol under Ar 
atmosphere at room temperature (22°C). The yellow solution is cooled down to 0°C and a solution of 
368.2 mg of KOH (6.5 mmol, 1.2 eq.) in 50 mL of methanol are added drop wise over a period of 10 
min. 52.6 mg of MgSO4 (0.43 mmol, 0.08 eq.) are added to the reaction mixture. A fresh prepared 
solution of 592.4 mg of KMnO4 (3.7 mmol, 0.8 eq.) in 80 mL of demineralized water is then added 
dropwise over a period of 25 min yielding to the precipitation of MnO2. The reaction mixture is 
allowed to stir at 0°C over a period of 10 min. 
The reaction mixture is diluting over stirring with 10 mL of toluene and is filtered over a layer of 
celite. The collected material is washed four times with 100 mL of toluene. The filtrates and washings 
are combined and extracted two times with 200 mL of brine whereas the resulting aqueous phases 
are extracted three times with 200 mL of toluene. The combined organic layers are dried over MgSO4 
and concentrated on vacuum to yield 1.01 g of a colourless liquid 34 (76%).  
 
1H NMR (400 MHz, CDCl3-d) δH (ppm) 
0.89 (dd, J1= 10 Hz, J2= 7 Hz, 6H, CH3iPr), 1.74-1.82 (m, 1H, CHiPr), 2.13 - 2.26 (m, 1 H, CHCHiPr), 2.39 
(dd, J1= 6 Hz, J2= 2 Hz, 2H, CH2CO), 3.30 (t, J=9 Hz, 1H, HCH-O), 3.51 (dd, J1= 9 Hz, J2= 5 Hz, 1H, HCH-
O), 3.81 (s, 3H, OCH3), 4.39 (s, 2H, CH2Benz), 6.78 - 6.98 (m, 2H, CHarom), 7.21-7.24 (m, 2H, CHarom), 9.63 
- 9.91 (s, 1H, HC=O) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
18.73 (CH3iPr), 19.79 (CH3iPr), 28.71 (CHiPr), 38.96 (CHCHiPr), 43.51 (CH2CO), 54.95 (OCH3) 70.98 (CH2O), 
71.91 (CH2Benz), 112.45 (CHarom), 128.49 (CHarom), 130.41 (Carom), 158.64 (O-Carom), 203.06 (HC=O) 
 
IR: (FTIR-microscopy in transmission)  
2959 (C-Haliph), 2838(OCH3), 2725 (Aldehyde), 1723 (C=O), 1613-1514 (Phenyl), 1368 ((CH3)2δ), 1087-
1036 (C-O), 821 (C-Hδaromatic para subst.) 
 
MS: M+NH4
+ = 268           
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I.3.3. Henry products 
 
 (2S,4S,5S,7S)-2-isopropyl-8-methyl-4-nitro-7-(tetrahydropyran-2-yloxymethyl)-nonane-1,5-diol  54 
 
Methode 1 
OH
NO
2
OH
O
OH
ONO2
NH
N
H
N
OH
O
O
O
MW: 161.20
+
AcN, Cu(OAc)2
21°C -> 35°C
MW: 375.52MW: 214.31
(S)-8 (S)-45 (S,S,S,S)-54
+ other Stereoisomers
A
 
34.3 mg of the ligand A (0.09 mmol, 0.02 eq.) are dissolved at 21°C in 1.4 mL of acetonitrile and 19.2 
mg of copper (II) acetate monohydrate (0.09 mmol, 0.02 eq.) are added to the solution. After 30 min, 
938.1 mg of nitro compound 8 (6.09 mmol, 1.3 eq.) and 1.01 g of aldehyde 45 (4.7 mmol, 1.0 eq.) are 
added at 22°C to the green reaction mixture. The reaction mixture is heated to 35°C and is stirred 
over 5.5 days.  
The reaction mixture is cooled down to room temperature and diluted in 100 mL of a mixture of 
hexan/demineralized water/methanol (70:20:10 v/v/v), yielding to the precipitation of a green solid. 
The layers are separated and the aqueous phase is extracted again once with 75 mL and two times 
with 25 mL of dichloromethane. Both organic phases are dried over MgSO4 and concentrated on 
vacuum to yield 670.0 mg of a green oil (containing the nitro diol in mixture with the starting nitro 
compound 54 and aldehyde 45) and 640.0 mg of a green oil (containing the nitro diol 54 in mixture 
with 8).   
The diastereoisomeric ratio measured on CHIRALPAK AD-H (mixture of 
hexan/isopropanol/methanol/ethanol  973:9:9:9, 1 mL/min, at 40°C) shows the presence of four 
diastereoisomers with a ratio of 4:10:11:75. 
The crude material (640 mg) is purified by column chromatography on silicagel (40 g) with 
heptane/ethyl acetate (4:1) to give in the pure fractions 456.0 mg of the desired nitro compound 54 
(yield 26%) as a yellow oil containing two diastereoisomers the (S,S,S,S,S) and (R,S,S,S,S) isomers and 
185.3 mg of a yellow oil  (10%) as a mixture of diastereoisomers  with a ratio of 24:20:2:38.  
 
Spectroscopic data of (S,S,S,S)-54 
OH OH
O O
NO
2
(S,S,S,S)-54
MW: 375.51  
 
1H NMR (600 MHz, dmso-d6) δH (ppm) (mixture of 2 diastereoisomers) 
0.75-0.91 (m, 12H, CH3iPr), 1.13-1.86 (m, 14H, CHCHiPr, CHiPr, CH2THP, CH2O, CH2), 3.13-3.48 (m, 6H, CH2-
O-THP, CH2-O, CH2-OTHP), 4.47-4.66 (m, 3H, CH-NO2, OH, CHTHP), 5.23-5.36 (m, 1H, OH) 
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13C NMR (151 MHz, DMSO-d6) δC (ppm) (mixture of 2 diastereoisomers) 
18.42 (CH3iPr), 19.07 (CH3iPr), 19.30-20.05 (CH2THP), 20.22 (CH3iPr), 20.31 (CH3iPr), 25.18 (br. s., 1 C), 
25.24 (CH2THP), 27.89, 28.73, 28.96, 29.24, 30.37, 31.30, 31.49 (CH2-CHNO2, CHiPr), 32.48 (CH2-CHOH), 
39.92 (CHCHiPr), 42.79 (CHCHiPr), 61.06 (CH2-OTHP), 67.57 (CH2-OH), 68.00 (CH2-O-THP), 70.60-71.03 
(CH-OH), 93.27 (CH-NO2), 97.83-98.22 (CH-OTHP) 
 
IR: (FTIR-microscopy in transmission)  
3406 (OH), 2957-2875 (C-Haliph), 1553 (NO2νas), 1467-1385 (CHδ), 1370 (NO2νs), 1119-1062 (C-O), 1024 
(C-OH) 
 
MS: MH+ = 376,  M+NH4
+ = 393  
 
HRMS (C19H38O6N, 0.3 ppm/MH+): [M+H] 
+= 376.26926, cal. 376.26937, C19H38O6N 
 
 
Chirale HPLC (CHIRALPAK AD-H with a mixture of hexan/isopropanol/methanol/ethanol  973:9:9:9, 1 
mL/min, at 40°C) and 1H NMR (600 MHz, dmso-d6) of (S,S,S,S)-54: 
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Spectroscopic data of 54, as a mixture of diastereoisomers 
 
1H NMR (600 MHz, dmso-d6) δH (ppm) (mixture of 6 diastereoisomers) 
0.71-0.90 (m, 12H, CH3iPr), 1.23-1.92 (m, 14H, CHCHiPr, CHiPr, CH2THP, CH2O, CH2), [3.23-3.46 (m, 4H), 
3.62-3.71 (m, 1H), 3.71-3.74 (m, 1H) CH2-O-THP, CH2-O, CH2-OTHP], 3.76-3.82 (m, 1H, CH-OH), 4.50-
4.66 (m, 3H, CH-NO2, OH, CHTHP), 5.26-5.29 (d, J=9 Hz, 1H, OH), 5.29-5.31 (d, J=9 Hz, 1H, OH) 
 
IR: (FTIR-microscopy in transmission)  
3406 (OH), 2968-2875 (C-Haliph), 1550 (NO2νas),  1467-1386 (CHδ), 1370 (NO2νs), 1120-1075-1062 (C-O), 
1025 (C-OH) 
 
MS: MH+ = 376,  M+NH4
+ = 393 (mixture of stereoisomers) 
 
 
Methode 2 
O
O
O
O
OHOH
ONO
2
NH
N
H
N
OH
OH
NO
2
CuI, THF, Huenig Base
35°C
+
(S,S,S,S)
other diastereoisomers
8 45
B
54
MW: 161.20 MW: 214.31
MW: 375.51
 
 
 
840.1 mg of the ligand B (2.8 mmol, 0.06 eq.) are dissolved at 21°C in 3.0 mL of THF and 866.7 mg of 
copper (I) iodide in 15 mL THF (4.5 mmol, 0.10 eq) are added. After 20 min, 400 µL of diisopropyl 
ethyl amine (2.3 mmol, 0.5 eq) are added and the mixture is allowed to stir at 30°C for 27 min. A 
solution of 9.92 g of aldehyde 45 (46.3 mmol, 1.00 eq) in 8 mL of THF and 12.63 g of nitro compound 
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8 (78.3 mmol, 1.70 eq.) are added at 30°C to the green reaction mixture. The reaction mixture is 
stirred over 2.5 days.  
The reaction mixture is cooled down to room temperature and diluted in 300 mL of a mixture of 
hexan/demineralized water/methanol (70:20:10 v/v/v), yielding to the precipitation of a green solid. 
The layers are separated and the organic phase is extracted again twice with 100 mL of 
dichloromethane. Both organic phases are dried over MgSO4 and concentrated on vacuum to yield 
6.23 g of a green oil (containing the nitro diol in mixture with the starting material 8 and aldehyde 
45) and 10.1 g of a green oil (containing the nitro diol 54 in mixture with 8).   
The determination of the diastereoisomeric ratio measured on CHIRALPAK AD-H (mixture of 
hexan/isopropanol/methanol/ethanol  973:9:9:9, 1 mL/min, 40°C) shows the presence of four 
diastereoisomers with a ratio of 13:11:19:57. 
 
10.01 g of the crude material are purified by chromatography on CHIRALPAK AD-H (30*250 nm) with 
CO2/isopropanol (8:2) and a flow of 120 g/min to yield in the pure fractions 1.20 g of  54 (yield 12%) 
as a yellow oil containing 98% of the (S,S,S,S) configured 54 (as 50:50 ratio of (R,S,S,S,S) and 
(S,S,S,S,S) isomers). 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm) (mixture of 2 diastereoisomers) 
0.83 (m,12H, CH3iPr), 1.23-1.89 (m, 14H, CHCHiPr, CHiPr, CH2THP, CH2O, CH2), [3.38 - 3.51 (m, 4H), 3.62 - 
3.69 (m, 1H), 3.69 - 3.77 (m, 1 H) CH2-O-THP, CH2-O, CH2-OTHP], 3.78 - 3.88 (m, 1H, CH-OH), 4.49 - 4.68 
(3H, CH-NO2, OH, CHTHP), 5.20 - 5.31 (m, 1H, OH) 
 
13C NMR (151 MHz, DMSO-d6) δC (ppm) (mixture of 2 diastereoisomers) 
18.42 (CH3iPr), 19.07 (CH3iPr), 19.31-20.05 (CH2THP), 20.23 (CH3iPr), 20.29 (CH3iPr), 25.18 (br. s., 1 C), 
25.24 (CH2THP), 27.89, 28.73, 28.80, 29.25, 30.41, 31.57 (CH2-CHNO2, CHiPr), 32.48 (CH2-CHOH), 39.92 
(CHCHiPr), 42.79 (CHCHiPr), 61.06 (CH2-OTHP), 67.03 (CH2-OH), 68.09 (CH2-O-THP), 70.62-70.97 (CH-OH), 
93.36 (CH-NO2), 97.84-98.23 (CH-OTHP) 
 
 
 
Chirale HPLC (CHIRALPAK AD-H with a mixture of hexan/isopropanol/methanol/ethanol  973:9:9:9, 1 
mL/min, at 40°C) and 1H NMR (600 MHz, dmso-d6) of (S,S,S,S)-54: 
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 (2S,4S,5S,7S)-2,7-diisopropyl-5-nitro-octane-1,4,8-triol 14 
O
OHOH
ONO
2
OH
OHOH
NO
2
MW: 291.39MW: 375.52
(S,S,S,S)-54 (S,S,S,S)-14
 
 
66 mg of nitro aldol (S,S,S,S)-54 (0.17 mmol, 1.0 eq.) are dissolved at 21°C in 1 mL of methanol and 
1.5 mg of p-toluene  sulfonic acid (0.04 mmol, 0.3 eq.) is added to the solution. After stirring at room 
temperature over 2 hours, the reaction mixture is diluted in 4 mL of dichloromethane. The organic 
phase is extracted with 2 mL of an aqueous solution of NaHCO3 (10%), and the resulting aqueous 
layer is extracted two times with 4 mL of dichloromethane. 
The organic phase is dried over MgSO4 and concentrated in vacuum to give nitro diol 14 (86% yield). 
 
N
O O
OHOH
O O
2 4
5 7
Peak No. 4, (P4)
(S,S,S,S)
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1H NMR (600 MHz, DMSO-d6) δH (ppm)  
0.75-0.85 (m, 12H, CH3iPr), 0.86-0.97 (m, 1H, CHCHiPr), 1.17-1.95 (m, 14H, CHCHiPr, CHiPr, CH2CHO, 
CH2CHNO2), 3.37-3.42 (m, 4H, CH2-OH), 3.69-3.79 (m, 1H, CH-OH), 4.45-4.47 (m, 1H, OH), 4.55-4.58 
(m, 1H, OH), 4.65-4.67 (m, 1H, CHNO2), 5.25 (d, J=9Hz, 1H, OH) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
18.57 (CH3iPr), 18.89 (CH3iPr), 20.10 (CH3iPr), 20.34 (CH3iPr), 27.88 (CHiPr), 28.07 (CHiPr), 28.62 
(CH2CHNO2), 31.39 (HOC-CH2-CH- CHiPr), 41.36 (CH- CHiPr), 42.80 (CH- CHiPr), 61.00 (CH2-OH), 70.51 
(CH2-OH), 74.67 (CH-OH), 93.46 (CH-NO2)
 
 
IR: (FTIR-microscopy in transmission)  
3358 (NH), 2960-2876 (C-Haliph), 1555 (NO2νas), 1466(CHδ), 1371 (NO2νs), 1043 (C-OH) 
 
MS: MH+ = 292, M+NH4
+ = 309           
 
HRMS (C14H30O5N, 0.5 ppm/MH+): [M+H] 
+= 292.2169, cal. 292.21185, C14H30O5N 
 
 
benzoic acid (2S,4S,5S,7S)-4-hydroxy-7-hydroxymethyl-2-isopropyl-8-methyl-5-nitro-nonyl ester 55 
 
OH
NO
2
OH
O
OH
O
NO
2
NH
N
H
N
OH
O
O
O
AcN, Cu(OAc)2
21°C -> 35°C
MW: 161.20
+
(S)-8 (S)-49
(S,S,S,S)-55
MW: 395.50
+ other stereoisomersMW: 234.30
 
29.9 mg of the ligand (0.08 mmol, 0.09 eq.) are dissolved at 21°C in 1 mL of acetonitrile and 15.6 mg 
of copper (II) acetate monohydrate (0.08 mmol, 0.09 eq.) are added to the solution. After 35 min, 
180.3 mg of aldehyde 49 (0.77 mmol, 1.0 eq.) and 115.3 mg of nitro compound 8 (0.72 mmol, 0.9 eq.) 
are added at 22°C to the green reaction mixture. The reaction mixture is heated to 35°C and is stirred 
over 7 days.  
The diastereoisomeric ratio is measured on CHIRALPAK AD-H (mixture of 
hexan/isopropanol/methanol/ethanol  973:9:9:9, 1 mL/min, 40°C)  and shows the presence of four 
picks 7:7:27:59. 
The reaction mixture is cooled down to room temperature and diluted in 55 mL of a mixture of 
hexan/demineralized water/methanol (40:10:5v/v/v) yielding to the precipitation of a green solid. 
The layers are separated and the aqueous phase is extracted again three times with 10 mL of 
dichloromethane. Both organic phases are dried over MgSO4 and concentrated on vacuum to yield 
188.1 mg of a green oil (containing the nitro diol 55 in mixture with the starting nitro compound 8 
and aldehyde 49) and 175.3 mg of a green oil (containing the nitro diol 55 in mixture with the starting 
nitro compound 8).   
The diastereoisomeric ratio measured on CHIRALPAK AD-H (mixture of 
hexan/isopropanol/methanol/ethanol  973:9:9:9, 1 mL/min, 40°C)   reveals the presence of four 
diastereoisomers with a ratio of 7:7:27:59. 
 
The crude material is purified by column chromatography on silicagel (3 g) with heptane/ethyl 
acetate  (4:1) to give in the pure fractions  48.3 mg of the desired compound 55 (yield 16%) as a 
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yellow oil containing the single (S,S,S,S) isomer and 63.1 mg of a yellow oil  (20 %) as a mixture of 
diastereoisomers.  
 
Spectroscopic data of (S,S,S,S)-55 
OH
O
OH
O
NO
2
(S,S,S,S)-55  
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.61 - 0.69 (m, 12H, CH3iPr), 0.69 - 0.78 (m, 3H, CH3iPr), 0.75 - 0.88 (m, 1H, CHCHiPr), 0.89 - 0.99 (m, 6H, 
CH3iPr), 1.21 - 1.98 (m, 7H, CH2CHCO, CH2CHNO2, 2*CHiPr, CHCHiPr), 3.34 - 3.49 (m, 2H, CH2-OH), 3.78 - 
3.92 (m, 1H, CH-O), 4.25 - 4.34 (m, 1H, HCH-O-) 4.34 - 4.45 (m, 1H,HCH-O-), 4.45 - 4.54 (t, J=5Hz, 1H, 
OH), 4.57 - 4.73 (m, 1H, CHNO2), 5.29 - 5.49 (d, J= 7Hz,1H, OH), 7.44 - 7.56 (m, 2H, CHarom), 7.61 - 7.76 
(m, 1H, CHarom), 7.88 - 8.05 (m, 2H, CHarom) 
 
13C NMR (151 MHz, DMSO-d6) δC (ppm)  
18.29 (CH3iPr), 19.43 (CH3iPr), 20.16 (CH3iPr), 27.82 (CHiPr), 28.69 (CH2-CHNO2), 29.34 (CHiPr), 31.61 (CH2-
CHOH), 38.93 (CHCHiPr), 42.73 (CHCHiPr), 61.13 (CH2-OH), 64.68 (CH2-OH, CH2-O), 70.43 (CH-OH), 
93.15 (CH-NO2), 128.88 (CHarom.), 129.15 (CHarom), 129.80 (Carom), 133.44 (CHarom), 165.77 (C=O) 
 
 
IR: (FTIR-microscopy in transmission)  
3456 (OH), 3066-3034 (C-Harom), 2960 (C-Haliph), 2876 (CH3δs), 1703 (C=Oester), 1584-1452 (Phenyl), 
1553 (NO2νas), 1372 (NO2νs), 1277 (C-Oester), 1115 (C-O, C-OH), 713 (Phenylδmonosub, CHδ) 
 
MS: (EI+) MH+= 396 
       (EI-) MH-= 394 
 
HRMS (C21H34O5N, 0.08 ppm/MH+): [M+H] 
+= 396.23810, cal. 396.23807, C21H34O5N 
 
 
 
Spectroscopic data of 55, as a mixture of diastereoisomers 
 
1H NMR (400 MHz, dmso-d6 H (ppm) (mixture of diastereoisomers) 
0.66 - 1.03 (m, 13H, CHCHiPr, 3*CH3iPr), 1.12 - 1.97 (m, 7H, CH2CHCO, CH2CHNO2, 2*CHiPr, CHCH3iPr), 
3.33 - 3.47 (m, 2H, CH2-OH), 3.78 - 4.06 (m, 1H, CH-O), 4.23 - 4.46 (m, 1H, HCH-O-) 4.34 - 4.45 (m, 
1H,HCH-O-), 4.48 - 4.55 (m, 1H, OH), 4.55 - 4.74 (m, 1H, CHNO2), 5.40 - 5.44 (d, J= 7Hz, OHDia1), 5.45 - 
5.48 (d, J= 6.5Hz, OH Dia2), 7.51-7.55 (m, 2H, CHarom), 7.61 - 7.69 (m, 1H, CHarom), 7.94-7.98 (m, 2H, 
CHarom) 
 
 
 
 
 
 
 
 163 
 
(2S,4S,5S,7S)-2-isopropyl-7-(1-methoxy-1-methyl-ethoxymethyl)-8-methyl-4-nitro-nonane-1,5-diol 
56 
OH
NO
2
OH
O
O
OH
NO
2
NH
N
H
N
OH
O
O
O
MW: 161.20
+
AcN, Cu(OAc)2
21°C -> 35°C
MW: 202.30 MW: 363.50
(S)-8 (S)-47 (S,S,S,S)-56
+ other Stereoisomers  
 
36.6 mg of the ligand (0.10 mmol, 0.02 eq.) are dissolved at 21°C in 1.5 mL of acetonitrile and 19.9 
mg of cupper (II) acetate monohydrate (0.10 mmol, 0.02 eq.) are added to the solution. After 30 min, 
1.001 g of aldehyde 47 (4.9 mmol, 1.0 eq.) and 1.048 g of nitro compound 8 (6.5 mmol, 1.3 eq.) are 
added at 22°C to the green reaction mixture. The reaction mixture is heated to 35°C and is stirred 
over 4 days.  
The diastereoisomeric ratio measured on CHIRALPAK AD-H (40°C, 93:7 hexane/isopropanol, isocratic, 
2 mL/min) shows the presence of three major picks 25:17:58. 
Analytic measurement also shows a convertion rate of 65% and the presence of 25% of deprotected 
Henry product. 
The reaction mixture is cooled down to room temperature and diluted in 100 mL of a mixture of 
hexan/demineralized water/methanol (70:20:10 v/v/v) yielding to the precipitation of a green solid. 
The layers are separated and the aqueous phase is extracted again once with 75 mL and twice with 
25 mL of dichloromethane. Both organic phases are dried over MgSO4 and concentrated on vacuum 
to yield 870 mg of a green oil (containing 56 in mixture with the starting nitro compound 8 and 
aldehyde 36) and 770 mg of a green oil (containing 56 in mixture with the deprotected starting 
material).   
The residue (870 mg) is diluted in 100 mL of a mixture of hexan/demineralized water/methanol 
(70:25:5 v/v/v). The layers are separated and the organic phase is washed twice with 50 mL of 
demineralized water. The hexan phase is dried over MgSO4 and concentrated on vacuum to yield 590 
mg of a green oil (containing 56 in mixture with the starting nitro compound 8 and aldehyde 47), 
whereas the aqueous phase is extracted three times with 50 mL of dichloromethane. The resulting 
organic phase is dried over MgSO4 and concentrated in vacuum to yield 156 mg of a green oil. 
Chiral HPLC analysis measured on CHIRALPAK AD-H (mixture of 
hexan/isopropanol/methanol/ethanol  973:9:9:9, 2 mL/min, at 40°C) reveals the presence of three 
signals with a ratio of 25:17:58 
 
The crude material (590 mg) is purified by column chromatography on silicagel (30 g) with 
heptane/ethyl acetate/triethylamine (3:1) to give in the pure fractions 112 mg of the desired nitro 
compound 56 (yield 6%) as a yellow oil containing the (S,S,S,S) and 262.3 mg of a yellow oil  (15%) as 
a mixture of diastereoisomers (14:64:22).  
 
 
Spectroscopic data of 56 
OH
O
O
OH
NO
2
(S,S,S,S)-56  
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1H NMR (600 MHz, dmso-d6) δH (ppm)  
0.53-0.86 (m, 12H, CH3iPr), 0.96-0.98 (m, 1H, CH2O-CH-CHiPr), 1.26 (S, 6H, CH3MIP), 1.36-1.38 (m, 1H, 
HCHCHNO2), 1.55 - 1.85 (m, 6H, CH2CHCO, HCHCHNO2, 2*CHiPr, CHCHiPr), 3.11 (s, 3H, CH3MIP), 3.25 (d, 
J= 2Hz, 2H, CH2OMIP), 3.30 - 3.45 (m, 2H, CH2-O), 3.71 - 3.81 (m, 1H, CH-O), 4.57 (m, 1H, CHNO2), 4.65 
(t, J=6 Hz, 1H, OH), 5.11 (d, J= 6 Hz,1H, OH) 
 
IR: (FTIR-microscopy in transmission)  
3406 (OH), 2959 (C-Haliph), 1555 (NO2νas), 1466 (CHδ), 1371 (NO2νs), 1152 (C-O, C-OH), 1049 (C-OH) 
 
MS: (EI+) M-MIPH
+= 291  
        (FIA) M+NH4
+=381.3 
  
Rf (heptane/ethyl acetate/triethylamine 3:1) =0.19 
 
 
I.4. Atom economy strategy for the preparation of Aliskiren 
 
I.4.1. Preparation of racemic-59 
 
(R)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-methyl-butyraldehyde 61 
CAS Number: 1027979-11-8 
First described by : S.M.A. De Wildeman, H.M.M.G Straatman, G.K.M. Verzijl, V. Vermote, A.H.M. De 
Vries, WO  2009-007460  
L. Heng, S. Xia, C. He, 2008, CN  101284769  
 
 
O
O
O
OH
O
O
O
O
H
 Dess-Martin Periodinane, DCM 
0°C
(R)-62 (R)-61
MW: 296.41 MW: 294.39  
 
20.0 g of 62 (67.5 mmol, 1.0 eq.) are dissolved at room temperature in 300 mL of methylene chloride. 
32.2 g of Dess-Martin reagent (19.7 mmol, 0.3 eq.) are added at 10°C in 5 portions to the yellow 
mixture over a period of 5 min. The resulting white suspension is allowed to warm to room 
temperature and is stirred for 2 hours, until total conversion of the starting material (HPLC control).  
The reaction mixture is concentrated on vacuum (the bath temperature is 25°C). 200 mL of t-butyl 
methyl ether are added to the residue, resulting in the precipitation of a white solid, which is filtered 
off and washed with 100 mL of t-butyl methyl ether. The organic phase is extracted four times with 
500 mL of a solution of 1:1 (v/v) of aqueous Na2S2O3 (10%) and saturated aqueous NaHCO3. The 
organic layer is washed again with 500 mL of brine and 500 mL of water. The organic phase is dried 
over MgSO4 and concentrated in vacuum to yield 19.4 g of crude product 61 (98%)  as a yellow liquid. 
 
Determination of the enantiomeric ratio by HPLC with a CHIRALCEL OD-H columm at λ = 215 nm 
(Hex/iPrOH = 9:1, 0.5 mL/min, 20°C) reveals the presence of 98% of the (R)-enantiomer of 61 at 39.5 
min and of 2 % of the (S)-enantiomer of 61 at 41.3 min. 
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1H NMR (400 MHz, CDCl3) δH (ppm)  
1.03 (dd, J1=7 Hz, J2=4Hz, 6H, CH3iPr), 2.03 - 2.14 (m, 3H, CH2MOP, CHiPr), 2.41 - 2.52 (m, 1H, CHiPr), 2.70 
(dd, J1=14 Hz, J2=5 Hz, HCHbenz), 2.92 (dd, J1=14 Hz, J2=9 Hz, 1H, HCHbenz), 3.36 (s, 3H, CH3OMOP),  3.57 
(t, J=6 Hz, 2H, OCH2MOP), 3.82 (s, 3H, CH3O), 4.09 (t, J=6Hz, 2H, CH2OMOP), 6.66 - 6.70 (m, 2H, Harom), 
6.75 - 6.79 (m, 1H, Harom), 9.68 (d, J=2 Hz, 1H, CH=O) 
 
13C NMR (101 MHz, CDCl3) δC (ppm)  
20.04 (CH3iPr), 20.23 (CH3iPr), 28.62 (CHiPr), 29.88 (CH2MOP), 32.01 (CH2benz), 56.33 (CHiPr,βHC=O), 58.92 
(OCH3), 60.02 (OCH3MOP),   64.83 (CH2MOP),  69.63 (CH2MOP),  112.24 (CHarom), 114.52 (CHarom), 121.34 
(CHarom), 132.46 (Carom), 148.25 (Carom), 148.72 (Carom), 205.40 (CH=O) 
 
IR: (FTIR-microscopy in transmission)  
2933 (C-Haliphatic), 2834 (OCH3s), 2726 (C-H aldehyde), 1722 (C=O, aldehyde), 1590 (phenyl), 1517 
(phenyl), 1262 (Ph-O), 1140 (C-O-C), 1027 (C-O), 866-809 (C-Haliph)  
 
MS: (ES+); [M+NH4
+] = 312.2, [M+Na+] = 317.3 
 
HRMS(C17H26O4,0.14 ppm) [M+NH4] 
+= 312.21698, cal. 312.21694, C17H30O4N 
  
αD (1% CHCl3, 1dm, 20°C) = -52.2° (436 nm), -22.5° (546 nm), -18.6° (578 nm), -17.4° (589 nm) 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220 nm. tr= 6.2 min 
 
Rf (hexan/ethyl acetate 1:1) = 0.53 
 
 
4,2-isopropyl-4-nitro-but-3-enyl)-1-methoxy-2-(3-methoxy-propoxy)-benzene rac-64 
 
O
O
O
NO
2
O
O
O
O
H
NH4OAc, NO2Me
70°C
MW: 294.39
MW: 337.42
(S)-61 rac-64
 
 
103.4 mg of compound 61 (0.35 mmol, 1.0 eq.) are added to 306.5 mg of nitromethane (5.01 mmol, 
14.7 eq.) at room temperature.  The yellow mixture is stirred over a period of 5 min, and 46.9 mg of 
ammonium acetate (0.60 mmol, 1.7 eq.) are added at room temperature. The reaction mixture is 
heated to 70°C and stirred at 70°C for 13 hours. The reaction is then quenched at room temperature 
by addition of 15 mL of demineralized water. The aqueous layer is then extracted three times with 25 
mL of toluene. The resulting organic phase is extracted with 40 mL of demineralized water, and 40 
mL of brine. The toluene phase is dried over MgSO4 and concentrated in vacuum to yield 137.9 mg of 
crude product 64 as a yellow oil.  Compound 64 which is almost pure according to the 1H NMR, and is 
used without further purification in the next step.  
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.93 - 1.03 (dd, 6H, CH3iPr), 1.86 (dq, J1=12 Hz, J2=7 Hz, 1H, CHiPr), 2.05 - 2.14 (m, 2H, CH2MOP), 2.28 - 
2.39 (m, 1H, CHiPr), 2.57 (dd, J1=13 Hz, J2=9 Hz, 1H, HCHbenz), 2.87 (dd, J1=13 Hz, J2=5 Hz, 1H, HCHbenz), 
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3.37 (s, 3 H, CH3OMOP), 3.54 - 3.61 (m, 2H, OCH2MOP), 3.84 (s, 3H,  CH3O), 4.03 - 4.13 (m, 2H, CH2OMOP), 
6.59 - 6.80 (m, 4H, C=CH & Harom), 7.13 (dd, J1=13 Hz, J2=10 Hz, 1H, HC=C) 
 
13C NMR (101 MHz, CDCl3) δC (ppm)  
18.70 (CH3iPr), 20.86 (CH3iPr), 29.58 (CHiPr),  31.17 (CH2MOP), 37.74 (CH2benz), 47.95 (CHCHiPr), 56.01 
(OCH3), 58.66 (OCH3MOP), 66.20 (CH2OMOP), 69.32 (CH2OMOP), 111.87 (CHarom), 114.16 (CHarom), 
121.18 (CHarom), 131.39 (Carom), 139.99 (CH=CH), 143.78 (CH=CH), 148.17 (Carom), 148.43 (Carom) 
 
IR: (FTIR-microscopy in transmission)  
3099 (C-Harom), 2960-2932-2875 (C-Haliphatic), 2835 (OCH3), 1644 (C=C), 1518 (NO2, as), 1350 (NO2, 
s), 1260 (Ph-O), 1140 (C-O-C), 1027 (C-O), 805 (C-Haliph.)  
 
MS: (ES+); [M-H+] = 338.4, [M+NH4] 
+= 355.3 
        (ES-); [M-H+] = 336.3 
 
HRMS(C18H27O5N, 0.5 ppm): [M-H]
 + = 338.19601, cal. 338.19620, C18H28O5N 
               
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220 nm. tr= 7.7 min 
 
 
1-methoxy-2-(3-methoxy-propoxy)-4-[3-methyl-2-(2-nitro-ethyl)-butyl]-benzene rac-59 
 
 
O
O
O
NO
2
O
O
O
NO
2
0°C
NaBH4 DMF
MW: 339.44
MW: 337.42
rac-64 rac-59
 
 
129.3 mg (0.38 mmol, 1.0 eq.) of crude racemic nitroalkene 64 are dissolved at room temperature in 
2 mL of DMF. The resulting solution is cooled down to 0°C and 114.2 mg (3.1 mmol, 7.9 eq.) of 
sodium borohydride are added in three portions. The reaction mixture is stirred at 0°C over a period 
of  90 min, and then quenched at room temperature with 3 mL of aqueous HCl (1M). The aqueous 
layer is then extracted three times with 25 mL of toluene, and the resulting organic phase is then 
washed  with 40 mL of demineralized water, and 40 mL of brine. The toluene phase is dried over 
MgSO4 and concentrated in vacuum to yield 125.0 mg of crude 59. 
The crude product is purified by column chromatography on silicagel (0.040-0.063 nm) (10 g) with 
heptan: ethyl acetate (6:1) to give in the pure fractions 60.3 mg of nitro compound 59 (48% starting 
from aldehyde 61, 2 steps) as a colorless oil. 
The enantiomeric ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, 1 mL/min) 
proves a ratio of 50:50 of both enantiomers (S-enantiomer at 11.3 min, R-enantiomer at  16.9 min). 
 
1H NMR (400 MHz, CDCl3-d) δH (ppm)  
0.79 - 0.99 (dd, J1=6 Hz, 6H, CH3iPr), 1.54 - 1.62 (m, 1H, CHiPr ), 1.74 (dddd, J1=10 Hz, J2=7Hz, J3=3 Hz, 
1H, CHiPr), 1.80 - 1.95 (m, 1H, HCHCH2NO2) 2.00 - 2.10 (m, 1H, HCHCH2NO2) 2.07 - 2.18 (m, 2 H, 
CH2MOP), 2.34 (dd, J1=14 Hz, J2=6 Hz, 1H, HCHbenz), 2.67 (dd, J1=14 Hz, J2=6 Hz, 1H, HCHbenz), 3.37 (s, 3H, 
OCH3MOP),  3.55 - 3.67 (m, 2H, CH2OMOP), 3.85 (s, 3H, OCH3), 4.07 - 4.17 (m, 2H, CH2OMOP), 4.21 (t, J1=7 
Hz, 2H, CH2NO2), 6.65 - 6.75 (m, 2H, Harom), 6.77 - 6.91 (m, 1H, Harom) 
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13C NMR (101 MHz, CDCl3) δC (ppm)  
18.57 (CH3iPr), 18.93 (CH3iPr), 28.48 (CHiPr), 29.55 (CH2MOP),  29.72 (CH2CH2NO2), 36.77 (CH2benz), 43.25 
(CHCHiPr ), 56.09 (OCH3), 58.68 (OCH3MOP), 66.20 (CH2OMOP), 69.39 (CH2OMOP), 74.67 (CH2NO2), 111.99 
(CHarom),  114.17 (CHarom), 121.13 (CHarom), 133.01 (Carom), 148.02 (Carom), 148.56 (Carom) 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220 nm. tr= 7.8 min 
 
Rf (hexan/ethyl acetate 1:1) = 0.75 
 
 
I.4.1. Preparation of enantiopure 59 
 
 
(R)-3-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-4-methyl-1-nitro-pentan-2-ol 70 
method 1 
 
O
O
O
OH
NO
2
O
O
O
O
 NO2Me, Sparteine 
30°C
+ other stereoisomers
(R)-61 70
(S:R):(S,S)
(S):(R)=80:20
MW: 355.43MW: 294.39
 
 
19.9 g of compound 61 (67.6 mmol, 1.0 eq.) are added to 25.86 g of nitromethane (423.6 mmol, 6.2 
eq.) at room temperature. 4.63 g of sparteine (19.7 mmol, 0.3 eq.) are added dropwise to the orange 
mixture for 10 min. The resulting brown solution is stirred at 30°C (IT) for 1 hour 30 min (90% 
conversion, HPLC control). The reaction mixture is diluted at room temperature with 200 mL of ethyl 
acetate. The organic phase is extracted with 600 mL of water (pHaq. Phase = 9), 500 mL aqueous citric 
acid solution (10%) (pHaq. Phase = 3), and three times with 1L of demineralized water (pHaq. Phase = 5) 
until complete extraction of nitromethane from the organic layer. The ethyl acetate phase is dried 
over MgSO4 and concentrated in vacuum to yield 19.2 of crude product 70 in mixture with 30% of 
unreacted aldehyde 61 (yield 60% according to NMR spectrum).   
The diastereoisomeric ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, isocratic, 
1mL/min) is 78% of  diastereoisomer 4  / 19 % of diastereoisomer 3 / 3% diastereoisomers 1,2. 
 
The crude product is purified two times by column chromatography on silicagel (0.040-0.063 nm) 
(400g and 200g) with heptan:ethyl acetate (4:1) to give in the pure fractions 10.2 g of Henry product 
70 (42% isolated yield) and 4.4 g of a mixture of compounds 61 and 70 as a yellow oil.  
The enantiomeric ratio measured on CHIRALCEL OD-H (20°C, 97:3 hexane/isopropanol, isocratic, 
1mL/min) is 78% of  diastereoisomer 4  / 19 % of diastereoisomer 3 / 3% diastereoisomer 1,2. 
A part of the diastereoisomeric mixture is purified by chromatography on CHIRALPAK AD 
(heptan/ethanol/methanol, 90:5:5, 400 mL/min) to yield the diastereoisomer 3 as single isomer with 
93% purity and the diastereoisomer 4 as single isomer with 98% purity. 
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Spectroscopic data of 70 as isomeric mixture: 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm), mixture of diasteroisomers 
0.80 - 0.96 (m, 6H, CH3iPr), 1.60 (bm, 1H, CH-CHiPr), 1.72 (bm, 1H, CH-CHiPrDia4), 1.89-1.96 (m, 
CH2CH2OCH3MOP, CH3iPrDia3), 2.52 - 2.63 (m, 2H, CH2benz), 3.24 (s, OCH3MOPDia3 ), 3.29 (s, OCH3MOPDia4), 3.46 
(t, J=6 Hz, 2H, CH2-OMOP), 3.72 (s, 3H, OCH3), 3.97 (t, J=6 Hz, 2H, CH2-OMOP), 4.14 (br. s., CH-OHDia3), 
4.25 - 4.34 (m, HCHNO2, CH-OHDia4), 4.55 - 4.62 (m, 1H, HCHNO2Dia3), 4.64 (d, J=9 Hz, HCHNO2Dia4), 5.27 
(d, J=5 Hz, OHDia4), 5.40 (d, J=6 Hz, OHDia3), 6.69 - 6.75 (m, 1H, Harom), 6.78 - 6.82 (m, 1H, Harom), 6.83 - 
6.87 (m, Harom) 
 
 
 
 
 
 
13C NMR (101 MHz, CDCl3) δH ppm  
20.16 (m, CH3iPr), 20.33 (m, CH3iPr), 21.63 (CH3iPrDia3), 27.45 (CHiPrDia3), 29.61 (CHiPrDia4), 31.37 
(CH2benzDia3), 31.96 (CH2benzDia4), 49.18 (CH-CHiPrDia3), 49.48 (CH-CHiPrDia4), 56.07 (OCH3), 58.68 (OCH3MOP), 
65.98 (CH-OHDia3), 66.20 (CH-OHDia4), 69.34 (CH2-OMOP), 69.85 (CH2-OMOP), 80.56 (CHNO2), 112.00 
(CHarom), 114.31 (CHarom), 120.94 (CHaromDia3), 121.20 (CHaromDia4), 133.49 (Carom), 148.04 (Carom-
OCH3MOP), 148.58 (Carom-OCH3) 
 
 
IR: (FTIR-microscopy in transmission)  
3506 (OH), 2933 (C-Haliphatic), 2836 (OCH3,s), 1556 (NO2, as), 1385 (NO2, s), 1261 (Ph-O), 1140 (C-
O-C), 1027 (C-O)  
 
MS: (ES+); [M-H +] = 356.4 
         (ES-); [M-H-] = 354.4 
 
HR-MS(C18H29O6N, 0.12 ppm): [M+H] 
+= 356.20627, cal. 356.20677, C18H30O6N 
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HPLC method: reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 6.1 min (Diastereoisomer 1), tr = 6.2 min 
(Diastereoisomer 2) 
 
Rf (hexan/ethyl acetate 4:1) = 0.44 
 
Spectroscopic data of 70-Diastereoisomer 3 (P3): 
 
O
O
O
OH
NO
2
70  
 
1H NMR (600 MHz, DMSO-d6) δH (ppm),  
0.89 - 0.98 (m, 6H, CH3iPr), 1.63 (bm, 1H, CH-CHiPr), 1.88 - 1.99 (m, CH2CH2OCH3MOP, 3H, CHiPr), 2.51 - 
2.54 (m, 2H, CH2benz), 3.26 (OCH3MOP), 3.49 (t, J=6 Hz, 2H, CH2-OMOP), 3.74 (s, 3H, OCH3), 3.96 - 4.04 (m, 
2H, CH2-OMOP), 4.11 - 4.18 (br. s., CH-OH), 4.28 - 4.36 (m, 1H, HCHNO2), 4.60 (dd, J1=12 Hz, J2=2Hz, 1H, 
HCHNO2), 5.44 (d, J=6 Hz, 1H, OHDia3), 6.75 (d, J=8 Hz, 1H, Harom), 6.82 (s, 1H, Harom), 6.87 (d, J=8 Hz, 
1H, Harom) 
 
MS: (ES+); [M+NH4
 +] = 373.4 
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Spectroscopic data of 70-Diastereoisomer 4 (P4): 
 
O
O
O
OH
NO
2
70  
 
1H NMR (600 MHz, DMSO-d6) δH (ppm),  
0.83 - 0.96 (m, 6H, CH3iPr), 1.55 - 1.65 (m, 1H, CH-CHiPr), 1.70-1.75 (m, 1H, CHiPr), 1.93 (m, 2H, 
CH2CH2OCH3MOP), 2.52 (d, J=7 Hz, 1H, HCHbenz), 2.58 (d, J=7 Hz, 1H, HCHbenz), 3.25 (OCH3MOP), 3.47 (t, 
J=6Hz, 2H, CH2-OMOP), 3.72 (s, , 3H, OCH3), 3.98 (t, J=6 Hz, 2H, CH2-OMOP), 4.28-4.29 (m, 2H, HCHNO2, 
CH-OH), 4.65 (d, J=9 Hz, 1H, HCHNO2), 5.30 (d, J=5 Hz, OHDia4), 6.72 (d, J=8 Hz, 1H, Harom), 6.81 (s, 1H, 
Harom), 6.85 (m, 1H, Harom) 
 
MS: (ES+); [M+NH4
 +] = 373.4 
 
 
 
Method 2 (Table 9, Entry 1) 
 
9.9 mg of the (R,R) ligand  A (0.025 mmol, 0.05 eq.) are dissolved at 22°C in 0.5 mL of ethanol and 4.5 
mg of cupper (II) acetate monohydrate (0.025  mmol, 0.05 eq.) are then added at 22°C. After 20 min, 
a solution of   67.7 mg of nitromethane 27 (1.1 mmol, 2.1 eq.) in 0.2 mL of ethanol and a solution of  
150.3 mg of aldehyde 61 (0.5 mmol, 1.0 eq.) in 0.3 mL of ethanol are added  at 22°C to the green 
reaction  mixture. The reaction  mixture is heated to 35°C and is stirred at 35°C 
 
The enantiomeric ratio measured on CHIRALCEL OD-H (20°C, 97:3 hexane/isopropanol, isocratic, 
1mL/min) is 89% of  diastereoisomer 4  / 1% of diastereoisomer 3 / 1% diastereoisomers 1,2. 
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Method 3 (Table 9, Entry 2) 
 
9.6 mg of the (S,S) ligand  A (0.025 mmol, 0.05 eq.) are dissolved at 22°C in 0.5 mL of ethanol and 4.5 
mg of cupper (II) acetate monohydrate (0.025  mmol, 0.05 eq.) are then added at 22°C. After 20 min, 
a solution of   67.0  mg of nitromethane 27 (1.1 mmol, 2.1 eq.) in 0.2 mL of ethanol and a solution of  
147.9  mg of aldehyde 61 (0.5 mmol, 1.0 eq.) in 0.3 mL of ethanol are added  at 22°C to the green 
reaction  mixture. The reaction mixture is heated to 35°C and is stirred at 35°C. 
 
The enantiomeric ratio measured on CHIRALCEL OD-H (20°C, 97:3 hexane/isopropanol, isocratic, 
1mL/min) is 77% of  diastereoisomer 4  / 6% of diastereoisomer 3 / 1% diastereoisomers 1,2 
 
Method 4 (Table 9, Entry 3) 
 
9.4 mg of the (S,S) ligand  A (0.025 mmol, 0.05 eq.) are dissolved at 22°C in 0.5 mL of ethanol and 4.7 
mg of cupper (II) acetate monohydrate (0.025 mmol, 0.05 eq.) are then added at 22°C. After 20 min, 
a solution of   69.2  mg of nitromethane 27 (1.1 mmol, 2.1 eq.) in 0.2 mL of ethanol and a solution of  
151.1  mg of aldehyde 61 (0.5 mmol, 1.0 eq.) in 0.3 mL of ethanol are added  at 22°C to the green 
reaction  mixture. The reaction mixture is heated to 35°C and is stirred overnight.  
 
 
((Z)-(R)-2-Isopropyl-4-nitro-but-3-enyl)-1-methoxy-2-(3-methoxy-propoxy)-benzene 64 
 
Method 1 
O
O
O
NO
2
O
O
O
OH
NO
2  Alox [H+], DCM  
25°C
MW: 337.42MW: 355.43
70 64 (S):(R)=98:2
 
 
To a solution of 10.2 g of compound 70 (28.7 mmol, 1.0 eq.) in 100 mL of dichloromethane are added 
at room temperature 15.2 g of Alox (Brockmann Activity I). After 30 min stirring at room 
temperature, 97% of the starting material is consumed, but nevertheless the resulting white 
suspension is stirred at room temperature over 3 days. The Alox is filtered off and washed with 100 
mL of dichloromethane. The dichloromethane phase is concentrated in vacuum to yield 8.0 g of 
crude product 64 (yield 83%) as a yellow oil.   
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.89 - 1.03 (dd, 6H, CH3iPr), 1.76 - 1.94 (m, 1H, CHiPr), 2.09 (quin, J1=6  Hz, 2H, CH2MOP), 2.26 - 2.42 (m, 
J1= 10 Hz, J2= 5 Hz, 1H, CHiPr), 2.57 (dd, J1= 14 Hz, J2= 10 Hz, 1H, HCHbenz), 2.87 (dd, J1=14 Hz, J2=5 Hz, 
1H, HCHbenz),  3.37 (s, 3H, CH3OMOP), 3.50 - 3.63 (m, 2H, OCH2MOP), 3.84 (s, 3 H, CH3OMOP), 3.96 - 4.17 
(m, 2H, CH2OMOP),  6.57 - 6.84 (m, 4H, C=CH & Harom),  7.13 (dd, J1=13 Hz, J2=10 Hz, 1H, HC=C) 
 
13C NMR (101 MHz, CDCl3) δC (ppm)  
148.43 (Carom), 148.14 (Carom), 143.78 (CH=CH), 140.01 (CH=CH), 131.39 (Carom), 121.18 (CHarom), 114.16 
(CHarom), 111.89 (CHarom), 69.32 (CH2OMOP), 66.22 (CH2OMOP), 58.66 (OCH3MOP), 56.01 (OCH3), 47.98 
(CHCHiPr), 37.74 (CH2benz), 31.19 (CH2MOP), 29.59 (CHiPr), 20.85 (CH3iPr), 18.70 (CH3iPr)  
 
MS: (ES+); [M-H+] = 338.4 
        (ES-); [M-H+] = 336.3 
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The enantiomeric ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, isocratic, 
1mL/min) is 98% of  (S)-enantiomer  and 2 % of (R)-enantiomer 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220 nm. tr= 7.7 min 
 
 
Method 2 (Table 10, Entry 2) 
 
To a solution of  100.1 mg of  70 (0.3 mmol) in 1 mL of 1,2-dichloroethane are added at room 
temperature 152.4 mg of Alox (Brockmann Activität I). The reaction mixture is stirred over night at 
40°C. 
 
 
Method 3 (Table 10, Entry 3) 
 
To a solution of  102.7  mg of  70 (0.3 mmol) in 1 mL of 1,2-dichloroethane are added at room 
temperature 151.0  mg of Alox (Brockmann Activität I). The reaction mixture is stirred over 1hour 45 
min at 60°C. 
 
Method 4 (Table 10, Entry 4) 
 
To a solution of  100.6 mg of  70 (0.3 mmol, 1.0 eq.) in 1 mL of 1,2-dichloroethane are added at room 
temperature 153.0  mg of KHSO4 (1.12  mmol, 3.7 eq.). The reaction mixture is stirred over night at 
25°C. 
 
Method 5 (Table 10, Entry 5) 
 
To a solution of  101.0 mg of  70 (0.3 mmol, 1.0 eq.) in 1 mL of 1,2-dichloroethane are added at room 
temperature 305.8  mg of KHSO4 (1.12  mmol, 7.5 eq.). The reaction  mixture is stirred over night at 
25°C. 
 
Method 6 (Table 10, Entry 6) 
 
To a solution of  103.1 mg of  70 (0.3 mmol, 1.0 eq.) in 1 mL of 1,2-dichloroethane are added at room 
temperature 153.1 mg of SiO2. The reaction mixture is stirred over night at 25°C. 
 
 
1-methoxy-2-(3-methoxy-propoxy)-4-[(S)-3-methyl-2-(2-nitro-ethyl)-butyl]-benzene 59 
 
O
O
O
NO
2
O
O
O
NO
2 NaBH4, EtOH 
10°C
MW: 339.44MW: 337.42
(S)-64 (S)-59
 
 
 
 173 
 
5.05 g of compound 64 (15.0 mmol, 1.0 eq.) are diluted in 40 mL of abs. ethanol at room 
temperature. The reaction mixture is cooled down to 10°C, and 3.85 g of sodium borohydride (101.9 
mmol, 6.8 eq.) are added portionswise over a period of 20 min. The reaction mixture is allowed to 
stir for 15 min until completion of the reaction (HPLC control), and 10 mL of toluene are added at 
room temperature. The reaction mixture is then quenched with 5 L of demineralized water 
(exothermic addition) and then diluted in 200 mL of a solution of 100 mL demineralized water and 
100 mL of brine. The aqueous phase is extracted four times with 100 mL, five times with 200 mL once 
with 300 mL of toluene, three times with 50 mL of dichloromethane, and once with 200 mL of ethyl 
acetate. The combined organic phase is dried over MgSO4 and concentrated in vacuum to yield 4.72 
of crude product 59 (yield 93%) as slighty yellow oil.   
A part of the crude product (3.51g) is purified by column chromatography on silicagel (0.040-0.063 
nm) (60g) with heptan:ethyl acetate (4:1) to give in the pure fractions 1.21 g of nitro compound 59 as 
a colorless oil. 
 
The enantiomeric ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, isocratic, 
1mL/min) is 98% of  (S)-enantiomer  and 2 % of (R)-enantiomer 
1H NMR (600 MHz, DMSO-d6) δH (ppm)  
6.85 (d, J=8Hz, 1H, Harom), 6.77 (s, 1H, Harom), 6.68 (dd, J1=8 Hz, J2=1 Hz, 1H, Harom), 4.46 (t, J=7 Hz, 2 H, 
CH2NO2), 3.99 (t, J=6 Hz, 2H, CH2OMOP), 3.74 (s, 3H, OCH3), 3.47 (t, J=6 Hz, 2H, CH2OMOP), 3.25 (s, 3H, 
OCH3MOP),  2.47 - 2.58 (m, 1H, HCHbenz), 2.38-2.41 (dd, J1=13, J2=7 Hz, 1H, HCHbenz), 1.94 (q, 3H, CH2MOP, 
HCHCH2NO2), 1.72 (dd, J1=14 Hz,  J2=7 Hz, 1H, HCHCH2NO2), 1.61 - 1.68 (m, 1H, CHiPr) 1.53 (br. s., 1H, 
CHiPr ) 0.88 (dd, J1=6 Hz, 6H, CH3iPr)  
 
13C NMR (101 MHz, CDCl3) δC (ppm)  
148.25 (Carom), 147.69 (Carom), 132.68 (Carom), 120.80 (CHarom), 113.84 (CHarom), 111.67 (CHarom), 74.36 
(CH2NO2), 69.06 (CH2OMOP), 65.88 (CH2OMOP), 58.36 (OCH3MOP), 55.77 (OCH3), 42.92 (CHCHiPr ), 36.46 
(CH2benz), 29.32 (CH2CH2NO2), 29.21 (CH2MOP), 28.15 (CHiPr), 18.61 (CH3iPr), 18.26 (CH3iPr) 
 
IR: (FTIR-microscopy in transmission) 2933 (C-Haliphatic), 2835 (OCH3,s), 1589 (Phenyl), 1554 (NO2, 
as), 1516(Phenyl), 1386 (NO2, s), 1237 (Ph-O), 1121 (C-O-C), 1028 (C-O)  
 
MS: (ES+); [M-H +] = 340.4, [M+NH4] 
+= 357.3 
        (ES-); [M-H-] = 338.4 
 
HRMS(C18H29O5N, 0.04 ppm/MH+): [M-H
 +] = 340.21198, cal. 340.21185, C18H30O5N 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.8 min  
 
Rf (hexan/ethyl acetate 4:1) = 0.75 
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I.4.1. Preparation of 60 
 
(3S,5S,6S,8S)-8-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-2,9-dimethyl-6-nitro-3-(tetrahydro-
pyran-2-yloxymethyl)-decan-5-ol 71 
 
Methode 1 
O
O
OH
O
O ONO
2
O
O
O
NO
2
O O
O
H
N
H
NH
N
OH
 CuI, HünigBase, THF
 30°C
+ other stereoisomers
MW: 553.74
MW: 339.44
(S)-59
(S)-45
(S,S,S,S,)-71
B
 
 
51.9 mg of ligand (R,R)-B (0.11 mmol, 0.04 eq.) are diluted in 2 mL of THF at room temperature. After 
12 min, 61.0 mg of CuI (0.32 mmol, 0.10 eq.) and 24.2 µL of Hünig base (0.08 mmol, 0.03 eq.), are 
added to the solution resulting in a slightly yellow suspension. The reaction is stirred for 45 min at 
25°C, turning into a dark green suspension. 
 A solution of 1.009 g of nitro-compound 59 (2.9 mmol, 1.0 eq.) in 4 mL of THF and a solution of 850.8 
mg of aldehyde component 45 (3.96 mmol, 1.3 eq.) in 4 mL of THF are added at room temperature. 
The reaction mixture is heated to 30°C and stirred at 30°C over a week. 213.3 mg of aldehyde 
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component 45 (0.19 mmol, 0.07 eq., bad quality, C=20%) are added to the reaction mixture, which is 
stirred over six days.  
 
A pre-stirred (20 min at 25°C) suspension of 51.9 mg of ligand (0.11 mmol, 0.04 eq.), 81.0 mg of CuI 
(0.42 mmol, 0.14 eq.) and 12.2 µL of Hünig base (0.04 mmol, 0.01 eq.) in 500 µL of THF is added to 
reaction mixture at 30°C, followed by addition of 431.7 mg of a better quality of aldehyde 45 (2.01 
mmol, 0.7 eq.). The reaction mixture is stirred over 2 days at 30°C. The reaction mixture is diluted in 
10 mL of ethyl acetate at room temperature. The organic layer is washed two times with 50 mL of 
water, once with 60 mL of an aqueous solution of citric acid (10%), and again two times with 50 mL of 
water. The organic phase is dried over MgSO4 and concentrated in vacuum to yield 2.575 g of crude 
product 71 in mixture with both reactants. The aqueous layer is extracted with 50 mL of 
dichloromethane. The organic phase is dried over MgSO4 and concentrated in vacuum to yield 396.3 
mg of crude product 71. 
 
Determination of the diastereoisomeric ratio of the crude material measured on CHIRALCEL OD-H 
(20°C, 93:7 hexane/isopropanol, isocratic, 1mL/min) reveals the presence of 66% of  the major 
diastereoisomer. 
 
The crude product (2.575 g) is purified by column chromatography on silicagel (0.040-0.063 nm) 
(75g) with heptan:ethyl acetate (4:1) to remove the unreacted starting material and give in the pure 
fractions 189.0 mg of 71 in mixture with nitro compound 59.  
The diastereoisomeric ratio of theses fractions measured on CHIRALCEL OD-H (20°C, 97:3, 
hexane/isopropanol, isocratic, 1mL/min) is 80 % of  the major diastereoisomer. 
 
588.0 mg of 71 (78% of major diastereoisomer, in mixture with nitro compound 59) and 283 mg of 71 
(66% of major diastereoisomer, in mixture with side product) are also isolated from this column 
chromatography. 
 
The 189.0 mg of the purest fractions are purified again by column chromatography on silicagel 
(0.040-0.063 nm) (40g) with heptan:ethyl acetate (4:1), to give in the pure fractions 99.0 mg of 71 as 
isomeric mixture containing 80% of the major diastereoisomer and 74 mg of 71 as isomeric mixture 
containing 67% of the major diastereoisomer.   
 
Yield: 40%  
 
1H NMR (600 MHz, DMSO-d6) δH (ppm) (isomeric mixture) 
0.69 - 0.76 (m, 1H, CH3iPr), 0.76 - 0.89 (m, 10H, CH3iPr), 0.90 - 0.96 (m, 1H, CH3iPr) , 1.01 - 1.88 (m, 14H, 
CH2βNO2, CH2αCH2OH, 3*CH2THP, 2*CHiPr, 2*CHCHiPr), 1.89 - 1.98 (m, 2H, CH2MOP), 2.16 (dd, J1=13 Hz, J2=9 
Hz, 1H, HCHbenz), 2.35 - 2.48 (m, HCHbenz), 2.58 (dd,  J1=14 Hz, J2=5Hz, , HCHbenz), 3.22 - 3.27 (m, 
1H,CH2OTHP), 3.43 (s, 3H, OCH3MOP) 3.52 - 3.64 (m, 2 H), 3.37 - 3.43 (m, CH2THP), 3.44 - 3.50 (m, 2H, 
CH2OMOP), 3.52 - 3.64 (m, 1H,CH2OTHP), 3.72 (s, 3H, OCH3), 3.73-3.75 (m, 1h, CHOH), 3.97 (t, J1=6Hz, 
2H, CH2OMOP), 4.08 - 4.16 (m, 1H, CHTHP), 4.41 - 4.58 (m, 1H, CHNO2),  5.22 - 5.33 (m, 1H, OH), 6.52 - 
6.72 (m, 1H, Harom), 6.75 (s, 1H, Harom) 6.77 - 7.05 (m, 1H, Harom) 
 
13C NMR (151 MHz, DMSO-d6) δC (ppm) (isomeric mixture) 
16.91-17.21-19.12-19.80-20.06 (CH3iPr), 27.98 (CHiPr), 25.18 (CH2THP), 29.18 (CH2MOP, CH2-CHNO2, CH2), 
30.37 (CH2THP),  31.56 (CHiPr), 36.88 (CH2Bz), 41.89 (CH-CHiPr), 42.57 (CH-CHiPr), 55.46 (O-CH3), 58.01 
(CH3MIP), 61.07 (CH2-OH), 65.27 (CH2MIP), 68.65 (CH2MIP), 70.63 (CH-OH), 93.64 (CH-NO2), 98.23 (O-
CHTHP), 111.80 (CHarom.), 113.78 (CHarom.), 120.93 (CHarom.), 132.82 (Carom.), 146.98 (Carom.), 147.90 
(Carom.)        
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IR: (FTIR-microscopy in transmission)  
3413 (OH), 2957 (C-Haliphatic), 1590-1516 (Phenyl), 1553 (NO2, as), 1386 (NO2, s), 1261 (Ph-O), 
1121 (C-O-C), 1028 (C-O)  
 
MS: (ES+); [M+NH4
+] = 571.6, mixture of three isomers 
         (ES-); [M-h-] = 552.5 
 
HR-MS(C30H51O8N, 0.26 ppm): [M+NH4] 
+= 571.39529, cal. 571.39529, C30H55O8N2 
                      [M+Na] += 576.35069, cal. 576.35034, C30H51O8NNa 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 9.2 min (Diastereoisomer 1), tr = 9.4 min 
(Diastereoisomer 2), tr = 9.7 min (Diastereoisomer 2) 
 
Rf (Hexan/Ethyl acetate 5:1) = 0.08 
 
 
Methode 2 (Table 11, Entry 1) 
 
To 15.4 mg of ligand (R,R)-B (0.03 mmol, 0.09 eq.) in 200 µL of dioxane are added at room 
temperature 10.5 mg of Cu(OTf)2 (0.03 mmol, 0.09 eq.) and and 8 µL of Hünig base (0.04 mmol, 0.12 
eq.). After 10 min, are  added at 25°C a solution of 109.1 mg of nitro compound  59  (0.32 mmol, 1.00 
eq.). in 700 µL of  dioxan and a solution of 85.7 mg of aldehyde component 45 (0.39 mmol, 1.25 eq.) 
in 200 µL of  dioxane. The reaction mixture is stirred at 25°C.  
The diastereoisomeric ratio of theses fractions measured on CHIRALCEL OD-H (20°C, 97:3, 
hexane/isopropanol, isocratic, 1mL/min) is 72 % of  the major diastereoisomer in a ratio of 72:12:15. 
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Methode 3 (Table 11, Entry 2) 
 
108.1 mg of nitro compound  59  (0.31 mmol, 1.00 eq.) are diluted in 800 µL of  ethanol. 81.6 mg of 
45 (0.38 mmol, 1.23 eq.) and 20 µL of sparteine (0.1 mmol, 0.26 eq.). The reaction mixture is stirred 
at 25°C.  
The diastereoisomeric ratio of theses fractions measured on CHIRALCEL OD-H (20°C, 97:3, 
hexane/isopropanol, isocratic, 1mL/min) is 72 % of  the major diastereoisomer in a ratio of 50:26:24. 
 
Methode 3 (Table 11, Entry 3) 
 
To 7.9 mg of Ligand (R,R)-B (0.017 mmol, 0.05 eq.) in 800 µL of THF are added at room temperature 
2.0 mg of CuOAc2 (0.017 mmol, 0.05 eq.) and 8 µL of Hünig base (0.04 mmol, 0.11 eq.). After 10 min, 
are  added at 25°C a solution of 115.1 mg of nitro compound  59  (0.34 mmol, 1.00 eq.) in 200 µL of  
THF and 94.7 mg of 45 (0.44 mmol, 1.30 eq.). The reaction mixture is stirred at 25°C.  
The diastereoisomeric ratio of theses fractions measured on CHIRALCEL OD-H (20°C, 97:3, 
hexane/isopropanol, isocratic, 1mL/min) is 72 % of  the major diastereoisomer in a ratio of 67:17:16. 
 
(2S,4S,5S,7S)-2-isopropyl-7-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-8-methyl-5-nitro-nonane-
1,4-diol 73 
 
O
O
OH
O
NO
2
O
O
OH
O
OHNO
2
apTS, MeOH
OTHP
22°C
+ other stereoisomers + other stereoisomers
MW: 469.62MW: 553.74
(S,S,S,S,)-71 (S,S,S,S)-73
 
 
210.8 mg of compound 71 (0.38 mmol, 1.0 eq.) are diluted in 4 mL of methanol at room 
temperature. 1.6 mg of p-toluenesulfonic acid monohydrate (0.008 mmol, 0.02 eq.) is added to the 
yellow solution at room temperature. After 45 min, 4.4 mg of p-toluenesulfonic acid monohydrate 
(0.023 mmol, 0.06 eq.) are added. The reaction mixture is allowed to stir for 5 hours and 1.1 mg of p-
toluenesulfonic acid monohydrate (0.005 mmol, 0.01 eq.) is added, followed after one hour 30 min 
by addition of 3.1 mg of p-toluenesulfonic acid monohydrate (0.016 mmol, 0.04 eq.).  After 30 min, 
all the starting material is consumed (HPLC control). 
The reaction mixture is diluted with 10 mL of dichloromethane and the organic layer is washed with 
10 mL of an aqueous solution of sodium bicarbonate (10%) (pH of the resulting aqueous phase is 9), 
with 10 mL of demineralized water (pH of the resulting aqueous phase is 6). The aqueous phase is 
extracted once with 10 mL of dichloromethane. The combined organic phase is dried over MgSO4 and 
concentrated in vacuum to yield 659.0 mg of crude product 73. 
 
The crude product (659.0 mg) is purified by column chromatography on silicagel (0.040-0.063 nm) 
(40g) with heptan:ethyl acetate (3:1) to give in the pure fractions 138.5 mg of nitro-diol 73 (77%) as a 
colorless oil. 
 
1H NMR (600 MHz, DMSO-d6) δH (ppm) (isomeric mixture) 
0.71 - 0.89 (m, 12H, CH3iPr), 0.99 - 1.15 (m, 1H, CH2αCH2OH), 1.19 - 1.33 (m, 2H, CH2αCH2OH, CHCHiPr), 1.38 
- 1.49 (m, 2H, CHCHiPr, CH2βNO2), 1.52 - 1.62 (m, 1H, CHiPr), 1.65 - 1.84 (m, 1H, CHiPr), 1.84 - 1.89 (m, 1H, 
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CH2βNO2), 1.93 (sxt, J1=6 Hz, 2H, CH2MOP), 2.17 (dd, J1=14 Hz, J2=9Hz, 1H, HCHbenz), 2.36- 2.63 (m, 1H, 
HCHbenz), 3.25 (s, 3H, OCH3MOP), 3.26 - 3.42 (m, 2 H, CH2OH), 3.43 - 3.52 (m, 2H, CH2OMOP), 3.73 (s, 3H, 
OCH3 ) 3.77 - 3.87 (m, 1H, CHOH), 3.92 - 4.04 (m, 2H, CH2OMOP), 4.07 - 4.17 (m, 1H, CHNO2), 4.34 - 
4.58 (m, CH2OH), 5.23 (d, J1=6 Hz, CHOH), 5.26 (d, J1=6 Hz, CHOH), 6.60 - 6.78 (m, 2H, Harom) 6.81 - 
6.87 (m, 1H, Harom) 
  
13C NMR (151 MHz, DMSO-d6) δC (ppm) (isomeric mixture) 
17.07-18.77-19.86-20.50 (CH3iPr), 27.98 (CHiPr), 29.17 (CH2MOP, CH2-CHNO2, CH2), 31.29 (CHiPr), 36.89 
(CH2Bz), 42.68 (CH-CHiPr), 55.48 (O-CH3), 58.03 (CH3MIP), 61.01 (CH2-OH), 65.28 (CH2MIP), 68.66 (CH2MIP), 
70.27 (CH-OH), 93.92 (CH-NO2), 111.84 (CHarom.), 113.90 (CHarom.), 121.06 (CHarom.), 133.15 (Carom.), 
147.30 (Carom.), 147.90 (Carom.)        
 
 
 
IR: (FTIR-microscopy in transmission)  
3380 (OH), 2958-2933 (C-Haliphatic), 1590-1516 (Phenyl), 1553 (NO2, as), 1388 (CH3, δ), 1370 (NO2, 
s), 1261 (Ph-O), 1121 (C-O-C), 1029 (C-O)  
 
MS: (ES+); [M-H +] = 470, mixture of three isomers 
 
HRMS (C25H44O7N, 0.2 ppm/MH+):  [M+H] 
+= 470.31131, cal. 470.31123, C25H44O7N 
 
 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.5 min  
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Rf (hexan/ethyl acetate 1:1) = 0.29 
 
 
((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-{(S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-
methyl-butyl}-5-methyl-hexyl)-carbamic acid tert-butyl ester 60 
O
O
NHBOC
OH
O
OH
O
O
OH
O
OHNO
2
O
O
OH
O
O ONO
2
O
O
O
NO
2
O O
O
H
N
H
NH
N
OH
H2, Ra-Ni, EtOH,
Boc2O
25°C
+ other stereoisomers
MW: 539.76
(S,S,S,S)-60
apTS, MeOH
22°C
+ other stereoisomers
MW: 469.62
(S,S,S,S)-73
 CuI, HünigBase, THF
 30°C
+ other stereoisomers
MW: 553.74
MW: 339.44
(S)-59
(S)-45
(S,S,S,S,)-71
B
 
 
5.7 mg of ligand (R,R)-B (0.01 mmol, 0.04 eq.) are diluted in 0.5 mL of THF at room temperature. 
After 15 min, 5.5  mg of CuI (0.03 mmol, 0.10 eq.) and 2 µL of Hünig base (0.008 mmol, 0.03 eq.), are 
added to the solution, resulting in a slightly yellow suspension. The reaction is stirred for 20 min at 
25°C, turning into a dark green suspension. 
 A solution of 100.1 mg of nitro-compound 59 (0.3 mmol, 1.0 eq.) in 0.5 mL of THF and 121.6 mg of 
aldehyde component 45 (0.5 mmol, 1.6 eq.) are added at room temperature. The reaction mixture is 
heated to 35°C and stirred at 35°C over three days. The reaction mixture is cooled down to room 
temperature and diluted with 15 mL of dichloromethane. The organic layer is washed once with 20 
mL and once  with 10 mL of demineralized water. The organic phase is dried over MgSO4 and 
concentrated in vacuum to yield 151.0 mg of crude product 71 in mixture with nitro-compound 59  
(10%) and aldehyde component 45 (47%). 
The diastereoisomeric ratio of the crude material measured on CHIRALCEL OD-H (20°C, 93:7 
hexane/isopropanol, isocratic, 1mL/min) is 66% of  the major diastereoisomer. 
 
The crude product (151.0  mg) is diluted in 1 mL of methanol and 3.1 mg of p-toluenesulfonic acid 
monohydrate (0.016 mmol). The reaction mixture is stirred at room temperature over a period of 45 
min, and 15 mL of demineralited water are added. The acidic aqueous phase is extracted twice with 
20 mL of dichloromethane. The organic phase is dried over MgSO4 and concentrated in vacuum to 
yield 107.0 mg of crude product 73. 
 
The crude product is purified again by column chromatography on silicagel (0.040-0.063 nm) (10g) 
with heptan:ethyl acetate (3:1) to give in the pure fractions 63.0 mg of 73 as isomeric mixture 
containing 58% of the major diastereoisomer. 
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63.0 mg of compound 73 (0.13 mmol, 1.0 eq.) are diluted in 2.2 mL of ethanol at room temperature.  
31.3 mg of Boc2O (0.14 mmol, 1.1 eq.) and 30.0 mg of nickelraney in suspension in water are added to 
the reaction mixture. The mixture is hydrogenated at normal pressure and room temperature over 
night (16 hours). The catalyst is filtered off and washed with 10 mL of ethanol. The solvent is 
removed in vacuum to give an oil which is purified by chromatography to remove the excess of 
Boc2O. 
 
The column chromatography on silicagel (0.040-0.063 nm) (15g) with heptan:ethyl acetate (2:1) gives 
in the pure fractions 28.0 mg of 60 (17%, over three steps) as a colorless oil. 
 
The measurement of the diastereoisomeric excess on CHIRALCEL OD-H (20°C, 93:7 
hexane/isopropanol, isocratic, 1mL/min) shows the presence of the desired (S,S,S,S)-diastereoisomer 
as the major one at 7.6 min.  
The 1H NMR spectrum (DMSO-d6, 400 MHz) proves also the presence of a majority of 
diastereoisomer with the desired (S) stereochemistry on the amino group. 
 
1H NMR (400 MHz, DMSO-d6) δH  (ppm)  
0.65 - 0.89 (m, 12H, CH3iPr), 1.15-1.43 (m, 4H, CH2) 1.43 (s, 9H, CH3Boc), 1.43-1.96 (m, CHiPr, CH-CHiPr, 
CH2MIP), 2.15 - 2.70 (m, 2H, CH2Benz), 3.26 (m, 3H. OCH3MIP), 3.40 - 3.49 (m, 5H, CH2MIP, CH2O, CHO), 
(3.69-3.72 s, 3H, OCH3Dia), 3.74 (s, 3H, OCH3), 3.91 - 4.00 (m, 2H, CH2MIP), 4.20 - 4.30 (m, 1H, CHNHBoc), 
4.22- 4.67 (m, CHNHBocDia), 6.04 - 6.15 (m, 1H, NHBoc), 6.41 - 6.49 (m, NHBocDia2), 6.60 - 6.73 (m, 1H, 
CHarom), 6.73 - 6.88 (m, 2H, CHarom) 
 
13C NMR (151MHz, DMSO-d6) δC (ppm)  
18.33 (CH3iPr), 20.48 (CH3iPr), 27.58-28.30 (CH3Boc), 29.18 (CHiPr), 33.63 (CH2), 34.94 (CH2-CH-NHBoc), 
36.59 (CH2Bz), 41.78 (CH-CHiPr), 52.97 (CH-NHBoc), 55.47 (CH3Boc), 57.99 (CH3MOP), 61.48 (CH2-OH), 65.17 
(CH2MOP), 68.60 (CH2MOP), 71.08 (CH-OH), 77.41 (CBoc), 111.64 (CHarom), 113.75 (CHarom), 121.12 
(CHarom), 134.18 (Carom), 146.98 (Carom), 147.78 (CHarom), 156.52 (C=OBoc) 
 
LC-MS : M-H+= 540.4, M+Na+=562.4 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.8 min  
 
HRMS (C30H53O7N, 0.5 ppm/MH+):  [M+H] 
+= 540.38922, cal. 540.38948, C30H54O7N 
 
Rf (hexan/ethyl acetate 2:1) = 0.11 
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 ((1S,2S,4S)-2-hydroxy-4-hydroxymethyl-1-{(S)-2-[4-methoxy-3-(3-methoxy-propoxy)-benzyl]-3-
methyl-butyl}-5-methyl-hexyl)-carbamic acid tert-butyl ester 60 
 
 
O
O
NHBOC
OH
O
OH
O
O
NHBoc
OH
O
O
O
OH
O
NO
2
apTS, MeOH
22°C
+ other stereoisomers
MW: 539.76
(S,S,S,S)-60
H2, Ra-Ni, EtOH,
Boc2O
25°C OTHP
OTHP
+ other stereoisomers
MW: 553.74
(S,S,S,S,)-71
MW: 623.88
(S,S,S,S,)-72
+ other stereoisomers
 
 
76.5 mg of compound 71 (0.14 mmol, 1.0 eq.) (containing the major diastereoisomer with a ratio of 
60:20:20) are diluted in 2 mL of ethanol at room temperature.  35.2 mg of Boc2O (0.16 mmol, 1.1 eq.) 
and 35.0 mg of nickelraney in suspension in water are added to the reaction mixture. The mixture is 
hydrogenated at normal pressure and room temperature over night (16 hours). The catalyst is 
filtered off and washed with 10 mL of ethanol. The solvent is removed in vacuum to give 72 in 
mixture with Boc2O.  
81.9 mg of compound 72 (0.13 mmol, 1.0 eq.) are diluted in 2 mL of methanol at room temperature. 
16.5 mg of p-toluenesulfonic acid monohydrate (0.008 mmol, 0.07 eq.) are added at room 
temperature. The reaction mixture is allowed to stir for 55 min until completion of the reaction 
(HPLC control). The reaction mixture is diluted with 7 mL of dichloromethane and the organic layer is 
washed two times with 15 mL of demineralized water. The organic phase is dried over MgSO4 and 
concentrated in vacuum to yield 68.1 mg of crude product 60 (97%).  
The crude product (68.1 mg) is purified by column chromatography on silicagel (0.040-0.063 nm) 
(500 mg) with  first, heptan:ethyl acetate (2:1) and then pure ethyl acetate to give in the pure 
fractions 31.0 mg of 60 (41% from Henry product 71) as a colorless oil. 
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The measurement of the diastereoisomeric ratio on CHIRALCEL OD-H (20°C, 93:7 
hexane/isopropanol, isocratic, 1mL/min) shows the presence of the desired diastereoisomer (S,S,S,S) 
as the major one at 7.6 min.  
The 1H NMR spectrum (DMSO-d6, 400 MHz) proves also the presence of a majority of 
diastereoisomer with the desired (S) stereochemistry on the amino group. 
 
 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.68 - 0.91 (m, 12H, CH3iPr), 1.03-1.25 (m, 4H, CH2), 1.43 (s, 9H, CH3Boc), 1.43-1.96 (m, CHiPr, CH-CHiPr, 
CH2MIP), 2.17 - 2.71 (m, 2H, CH2Benz), 3.30 (s, 3H. OCH3MIP), 3.37 - 3.457 (m, 5H, CH2MIP, CH2O, CHO), 
3.76 (s, 3H, OCH3), 3.90 - 4.00 (m, 2H, CH2MIP), 4.23 - 4.36 (m, 1H, CHNHBoc), 4.36- 4.69 (m, CHNHBocDia), 
6.05 - 6.16 (m, 1H, NHBoc), 6.41 - 6.50 (m, NHBocDia2), 6.74 - 6.86 (m, 1H, CHarom), 6.73 - 6.88 (m, 2H, 
CHarom) 
 
HRMS (C30H53O7N, 0.9 ppm/MH+):  [M+H] 
+= 540.38995, cal. 540.38948, C30H54O7N 
 
LC-MS : M-H+= 540.4, M+Na+=562.4 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.8 min  
 
Rf (hexan/ethyl acetate 2:1) = 0.11 
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1HNMR (DMSO-d6) and chiral HPLC (CHIRALPAK AD-H) of the (S,S,S,S) configured isomer of 60. It was 
prepared in the laboratory by B. Berod from the API- intermediate 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H 
H 
O
O
NHBoc
OH
O
OH
60
( S, S, S, S)
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I.5. Alternative synthesis: pathway A 
 
(S)-4-methyl-3-(tetrahydro-pyran-2-yloxymethyl)-pentanoic acid 86 
 
 
OO
NO
2
O
O
O
OH
tBuOH
1. KOH/K2HPO4/H2O
2. KMnO4/H2O
MW: 245.32 MW: 230.31
(S)-32 (S)-86
 
 
2.00 g of compound 32 (8.1 mmol, 1.0 eq.) are dissolved at room temperature under argon 
atmosphere in 38 mL of t-butanol. An aqueous solution of 1.31 g of potassium hydroxide (0.5M) 
(23.4 mmol, 2.8 eq.) 9 mL of methyl butene (83.4 mmol, 9.2 eq.) are added to the mixture. The 
exothermic addition of a solution of 1.22 g of NaClO2 (13.5 mmol, 1.5 eq.) and of 1.87 g of KH2PO4 
(83.4 mmol, 9.2 eq.) in 10 mL of demineralized water is performed at 0°C over a period of 5 min. The 
reaction mixture is allowed stir over 45 min until completion of the reaction (HPLC control). Both 
phases are then separated. The aqueous phase is acidified to pH 5 by addition of 15 mL of an 
aqueous solution of citric acid 10% and extracted twice with 30 mL of toluene. The organic phases 
are dried over MgSO4 and concentrated in vacuum to yield 1.74 g of crude product 86 as a colorless 
oil. 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm) (mixture of diastereoisomers 1:1) 
0.77 - 0.94 (m, 6H, CH3iPr), 1.34 - 1.53 (m, 4H, 2*CH2THP), 1.59 (m, 1H, CHiPr), 1.65-1.82 (m, 2H, CH2THP), 
1.88-1.95 (m, 1H, CH-CHiPr), 2.07 - 2.31 (m, 2H, CH2CO2H), [3.17-3.21 (m, 0.5H), 3.27-3.31 (m, 0.8H), 
3.40-3.43 (m, 1H), 3.51-3.55 (m, 0.5H), 3.59-3.63 (m, 0.5H), 3.77-3.74 (m, 1H)] (CH2-0, CH2-OTHP), 4.51 
(m, 1H, CHTHP), 11.98 (br. s., 1H, CO2H) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm) (mixture of diastereoisomers 1:1) 
18.87, 18.97, 19.01, 19.17,19.47,19.56 (CH3iPr, CH2THP), 25.04 (CH2THP), 27.83-28.04 (CHiPr) 30.18 
(CH2THP), 33.28-33.56 (CH-CHiPr), 40.52-40.60 (CH2CO2H, 61.07 (CH2-OTHP), 67.54-67.64 (CH2-0), 97.90-
98.04 (CHTHP), 174.31 (CO2H) 
 
IR: (FTIR-microscopy in transmission)  
3300-2600 (OHacid), 2957 (C-Haliphatic), 1708 (C=Oacid), 1388-1354 (C-H3δ), 1284 (C-Oacid), 1120-1024 (C-
O) 
 
MS: (ES+)  [M+Na]+ = 253.4 
               [M-H]- = 229.3 
 
HRMS (C12H22O4N, 0.07 ppm/MH+):  [MH] 
+= 231.15910, cal. 231.15909, C12H23O4N 
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 (S)-3-benzyloxymethyl-4-methyl-pentanoic acid (S)-3-methyl-2-(2-nitro-ethyl)-butyl ester 82 
 
O
O
OH
OH
N
+
O
O
O
O
N
O
OO
MW: 236.31
Ion Austausch, MED, RT
MW: 161.20
MW: 379.50
(S)-76 (S)-8
(S,S)-82
+
 
 
1.06 g of acid 76 (4.5 mmol, 1.0 eq.) are dissolved at room temperature in 11 mL of dichloromethane. 
8.92 mg of Amberlyst 15 are then added at room temperature. The reaction mixture is diluted in 6 
mL of dichloromethane. After 7 min, 804.1 mg of nitro alcohol 8 (5.0 mmol, 1.1 eq.) are added and 
the reaction mixture is allowed to stir at room temperature over 5 days. 5 mL of dichloromethane 
are then added to the mixture and the Amberlyst 15 is filtered off and washed with 75 mL of 
dichloromethane. The organic phase is concentrated in vacuum to yield 1.63 g of crude product 82 as 
a yellow oil. 
The crude product is purified by column chromatography on silicagel (30 g) with heptane/ethyl 
acetate (6:1) to give in the purest fractions 1.024 g of the desired ester (59%). 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.75 - 0.91 (m, 12H, CH3iPr), 1.37 - 1.56 (m, 1H, CH-CHiPr), 1.64 - 1.88 (m, 3H, HCHNO2,2*CHiPr), 1.92 - 
2.09 (m, 2H, CH-CHiPr, HCHNO2), 2.19 - 2.30 (m, 1H, HCH-C=O), 2.30 - 2.39 (m, 1H, HCH-C=O), 3.26 - 
3.37 (m, 1H, HCH-O-CH2Benz) 3.43 (dd, J1=9 Hz, J2=5Hz, 1H, HCH-O-CH2Benz), 3.86 (dd, J1=11 Hz, J2=6 Hz, 
1H, HCH-O-C=O),  3.95 - 4.05 (m, 1H, HCH-O-C=O), 4.42 (s, 2H, CH2Benz), 4.49 - 4.68 (m, 2H, CH2NO2), 
7.05 - 7.61 (m, 5H, CHarom) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
19.01 (CH3iPr), 19.05 (CH3iPr), 19.53 (CH3iPr), 25.89 (CH2 CH2NO2), 28.11 (CHiPr), 33.73 (CH2C=O), 36.02 
(CHiPr), 39.85 (CH-CHiPr), 40.88 (CH-CHiPr), 64.33 (CH2-O-C=O) 70.84 (CH2-O-CH2Benz), 72.10 (CH2Benz), 
74.01 (CH2NO2), 127.33 (CHarom), 128.16 (CHarom), 137.9 (Carom), 172.71 (C=O),  
 
IR: (FTIR-microscopy in transmission)  
3031 (C-Haromatic), 2962 (C-Haliphatic), 1734 (C=Oester), 1554 (NO2νas), 1496 (phenyl), 1455 (phenyl), 1371 
(NO2νs), 1251 (C-Oester), 1169-1104 (C-O), 1028 (C-Hδmonosubst.), 738 (C-Hδmonosubst.), 699 (Phenylδmonosubst.),  
 
MS: (ES+)  MH+ = 380 
 
HRMS (C21H33O5N, 0.2 ppm/MH+): [MH] 
+= 380.24323, cal. 380.24315, C21H34O5N 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 5.9 min  
 
Rf (hexan/ethyl acetate 5:1) = 0.50 
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I.6. Alternative synthesis : pathway B 
 
(S, R) and (S, S) -4-hydroxymethyl-5-methyl-2-nitro-hexanoic acid methyl ester 79; (S, R) and (S, S)-
5-Isopropyl-3-nitro-tetrahydro-pyran-2-one 77 
 
O
O
NO
2
 
O O
OH
NO
2
 
O
H
O
O
NO
2
OH O
O
NO
2
O O
NO
2
N
H
O Si
aque. 
H2C=O
NaBH3CN
AcOH,Toluol, 
35°C
+ stereoisomer
77
79
10
19
21
20
I
MW: 86.13
MW: 119.08
MW: 187.20
(S,R) or (S:S)
or vice-versa
(S,R) or (S:S)
or vice-versa
(S,R) or (S:S)
or vice-versa
 
338.2 mg of (S)-diphenyl-prolinol-O-TMS-ether I (0.89 mmol, 0.08 eq.) are dissolved in 40 mL THF. 1.7 
mL of acetic acid (30 mmol, 2.5 eq.) and 1.3 mL of isovaleraldehyde 10 (12 mmol, 1.0 eq.) are added 
to the mixture at room temperature. The mixture is then warmed to 35°C.  A solution of 1.497 g of 
methyl nitroacetate 21 (12 mmol, 1.0 eq.) in 20 mL of THF and a solution of 1.124 g of formaldehyde 
(~37% in water) (13 mmol, 1.0 eq.) in 20 mL of THF are added simultaneously at 35°C for 20 min. This 
solution is then stirred at 35°C during 25 min., until complete conversion of nitroacetate is detected 
(HPLC control). 
The reaction mixture is cooled down to 0°C and 5.812 g of NaBH3CN (92.4 mmol, 7.7 eq.) are added 
in five portions over a period of 1 hour 40 minutes. (pH=6).  
The reaction mixture is quenched with 20 mL of water, and extracted with 100 mL of ethyl acetate. 
The organic phase is dried over MgSO4, and concentrated in vacuum to yield 760 mg of crude 
product. 
The aqueous phase is again extracted two times with 100 mL of ethyl acetate. The organic phase is 
dried over MgSO4, and concentrated in vacuum to yield 113 mg of crude product. 
The crude product is purified by column chromatography on silicagel (20 g) with heptane/ethyl 
acetate (3:1) to give in the pure fractions the desired alcohol 79 in mixture with the corresponding 
lactone 77. 
 
Determination of the diastereoisomeric ratio of the alcohol 79 by 1H-NMR (CDCl3, 400 MHz) shows 
the presence of 71% of the diastereoisomere A and 29% of the diastereoisomere B. Addition of 
trifluoracetic acid to a mixture of alcohol 79-lactone 77 mixture leads to the formation of pure 
lactone 77. 
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Spectroscopic data of methyl ester nitroalcohol 79: 
 
OH O
O
NO
2
OH O
O
NO
2
79
A B
MW: 219.24 MW: 219.24
or vice-versa
 
 
1H-NMR: (400 MHz, CDCl3) δH (ppm)  
 [0.90 - 0.97 (m, CH3iPr Dia1), 0.97 - 1.05 (m, CH3iPr Dia2)], 1.69 - 1.85 (m, 1H,  CHiPr,), 2.08 - 2.18 (m, 1H, 
CH2CHNO2), 2.32 (t, J1=7 Hz, 1H, CHiPr) 2.38 - 2.52, (m, 1H, CH2CHNO2),  [3.52 - 3.69 (m, CH2OH), 3.71 - 
3.83 (m, 1H, CH2OH), 2H], [3.83 (s, CH3ester dia1),  3.89 (s, CH3ester dia2), 3H], [5.46 (t, J=7 Hz, CHNO2 dia1) 
5.64 (dd, J1=11 Hz, J2= 3 Hz, CHNO2 dia2), 1H] 
 
IR: (FTIR-microscopy in transmission)  
3422 (OH), 2962 (CH-aliphatic), 2879 (O-CH3), 1754 (C=O ester), 1562 (NO2 as), 1371 (NO2 s), 1258 
(C-O), 1015 (C-O) 
 
MS: MH+ = 220, M+NH4
+ = 237 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm. tr=3.4/3.6  min 
 
 
Spectroscopic data of  lactone derivative 77: 
 
O O
NO
2
77
MW: 187.20
(S,R) or (S:S)
or vice-versa
 
 
 
1H-NMR: (400 MHz, CDCl3) δH (ppm) (isomeric mixure 50:50 cis/trans) 
0.66 - 1.03 (m, 6H, CH3iPr), 1.51 - 1.72 (m, 1H, CHiPr), 1.91 - 2.02 (m, 1H, CHiPr), 2.14 (td, J1=12 Hz, 
J2=10 Hz, 0.5H, CH2-CH-NO2), 2.32 - 2.45 (m, 1H, CH2-CH-NO2), 2.62 (dd, J1=7 Hz, J2=5 Hz, 0.5H, CH2-
CH-NO2), 4.13 - 4.33 (m, 1H, CH2-O), 4.33 - 4.41 (m, 0.5H, CH2-O) 4.45 (ddd, J1=11 Hz, J2=5 Hz, J3=1 Hz, 
0.5H, CH2-O), 5.98 (dd, 0.5H, CH-NO2cis), 6.04 (t, J1=9 Hz, 0.5H, CH-NO2trans) 
  
IR: (FTIR-microscopy in transmission)  
2964, 2930 (C-H aliphatic), 1757 (C=O lactone), 1565 (NO2 as), 1373(C(CH3)2), 1347 (NO2 s), 1265 (C-
O), 1015 (C-O) 
 
MS: MH+ = 188, M+NH4
+ = 205 
        MH- = 186 
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Spectroscopic data of nitro-aldehyde 20: 
 
O O
OH
NO
2
O O
OH
NO
2
20
MW: 217.22
A Bor vice-versa
 
 
1H NMR (400 MHz, CDCl3-d) δH (ppm) mixture of two diastereoisomers 
 0.94 - 1.07 (m, 6H, CH3iPr), 2.19 - 2.34 (m, 3H) 2.40 - 2.62 (m, 1H, CH2CHNO2), [3.84 (s, CH3ester dia1), 
3.86 (s, CH3ester dia2), 3H ], [5.22 (dd, J1=9Hz, J2=5Hz, CHNO2 dia1), 5.25 - 5.32 (m, CHNO2 dia2), 1H ], 9.70 
(d, J=6Hz, 1H, HC=O) 
 
MS: MH+= 218, M+NH4
+= 235 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220 nm. tr=4.8 min 
 
 
I.7. Synthesis of Aliskiren: Pathway C 
 
(S)-4-benzyloxymethyl-5-methyl-1-nitro-hexan-2-ol 87 
 
Methode 1 
 
O
O
H
NO
2
O
OH
NO
2
MW: 220.31MW: 61.04
MW: 281.35
27 87
(S,R):(S,S)
+
Sparteine
28
 
 
443.2 mg of compound  28 (2.0  mmol, 1.0 eq.) are diluted at room temperature in 163.2 mg of 
nitromethane 27 (2.7 mmol, 1.3 eq.). 182.7 mg of sparteine (19.7 mmol, 0.78 eq.) are then added at 
room temperature. The reaction mixture is heated to 30°C and is stirred overnight (15 hours). After 
cooling to room temperature, the reaction mixture is diluted in 10 mL of ethyl acetate. The resulting 
organic layer is extracted three times with 10 mL of demineralized water, and the coresponding 
aqueous phase is extracted with 10 ml of ethyl acetate. The organic phase is dried over MgSO4 and 
concentrated in vacuum to yield 339.0 mg of crude product 87 as a yellow liquid. 
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The crude material is purified by column chromatography on silicagel (0.040-0.063 nm) (50g) with 
heptane:ethyl acetate (4:1) to give in the pure fractions 254 mg (45%) of nitroaldol compound 87 as 
an isomeric mixture (syn/anti 60:40) 
 
1H NMR (600 MHz, DMSO-d6) δH (ppm) (mixture of diastereoisomer ≈ 60/40) 
0.82-0.91 (m, 6H, CH3iPr), 1.28-1.44 (m, 2H, CH2-CHOH), 1.63 - 1.66 (m, 0.4H, CH-CHiPr, Dia2) 1.66 - 1.70 
(m, 0.6H, CH-CHiPr Dia1), 1.76 - 1.85 (m, 1H, CH-CHiPr), 3.33-3.43 (m, 2H, CH2-O), 4.13-4.23 (m, 1H, 
CHOH), 4.20 - 4.36 (m, 1H, HCHNO2), 4.40-4.51 (m, 2H, CH2Benz ), 4.66 (dd, J1=12 Hz, J2=3 Hz, 0.6H, 
HCHNO2 Dia1), 4.73 (dd, 0.4H, HCHNO2 Dia2), 5.32 (m, 1H, OH), 7.25 - 7.43 (m, 5H, Harom) 
 
IR: (FTIR-microscopy in transmission)  
3399 (OH), 3089-3064 (CHaromatic), 2960-2931-2874 (C-Haliphatic), 1555 (NO2 ass), 1372 (NO2 δs, 
CH3δ), 1090-1073 (C-O), 740-700 (phenylmonosubs) 
  
MS: (ES+); MH+= 282 
        (ES-); MH-= 280 
 
HPLC method:  reverse phase, inertsil ODS3 C18 4.6 mu 22 cm , AcN / H2O + 0.01% NH4H2PO4, 
gradient: from 55% to 97% AcN,  40°C, λ=220nm, tr = 7.2 min  
 
Rf (hexan/ethyl acetate 4:1) = 0.11 
 
Methode 2 
 
18.3 mg of the (R,R) ligand (0.05 mmol, 0.05 eq.) are dissolved at 22°C in 0.5 mL of acetonitrile. 9.3 
mg of copper (II) acetate monohydrate (0.05 mmol, 0.05 eq.) are then added at 22°C. After 31 min, a 
solution of 220.1 mg of aldehyde 28 (1.0 mmol, 1.0 eq.) in 0.5 mL of acetonitrile and 83.7 mg of 
nitromethane 27 (1.4 mmol, 1.4 eq.) are added at 22°C to the green reaction mixture. The reaction 
mixture is heated to 30°C and is stirred over night (14 hours 30 min).  
The isomeric (syn/anti) ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, 
isocratic, 1.5 mL/min) is 2% of the isomer 1 (tR=7.7 min) and 98% of the isomer 2 (tR=15.3 min). 
 
Methode 3 
 
18.4 mg of the (S,S) ligand (0.05 mmol, 0.05 eq.) are dissolved at 22°C in 0.5 mL of acetonitrile. 9.3 
mg of copper (II) acetate monohydrate (0.05 mmol, 0.05 eq.) are then added at 22°C. After 31 min, a 
solution of 220.6 mg of aldehyde 28  (1.0 mmol, 1.0 eq.) in 0.5 mL of acetonitrile and 82.9 mg of 
nitromethane 27 (1.4 mmol, 1.4 eq.) are added at 22°C to the green reaction mixture. The reaction 
mixture is heated to 30°C and is stirred over night (14 hours 30 min).  
The isomeric (syn/anti) ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, 
isocratic, 1.5 mL/min) is 98% of the isomer 1 (tR=7.8 min) and 2% of the isomer 2 (tR=14.2 min). 
 
Methode 4 
 
36.4 mg of the (R,R) ligand (0.1 mmol, 0.1 eq.) are dissolved at 22°C in 1.0 mL of THF and  19.9 mg of 
copper (I) iodide (0.1 mmol, 0.1 eq) are added. After 16 min, 9 µL of diisopropyl ethyl amine (0.05 
mmol, 0.5 eq) are added and the mixture is allowed to stir at 22°C for 15 min. 220.5 mg of aldehyde 
28 (1.0  mmol, 1.0 eq) and 84.5 mg of nitromethane 27 (1.4 mmol, 1.4 eq.) are added at 22°C to the 
green reaction mixture. The reaction mixture is heated to 35°C and is stirred over night (14 hours 30 
min).  
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The isomeric (syn/anti) ratio measured CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, isocratic, 
1.5 mL/min) is 2% of the isomer 1 (tR=7.8 min) and 98% of the isomer 2 (tR=14.9 min). 
 
Methode 5 
 
47.3 mg of the (R,R) ligand (0.1 mmol, 0.1 eq.) are dissolved at 22°C in 1.0 mL of THF and  19.5 mg of 
copper (I) iodide (0.1 mmol, 0.1 eq) are added. After 20 min, 9 µL of diisopropyl ethyl amine (0.05 
mmol, 0.5 eq) are added and the mixture is allowed to stir at 22°C for 10 min. A solution of 219.3 mg 
of aldehyde 28 (1.0 mmol, 1.0 eq) in 0.5 mL of THF and 83.5 mg of nitromethane 27 (1.4 mmol, 1.4 
eq.) are added at 22°C to the green reaction mixture. The reaction mixture is heated to 35°C and is 
stirred over 2.5 days. The reaction mixture is cooled down to room temperature and concentrated in 
vacuum. The residue is diluted in 10 mL of ethyl acetate, and the resulting organic layer is extracted 
once with 10 mL of brine and twice with 10 mL of demineralized water yielding 226 mg of the β- 
hydroxy nitro compound 87 as an isomeric  mixture. 
 
The isomeric (syn/anti) ratio measured on CHIRALCEL OD-H (20°C, 93:7 hexane/isopropanol, 
isocratic, 1.5 mL/min) is 1% of the isomer 1 (tR=7.7 min) and 99% of the isomer 2 (tR=15.3 min). 
 
The crude material can be purified by column chromatography on silicagel (0.040-0.063 nm) (30g) 
with heptane:ethyl acetate (4:1) to give in the purest fractions 112 mg (41%) of nitroaldol compound 
87 as an isomeric mixture (syn/anti 99:1). 
 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.84 (dd, J1= 17 Hz, J2= 7 Hz, 6H, CH3iPr), 1.29-1.39 (m,2H, CH2-CHOH), 1.64 - 1.74 (m, 1H, CH-CHiPr), 
1.73 - 1.85 (m, 1H, CH-CHiPr), 3.40 (d, J=5 Hz, 2H, CH2-O), 4.12 - 4.22 (m, 1H, CHOH), 4.32 (dd, J1=12 
Hz, J2= 9 Hz, 1H, HCHNO2), 4.46 (m, 2H, CH2Benz), 4.65 (dd, J1=12 Hz, J2=3 Hz, 1H, HCHNO2),5.28 (bs, 
1H, OH), 7.14 - 7.40 (m, 5H, Harom) 
 
Methode 6 
 
1.001 g of the (R,R) ligand (2.7 mmol, 0.05 eq.) are dissolved at 22°C in 10 mL of ethanol. 495.1 mg of 
copper (II) acetate (2.7 mmol, 0.05 eq.) are then added at 22°C. After 30 min, 11.86 g of aldehyde 28 
(53.8 mmol, 1.0 eq.) and 16.40 g of nitromethane 27 (267.1 mmol, 4.9 eq.) are added at room 
temperature  to the green suspension. The reaction mixture is heated to 35°C and is stirred overnight 
(18 hours 45 min). The reaction mixture is cooled down to room temperature and concentrated in 
vacuum. The yellow residue is diluted in 50 mL of ethyl acetate, and the resulting organic layer is 
extracted with 50 mL of brine and 20 mL of demineralized water yielding to the precipitation of a 
brown solid and the formation of three phases. The ethyl acetate phase is extracted with 50 mL of 
demineralized water and four times with 200 mL of brine. The second organic phase (in which 87 is 
the major compound) is extracted with 100 mL of brine. And after addition of 100 mL of methylene 
chloride, the organic layer is extracted two times with 100 mL, 400 mL and 500 mL of brine. Both 
organic phases are dried over MgSO4 and concentrated in vacuum to yield 5.17 g and 5.82 g of crude 
product 87 as isomeric mixtures (syn/anti 98:2). 
 
The isomeric ratio of the crude material is measured on CHIRALCEL OD-H (20°C, 93:7 
hexane/isopropanol, isocratic, 1.5 mL/min), is 2% of the isomer 1 (tR=7.9 min) and 98% of the isomer 
2 (tR=15.3 min).  
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A part of the crude material (5.167 g) is purified by column chromatography on silicagel (0.040-0.063 
nm) (200g) with heptane:ethyl acetate (5:1) to give in the pure fractions 3.095 g (57%) of nitroaldol 
compound 87 as a diastereoisomeric mixture (syn/anti 98:2). 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.83 (dd, J1= 17 Hz, J2= 2 Hz, 6H, CH3iPr), 1.25-1.39 (m, 2H, CH2-CHOH), 1.61 - 1.73 (m, 1H, CH-CHiPr), 
1.73 - 1.94 (m, 1H, CH-CHiPr), 3.39 (d, J=5 Hz, 2H, CH2-O), 4.18 (m, 1H, CHOH), 4.26 - 4.38 (m, 1H, 
HCHNO2), 4.45 (d, J= 5Hz, 2H, CH2Benz ) 4.65 (dd, J1=12 Hz, J2=3 Hz, 1H, HCHNO2), 5.30 (m, 1H, OH), 
7.15 - 7.47 (m, 5H, Harom) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
18.84 (CH3iPr), 19.92 (CH3iPr), 28.49 (CHiPr), 32.40 (CH2-CHOH), 39.20 (CH-CHiPr), 66.59 (CHOH), 70.45 
(O-CH2-CH-iPr), 72.16 (CH2Benz), 82.10 (CH2NO2), 127.39 (CHarom) 128.25 (CHarom) 138.69 (Carom)  
 
IR: (FTIR-microscopy in transmission)  
3418 (OH), 3064-3032 (CHaromatic), 2959-2878 (C-Haliphatic), 1556 (NO2 ass), 1373 (NO2 δs, CH3δ), 
1089-1073-1028 (C-O), 740-700 (phenylmonosubs) 
 
MS: (ES+); MH+= 282 
        (ES-); MH-= 280 
 
HRMS(C15H24O4N, 0.14 (ppm)/MH
+):  [M+N]+= 282.16995, calcul. 282.16999, C15H24O4N 
 
 
  
 [(2S,4S)-2-isopropyl-4-(1-methoxy-1-methyl-ethoxy)-5-nitro-pentyloxymethyl]-benzene 81 
 
O
OH
NO
2
O
O
O
NO
2
MW: 281.35 MW: 353.46
(S,S)-87 (S,S)-81
 
 
1.07 g of compound 87 (3.8 mmol, 1.0 eq.) is dissolved at 22°C (room temperature) in 20 mL of 2-
methoxy propene (72.1 mmol, 55.0 eq.) and 24.1 mg of polymer bound pyridinium toluene-4-
sulfonate (3.5 mmol/ g, 0.08 mmol, 0.02 eq.) are added to the solution. The reaction mixture is 
heated to 36°C and is stirred overnight. The reaction mixture is cooled down to room temperature 
and the polymer is filtered off and washed with 10 mL of ethyl acetate. The organic layer is 
concentrated in vacuum to yield 1.31 g of protected compound 81 (97%). 
 
The crude material is purified by column chromatography on silicagel (0.040-0.063 nm) (40g) with 
heptane:ethyl acetate (5:1) to give in the pure fractions 1.05 g (78%) of compound 81. 
 
 
1H NMR (400 MHz, DMSO-d6) δH (ppm)  
0.84 (t, J= 6Hz, 6H, CH3iPr), 1.23 (s, 6H, CH3MIP), 1.34 - 1.49 (m, 1H, HCH-CHOH), 1.51 - 1.66 (m, 2H, 
HCH-CHOH, CH-CHiPr), 1.73 - 1.87 (m, 1H, CHiPr), 3.09 (s, 3H, OCH3), 3.32 - 3.44 (m, 2H, CH2-O), 4.32 - 
 192 
 
4.40 (m, 1H, CHOH), 4.45 (s, 2H, CH2Benz), 4.49 - 4.59 (dd, J1=12 Hz, J2=4 Hz, 1H, HCHNO2), 4.60 - 4.69 
(dd, J1=13 Hz, J2=6 Hz, 1H, HCHNO2), 7.18 - 7.48 (m, 5H, Harom) 
 
13C NMR (101 MHz, DMSO-d6) δC (ppm)  
19.01 (CH3iPr), 19.29 (CH3iPr), 24.59 (CH3MIP), 24.69 (CH3MIP), 28.27 (CH-CHiPr), 32.23 (CH2-CH-OMIP), 
39.61 (CHiPr), 48.86 (OCH3MIP), 67.83 (CH-OMIP), 70.89 (CH2-0), 72.18 (CH2Benz), 80.02 (CH2NO2), 100.80 
(CMIP), 127.34 (CHarom), 127.46 (CHarom), 128.19 (CHarom), 138.55 (Carom) 
 
IR: (FTIR-microscopy in transmission)  
3064-3089 (CHaromatic), 2959-2874(C-Haliphatic), 1555 (NO2 ass), 1383 (NO2 δs, CH3δ),  1073-1049 
(C-O), 738-699 (phenylmonosubs) 
 
MS: (ES+); M+Na+= 376, m/z (-0CH3)= 322, m/z (-MIP)= 282 
        
HRMS (0.14 ppm/MH4+):  M+NH4] += 312.21694, C17H30O4N 380.24315 
 
HPLC method:  CHIRALCEL OD-H, 93:7 Hex/iPrOH, 1.0 mL/min, 20°C, tR= 34 min 
 
Rf (heptan/ethyl acetate 5:1, NEt3) = 0.12 
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II. EXPERIMENTAL PART OF CHAPTER 3  
 
2-Bromo- 1 -tert-butvldimethylsilyloxy-ethane 112 
CAS Number: 86864-60-0 
J. Vader, H. Sengers, A. De Groot,  Tetrahedron  1989,  45(7),  2131-42 
 
Br
OH Br
O
Si
TBSOTf, Imidazole
DMF
O°C to RT
114
112
MW: 124.97
MW: 239.23
 
 
14.15 mL of tert-butyldimethylsilyl trifluoromethanesulfonate (61.6 mmol, 1.0 eq.) and 10.0 mL of 
bromoethanol 114 (61.6 mmol, 1.0 eq.) are added dropwise at 0°C to a solution of 5.44 g of 
imidazole (80.1 mmol, 1.0 eq.) in 40 mL of dimethylformamide over a period of 20 min.  The reaction 
mixture is allowed to warm up to room temperature (21°C) and stirred overnight. 4.2 mL tert-
Butyldimethylsilyl trifluoromethanesulfonate (18.4 mmol, 0.3 eq.) are added and the reaction 
mixture is allowed to stirr over 25 hours until completion of the reaction. The reaction mixture is 
diluted in 120 mL of ethyl acetate, and extracted with 120 mL of brine. Both phases are separated 
and the organic layer is washed again with 80 mL of brine. The combined aqueous phase is extracted 
with 120 ml of ethyl acetate. The combined organic phases are dried over Na2SO4 and concentred in 
vacuum to yield 10.235 g of crude material 112 (69%).  
5.52 g of crude material are purified by column chromatography on silicagel (0.040-0.063 nm) with 
hexane:ethyl acetate (10:1) to give in the pure fractions 1.68 g of (2-bromo-ethoxy)-tert-butyl-
dimethyl-silane 112 (30%) and 1.60 g of 114. 
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.10 (s, 3H, CH3TBDMS), 0.91 (s, 9H, CH3tBu, TBDMS), 3.41 (t, J=6.5 Hz, 2H, CH2-0), 3.90 (t, J=6.5 Hz, 2H, CH2-
Br) 
 
IR: (FTIR-microscopy in transmission)  
2999-2821 (C-Haliph.), 1398 -1348 ((CH3)3δ), 1257 ((CH3)Si-(CH3)2δ ), 1153-1068 (Si-O-C), 839 (Si-C) 
 
(GC) MS: [M-C4H9]
+ = 181, 182 
 
Rf (heptan:ethyl acetate 10 :1) = 0.39 
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2-[(phenylmethoxy)( tert-butylsilyloxy) amino]- tert-butyldimethylsilyloxy-ethane 113 
 
N
O
O O
O
R
NH
O
O O
O
R Br
1. NaH, DMF, RT
2.                 
          
          
83%
R=TBS
108 113
112
, 60°C
MW: 223.27
R=TBS
MW: 381.59
 
 
1.11 g of tert-Butyl N-(benzyloxy)carbamate 108 (4.3 mmol, 1.0 eq.) is dissolved at room temperature 
in 22 mL of dry dimethylformamide. 228 mg of NaH (ca 50% dispersion in mineral oil) (4.7 mmol, 1.1 
eq.) are added portionwise and the reaction mixture is allowed to stir over a period of 20 min. 1.05 g 
of 2-bromo-1-tert-butyldimethylsilyloxy-ethane 112 is added dropewise over a period of 15 min. The 
reaction mixture is warmed to 60°C and allowed to stir at 60°C over 2 hours. The reaction mixture is 
cooled down to room temperature, poured into 50 mL of demineralized water and extracted thrice 
with 60 mL of tert-butyl-mehyl ether. The combined organic layers are dried over Na2SO4, and 
concentred in vacuum to yield 1.36 g of 113 (83%). 
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
0.07 (s, 3H, CH3TBDMS), 0.90 (s, 9H, CH3tBu, TBDMS), 1.51 (s, 9H, CH3BOC), 3.56 (t, J=6.5 Hz, 2H, CH2-N), 3.75 
(t, J=6.5 Hz, 2H, CH2-O), 4.86 (s, 2H, CH2Benz.), 7.38 (m, 5H, CHArom.) 
 
IR: (FTIR-microscopy in transmission)  
3120-3001 (CHarom.), 3006-2802 (CHaliph.), 1707(C-OBOC), 1608 (Phenyl),  1589 (Phenyl), 1498 
(Phenyl), 1456 (Phenyl), 1408-1342 (C-NBOC, (CH3)3δ), 1252 ((CH3)Si-(CH3)2δ ), 1173 (C-OBOC), 1157-1068 
(C-O, N-O,Si-O), 837 (Si-C), 748 (Phenylδmono), 698 (Phenylδmono) 
 
MS: [M-H]+ = 382 
 
HRMS (C20H36NO4SiNa, 0.5 ppm/M-Na+):  [M-Na]+= 404.22295, calculated 404.22276, C20H36NO4SiNa 
 
2-[(phenylmethoxy)amino]-ethanol 107 
CAS Number: 16115-60-9 
E. Fleckenstein, E. Heinrich, R. Mohr, 1974  DE -2230392  
 
O
N
OTBS
O O
O
N
H
OHO
NH
2
+
OH
1. TFA, CH2Cl2
O°C - RT -TFA
EE
K2CO3 in H2O
MW: 267.33 MW: 167.21
107
113
 
 
485.2 mg of 2-[(phenylmethoxy)( tert-butylsilyloxy) amino]- tert-butyldimethylsilyloxy-ethane 113  
(1.81 mmol, 1.0 eq.) are dissolved at room temperature in 15 mL of dry dichloromethane. The 
reaction mixture is cooled down to 0°C and 10 mL of trifluoroacetic acid (12.9 mmol, 7.1 eq.) are 
 195 
 
added dropwise over a period of 15 min. After being stireed at 0°C over a period of one hour, the 
reaction mixture is warmed to room temperature, and diluted in 20 mL of dichloromethane. 20 mL of 
demineralized water are slowly added to the solution. Both layers are separated, and the organic 
phase is extracted again twice with 60 mL of water. An aqueous solution of potassium carbonate 
(20% m/m) is added to the resulting aqueous phase until pH 8. The resulting solution is washed three 
times with 40 mL of ethyl acetate. Both organic phases are dried over Na2SO4, and concentred in 
vacuum to yield 646 mg of crude material. The crude material is diluted in 50 mL of ethyl acetate and 
80 mL of a saturated solution of potassium carbonate are added to the solution until pH 9. The 
biphasic reaction mixture is stirred vigorously at room tempature over 30 min and both phases are 
separated. The aqueous phase is extracted with twice with 20 mL of ethyl acetate. The combined 
organic phases are dried over Na2SO4, and concentred in vacuum to yield 292.1 mg of 2-
[(phenylmethoxy)amino]-ethanol 107 as a colorless oil. 
 
1H NMR (400 MHz, CDCl3) δH (ppm)  
3.07 (m, 2H, CH2-N), 3.73 (m, 2H, CH2-O), 4.73 (s, 2H, CH2Benz), 7.35 (m, 5H, CHarom) 
 
IR: (FTIR-microscopy in transmission)  
3995-3109 (OH, NH) 3107-2995 (CHarom.), 2970-2785 (CHaliph.), 1604 (Phenyl),  1587 (Phenyl), 1496 
(Phenyl), 1454 (Phenyl), 1119-930 (C.O, N-O), 746 (CHδmono), 698 (Phenylδmono) 
 
(LC) MS: [M-H]+ = 168 
 
HRMS (C9H14NO2, 0.4 ppm/M-H+):  [M-H] += 168.10184, calculated 168.10191, C9H14NO2 
 
 
N-carbobenzoxy-O-benzylhydroxylamine 109 
CAS Number: 15255-86-4 
T. Kolasa, M. J. Miller,  Journal of Organic Chemistry  1987,  52(22),  4978-84 
 
N
H
O
O
ONH2
O
O
N
O
O
Cbz
HCl. DMAP, THF
89%
109
111
88
 
 
10.00  g of O-benzylhydroxylamine hydrochloride 111 (62.6 mmol, 1.0 eq.) are dissolved at room 
temperature in 150 mL of dry tetrahydrofuran and  a solution of  784.1 mg of DMAP (6.4 mmol, 0.1 
eq.) and 15.60 g of N-(benzyloxycarbonyloxy) succinimide 88 (62.6 mmol, 1.0 eq.) in 100 mL of dry 
THF is added dropwise. The reaction mixture is warmed to 70°C and allowed to stir at reflux 
overnight. The reaction mixture is cooled down to room temperature and concentred (2/3) in 
vacuum. The resulting solution is diluted with 60 mL of ethyl acetate and washed twice with 20 mL of 
demineralized water. The organic layer is dried over Na2SO4, and concentrated in vacuum to yield 
15.132 g of a white solid. The residue is recrystallized from ethyl acetate/hexane (1:2 v/v) to give 
14.33 g of 109 as a white solid (89% yield). 
 
1H NMR (600 MHz, DMSO-d6) δH (ppm)  
4.76 (s, 2H, CH2Benz), 5.06 (s, 2H, CH2,Z), 7.23-7.37 (m, 5H, CHarom) 
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13C NMR (150 MHz, DMSO-d6) δC (ppm)  
65.8 (CH2,Z), 77.3 (CH2Benz), 127.8, 128.0, 128.1, 128.2, 128.4, 128.5, 128.5, 128.7, 128.9 (CHarom), 
135.9 (Carom), 136.4 (Carom), 156.7 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3288 (NH), 3091-3036 (CHarom.), 2938-2879 (CHaliph.), 1715 (C=O), 1489 (Phenyl), 1455 (Phenyl), 
1275 (C.O), 1125 (C.O), 744 (CHδmono), 698 (Phenylδmono) 
 
MS: [M-H]- = 256, [M-H]+ = 258 
 
HRMS (C9H14NO2, 0.4 ppm/M-H+):  [M-H] += 168.10184, calculated 168.10191, C9H14NO2 
 
Rf(hexane/ethyl acetate 1:1): 0.57 
 
carbamic acid, N-(3-oxocyclohexyl)-N-(phenylmethoxy)-, 1,1-dimethylethyl ester 115 
CAS Number: 1033064-95-7 
J. Lee, M-H  Kim, S.-S. Jew, H.-G. Park, B.-S. Jeong, Chemical Communications 2008, 16, 1932-1934 
O
O
NH
O
O
O
N
O
O
O
+
TBAB, KOH,
Toluene
RT
MW: 96.13 MW: 223.27 MW: 319.40
*
93 108 115
 
 
329.4 mg of tetrabutylammonium bromide (1.0 mmol, 0.1 eq.) are added at room temperature to a 
solution of  4.47  g of  tert-butyl N-(benzyloxy)carbamate 108 (20.0 mmol, 2.0 eq.) in 40 mL of 
toluene, followed by the dropwise addition of a solution of  481 mg of KOH (12.0 mmol, 1.2 eq.) in 
481 µL water. 935.3 µL of cyclohexenone 93 (10.0 mmol, 1.0 eq.) are added dropwise to the viscous 
solution, the reaction mixture turning into a brown suspension during the addition. The reaction 
mixture is stirred at room temperature over a period of 50 min and is in 80 mL of ethyl acetate 
diluted. The organic phase is washed twice with 80 mL of brine, while the resulting aqueous phase is 
extracted twice with 80 mL of ethyl acetate. The organic layer is dried over Na2SO4, and concentrated 
in vacuum to yield 4.549 g of crude material containing tert-butyl N-(benzyloxy)carbamate 108 and 
the Michael adduct 115.  
The  crude material is purified by column chromatography on silicagel (0.040-0.063 nm) (100 g) with 
cyclohexane:ethyl acetate (9:1) to give in the pure fractions 0.642 g of 115 (20%) and 1.825 g of the 
starting material 108 in mixture with 115. 
 
Data are confirmed by iterature data 
1H NMR (400 MHz, CDCl3-d) δH (ppm)  
1.61 - 1.71, 1.89 - 2.13 (m, 4H, CH2CH2CHcyclohex., CH2, βC=O),  2.17 - 2.30 (m, 1H, HCH, αC=O), 2.32-2.36  (m, 
1H, HCH, αC=O), 2.53 (dd, J1=14 Hz, J2= 2 Hz, 1H, HCH,α’C=O), 2.70 (t, J=12  Hz, 1H, HCH, α’C=O), 4.15 - 4.28 
(m, 1H, CH-N), 4.85 (s, 2H, CH2,CbZ), 7.33 - 7.45 (m, 5H, CHarom) 
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carbamic acid, N-(3-oxocyclohexyl)-N-(phenylmethoxy)-, 1,1-dimethylethyl ester 115 
CAS Number: 1033064-95-7 
O
O
NH
O
O
O
N
O
O
O
+
MW: 96.13 MW: 223.27 MW: 319.40
*
93 108 115
Base, Kat, T°C
 
 
To 101.4 µL of cyclohexenone 93 (1.07 mmol, 1.0 eq.) in 4 mL chloroform are added at room 
temperature 22.3 mg of (R)-5-pyrrolidin-2-yltetrazole (0.16 mmol, 0.16 eq.), 374.6 mg of 108 (1.61 
mmol,1.5 eq.) and 114.6 µL of morpholine (1.07 mmol, 1.0 eq.). The reaction mixture is stirred at 
room temperature over two days and is diluted in 15 mL of ethyl acetate. The organic phase is 
extracted twice with 10 mL of an saturated aqeous solution of citric acid, and once with 10 mL of 
demineralized water. The organic layer is dried over MgSO4, and concentrated in vacuum to yield 
108.3 mg of crude material.  
Chiral HPLC measurement of the crude material on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 
mL/min, 25°C, λ=215 nm) revealed the presence of two enantiomers with a ratio of 36 % at 5.3 min 
and 64% at 5.9 min 
The  crude material are purified by column chromatography on silicagel (0.040-0.063 nm) (100 g) 
with cyclohexane:ethyl acetate (9:1) to give in the pure fractions 63 mg of 115 (19%). 
Chiral HPLC measurement on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 mL/min, 25°C, λ=215 
nm) reveals the presence of two enantiomers with a ratio of 36% at 5.2 min and 64% at 5.9 min. 
 
Spectroscopic data of 115 are confirmed by the literature data 
 
1H NMR (400 MHz, CDCl3-d) δH (ppm)  
1.60 - 1.71, 1.89 - 2.13 (m, 4H, CH2CH2CH,cyclohex., CH2, βC=O),  2.17 - 2.30 (m, 1H, HCH, αC=O), 2.32-2.36  
(m, 1H, HCH, αC=O), 2.52 (dd, J1=14 Hz, J2= 2 Hz, 1H, HCH,α’C=O), 2.70 (t, J=12  Hz, 1H, HCH, α’C=O), 4.15 - 
4.28 (m, 1H, CH-N), 4.84 (s, 2H, CH2,Bz), 7.33 - 7.46 (m, 5H, CHarom.) 
 
13C NMR (151 MHz, DMSO-d6) δC (ppm)  
21.51 (CH2,cyclohex.), 27.55 (CH2,cyclohex),  27.93 (CH3,Boc), 39.94 (O=C-CH2,cyclohex.), 44.32 (CH-CH2,cyclohex.),  
57.64 (CH,cyclohex.), 77.95 (CH2Bz), 81.23 (CBoc),  128.40-129.43 (CHarom.), 135.32(Carom.), 155.88 (C=OBoc), 
208.47 (C=,cyclohex.) 
 
LCMS: [MH-H]+=320.3, [M+NH4]+=337.3 
 
HRMS (C18H25NO4Na, 0.6 ppm/M-Na+):  [M+Na] += 342.16736, calculated 342.16758, C18H25NO4Na 
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benzyl-cyclohex-2-en-(E/Z)-ylidene-oxonium 126 
CAS Number: 1059652-35-5 (Z) 
CAS Number: 1059651-58-9 (E) 
M. Ueda, H. Miyabe, H. Shimizu, H. Sugino, O. Miyata, T. Naito, Takeaki, Angew. Ch. Int. Ed.  2008, 
47(30), 5600-5604 
 
O
N
O
O
O
N
O
N
O
TFA, CH2Cl2
+
MW: 319.40 MW: 201.27 MW: 201.27
Z-126 E-126
*
115
 
 
154.1 mg of  115 (0.48 mmol, 1.0 eq.) are diluted in 3 mL of dry dichloromethane at 0°C and 105.7 µL 
of trifluoro acetic acid (1.38 mmol, 2.8 eq.)  are added to the solution. The reaction mixture is stirred 
at room temperature  over two hours and is concentrated in vacuum to yield 65.6 mg of crude 
material. 
Column chromatography on silicagel (0.040-0.063 nm) (30 g) with cyclohexane:ethyl acetate (6:1) 
yield in the pure fractions 53.2 mg of benzyl-cyclohex-2-en-(E/Z)-ylidene-oxonium (55%) (Z-126 and 
E-126). 
 
E-126 
1H NMR (400 MHz, CDCl3-d) δH (ppm) E isomer 
1.66 (q, J=6 Hz, 2H, CH2βC=N), 2.03 - 2.13 (m, 2H, CH2δC=N), 2.54 (t, J=6 Hz, 2H, CH2αC=N), 5.04 (s, 2H, 
CH2Benz), 6.06 (dt, J1=10 Hz, J2=1Hz, 1H, N=C-CH=CH), 6.15  (dt, 1H, J1=10 Hz, J2=5 Hz,1H,  N=C-CH=CH), 
7.19 - 7.38 (m, 5H, Harom.) 
 
Z-126 
1H NMR (400 MHz, CDCl3-d) δH (ppm) Z isomer 
1.73 - 1.81 (q., J=6Hz, 2H, CH2βC=N), 2.12 - 2.20 (m, 2H, CH2δC=N), 2.32 (t, J=6 Hz, 2H, CH2αC=N), 5.02 
(s, 2H, CH2Benz), 6.23 (dt, J1=10Hz, J2=4 Hz, 1H, N=C-CH=CH), 6.72 (dt, J1=10 Hz, J2=1 Hz,1H, N=C-
CH=CH), 7.19 - 7.38 (m, 5H, Harom.) 
 
MS: [M-H]+ = 202, mixture of two isomers 
 
Rf(hexane/ethyl acetate 1:1): 0.21 
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carbamic acid, N-(3-oxocyclohexyl)- N-(phenylmethoxy)-, phenylmethyl ester as racemic mixture 
116 
 
O
O
NH
O
O
O
N
O
O
O
+
TBAB, KOH,
Toluol
RT
*
MW: 353.42MW: 257.29MW: 96.13
93 109 116
 
 
103.5 mg of tetrabutylammonium bromide (0.31 mmol, 0.1 eq.) are added at room temperature to a 
solution of  772.0  mg of  N-carbobenzoxy-O-benzylhydroxylamine 109 (3.0 mmol,0.9 eq.) in 12 mL of 
toluene, followed by the dropwise addition of a solution of  154.5 mg of KOH (1.28 mmol, 1.2 eq.) in 
154.5 µL water. 301.24 µL of cyclohexenone 93 (3.12 mmol, 1.0 eq.) are added dropwise to the 
viscous solution, the reaction mixture turning into a brown suspension during the addition. The 
reaction mixture is stirred at room temperature over a period of 6 hours and  is diluted in 40 mL of 
ethyl acetate. The organic phase is washed three times with 100 mL of brine, while the resulting 
aqueous phase is extracted twice with 80 mL of ethyl acetate. The organic layer is washed twice with 
100 mL of an aqueous solution of citric acid (20%, pH 6) and is dried over Na2SO4, and concentrated in 
vacuum to yield 0.920 g of crude material containing 109 and 116.  
The  crude material is purified by column chromatography on silicagel (0.040-0.063 nm) (30 g) with 
cyclohexane:ethyl acetate (6:1) to give in the pure fractions 0.821 g of 116 (77%). 
 
1H NMR (400 MHz, CDCl3-d) δH (ppm)  
1.51 – 1.68, 1.91 - 2.11 (m, 4H, CH2CH2CHcyclohex.,CH2, βC=O), 2.18 - 2.29 (m, 1H, HCH, αC=O), 2.33-2.38 (m, 
1H, HCH, αC=O), 2.52-2.56 (m, 1H, HCH,α’C=O), 2.71 (dd, J1=14  Hz, J2=11 Hz, 1H,  HCH, α’C=O), 4.25 - 
4.35 (m, 1H, CH-N), 4.87 (s, 2H, CH2,CbZ), 5.20 - 5.29 (m, 2H, CH2Benz), 7.34-7.42 (m, 10H, CHarom) 
 
carbamic acid, N-(3-oxocyclohexyl)- N-(phenylmethoxy)-, phenylmethyl ester 116 
O
O
NH
O
O
O
N
O
O
O
Base, Kat, T°C
+
*
MW: 353.42MW: 257.29MW: 96.13
93 109 116
 
 
To 301.2 µL of cyclohexenone 93 (3.00 mmol, 3.0 eq.) are added at room temperature, 22.4 mg of 
(R)-5-pyrrolidin-2-yltetrazole (0.16 mmol, 0.16 eq.), 260.1 mg of the amine 109 (1.00 mmol,1.0 eq.) 
and 97.6 µL of morpholine (1.0 mmol, 1.0 eq.). The reaction mixture is stirred at room temperature 
over fours days and is diluted in 10 mL of ethyl acetate. The organic phase is extracted twice with 10 
mL of an saturated aqueous solution of citric acid, and once with 10 mL of demineralized water. The 
organic layer is dried over MgSO4, and concentrated in vacuum to yield 104.2 mg of crude material.  
The  crude material is purified by column chromatography on silicagel (0.040-0.063 nm) (12 g) with 
hexane:ethyl acetate (4:1) to give in the pure fractions 41.4 mg of 116 (12%). 
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Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of two enantiomers with a ratio of 63.5 % at 11.8 min and 36.5% at 
13.3 min. 
 
1H NMR (500 MHz, CDCl3-d) δH (ppm)  
1.31 – 1.65, 1.82- 2.20 (m, 4H, CH2CH2CHcyclohex.,CH2, βC=O), 2.28 - 2.36 (m, 1H, HCH, αC=O), 2.34-2.45 (m, 
1H, HCH, αC=O), 2.50-2.58 (m, 1H, HCH,α’C=O), 2.71 (dd, J1=14  Hz, J2=11 Hz, 1H,  HCH, α’C=O), 4.25 - 
4.34 (m, 1H, CH-N), 4.87 (s, 2H, CH2,CbZ), 5.21 - 5.28 (m, 2H, CH2Benz), 7.31-7.42 (m, 10H, CHarom) 
 
13C NMR (125 MHz, DMSO-d6) δC (ppm)  
21.5 (CH2, βC=O), 40.4 (CH2, αC=O), 44.3 (CH2, α’C=O), 58.0 (CH-N), 67.7 (CH2,CbZ), 78.6 (CH2Benz), 127.8, 128.0, 
128.1, 128.2, 128.3, 129.0 (CHarom), 134.4 (Carom), 135.3 (Carom), 156.74 (C=OCbZ), 208.3 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3090-3033 (CHarom.), 2953-2883 (CHaliph.), 1713 (C=O), 1587, 1498, 1455 (Phenyl), 1392 (C-N), 
1298, 1259,1220 (C.O),1029-1114 (N-O, C.O), 752 (CHδmono), 699 (Phenylδmono) 
 
MS: [M-H]+ = 354 
 
HRMS (C21H24 O4N, 0.5 ppm/M-H+):  [M-H] += 354.17018, calculated 354.16999, C21H24 O4N 
 
 
3-{N-(2-hydroxy-ethyl)-N'-[1-phenyl-meth-(E)-ylidene]-hydrazino}-cyclohexanone 119 
 
O
O
N
N
OH
NH
N
OH
Hydro-Quinidin
+
MW: 96.13 MW: 164.21 MW: 260.34
93 110 119
 
 
To a solution of 660.5 mg of hydroquinidine (2.0 mmol, 0.19 eq.) in 20 mL toluene are added 1.6913 
mg of 110 (10.3 mmol, 1.0 eq.) and dropwise 2 mL of cyclohexenone 93 (20.6 mmol, 2.0 eq.). The 
reaction mixture is stirred at room temperature over 3 days, and is concentred in vacuum to yield 
3.852 g of an orange oil 119.  
 
Table 12: general procedure 
 
To 110.4 µL of cyclohexenone 93 (1.04 mmol, 1.0 eq.) in 4 mL of chloroform are added at room 
temperature the selected catalyst (0.15 mmol, 0.15 eq.), 260.1 mg of 108  (1.00 mmol,1.0 eq.) and 
97.6 µL of morpholine (1.0 mmol, 1.0 eq.). The reaction mixture is stirred at room temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 3.6 min and 4.3 min. 
Chiral HPLC measurement on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 mL/min, 25°C, λ=215 
nm) reveals the presence of the two enantiomers at 5.2 min and 5.9 min. 
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Table 13: general procedure 
 
To 301.2 µL of cyclohexenone 93 (3.0 mmol, 1.0 eq.) in 4 mL of chloroform are added 20.8 mg of 
catalyst (0.15 mmol, 0.15 eq.), 108 (1.00 mmol,1.0 eq.) and 97.6 µL of morpholine (1.0 mmol, 1.0 
eq.). The reaction mixture is stirred at the selected temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 3.6 min and 4.3 min. 
Chiral HPLC measurement on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 mL/min, 25°C, λ=215 
nm) reveals the presence of the two enantiomers at 5.2 min and 5.9 min. 
 
Table 14: general procedure 
 
To 110.4 µL of cyclohexenone 93 (1.04 mmol, 1.0 eq.) in 4 mL of chloroform are added the selected 
catalyst  (0.15 mmol, 0.15 eq.), 260.1 mg of 108  (1.00 mmol,1.0 eq.) and 97.6 µL of morpholine (1.0 
mmol, 1.0 eq.). The reaction mixture is stirred at the selected temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 3.6 min and 4.3 min. 
Chiral HPLC measurement on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 mL/min, 25°C, λ=215 
nm) reveals the presence of the two enantiomers at 5.2 min and 5.9 min. 
 
Table 15: general procedure 
 
To 110.4 µL of cyclohexenone 93 (1.04 mmol, 1.0 eq.) in 4 mL of chloroform are added the selected 
catalyst  (0.15 mmol, 0.15 eq.), 260.1 mg of 108  (1.00 mmol,1.0 eq.) and the selected base additive 
(1.0 mmol, 1.0 eq.) The reaction mixture is stirred at the selected temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) revealed the presence of the two enantiomers at 3.6 min and 4.3 min. 
Chiral HPLC measurement on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 mL/min, 25°C, λ=215 
nm) revealed the presence of the two enantiomers at 5.2 min and 5.9 min. 
 
Table 16: general procedure 
 
To 110.4 µL of cyclohexenone 93 (1.04 mmol, 1.0 eq.) in 4 mL of chloroform are added the selected 
catalyst  (0.15 mmol, 0.15 eq.), 260.1 mg of 108  (1.00 mmol,1.0 eq.) and the selected base additive. 
The reaction mixture is stirred at the selected temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 3.6 min and 4.3 min. 
Chiral HPLC measurement on CHIRALCEL OD-H (hexan/iPrOH/MeOH 97:2:1, 1.5 mL/min, 25°C, λ=215 
nm) reveals the presence of the two enantiomers at 5.2 min and 5.9 min. 
 
Table 17: general procedures 
 
To 110.4 µL of cyclohexenone 93 (1.04 mmol, 1.0 eq.) in 4 mL of chloroform are added the selected 
catalyst  (0.15 mmol, 0.15 eq.), 530.1 mg of 109 (1.50 mmol,1.5 eq.) and of the selected base 
additive. The reaction mixture is stirred at the selected temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 11.6 min and 13.1 min. 
 
To 110.4 µL of cyclohexenone 93 (1.04 mmol, 1.0 eq.) in 4 mL of chloroform are added 20.8 mg of 
catalyst (0.15 mmol, 0.15 eq.), 353.4 mg of 109 (1.00 mmol,1.0 eq.) and the selected base additive. 
The reaction mixture is stirred at the selected temperature.  
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Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 11.6 min and 13.1 min. 
 
To 301.2 µL of cyclohexenone 93 (3.0 mmol, 1.0 eq.) are added 20.8 mg of catalyst  (0.15 mmol, 0.15 
eq.), 353.4 mg of 109 (1.00 mmol,1.0 eq.) and the selected base additive. The reaction mixture is 
stirred at the selected temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) revealed the presence of the two enantiomers at 11.6 min and 13.1 min. 
 
Table 18: general procedure 
 
To 602.4 µL of cyclohexenone 93 (6.0 mmol, 3.0 eq.) in 8 mL chloroform are added at room 
temperature  41.6 mg of catalyst  (0.30 mmol, 0.15 eq.), 103.8 µL of aziridine 102 (2.00 mmol, 1.0 
eq.) and 97.6 µL of morpholine (1.0 mmol, 1.0 eq.). The reaction mixture is stirred at the selected 
temperature.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two enantiomers at 6.0 min and 6.6 min. 
 
Table 19,20: general procedure:  
 
To a solution of  200.1 mg of 95 (0.9 mmol, 1.0 eq.) in 4 mL of the selected solvent, are added the 
selected additive, 11.4 mg of  L-proline (0,04 mmol, 0.05 eq.) and one equivalent of the base 
additive.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two diastereoisomers at 7.9 min and 10.2 min. 
 
Table 21: general procedure 
 
To a solution of  200.1 mg of 95 (0.9 mmol, 1.0 eq.)  in 4 mL of the selected solvent, are added the 
selected additive, 0.1 mmol of the catalyst  and 1.0 mmol of the base additive.  
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two diastereoisomers at 7.9 min and 10.2 min. 
 
Table 22: general procedure 
 
To a solution of  200.1 mg of 96 (0.9 mmol, 1.0 eq.)  in 4 mL of DMSO, are added 33.2 mg of TBAI (0.1 
mmol, 0.1 eq.), 22.8 mg of  L-proline (0.09 mmol, 1.0 eq.)  and 129.3 mg of Hünig base (1.0 mmol, 1.0 
eq.). 
Chiral HPLC measurement on CHIRALPAK AD-H (hexan/iPrOH/MeOH 90:7.5:2.5, 1.5 mL/min, 25°C, 
λ=215 nm) reveals the presence of the two diastereoisomers at 7.9 min and 10.2 min. 
 
 
 
 
 
 
 
 
 
 
 
 203 
 
III. EXPERIMENTAL PART OF CHAPTER 4 
 
3-((E)-2-nitro-propenyl)-1H-indoles 156b-d 
 
R
R NH
N
O
NO
2
R
R
N
H
NO
2
dichloromethane, TFA
147 156
155
 
 
To a solution of 1 equivalent of 155  in  dichloromethane (360µL/mmol) are added at 0°C under a Ar 
atmosphere trifluoroacetic acid (500 µL/mmol) and 1 equivalent of the selected indole 147 (5.0 
mmol, 1 eq.). The orange reaction mixture is stirred in a argon atmosphere for 20 min, turning into a 
black suspension. The precipitate is filtered off, washed with 10 mL of cold dichloromethane and 
dried in vacuum to yield an orange solid (75%). The resulting mother layer is concentrated in vacuum 
and trifluoroacetic acid (100 µL/mmol) is added. The black reaction mixture ist stirred overnight 
turning into a black suspension. The precipitate is filtered off, washed with cold dichloromethane and 
dried in vacuum to yield again an orange product 156, which is dried in vacuum. 
 
 
5,6-difluoro-3-((E)-2-nitro-propenyl)-1H-indole 156b 
CAS Number: 1235587-40-2 
B.K.S. Yeung, B. Zou,M. Rottmann,S.B.  Lakshminarayana , S. H. , S.Y. Leong, J. Tan , J. Wong, S. Keller-
Maerki, C. Fischli, A. Goh, E.K. Schmitt, P. Krastel , E. Francotte ,K. Kuhen ,D. Plouffe , K. Henson,T. 
Wagner , E.A. Winzeler, F. Petersen,R. Brun, V. Dartois, T. T. Diagana, T.H. Keller J. Med. Chem.  2010,  
53(14),  5155-64 
 
F
F
N
H
NO
2
MW: 238.20
156b
 
 
Yield: 87% 
1H NMR (500 MHz, DMSO-d6) δH (ppm)  
2.47 (s, 3H. CH3), 7.46 - 7.57 (dd, J1=7 Hz, J2= 4 Hz, 1H, CHarom), 7.93 - 8.03 (dd, J1=8 Hz, J2= 4 Hz, 1H, 
CHarom), 8.05 (s, 1H, C=CH-NH), 8.40 (s, 1H, Hvin), 12.31 (bs, 1H, NH) 
 
IR: (FTIR-microscopy in transmission)  
3258 (NH), 3074 (CHarom.), 1631 (C=C), 1276 (NO2) 
 
MS: MH- = 237.2  
 
HRMS (C11H7O2N2F2, 0.6 ppm/M-H-):  [M-H]
-= 237.04795, calculated 237.04811, C11H7O2N2F2 
 
Crystal data (100 °K, 1.54178 Å) 
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Empirical formula  C11 H10 F2 N2 O2 
Crystal system     Triclinic 
Space group     P-1 
Unit cell dimensions   a = 7.400(3) Å α= 97.89(2)° 
     b = 8.195(3) Å β= 90.67(3)° 
     c = 16.610(7) Å γ = 96.33(2)° 
Volume     991.3(7) Å3 
Z     4 
Density (calculated)   1.610 g/cm3 
Absorption coefficient   1.189 mm-1 
F(000)     496 
Crystal size    0.12 x 0.09 x 0.02 mm3 
Theta range for data collection  2.69 to 66.66° 
Index ranges    -8<=h<=8, -9<=k<=9, 0<=l<=19 
Reflections collected   3785 
Independent reflections  3785 [R(int) = 0.0000] 
Completeness to theta = 66.66° 97.8 %  
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmission  0.9766 and 0.8705 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  3785 / 0 / 310 
Goodness-of-fit on F2   1.000 
Final R indices [I>2sigma(I)]  R1 = 0.0481, wR2 = 0.1436 
R indices (all data)   R1 = 0.0614, wR2 = 0.1584 
Largest diff. peak and hole  0.357 and -0.264 e.Å-3 
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6-chloro-5-fluoro-3-((E)-2-nitro-propenyl)-1H-indole 156c 
CAS Number: 1193314-74-7 
B.K.S. Yeung, B. Zou,M. Rottmann,S.B.  Lakshminarayana , S. H. , S.Y. Leong, J. Tan , J. Wong, S. Keller-
Maerki, C. Fischli, A. Goh, E.K. Schmitt, P. Krastel , E. Francotte ,K. Kuhen ,D. Plouffe , K. Henson,T. 
Wagner , E.A. Winzeler, F. Petersen,R. Brun, V. Dartois, T. T. Diagana, T.H. Keller J. Med. Chem.  2010,  
53(14),  5155-64 
 
Cl
F
N
H
NO
2
156c
MW: 254.65  
 
Yield: 82% 
1H NMR (500 MHz, DMSO-d6) δH (ppm)  
2.47 (s, 3H. CH3), 7.64 - 7.70 (dd, J1=7 Hz, J2= 6 Hz, 1H, CHarom), 7.94 - 8.00  (dd, J1=10 Hz, 1H, 
CHarom), 8.08 (s, 1H, C=CH-NH), 8.39 (s, 1H, Hvin), 12.32 (bs, 1H, NH) 
 
IR: (FTIR-microscopy in transmission)  
3405(NH), 3059 (CHarom.), 1634 (C=C), 1278 (NO2) 
 
MS: MH- = 253.1  
 
 
4,5,6,7-tetrafluoro-3-((Z)-2-nitro-propenyl)-1H-indole 156d 
 
F
F
N
H
F
F
NO
2
156d
MW: 274.18  
 
Yield: 76% 
 
 
1H NMR (500 MHz, DMSO-d6) δH (ppm)  
2.44 (s, 3H. CH3), 8.11 (s, 1H, C=CH-NH), 8.31 (s, 1H, Hvin), 13.24 (bs, 1H, NH) 
 
IR: (FTIR-microscopy in transmission)  
3246 (NH), 3156 (CHarom.), 1637 (C=C), 1268 (NO2) 
 
MS: MH- = 273.1  
 
HRMS(C11H5O2N2F4, 0.7 ppm/MH
-):  [MH]- = 273.02905, calculated 273. 02926 C11H5O2N2F4 
 
Crystal data (100 °K, 1.54178 Å) 
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Empirical formula    C11 H6 F4 N2 O2 
Crystal system     Monoclinic 
Space group     P21/n 
Unit cell dimensions   a = 4.9310(10) Å α= 90° 
     b = 17.465(3) Å  β= 100.766(10)° 
     c = 12.378(2) Å  γ = 90° 
Volume     1047.2(3) Å3 
Z     4 
Density (calculated)   1.739 g/cm3 
Absorption coefficient   1.504 mm-1 
F(000)     552 
Crystal size    0.15 x 0.06 x 0.05 mm3 
Theta range for data collection  4.43 to 66.52° 
Index ranges    -5<=h<=5, -20<=k<=20, -14<=l<=13 
Reflections collected   9075 
Independent reflections  1840 [R(int) = 0.0297] 
Completeness to theta = 66.52° 99.6 %  
Max. and min. transmission  0.9286 and 0.8058 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters 1 840 / 0 / 173 
Goodness-of-fit on F2   1.044 
Final R indices [I>2sigma(I)]  R1 = 0.0299, wR2 = 0.0772 
R indices (all data)   R1 = 0.0314, wR2 = 0.0786 
Largest diff. peak and hole  0.207 and -0.227 e.Å-3 
3-(2-nitro-propyl)-1H-indole 148a  
 
General procedure, racemic route 
CH
3
NO
2
N
H
CH
3
NO
2
N
H
MW: 204.23MW: 117.15
147a 148a
150
 
 
To 13.5 mL of a solution of 1.1 mmol of 2-nitropropene 150 in 15 mL toluene (1.0 mmol, 1.0 eq.) are 
added at room temperature 117.1 mg of indole 147a (1.0 mmol, 1.0 eq.). The reaction mixture is 
stirred at 40°C over 20 hours turning into a black solution.  
HLPC analysis on reverse phase ODS3 C18 (using a mixture of acetonitrile and demineralized water 
buffered with 0.01% of NH4H2PO4 and a gradient of 55% to 97% acetonitrile in 15 min at 40°C) revals 
the presence of the signal corresponding to the 3-(2-Nitro-propyl)-1H-indole 148a at 6.4 min. 
 
General procedure, asymmetric route 
To 20 mL of a solution of 1.1 mmol of 2-nitropropene 150 in 15 mL toluene (1.0 mmol, 1.0 eq.) are 
added at room temperature 117.1 mg of indole 147a (1.0 mmol, 1.0 eq.) and 0.10 equivalent of the 
selected catalyst.The reaction mixture is stirred at room temperature over 3 days turning into a black 
solution.  
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HLPC analysis on reverse phase ODS3 C18 (using a mixture of acetonitrile and demineralized water 
buffered with 0.01% of NH4H2PO4 and a gradient of 55% to 97% acetonitrile in 15 min at 40°C) revals 
the presence of the signal corresponding to the 3-(2-nitro-propyl)-1H-indole 148a at 6.4 min. 
 
IV. EXPERIMENTAL PART OF CHAPTER 5  
 
(3R,5S,6S)-6-hydroxy-5-isopropyl-3-nitro-tetrahydro-pyran-3-carboxylic acid methyl ester 157a 
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AcOH, THF,40°C
L-Ph2Prolinol-OTMS
 THF,  40°C
+ other
stereoisomers
10
19
20
157a
158
21
(S)
(S)
(2S, 5R, 7R)
MW: 247.25
MW: 119.08MW: 30.03
MW: 86.13
MW: 131.09
I
24
24
 
65.2 mg of (S)-diphenyl-prolinol-O-TMS-ether I (0.2 mmol, 0.10 eq.) are dissolved at room 
temperature in 6 mL of THF. 324.2 µL of isovaleraldehyde 10 (3.0 mmol, 1.5 eq.) and 540 mg of acetic 
acid (8.9 mmol, 4.5 eq.) are added to the mixture at room temperature. The mixture is then warmed 
to 35°C. A solution of 237.5 mg of methyl nitroacetate 21 (1.99 mmol, 1.0 eq.) in 3 mL of THF and a 
solution of 165.2 mg of aqueous formaldehyde 24 (~37% in water) (2.0 mmol, 1.0 eq.) in 3 mL of THF 
are added simultaneously at 35°C over a period of 30 min. After 30 min (the formation of the Michael 
intermediate is controlled by HPLC and proved by NMR spectroscopy (1H NMR, 400 MHz, CDCl3-d
6). 
237.5 mg of aqueous formaldehyde (~37% in water) (2.9 mmol, 1.4 eq.) in 3 mL of THF are added 
dropwise at 35°C. The reaction mixture is allowed to stir over 7 hours at 35 °C and 5 mL of an 
aqueous solution of NaOH (2M) are added. The reaction mixture is allowed to stir overnight (~17h). 
The reaction mixture is cooled down to room temperature and diluted with 10 mL of 
dichloromethane. 10 mL of water are added and the organic and aqueous phases are separated. The 
aqueous layer is extracted with 5 mL of dichloromethane. The combined organic phases are dried 
over MgSO4, and concentrated in vacuum to yield 226.9 mg of 157 as a yellow oil, and as an isomeric 
mixture (LC-MS analysis shows the presence four diastereoisomers with a ratio of  
61:26:13(P1:P2/P3:P4)). 
 
The crude product is purified by column chromatography on silicagel (50 g) with hexane/ethyl 
acetate (3:1) to give in the pure fractions:  
- 41.3 mg of lactol as a yellow oil, as an isomeric mixture of two diastereomers, 8%  
- 52.7 mg of lactol as a yellow oil, as an isomeric mixture of diastereomers, 11% 
- 108.0 mg of 157a as white crystals, 22% 
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Spectroscopic data of  (3R,5S,6S)  157a 
O
OH
O
O
NO
2
157a
(2S, 5R, 7R)
 
 
1H NMR (400 MHz, CDCl3-d) δH (ppm) 
0.92 - 1.02 (m, 6H, CH3iPr), 1.37 - 1.63 (m, 2H, CH-iPr, CHiPr), 2.10 - 2.26 (m, 1H, CH2 CH-iPr), 2.74 - 2.87 
(m, 2H, CH2 CH-iPr), 2.43 (bs, OH), 3.78 (s, 3H, OCH3), 4.43 - 4.48 (m, 2H, CH2O), 5.25 (d, J=3 Hz, 1H, 
CH-OH)  
 
13C NMR (150.0 MHz, dmso-d6) δC (ppm)  
19.80 (CH3iPr), 27.72 (CH2CH-iPr), 28.42 (CH-iPr), 41.44 (CHiPr), 54.02 (OCH3), 59.22 (CH2), 91.42 (C-
NO2), 97.15 (CH2O), 165.19 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3380 (OH), 2975-2877 (CH-aliphatic), 1762 (C=O, ester), 1552 (NO2 ass), 1349 (NO2  
s), 1251 (C-O) 
 
MS: [M+H]+ = 248.2 (isomer A) 
 
Rf (hexan/ethyl acetate, 3:1) =0.31 
 
Crystal data  (100°K, 1.54178 Å) 
Crystal system     Orthorhombic 
Space group     P212121 
Unit cell dimensions   a = 5.842(2) Å  α= 90° 
     b = 8.756(3) Å  β = 90° 
     c = 24.449(7) Å  γ = 90° 
Volume     1250.6(7) Å3 
Z     4 
Density (calculated)   1.313 g/cm3 
Absorption coefficient   0.930 mm-1 
F(000)     528 
Crystal size    0.34 x 0.16 x 0.10 mm3 
Theta range for data collection  3.62 to 68.13° 
Index ranges    -6<=h<=6, -10<=k<=10, -29<=l<=29 
Reflections collected   38166 
Independent reflections  2263 [R(int) = 0.0270] 
Completeness to theta = 68.13° 98.9 %  
Absorption correction   Semi-empirical from equivalents 
Max. and min. transmission  0.9128 and 0.7428 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  2263 / 0 / 158 
Goodness-of-fit on F2   1.097 
Final R indices [I>2sigma(I)]  R1 = 0.0252, wR2 = 0.0673 
R indices (all data)   R1 = 0.0252, wR2 = 0.0673 
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Absolute structure parameter 0.00(14) 
Largest diff. peak and hole 0.211 and -0.171 e.Å-3 
 
 
Spectroscopic data for the 157 as mixture of two of the diastereoisomers 
 
O
OH
O
OO
2
N
O
OH
O
O
NO
2
O
OH
O
OO
2
N
157b 157c 157d
or or
 
 
1H NMR (400 MHz, CDCl3-d) δH (ppm) (isomeric mixture, dr 68:32) 
[0.88-0.92 (m, CH3iPr isom B), 0.96-1.03 (m, CH3iPr isom A), 6H],  [1.49 - 1.75 (m), 1.92 - 2.08 (m), 1.97 - 2.17 
(m), 2H, CH-iPr isom A and isom B, CHiPr isom A and isom B],  [2.17 (t, J=12 Hz), 2.70 - 2.81 (m), CH2 CH-iPr isom A and 
isom B],   [3.88 (s, OCH3 isom B) , 3.89 (s, OCH3 isom A ), 3H], [4.16 (d, J=12 Hz, CH2O isom A), 4.29 - 4.37 (m, 
CH2O isom B), 4.39 - 4.47 (m, CH2O isom A), 4.54 (dd, J1=12 Hz, J2=12z, CH2O isom B,  2H], [4.80 (d, J=8 Hz, CH-
OH isom B), 5.22 (d, J=3 Hz, CH-OH isom A), 1H] 
 
13C NMR (150.0 MHz, dmso-d6) δC (ppm) (isomeric mixture, dr 68:32 
[16.57, 19.92, 20.18, 20.54] (CH3iPr isom A and isom B), 28.54 (CH2 CH-iPr isom A and isom B), 29.97 (CH-iPr isom A and 
isom B), 43.71 (CHiPr isom A and isom B), 53.91 (OCH3 isom A and isom B), 59.09 (CH2 isom A), 64.63 (CH2 isom B), 89.49 (C-
NO2 isom B), 90.24 (C-NO2 isom A), 91.69 (CH2O isom B), 96.86 (CH-OH isom A), 165.19 (C=O isom A and isom B) 
 
IR: (FTIR-microscopy in transmission)  
340 (OH), 2963, 2877 (C-H-aliphatic), 1765 (C=O, , ester), 1553 (NO2 ass), 1345  (NO2 , s), 1242 (C-O) 
 
MS: [M+H]+ = 248.1, (isomer A) 
        [M+H]+ = 248.1, (isomer B) 
 
Rf (hexan/ethyl acetate, 3:1) =0.29 
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6-hydroxy-2-isobutyl-5-isopropyl-3-nitro-tetrahydro-pyran-3-carboxylic acid methyl  
ester 159 
O
O
O
2
N
 
O
O
H H O
O
O
2
N
O
O
O
NO
2
 
O
OH
O
O
NO
2
O
OH
O
O
O
NO
2
 
+
+
*
*
AcOH, 
THF, 40°C
L-Ph2ProlinolOTMS
 THF,  40°C
159
20 161
21
10
19
MW: 119.08MW: 30.03
MW: 86.13 MW: 131.09
MW: 303.36
I
10
24
 
433.4 mg of (S)-diphenyl-prolinol-O-TMS-ether I (0.5 mmol, 0.15 eq.) are dissolved at room 
temperature in 16 mL of THF. 1.99 mL of isovaleraldehyde 10 (18.5 mmol, 5.0 eq.) and 1.108 g of 
acetic acid (18.4 mmol, 4.9 eq.) are added to the mixture at room temperature. The mixture was 
then warmed to 35°C. A solution of 433.4 mg of methyl nitroacetate 21 (2.6 mmol, 1.0 eq.) in 4 mL of 
THF and a solution of 300 mg of formaldehyde 24 (~37% in water) (3.7 mmol, 1.0 eq.) in 4 mL of THF 
are added simultaneously at 35°C over a period of 40 min. The reaction mixture is stirred over 8 days 
at 35°C.  
The reaction mixture is cooled down to room temperature and diluted with 40 mL of ethyl acetate. 
10 mL of water are added and the organic and aqueous phases are separated. The organic phase is 
then dried over MgSO4, and concentrated in vacuum to yield 1.132 g of crude product 159 as an 
isomeric mixture of five diastereoisomers with a ratio of 29:9:42:10:10.   
The crude product is purified by column chromatography on silicagel (120 g) with heptane/ethyl 
acetate (8:1) to give in the purest fractions 300 mg of 159 as a yellow oil (isomeric ratio: 17:26:45:12) 
(38% yields). Addition of a 8:1 solution (v/v) of hexan-ethyl acetate leads to the precipitation of a 
white solid (desired lactol as an isomeric mixture). The resulting oil can be triturated of a 1:1 solution 
(v/v) of hexan-diethyl ether to yield 159 with an isomeric ratio of 23:11:61:5. 
Theses fractions are purified again by column chromatography on silicagel (50 g) with heptane/ethyl 
acetate (3:1) to give in the purest fractions 170 mg of the 159 as an isomeric mixture (isomeric ratio 
of 88:12), which can be recrystallised by addition of a 1:1 solution (v/v) of hexan-diethyl ether. 
 
1H NMR (600 MHz, DMSO-d6) δH (ppm) (isomeric mixture dr 88:12) 
0.80 - 0.95 (m, 12H, CH3iPr), 1.39 - 1.46 (m, 1H, CH2-CHiPr), 1.53 - 1.65 (m, 2H, CH2-CHiPr’, CH-CHiPr,  ), 
1.65 - 1.77 (m, 1H, CHiPr), 1.91 - 2.02 (m, 2H, CHiPr’, CH2-CH-iPr), 2.52 (m, 1H, CH2-CH-iPr), 3.79 (s, 3H, 
OCH3), 4.05 (d, J=9 Hz, 1H, CH-O), 4.65 (dd, J1=9 Hz, J2=7 Hz, 1H, CH-OH), 6.71 (d, J=7 Hz, 1H, OH) 
isomer B: 4.57 (d, J=9 Hz, 0.12H, CH-O), 5.04 - 5.10 (m, 0.12H, CH-O), 6.69 (d, J=5 Hz, 0.12H, OH) 
 
13C NMR (150.0 MHz, dmso-d6) δC (ppm)  
16.36 (CH3iPr), 20.49 (CH3iPr, CH-iPr), 22.91 (CH-iPr), 25.33 (CH2-CH-CHiPr), 38.82 (CH2-CHiPr), 43.32 (CH-
CHiPr), 53.35 (OCH3), 75.15 (CH-O), 91.06 (C-OH), 97.63 (C-NO2), 159.51 (C=O) 
 
IR: (FTIR-microscopy in transmission)  
3443 (OH), 2956-2933 (C-H-aliphatic), 1744 (C=O, , ester), 1559 (NO2 ass), 1342 (NO2 s), 1258 (C-O-
ester) 
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MS: [M+H+] = 304.2 (isomer A in mixture with B ) 
 
HRMS(C14H26O6N, 0.5 ppm):  [MH-H20]
+= 286.16475, C14H24O5N, calculated 286.16490 
     [M+NH4-H20]
+= 303.19145, C14H27O5N2, calculated 303.19145 
     [M+NH4]
+= 321.20184, C14H29O6N2, calculated 321.20201 
 
Rf (hexan/ethyl acetate, 3:1) =0.22 
 
(3R,5R)-5-Benzyl-6-hydroxy-3-nitro-tetrahydro-pyran-3-carboxylic acid methyl ester 89a 
 
O
O
O
O
2
N
 
O
H H
O
CH
3
O
O
2
N
O
O
O
CH
3
NO
2
OH
O
O
O
NO
2
 
O
H H
O
OH
O
O
NO
2
+
+
*
*
AcOH, 
THF,35°C
L-Ph2Prolinol-OTMS
 THF,  35°C
+ other 
stereoisomers
21
19162
163
164
MW: 119.08
MW: 30.03
MW: 131.09
MW: 134.18
MW: 295.29
160a
I
24
24
 
 
162.8 mg of (S)-diphenyl-prolinol-O-TMS-ether I (10.5mmol, 0.1 eq.) are dissolved at room 
temperature in 10 mL of THF. 1.3 mL of acetic acid (20.6 mmol, 4.5 eq.) and 670.9 mg of 
hydrocinnamaldehyde 162 (5.0 mmol, 1.0 eq.) are added to the mixture at room temperature. The 
mixture was then warmed to 35°C. A solution of 595.6 mg of methyl nitroacetate 21 (5.0 mmol, 1.0 
eq.) in 5 mL of THF and a solution of 405.7 mg of formaldehyde 24 (~37% in water) (5.0 mmol, 1.0 
eq.) in 5 mL of THF are added simultaneously at 35°C for 20 min. This solution is then stirred at 35°C 
within 15 min and 811.6 mg of formaldehyde 24 (~37% in water) (10.0 mmol, 2.0 eq.) are added 
dropwise. The reaction mixture is stirred over night (~24h) at 35°C.  
The reaction mixture is cooled down to room temperature and diluted with 40 mL of 
dichloromethane. 20 mL of an aqueous solution of NaOH (1M) are added and the both phases are 
separated. The organic phase is washed two times with 20 mL of water. The dichloromethane phase 
is then dried over MgSO4, and concentrated in vacuum to yield 868.3 mg of crude product as an 
isomeric mixture of three diastereoisomers (isomeric ratio 62:38, P1/P2:P3). 
The crude product is purified by column chromatography on silicagel (20 g) with hexane/ethyl 
acetate (5:1) to give in the pure fractions 452.3 mg of the lactol  160 (30%). 160a is obtained with a 
yield of 8%. 
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Spectroscopic data of 160a 
O
OH
O
O
NO
2
160a
MW: 295.29  
 
1H NMR: (500 MHz, dmso-d6) δH (ppm) (isomeric mixture, drOH 90:10, isomer A) 
1.86- 1.94 (m, 1H, CH-CH2Benz), 2.17 (t, 1H, CH2CNO2), 2.32-2.42 (m, 2H, CH2CNO2,  CH2benz), 2.64 - 2.70 
(m, 1H, CH2benz), 3.73 (s, 3H, OCH3), 3.78 (s, 3H, OCH3 isom B), 4.25-4.40 (m, 2H, CH2-O), 4.87 (t, J=3Hz, 1 
H, CH-OH), 6.82 (dd, 1H, OH),  7.18 - 7.26 (m, 3H, CHarom), 7.28 - 7.32 (m, 2H, CHarom) 
 
13C NMR: (101 MHz, dmso-d6) δH (ppm)  
28.82 (CH2-C-NO2), 36.74 (CH-CH2Benz), 36.82 (CH2benz), 53.89-53.92 (OCH3), 59.27-59.51 (CH2-O), 88.48 
(NO2-C-C=O), 90.95-91.49 (CH-OH), 126.10, (CHarom), 128.64 (CHar) 129.12 (CHar) 139.16 (Car), 164.69 -
165.47 (C=O-ester) 
 
IR: (FTIR-microscopy in transmission)  
3375 (OH), 3031 (CHphenyl), 2953-2923 (C-Haliphatic), 1745 (C=O, ester), 1560 (NO2 as), 1585-1549 
(phenyl ), 1446-1434 (phenyl δ), 1355 (NO2 s), 1263-1143-1029 (C-O), 747 (C-Hmonosubst δ), 702 
(Phenylmonosubst δ) 
 
MS: [M+NH4]
 + = 313, [M+NH4 -H2O]
 + = 295  
 
Rf (hexan/ethyl acetate, 5:1)=0.18 
 
Crystal data  (100°K, 1.54178 Å) 
Empirical formula    C14 H17 N O6 
Crystal system      Monoclinic 
Space group          P21 
Unit cell dimensions   a = 9.487(2) Å  α= 90° 
     b = 6.3360(10) Å β= 93.756(11)° 
     c = 11.759(3) Å  γ = 90° 
Volume     705.3(3) Å3 
Z     2 
Density (calculated)   1.390 g/cm3 
Absorption coefficient   0.926 mm-1 
F(000)     312 
Crystal size    0.15 x 0.14 x 0.07 mm3 
Theta range for data collection  3.77 to 68.25° 
Index ranges    -11<=h<=11, -7<=k<=7, -14<=l<=14 
Reflections collected   14405 
Independent reflections  2580 [R(int) = 0.0330] 
Completeness to theta = 68.25° 100.0 %  
Absorption correction   Semi-empirical from equivalents 
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Max. and min. transmission  0.9380 and 0.8735 
Refinement method   Full-matrix least-squares on F2 
Data / restraints / parameters  2580 / 1 / 192 
Goodness-of-fit on F2   1.091 
Final R indices [I>2sigma(I)]  R1 = 0.0268, wR2 = 0.0668 
R indices (all data)   R1 = 0.0281, wR2 = 0.0679 
Absolute structure parameter  0.00(14) 
Largest diff. peak and hole  0.156 and -0.155 e.Å-3 
 
 
Spectroscopic data of the isomeric mixture 160 
 
1H NMR: (500 MHz, dmso-d6) δH (ppm) (isomeric mixture, drOH 52:48) 
1.70- 1.80 (m, 1H, CH-CH2Benz isomer A), 1.88-2.00 (m, 2.6H, CH-CH2Benz isomere B , CH2CNO2  isomer B), 2.14 (t, 
2H, CH2CNO2 isomer A), 2.32-2.37 (m, 3H,  CH2CNO2,  CH2benz isomer A and isomer B), 2.63 - 2.68 (m, 2H, CH2benz 
isomer A), 2.98-3.04  (m, 0.8H, CH2benz isomer isomere B), 3.67 (s, 1.5H, OCH3 isomer B), 3.73 (s, 3H, OCH3 isomer  A), 
4.03-4.04 (m, 2H, CH2Oisomer B), 4.25-4.40 (m, 2H, CH2Oisomer A), 4.70 (t, J=3Hz, 1 H, CH-OH isomer A and isomer 
B), 6.85 (dd, 1H, OHisomer A), 6.97 (dd, 0.4H, OHisomer B), 7.16 - 7.25 (m, 3H, CHarom), 7.27 - 7.35 (m, 2H, 
CHarom) 
 
13C NMR: (101 MHz, dmso-d6) δC  (ppm)  
28.81 (CH2-C-NO2), 36.71 (CH-CH2Benz), 36.80 (CH2benz), 54.00 (OCH3), 59.4 (CH2-O), 88.46 (NO2-C-C=O), 
90.93-91.46 (CH-OH), 126.08 (CHarom), 128.31 (CHarom) 128.80 (CHarom), 138.81 (Car)) 165.45 (C=Oester)  
 
IR: (FTIR-microscopy in transmission)  
3375 (OH), 3030 (CH-phenyl), 2954-2923 (C-Haliphatic), 1746 (C=O, ester), 1560  (NO2 ,ass), 1604-
1495-1458 (Phenyl ), 1446-1434 (Phenyl δ), 1354 (NO2 s), 1263-1019  (C-O), 747 (C-Hmonosubst δ), 702 
(Phenylmonosubst δ) 
 
MS: [M+NH4]
 + = 313, [M+NH4
+ -H2O] = 295 (isomer A) 
        [M+NH4]
 + = 313, [M+NH4
+ -H2O] = 295 (isomer B) 
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CHAPTER 5: MULTICOMPONENT DOMINO-REACTIONS 
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